<SEC-DOCUMENT>0001731122-25-001544.txt : 20251114
<SEC-HEADER>0001731122-25-001544.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114160846
ACCESSION NUMBER:		0001731122-25-001544
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lunai Bioworks Inc.
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38758
		FILM NUMBER:		251486054

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO INC.
		DATE OF NAME CHANGE:	20240213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO BIOSCIENCES INC.
		DATE OF NAME CHANGE:	20230807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enochian Biosciences Inc.
		DATE OF NAME CHANGE:	20230804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e7036_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:RENB="http://renovarobio.com/20250930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_034_RENB_renovarobio.com_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20250701_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DDocumentFiscalYearFocus_2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNi0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000004" name="dei:DocumentFiscalYearFocus">2026</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000005" name="dei:CurrentFiscalYearEndDate">--06-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000007" name="dei:EntityCentralIndexKey">0001527728</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-09-30" id="xdx2ixbrl0049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-09-30" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:GainOnBankruptcyOfSubsidiary" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit" contextRef="From2025-07-01to2025-09-30" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:LossOnExtinguishmentOfDebt" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:GainOnSettlementOfAccountsPayable" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2025-07-01to2025-09-30" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-07-01to2025-09-30" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2025-07-01to2025-09-30" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:CancellationOfStockOptions" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-09-30_country_NL" id="xdx2ixbrl0907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="renb-20250930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-07-01to2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-08_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-09</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-20_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-19</xbrli:startDate>
        <xbrli:endDate>2023-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-04_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-04_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-042025-06-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-04</xbrli:startDate>
        <xbrli:endDate>2025-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-21_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-12-03_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-232025-02-24_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-23</xbrli:startDate>
        <xbrli:endDate>2025-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-152024-09-16_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-15</xbrli:startDate>
        <xbrli:endDate>2024-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-06_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-042024-02-05_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-04</xbrli:startDate>
        <xbrli:endDate>2024-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-02_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-022024-11-03_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-02</xbrli:startDate>
        <xbrli:endDate>2024-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-29</xbrli:startDate>
        <xbrli:endDate>2020-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-062025-07-07_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-06</xbrli:startDate>
        <xbrli:endDate>2025-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-30</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-30</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-05</xbrli:startDate>
        <xbrli:endDate>2020-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-142019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-14</xbrli:startDate>
        <xbrli:endDate>2019-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-092022-09-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-09</xbrli:startDate>
        <xbrli:endDate>2022-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_MarkDybulMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-022024-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-02</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-222025-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-22</xbrli:startDate>
        <xbrli:endDate>2025-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-16_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_RENBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_BioSymetricsMember412313203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_RENCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-26_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-252025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-25</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-032025-11-04_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-03</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-282025-10-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-28</xbrli:startDate>
        <xbrli:endDate>2025-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-282025-10-29_custom_SettlementAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-28</xbrli:startDate>
        <xbrli:endDate>2025-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-282025-10-29_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-28</xbrli:startDate>
        <xbrli:endDate>2025-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-162024-10-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-162025-10-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-16</xbrli:startDate>
        <xbrli:endDate>2025-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>U.S. SECURITIES AND
EXCHANGE COMMISSION</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_903_edei--DocumentType_c20250701__20250930_zlgDOAZQ7w8l"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 12pt"><span id="xdx_903_edei--DocumentQuarterlyReport_c20250701__20250930_zJ21WxWOt9Af"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span><span style="font-size: 12pt">&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended <b><span id="xdx_906_edei--DocumentPeriodEndDate_c20250701__20250930_zSVrEPnlmDSj"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">September 30, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 12pt"><span id="xdx_907_edei--DocumentTransitionReport_c20250701__20250930_zP0wzxh3aUUl"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span><span style="font-size: 12pt">&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ________ to ________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number <span id="xdx_908_edei--EntityFileNumber_c20250701__20250930_zxhz40OCqzLk"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000017" name="dei:EntityFileNumber">001-38758</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityRegistrantName_c20250701__20250930_zE18FnMbl0Y6"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000018" name="dei:EntityRegistrantName">Lunai Bioworks Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20250701__20250930_zuTbyS9myHJa"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20250701__20250930_zLidn08QgfB1"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000020" name="dei:EntityTaxIdentificationNumber">45-2259340</ix:nonNumeric></span> </b></span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer </span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt">incorporation or organization) </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Identification Number) </span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--EntityAddressAddressLine1_c20250701__20250930_zwFAZm7Izsy8"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000021" name="dei:EntityAddressAddressLine1">3400 Cottage Way</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20250701__20250930_z4Co76TI5W49"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000022" name="dei:EntityAddressAddressLine2">Suite G2 #32562</ix:nonNumeric></span><br/>
<span id="xdx_90D_edei--EntityAddressCityOrTown_c20250701__20250930_zFdlDiEYQejc"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000023" name="dei:EntityAddressCityOrTown">&#160;Sacramento</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250701__20250930_zxlB74ugp8Hb"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000024" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--EntityAddressPostalZipCode_c20250701__20250930_zRJfxld79bEc"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000025" name="dei:EntityAddressPostalZipCode">95825</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">+1<span id="xdx_905_edei--CityAreaCode_c20250701__20250930_z7vUV5vKgsO2"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000026" name="dei:CityAreaCode">(424)</ix:nonNumeric></span> <span id="xdx_90B_edei--LocalPhoneNumber_c20250701__20250930_zPPwO26uZs3a"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000027" name="dei:LocalPhoneNumber">222-9301</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">N/A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name, former address and former fiscal year,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20250701__20250930_zdk0NcgY43n"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000028" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20250701__20250930_zDuYZbD9mNAd"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000029" name="dei:TradingSymbol">LNAI</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20250701__20250930_zbiYuu405f6j"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <span id="xdx_901_edei--EntityCurrentReportingStatus_c20250701__20250930_zR0vYFShm3B4"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000031" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> No <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20250701__20250930_zOIANvMdQugc"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000032" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
No <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td>
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td>
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityFilerCategory_c20250701__20250930_zHkDYoS5kpId"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000033" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntitySmallBusiness_c20250701__20250930_zHL6WBIOVSKj"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact000034" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20250701__20250930_zsWzwcaB87z3"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleanfalse" id="Fact000035" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
<span id="xdx_90B_edei--EntityShellCompany_c20250701__20250930_zwvp33sQzMAa"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of November 10, 2025, the number of shares of the
registrant&#8217;s Common Stock outstanding was <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20251110_zJSmRp5xNqJ1" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-11-10" id="Fact000038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,432,391</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>- INDEX -</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 7%">&#160;</td>
    <td style="width: 86%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_001"><span style="font-size: 10pt">PART I &#8211; FINANCIAL INFORMATION:</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_002"><span style="font-size: 10pt">Financial Statements (Unaudited):</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_003"><span style="font-size: 10pt">Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and June 30, 2025</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_004"><span style="font-size: 10pt">Condensed Consolidated Statements of Operations&#160;for the Three Months Ended September 30, 2025, and 2024 (Unaudited)</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_005"><span style="font-size: 10pt">Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended September 30, 2025, and Loss for the Three Months Ended 2024 (Unaudited)</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_006"><span style="font-size: 10pt">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three Months Ended September 30, 2025, and 2024 (Unaudited)</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_007"><span style="font-size: 10pt">Condensed Consolidated Statements of Cash Flows&#160;for the Three Months Ended September 30, 2025, and 2024 (Unaudited)</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_008"><span style="font-size: 10pt">Notes to the Condensed Consolidated Financial Statements (Unaudited)</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_009"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_010"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_011"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_012"><span style="font-size: 10pt">PART II &#8211; OTHER INFORMATION:</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_013"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 1A.</span></td>
    <td><a href="#a_014"><span style="font-size: 10pt"><i>Risk Factors</i></span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_015"><span style="font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_016"><span style="font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_017"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 5.</span></td>
    <td><a href="#a_018"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Item 6.</span></td>
    <td><a href="#a_019"><span style="font-size: 10pt">Exhibits</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_020"><span style="font-size: 10pt">Signatures</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>Item 1. Financial Statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The accompanying financial statements
have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with
the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting
principles for complete financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the opinion of management, the
financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the
financial condition, results of operations, and cash flows of the Company for the interim periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The results for the period ended
September 30, 2025, are not necessarily indicative of the results of operations for the full year. These financial statements and related
footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company&#8217;s Form 10-K
for the fiscal year ended June 30, 2025, filed with the Securities and Exchange Commission on September 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_003"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zrfVvxng0Kxd" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20250930_zbCa7s1ayBHb" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20250630_zCo7I2YWD3u2" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">September 30,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center"><span style="font-size: 10pt">&#160;<b>(Unaudited)</b></span></td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zbqTZ9BncJph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">ASSETS</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zVPM7g47rcpi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">CURRENT ASSETS:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzUeu_zHa92bMDs0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-indent: -10pt">Cash</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,808</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,700</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EquitySecuritiesFvNi_i02I_maCzUeu_z8XyLVX9CoD9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Investment in equity securities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-06-30" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,851</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maCzUeu_zbH4MbO02Cd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Prepaids and other assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-09-30" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,552</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-06-30" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,081</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzUeu_maCzXZc_zvnAtbNtXRO9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Current Assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,360</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,632</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzXZc_z7WZl9WbJpia" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Property and equipment, net</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-09-30" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,465</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,843</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsNoncurrentAbstract_i01B_ztnq7XUZuO7c" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">OTHER ASSETS</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--DefiniteLifeIntangibleAssetsNet_i02I_maCzmfR_z0p5tGa80gQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Definite life intangible assets, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DefiniteLifeIntangibleAssetsNet" contextRef="AsOf2025-09-30" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,610</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DefiniteLifeIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,994</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_i02I_maCzmfR_zNvAhcLh8Mig" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Software platform, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2025-09-30" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,288</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2025-06-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--FiniteLivedTrademarksGross_i02I_maCzmfR_zlsJwvGdJr7a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Trademarks, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedTrademarksGross" contextRef="AsOf2025-09-30" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,082</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedTrademarksGross" contextRef="AsOf2025-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Goodwill_i02I_maCzmfR_z6KwKqJTM8Df" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-09-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzmfR_zCOBJCpKFjib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Deposits and other assets</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-09-30" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,858</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0077">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzmfR_zS0fF952oDEh" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Operating lease right-of-use assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0079">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,371</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzmfR_maCzXZc_z4XIoyry5bii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Total Other Assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-09-30" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,147,838</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-06-30" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,816,365</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--Assets_iTI_mtCzXZc_zVNwY4XtLwyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL ASSETS</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-09-30" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,960,663</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,230,840</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zFGsMgRCEUVd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">LIABILITIES</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zx2mu8T2i6C4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">CURRENT LIABILITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccountsPayableTradeCurrent_i02I_maCzN78_zseXN8ttXBY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Accounts payable &#8211; trade</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,094,428</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,555,839</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzN78_zhx8MHrZNjY6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Accrued expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,868,686</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,843,069</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzN78_zd8pR7GnBvo2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Other current liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,429</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378,282</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--ContingentConsiderationLiabilityCurrent_i02I_pp0p0_d0_maCzN78_zJp9ERhII2Xj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Contingent consideration liability</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2025-09-30" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">630,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_i02I_d0_maCzN78_zX01fWGykzcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Convertible notes payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-09-30" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-06-30" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzN78_zlM2MuMf9cUe" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Current portion of operating lease liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-09-30" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,775</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,047</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NotesPayable_i02I_maCzN78_zb2UIheXeMsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Notes payable, net</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-09-30" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,038,495</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-06-30" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,580,525</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--NotesPayableRelatedPartiesNetCurrent_i02I_maCzN78_zg2wGuREqOc5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Notes payable &#8211; related parties, net</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2025-09-30" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,661</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2025-06-30" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,610,372</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzN78_maCzBiT_z2YnvcKcTnSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Current Liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,722,474</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,156,134</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z7i0oXrZYbga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">NON-CURRENT LIABILITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzm6m_zz5gfk5pM3A1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Operating lease liabilities, net of current portion</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-09-30" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,963</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,547</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtCzm6m_maCzBiT_zp6pvLWSn6v2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Non-Current Liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-09-30" id="Fact000127" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">278,963</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-06-30" id="Fact000128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">424,547</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--Liabilities_i02TI_mtCzBiT_maLASEzxaF_zt61siI8KTx8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-09-30" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,001,437</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,580,681</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">STOCKHOLDERS&#8217; DEFICIT</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_maCz7Aa_z0uy7SBFU2Wa" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Preferred stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930_zcsI7fjQTpRc" title="Preferred stock, par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630_zZuRRNrHLAIh" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20250930_zS85Ng4DHgg" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20250630_zD3JNFYcsDba" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20250930_zI3nlTWIrHta" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20250930_zHM0wwpKAazd" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20250630_z7TRGSMk68Uh" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20250630_zCRLf4QGm9i9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000147" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000149" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000151" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000153" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30" id="Fact000136" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" id="Fact000137" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maCz7Aa_zzWHITaCMHnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250930_znDG05kjbdt8" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zfvbjtdgD819" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20250930_zirraUJXlH8b" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_ztPYDW6WHrCd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20250930_zgAh0aqvw4Td" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20250930_zEVIG0fN86u6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,180,277</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at September 30, 2025; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20250630_zVnWouKvo79" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_z3EIRacy9rz7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,739,291</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at June 30, 2025</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-09-30" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,318</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,774</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maCz7Aa_zTmABJfiTnE2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-09-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,728,618</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,296,113</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz7Aa_zfIB4CCUW75b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accumulated deficit</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">507,643,549</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">510,462,570</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCz7Aa_z0dDFzyhOK47" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accumulated other comprehensive (loss)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-09-30" id="Fact000180" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">128,161</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,814,842</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtCz7Aa_maLASEzxaF_zmDqKJGgL8a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Stockholders&#8217; Deficit</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,040,774</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,349,841</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzxaF_zZCBJpH6reZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,960,663</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,230,840</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_004"></span>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<br/>
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_zSHryw6vblsc" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20250701__20250930_zdS9r5xQGGmb" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49C_20240701__20240930_zXgPSU3AqGDd" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zyhbgf11SI4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzuO2_zaHsx3YgV3Ej" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,410,516</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,301,251</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzuO2_zqErosDnX6Uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Research and development</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,407</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,189</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--GoodwillImpairmentLoss_i01_pp0p0_d0_maCzuO2_zZO0fMTRp9Bc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Goodwill impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000198" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-07-012024-09-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,614,729</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_i01_pp0p0_maCzuO2_zYlQMxyzdJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2025-07-01to2025-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">831,915</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzuO2_zcZLKV5O4r4a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-07-01to2025-09-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,522</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-012024-09-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,385</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzuO2_msCzHGi_zZN2f8DijTb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-07-01to2025-09-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,308,360</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012024-09-30" id="Fact000208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,338,554</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtCzHGi_maCz4nz_zzVC5lVpFuF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,308,360</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,338,554</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zNvXultaFcFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expense)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--ChangeInFairValueOfContingentConsideration_i01_pp0p0_d0_maCzGcn_zk3z0RhL5XU3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2025-07-01to2025-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">370,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2024-07-012024-09-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,250,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_i01_maCzGcn_zSmoPqSWdwE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Change in fair value of equity securities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" contextRef="From2025-07-01to2025-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,849</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--GainOnBankruptcyOfSubsidiary_i01_maCzGcn_z4GVXw7THijk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Gain on bankruptcy of subsidiary</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:GainOnBankruptcyOfSubsidiary" contextRef="From2025-07-01to2025-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,019,227</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_d0_maCzGcn_zXn1UWIovgI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-07-01to2025-09-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,329,592</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-07-012024-09-30" id="Fact000226" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_i01N_di_msCzGcn_zCQ76ysQEWJb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Interest expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-07-01to2025-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,400</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-07-012024-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,080</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_40E_ecustom--InterestIncomeAndOtherIncomeExpense_i01_maCzGcn_zNVFpz7LDT5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Interest income and other income (expense)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,297</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,598</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCzGcn_maCz4nz_zbMhmoOklTDf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,127,381</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,126,518</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtCz4nz_zVK5RHItj6Se" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET INCOME (LOSS)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,819,021</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,212,036</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">BASIC AND DILUTED INCOME (LOSS PER SHARE)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250701__20250930_zCrN2ErL4MS4" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20250701__20250930_zo3vOWjiMYF9" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-01to2025-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-01to2025-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20240701__20240930_z4MCZvleGCd6" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20240701__20240930_z8kaWs5TGHA6" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.76</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING &#8211; BASIC
AND DILUTED</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20250930_zlvNpLKihoc8" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20250930_z4to7ywtlQyb" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-01to2025-09-30" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-01to2025-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,520,245</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20240930_zUS7ELZUf8yd" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20240930_z1VngFDuiJE2" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMoVU5BVURJVEVEKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,999,337</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<b><span id="a_005"></span>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_zyQfxVA6YuI9" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_499_20250701__20250930_zIsfJs92QeH8" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20240701__20240930_zbeNjZydJxKa" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ProfitLoss_maCzFTz_zKkLRuHgYcAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">Net Income (Loss)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,819,021</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-012024-09-30" id="Fact000257" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,212,036</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zsVCYix1o6b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Comprehensive Income (Loss)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_iN_di_msCzFTz_zZHGpbVgTTS" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt">Foreign Currency Translation, net of taxes</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2025-07-01to2025-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,943,003</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2024-07-012024-09-30" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,468,061</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzFTz_zpsRVCEHiaQ9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Comprehensive Loss</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-07-01to2025-09-30" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,123,982</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,743,975</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY (DEFICIT)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_zORkp70O1zk6" summary="xdx: Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zsHURZovhKea" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zwKli7BKtfm6" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zPC8m85esnnj" style="font-weight: bold; text-align: right">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zelnj5YbH5pg" style="font-weight: bold; text-align: right">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_4B3_zjF7IQHutXe3" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Common Shares</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares Amount</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Income (Loss)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_43B_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zQ5xNs6ACU7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">June 30, 2024</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0zaVsmpB2Lh" title="Beginning balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,845,264</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,585</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,601,486</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">332,455,081</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">)</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,846</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">)</td>
<td style="width: 2%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,977,144</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_zx5iAqfVzfk8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Issuance of common stock under private placement offering</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfjEyPcjyJ97" title="Issuance of common stock under private placement offering, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,346</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,096,166</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012024-09-30" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,096,181</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--RestrictedSharesIssuedForServicesRendered_zmD0i9IZzfN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Restricted shares issued for services rendered</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_ecustom--RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI5KKWGBiboh" title="Restricted shares issued for services rendered and executive compensation, shares" style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,399,980</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-012024-09-30" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_zeRf7uX83g41" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Forfeited shares of common stock</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkRZRfd4Facg" title="Forfeited shares of common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000298" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">83,333</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zM3ru73X6Xw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock-based compensation</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">&#8212;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,648</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,648</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_znL0ARLGk4td" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">&#8212;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,212,036</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,212,036</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_zd4Prg69LG3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign currency translation adjustment</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,468,061</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012024-09-30" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,468,061</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_436_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zvc8MUjcGjC7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">September 30, 2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRV3EVzNsoD5" title="Ending balance, shares" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,104,277</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,610</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,455,289</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">376,667,117</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,297,215</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,086,998</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20250701__20250930_eus-gaap--StockholdersEquity_iS_z58bUPYmRWri" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">June 30, 2025</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq1MHx8tYcB3" title="Beginning balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,739,291</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,774</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">$</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,296,114</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">510,462,570</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,814,842</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,349,841</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_iP3us-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_zAikhoT5N1ai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Issuance of common stock pursuant to conversion of convertible notes</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_eus-gaap--ConversionOfStockSharesIssued1_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za0uknk3NX62" title="Issuance of common stock pursuant to conversion of convertible notes, shares" style="text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,355,809</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,066,892</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2025-07-01to2025-09-30" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,067,427</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_iP3us-gaap--ConversionOfStockSharesIssued1_zsZkC1U4Juwf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Issuance of common stock pursuant to settlement of accounts payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_ecustom--IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares_iP3custom--IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zME4Wfl5nJbb" title="Issuance of common stock pursuant to settlement of accounts payable, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,147</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,300</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" contextRef="From2025-07-01to2025-09-30" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,308</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensation_zulMdFV2iGD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock-based compensation</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">&#8212;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,312</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-01to2025-09-30" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,312</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--SharesAddedForFractionalSharesPursuantToReverseStockSplit_iP3us-gaap--ShareBasedCompensation_zNVetzg2mLg2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares added for fractional shares pursuant to reverse stock split</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98B_ecustom--SharesAddedForFractionalSharesPursuantToReverseStockSplitShares_iP3custom--SharesAddedForFractionalSharesPursuantToReverseStockSplit_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6AkoKn6GnSf" title="Shares added for fractional shares pursuant to reverse stock split, shares" style="text-align: right"><ix:nonFraction name="RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_z6MEvPpoA9v7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net income</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">&#8212;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,819,021</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,819,021</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_zCdiBZR79vrb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign currency translation adjustment</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,943,003</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-07-01to2025-09-30" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,943,003</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_431_c20250701__20250930_eus-gaap--StockholdersEquity_iE_zm6OrjxbcbYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">September 30, 2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY4x8Z5uJxOl" title="Ending balance, shares" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,180,277</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,318</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,728,618</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">507,643,549</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">128,161</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000380" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,040,774</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_007"></span>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br/>
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_112_zWXGucMHTlHa" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20250701__20250930_zicd4abSp4n9" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20240701__20240930_zWy7EqSmVerh" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_ztIDNs4assW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzjUq_zjT4SgfLwzVj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net income (loss)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,819,021</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,212,036</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zv2AO3bkXW02" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">ADJUSTMENTS TO RECONCILE NET INCOME (LOSS) TO NET CASH USED IN OPERATING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_i02_maCzjUq_zWaxI2bJOzk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-07-01to2025-09-30" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,522</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-07-012024-09-30" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,385</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--LossOnExtinguishmentOfDebt_i02N_di_msCzjUq_znAQqUudiBxk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LossOnExtinguishmentOfDebt" contextRef="From2025-07-01to2025-09-30" id="Fact000396" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,329,593</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i02N_di0_msCzjUq_zFNklFXZSTHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in value of contingent consideration</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2025-07-01to2025-09-30" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,000</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2024-07-012024-09-30" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,250,000</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_i02N_di_msCzjUq_zpkjKTfgduOl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in value of equity securities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" contextRef="From2025-07-01to2025-09-30" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,849</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--NoncashStockbasedCompensationExpense_i02_maCzjUq_zbN7XNgI5F9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Stock-based compensation expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,312</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,648</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--GainOnBankruptcysOfSubsidiary_i02N_di_msCzjUq_zccrlbZ8piLf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Gain on bankruptcy of subsidiary</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:GainOnBankruptcysOfSubsidiary" contextRef="From2025-07-01to2025-09-30" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,019,227</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:GainOnBankruptcysOfSubsidiary" contextRef="From2024-07-012024-09-30" id="Fact000409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,400,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--ImpairmentExcludingLessorAssetUnderOperatingLease_i02_d0_maCzjUq_z7nRALOL7Ibi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease" contextRef="From2025-07-01to2025-09-30" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,915</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease" contextRef="From2024-07-012024-09-30" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,614,729</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--GainOnSettlementOfAccountsPayable_i02N_di_msCzjUq_zkn6p7cO0V8g" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Gain on settlement of accounts payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:GainOnSettlementOfAccountsPayable" contextRef="From2025-07-01to2025-09-30" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,324</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_d0_maCzjUq_zAVREIXdziC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Amortization of debt issuance cost</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2025-07-01to2025-09-30" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,495</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-07-012024-09-30" id="Fact000418" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--AmortizationOfDiscountOnNotePayable_i02_maCzjUq_zlz17E0ILCQl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Amortization of discount of notes payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2024-07-012024-09-30" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,718</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zv8cov3goHfh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in assets and liabilities:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_di_msCzjUq_zHi41AWMTChd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other receivables</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2025-07-01to2025-09-30" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,407</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2024-07-012024-09-30" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,961</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzjUq_zJGrqM43U0G2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses/deposits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-07-01to2025-09-30" id="Fact000429" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">269,264</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-07-012024-09-30" id="Fact000430" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,701</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzjUq_zEfudqbQlejk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-07-01to2025-09-30" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,206</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-012024-09-30" id="Fact000433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,539</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i03_d0_maCzjUq_zv21ypm0pzNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2025-07-01to2025-09-30" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,738</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-07-012024-09-30" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,891</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_d0_maCzjUq_zpiEj4xXTkH9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Other current liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2025-07-01to2025-09-30" id="Fact000438" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-07-012024-09-30" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,325</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzjUq_zOYPrSliZ9t7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Operating leases, net</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-07-01to2025-09-30" id="Fact000441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,369</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-07-012024-09-30" id="Fact000442" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,269</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzjUq_maCzFSa_zZFaftnf1rE9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN OPERATING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-07-01to2025-09-30" id="Fact000444" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,349,110</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-012024-09-30" id="Fact000445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,016,328</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_iB_zFrVPnGlrQS5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_i01_d0_maCzdZK_za9jskWugsNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Sale of equitable securities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="From2025-07-01to2025-09-30" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,700</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="From2024-07-012024-09-30" id="Fact000451" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzdZK_maCzFSa_zVoau0bZ20g4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN INVESTING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-07-01to2025-09-30" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,700</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_z2nepHTfzhqf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--RepaymentsOfFinanceAgreement_i01N_di_msCz8o0_zh4Kw5zVT7V7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Repayment of finance agreement</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2025-07-01to2025-09-30" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,643</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2024-07-012024-09-30" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,945</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maCz8o0_zP2KeTi2x7o2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from private placement</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-07-012024-09-30" id="Fact000463" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,096,181</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--ProceedsFromNotesPayable_i01_d0_maCz8o0_z33w74H5yMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from notes payable</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-07-01to2025-09-30" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,615,000</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-07-012024-09-30" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,947</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCz8o0_maCzFSa_zAnmNyOj64A1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-07-01to2025-09-30" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343,357</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-012024-09-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,029,183</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzFSa_zUEaNUjuQm91" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Effect of exchange rates on cash</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2025-07-01to2025-09-30" id="Fact000471" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,839</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-07-012024-09-30" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,751</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzFSa_z66yWyqpunP9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CHANGE IN CASH</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-07-01to2025-09-30" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,108</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-07-012024-09-30" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zhXJ5YxfSrIi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH, BEGINNING OF PERIOD</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,700</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zEBDC2HbqvXk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH, END OF PERIOD</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-09-30" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,808</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,571</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zuD80NqMFDtf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--CashPaidDuringYearForAbstract_i01B_zUchx413dh88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid during the period for:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestPaidNet_i02_zUkT0yMghfsg" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Interest</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-07-01to2025-09-30" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,559</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--DebtDiscountRelatedToConvertiblePromissoryNotes_i01_znDjTpEG71d1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Debt discount related to convertible promissory notes</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2024-07-012024-09-30" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,954</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--CancellationOfRestrictedStockAwards_i01_zdCZZuJwnQN2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cancellation of restricted stock awards</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CancellationOfRestrictedStockAwards" contextRef="From2025-07-01to2025-09-30" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,973</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CancellationOfRestrictedStockAwards" contextRef="From2024-07-012024-09-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--CancellationOfStockOptions_i01_zMLSddMVs571" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cancellation of stock options</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><ix:nonFraction name="RENB:CancellationOfStockOptions" contextRef="From2025-07-01to2025-09-30" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,032</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>LUNAI BIOWORKS INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_008"></span>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000504" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmM2k5cnxo5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8212; <span id="xdx_82E_zjmZBzzAvfB5">ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000506" name="RENB:BusinessPolicyTextBlock"><p id="xdx_846_ecustom--BusinessPolicyTextBlock_zM8bhbJd7Yuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zMJazVCBCdBc">Business</span> &#8211;</b>&#160;On
August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. (&#8220;Lunai&#8221;). On April 8, 2025,
Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics, Corp.&#8221;), as a wholly owned subsidiary pursuant
to a stock purchase agreement. On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro
Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) and
acquired GEDi Cube Intl Ltd and its subsidiaries GediCube B.V. and Grace Systems B.V. (&#8220;Renovaro Cube&#8221;), as a wholly owned
subsidiary pursuant to a stock purchase agreement. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform
for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights,
enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000508" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfhaeqhssCx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zRGXCqp0TaXi">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2025, and 2024
and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s June 30, 2025 audited financial
statements. The results of operations for the period ended September 30, 2025 are not necessarily indicative of the operating results
for the full year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000510" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zjYCGxlKlCRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zOQrRNCWX6Ne">Consolidation</span> &#8211;</b> For
the three months ended September 30, 2025, and 2024, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000512" name="RENB:BankruptcyPolicyTextBlock"><p id="xdx_848_ecustom--BankruptcyPolicyTextBlock_zxMyMLvyswRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86C_zayuz0B64oh5">Bankruptcy </span>-</b> The Company
accounts for bankruptcy under ASC 810, Consolidation. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;),
an indirect subsidiary of Lunai Bioworks, Inc. As of September 30, 2025 the Company deconsolidated Gedi Cube B.V., derecognizing its net
liabilities and releasing the cumulative translation adjustment balance to earnings. The bankruptcy resulted in a gain of $<span id="xdx_90B_ecustom--BankruptcyResultedInGain_c20250701__20250930_zYAcaX7EBWyj" title="Bankruptcy resulted in a gain"><ix:nonFraction name="RENB:BankruptcyResultedInGain" contextRef="From2025-07-01to2025-09-30" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,019,227</ix:nonFraction></span>
during the three months ended September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000516" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_z472sHq2DJw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zIUBCJ90PhLh">Accounting Estimates</span> &#8211;</b>
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000518" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zrgDFSUyEJoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_z2kWuceihXFb">Loss Per Share</span>&#160;</b>&#8211;Basic earnings per common share (EPS) are based on the weighted average
number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed
as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings
per share calculation include in-the-money stock options that have been granted but have not been exercised and shares issuable upon conversion
of convertible common stock and convertible notes. The Company had <span id="xdx_904_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250930_zz8t1Bt16A38" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000520" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,244,888</ix:nonFraction></span> and <span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240930_z2JKPdRrqSs2" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000522" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,729,342</ix:nonFraction></span> potential shares of Common Stock excluded from
the Diluted EPS calculation as of September 30, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_23B_zhNvWYvNlDAj" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zV8qKOXkey4c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zdCbbkwR5Pnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000525" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zbjCC4VyiJja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zn14GVueakDa">Functional Currency &amp; Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended September 30, 2025, and 2024. Translation gains and losses are deferred
and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement
of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000527" name="RENB:InvestmentinEquitySecuritiesPolicyTextBlock"><p id="xdx_849_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zRyaUyKr69Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zjlPOJV9f471">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchasedEquitySecurities_iI_c20250228_zgRDsGVwMiib" title="Purchased equity securities"><ix:nonFraction name="RENB:PurchasedEquitySecurities" contextRef="AsOf2025-02-28" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> of equity securities. During the period ended September 30, 2025, the Company recorded a change in fair value of equity
securities for $<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_c20250701__20250930_zbnqDYItSFFb" title="Fair value of equity securities"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,849</ix:nonFraction></span> and sold the securities for $<span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiGainLoss_c20250701__20250930_zckIHg6vJ15c" title="Investment in equity securities"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,700</ix:nonFraction></span>. The investment in equity securities balance at September 30, 2025, was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000535" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0NQ2pJr1opd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z1i7QDoyRl8d">New Accounting Pronouncements
Not Yet Adopted</span></b>&#160;- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000537" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMijwZetCg3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_823_zYNOhBxI1J8c">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations. As of September 30, 2025, the Company had cash and cash equivalents of $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250930_z7WMSpJD6zjc" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000539" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,808</ix:nonFraction></span>, an accumulated deficit
of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250930_z2q6zHX4ktSi" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000541" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">507,643,549</ix:nonFraction></span> and a working capital deficit of $<span id="xdx_90F_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250930_zT7GrhiBR2X3" title="Working capital deficit"><ix:nonFraction name="RENB:WorkingCapitalDeficit" contextRef="AsOf2025-09-30" id="Fact000543" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,922,114</ix:nonFraction></span>. These conditions raise substantial doubt about the Company&#8217;s ability
to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_232_zxcTcdGxQdKi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_z4FaKN0VWUG3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z9ByKkFhov8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_231_z371ZP7DfA0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management has reduced overhead
and administrative costs by streamlining the organization to focus around the development, validation, and commercialization of its AI-driven
neurology and oncology diagnostics and therapeutic development platform. The Company has tailored its workforce to focus on these activities.
In addition, the Company intends to secure additional required funding through equity or debt financing. However, there can be no assurance
that the Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on
reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders.
If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially
reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with
third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds
to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders
losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000547" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zo30AvUygzBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_827_znoD4YYDhpyg">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Level 3 liabilities held as of
September 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_906_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTPM5SKbod3" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,083,418</ix:nonFraction></span>
shares of Common Stock, and (ii) the right to receive up to <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zRgbLgqbUiml" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,954</ix:nonFraction></span> contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_90B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zNoAPtuTCE0k" title="Contingent consideration liability was recorded at fair value"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></span>
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of September 30, 2025,
there were <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250701__20250930__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zfc8vJkVAleh" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2025-07-012025-09-30_custom_RenovaroCubeMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">267,695</ix:nonFraction></span> contingent shares issuable in connection with the Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_239_z6cuy1X7JShd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_znuPcJnpLMQ" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zN9PWVjTYwrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#8217;s
underlying stock. The key inputs to valuing the contingent consideration liability as of September 30, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000558" name="us-gaap:FairValueConcentrationOfRiskTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--FairValueConcentrationOfRiskTextBlock_zVIeTjspzAje" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details )" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zTbxwmiSnMid" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAiDKvghFQXf" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember" id="Fact000560" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.42</ix:nonFraction></span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ziE7IUTNWTpa" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000562" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.30</ix:nonFraction></span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zsIQsBDmJDXh" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000564" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">19.20</ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOcOIkbpe40g" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000566" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">115.5</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z2MChPVYK1i6" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000568" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">143.3</ix:nonFraction></span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zieq7CsH6482" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000570" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.54</ix:nonFraction></span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAtgEuBTleve" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.94</ix:nonFraction></span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20250701__20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zfDogYXT7rvf" title="Expected Dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-07-012025-09-30_custom_BlackScholesOptionPricingModelMember" id="Fact000574" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zLpgHT05ft7b" title="Expected Term (years)"><ix:nonNumeric contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000576" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.45</ix:nonNumeric></span> &#8211; <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdaNRZRjMswi" title="Expected Term (years)"><ix:nonNumeric contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000578" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">8.13</ix:nonNumeric></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AB_zBjVMOv9TQUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth the Level 3 liability
at September 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000580" name="RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_zhEvZ0FZbhNf" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B2_zjBOizIiVET3" style="display: none">Schedule of fair value measurement on recurring basis</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_491_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYZKbCbh3COk" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_490_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z99ZK5ouloBl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze9UsuxrdEY7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fair Value Measurements at</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">&#160;<br/> Reporting Date Using</p></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z4zHG0uKm5Xl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Balance June 30, 2025</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000582" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000583" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,000</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zX4x6YbgKuha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel1Member" id="Fact000586" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel2Member" id="Fact000587" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel3Member" id="Fact000588" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">370,000</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zHn0Z3nefF8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at September 30, 2025</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member" id="Fact000590" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member" id="Fact000591" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><p id="xdx_8AD_z0KVcI4xDDTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000594" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_802_eus-gaap--IntangibleAssetsDisclosureTextBlock_zzg7412r9SB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8212; <span id="xdx_82A_zFHAbe2E1Yea">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 8, 2025, the Company acquired
Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $<span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQqqsZfF9uRf" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-04-08_custom_BioSymetricsMember" id="Fact000596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,500</ix:nonFraction></span>, software valued at $<span id="xdx_905_ecustom--Software_iI_c20250408_zkTjkjbtTqhd" title="Software"><ix:nonFraction name="RENB:Software" contextRef="AsOf2025-04-08" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></span> and Trademark valued at $<span id="xdx_90F_ecustom--Trademark_iI_c20250408_zqyg6ofM0flf" title="Trademark"><ix:nonFraction name="RENB:Trademark" contextRef="AsOf2025-04-08" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_23C_zFOd1H0mNzpd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zBNaDygreS8g" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z4Js9pHyNV3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_236_zFoo767En4Dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At September 30, 2025 and June
30, 2025, definite-life and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000604" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z3evUhPnV3mc" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6TEfz3w8Q9f" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt">Software platform</td>
<td style="width: 2%">&#160;</td>
<td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zc0nO79haeUh" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-09-30_custom_SoftwarePlatformMember" format="ixt-sec:duryear" id="Fact000606" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> Years</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z5Oj6hiCJaN" title="Net definite-life intangible assets at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember" id="Fact000608" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,000</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zqupOR3oik0d" title="Net definite-life intangible assets, Additions" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember" id="Fact000610" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zr27SdhVsM0e" title="Net definite-life intangible assets, Amortization" style="width: 9%; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,712</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zdDY9nqAbTog" title="Net definite-life intangible assets, Impairment" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember" id="Fact000614" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zZVvRURXm30g" title="Net definite-life intangible assets, Translation adjustment" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember" id="Fact000616" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z0uGuh274ZNb" title="Net definite-life intangible assets at ending" style="width: 8%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-09-30_custom_SoftwarePlatformMember" id="Fact000618" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,288</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z06kiu0KEXV8" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-09-30_custom_TrademarkMember" format="ixt-sec:duryear" id="Fact000620" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">2</ix:nonNumeric></span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlxnjTe714qb" title="Net definite-life intangible assets at beginning" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_TrademarkMember" id="Fact000622" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXfn5AY8mBg8" title="Net definite-life intangible assets, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-012025-09-30_custom_TrademarkMember" id="Fact000624" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zSpbmCUBXS51" title="Net definite-life intangible assets, Amortization" style="text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2025-07-012025-09-30_custom_TrademarkMember" id="Fact000626" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,918</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zDZArRFfc3K1" title="Net definite-life intangible assets, Impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-07-012025-09-30_custom_TrademarkMember" id="Fact000628" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zWvG7PmMKi2" title="Net definite-life intangible assets, Translation adjustment" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-012025-09-30_custom_TrademarkMember" id="Fact000630" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zFt0ve4ldaif" title="Net definite-life intangible assets at ending" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-09-30_custom_TrademarkMember" id="Fact000632" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,082</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdgXdGKDQs54" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-09-30_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact000634" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zN2aI7lYTa7a" title="Net definite-life intangible assets at beginning" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_us-gaap_PatentsMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">313,010</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXpbFKOw1iZ2" title="Net definite-life intangible assets, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember" id="Fact000638" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGSu1yyOMQF8" title="Net definite-life intangible assets, Amortization" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember" id="Fact000640" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuYNstgZR2a7" title="Net definite-life intangible assets, Impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember" id="Fact000642" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwBDWp3vi0f" title="Net definite-life intangible assets, Translation adjustment" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember" id="Fact000644" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,093</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxYIHPHW9Jj" title="Net definite-life intangible assets at ending" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-09-30_us-gaap_PatentsMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,917</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zIilEfxn708f" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">298,016</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zYQTgXXpVolc" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember" id="Fact000650" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zbXb3sF8kPOd" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember" id="Fact000652" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,659</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z0SZ4FSwEwV4" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember" id="Fact000654" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zc8RdkimNFvb" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember" id="Fact000656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,368</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zoSETgpApoH" title="Net definite-life intangible assets at ending" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-09-30_custom_LessAccumulatedAmortizationMember" id="Fact000658" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">294,307</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930_zgAPNZBLRsm8" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30" id="Fact000660" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,994</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z0bhNBNcAsqc" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-01to2025-09-30" id="Fact000662" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930_z8GcL5TFmKDe" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2025-07-01to2025-09-30" id="Fact000664" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,289</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930_zw7dnYUvfrr4" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-07-01to2025-09-30" id="Fact000666" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930_zlmMWp4mj791" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-01to2025-09-30" id="Fact000668" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,275</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930_zUZ4Mkw61TUd" title="Net definite-life intangible assets at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-09-30" id="Fact000670" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,980</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIrKAOOAP0xb" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-06-30_us-gaap_GoodwillMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zAyDwYSbZJn9" title="Total indefinite life intangible assets and goodwill, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember" id="Fact000674" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_988_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIC6TfGmdYua" title="Total indefinite life intangible assets and goodwill, Amortization" style="text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember" id="Fact000676" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zHFq70etLZc" title="Total indefinite life intangible assets and goodwill, Impairment" style="text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember" id="Fact000678" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9IeGzNOei4j" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember" id="Fact000680" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zXDGJ52QWeOj" title="Total indefinite life intangible assets and goodwill at ending" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-09-30_us-gaap_GoodwillMember" id="Fact000682" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930_zTZNX1tENBcl" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-06-30" id="Fact000684" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z9kONEG67yGj" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-07-01to2025-09-30" id="Fact000686" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930_zZn8LSkWOBSh" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2025-07-01to2025-09-30" id="Fact000688" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930_zd0gEmogMmKb" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2025-07-01to2025-09-30" id="Fact000690" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930_z9yYRn4vm0y9" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2025-07-01to2025-09-30" id="Fact000692" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930_z5EIu2Mhz8Y4" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-09-30" id="Fact000694" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A0_zr9O3zVLSYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000696" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zt8uoumTSSza" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_z501rc3v58Rf" style="display: none">Schedule of future amortization expense</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years ended&#160;June 30,</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 57%; text-align: left; text-indent: -10pt">2026</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250930_zUVcNtu43dyb" title="2026" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2025-09-30" id="Fact000698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,420</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250930_zaeQzlm9Q0Gb" title="2027" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2025-09-30" id="Fact000700" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,420</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2028</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250930_zV85U7gkWS02" title="2028" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2025-09-30" id="Fact000702" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,380</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2029</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250930_zu5NoeDnxCzc" title="2029" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2025-09-30" id="Fact000704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,380</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250930_zhmQ7e0Oassl" title="Thereafter" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2025-09-30" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,380</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250930_z8oeWpFbbx8b" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-09-30" id="Fact000708" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,980</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A0_zUCqy0lX6wGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000710" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zaOAFQIyG1Te" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_82B_zMhzSOo81tl1">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The January 2024 Note &#8212;</i></b>
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zCHwHAoLb57i" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> (the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zPi57CkjqAL4" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> in gross proceeds.&#160;The
January 2024 Note bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zX3BgDUPOfb2" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum and matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zhpM7Ldgj3Qa" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" format="ixt:datemonthdayyearen" id="Fact000718" name="us-gaap:DebtInstrumentMaturityDate">December 29, 2024</ix:nonNumeric></span>. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#8217;s
Common Stock at the Note Conversion Price of $33.80.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note that matured on December 29, 2024, was amended extending
the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29, 2025. Accordingly, the Note unless otherwise
amended, replaced, or otherwise altered by this First Amendment, any and all terms contained in the Note continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>December 2023 Notes &#8212;
</i></b>On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH0hPbkQyxIc" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-20_custom_DecemberNote2023Member" id="Fact000720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (the &#8220;December 2023 Notes&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z27msV7Ftt1a" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of <span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zj2egcfRJdNe" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2023-12-20_custom_DecemberNote2023Member" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum and matured one year after
their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The January 2024 Note and December
2023 Notes balance at September 30, 2025, was $<span id="xdx_909_ecustom--NotesBalance_iI_c20250930_zhvEpYczffVd" title="Notes balance"><ix:nonFraction name="RENB:NotesBalance" contextRef="AsOf2025-09-30" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_234_zIc65VUKwVKi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zEDnk1bTdri9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zH8sjAqF8qWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818_zveo9YHxfvU5" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-08-18" id="Fact000729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> incurring $<span id="xdx_901_ecustom--PlacementCosts_iI_c20250818_zs08gZ5k0yT2" title="Placement costs"><ix:nonFraction name="RENB:PlacementCosts" contextRef="AsOf2025-08-18" id="Fact000731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> of placement costs. The Notes bear an interest
rate of&#160;<span id="xdx_906_ecustom--InterestRate_iI_dp_c20250818_zK6cVGTXSved" title="Interest rate"><ix:nonFraction name="RENB:InterestRate" contextRef="AsOf2025-08-18" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">18</ix:nonFraction></span>%&#160;per annum and mature on&#160;the 6-month anniversary of the Issue Date,&#160;(the &#8220;Maturity Date&#8221;).
The Company is required to pay principal and interest on the Maturity Date. These notes balance at September 30, 2025, was $<span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20250930_zoE4FRQKgMO7" title="Notes balance"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2025-09-30" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,495</ix:nonFraction></span> net
amortization placement cost of $<span id="xdx_90F_ecustom--AmortizationPlacementCost_iI_c20250930_ziosMPfH3ja3" title="Amortization placement cost"><ix:nonFraction name="RENB:AmortizationPlacementCost" contextRef="AsOf2025-09-30" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,495</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">From July 3, 2025, to August 19,
2025, the Company issued Promissory Notes in the aggregate principal amount of $<span id="xdx_902_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703_zykCEXEf9MXf" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-03" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,000</ix:nonFraction></span>. The Notes bear an interest rate of&#160;<span id="xdx_906_ecustom--InterestRate_iI_dp_c20250819_zlnoec1u1Eng" title="Interest rate"><ix:nonFraction name="RENB:InterestRate" contextRef="AsOf2025-08-19" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>%&#160;per
annum and mature on&#160;June 30, 2026,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal and interest
on the Maturity Date<b>. </b>These notes balance at September 30, 2025, was $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20250703_zxGYUoD05xSi" title="Notes balance"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-07-03" id="Fact000743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zXt7wWrr0A7f" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ExchangeAgreementMember" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.7</ix:nonFraction></span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_90F_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_z7sKOxM4EG6b" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange resulted in a $6,329,592 loss on extinguishment
of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_z9SDHgLpktnh" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ConvertibleNotesMember" id="Fact000749" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million principal amount into an aggregate
of <span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zAQhZ08Hn1qh" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07" id="Fact000751" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.36</ix:nonFraction></span> million shares of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zUNFAe8oGjNg" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-07-07" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share conversion price. The
$3.00 (on a post reverse split basis) per share conversion price of the Convertible Notes represented a premium to the closing price of
the Company&#8217;s common stock on July 7, 2025, the date of execution and conversion. As a result, the issuance of the <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707_zMCCXt3MOs2k" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-07-07" id="Fact000755" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="Shares">5.36</ix:nonFraction></span> million
shares of common stock upon conversion of the Convertible Notes did not constitute a &#8220;below market&#8221; issuance under applicable
Nasdaq listing rules and did not trigger stockholder approval requirements under Nasdaq Listing Rule 5635(d). The shares were issued without
any additional consideration from the Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Bridge Loans &#8212; </i></b>From June 4, 2025
to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;)
and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zGX7GCjzbG8c" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-06-04_custom_PasecoApSMember" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,000</ix:nonFraction></span> to each note holder. The Company received $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zfBUrIuoyvqf" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-07-012025-09-30_custom_PasecoApSMember" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,450,000</ix:nonFraction></span>
in gross proceeds. The notes bear an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zUOaMX1twB9g" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-06-04_custom_TheNotesMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>% per annum and mature on December 31, 2025. On July 7, 2025, the Company entered
into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a
$<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250604__20250614_zTrkgFozO786" title="Loss on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-06-042025-06-14" id="Fact000763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,262,774</ix:nonFraction></span> loss on extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors
elected to convert the entire note balance for shares of common stock. The notes balance at September 30, 2025, was zero with Paseco ApS
and Laksya Ventures Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zbxqySSgYwve" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span>. The Company received $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zEfbYnqY3vV" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span> in gross proceeds. The notes bear an
interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zYJniwo5in62" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-10-21_custom_TheNotesMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>% per annum and mature from December 31, 2024 to December 31, 2025. <span id="xdx_90E_eus-gaap--MaturitiesOfTimeDepositsDescription_c20250701__20250930_zjDFf0d9V311" title="Maturity description"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000771" name="us-gaap:MaturitiesOfTimeDepositsDescription">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange
Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a $1,821,843 loss on
extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors elected to convert
the entire note balance for shares of common stock. The note balance at September 30, 2025, was zero with Paseco ApS and Laksya Ventures
Inc.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_903_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zY8fWR4upXVj" title="Agreement description"><ix:nonNumeric contextRef="From2024-11-122024-12-03_custom_PromissoryNotesMember" id="Fact000773" name="RENB:AgreementDescription">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory
notes. The exchange resulted in a $364,303 loss on extinguishment of debt. Immediately following the issuance of the convertible notes
on July 7, 2025, the investors elected to convert the entire note balance for shares of common stock. The note balance at September 30,
2025 was approximately zero with Paseco ApS and Laksya Ventures Inc.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_234_zAnDCu31b0W4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zqPxtPEP2ix5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zfn8Z00rKJQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zXApi2uHurpk" title="Agreement description"><ix:nonNumeric contextRef="From2025-02-232025-02-24_custom_PromissoryNotesMember" id="Fact000776" name="RENB:AgreementDescription">On November 1, 2024, Renovaro Cube
entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at September 30, 2025 was approximately
$270,000.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zS5FT7Prpbo3" title="Agreement description"><ix:nonNumeric contextRef="From2024-09-152024-09-16_custom_PromissoryNotesMember" id="Fact000778" name="RENB:AgreementDescription">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing
promissory note for a new convertible promissory note. The exchange resulted in a $71,112 loss on extinguishment of debt. Immediately
following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of
common stock. The note balance at September 30, 2025 was zero.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zdlFjVTqPdA2" title="Agreement description"><ix:nonNumeric contextRef="From2024-09-052024-09-06_custom_PromissoryNotesMember" id="Fact000780" name="RENB:AgreementDescription">On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025,
the Company entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange
resulted in a $41,319 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the
investor elected to convert the entire note balance for shares of common stock. The note balance at September 30, 2025 was zero with Paseco
ApS and Laksya Ventures Inc.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zCZqGmge1wgh" title="Agreement description"><ix:nonNumeric contextRef="From2024-02-042024-02-05_custom_PromissoryNotesMember" id="Fact000782" name="RENB:AgreementDescription">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to
exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $80,343 loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zM95opSLRQa2" title="Agreement description"><ix:nonNumeric contextRef="From2024-01-012024-01-02_custom_PromissoryNotesMember" id="Fact000784" name="RENB:AgreementDescription">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory
note for a new convertible promissory note. The exchange resulted in a $401,715 loss on extinguishment of debt. Immediately following
the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of common stock.
The note balance, net of discount at September 30, 2025 was zero.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zsIr3326eOJe" title="Agreement description"><ix:nonNumeric contextRef="From2024-11-022024-11-03_custom_PromissoryNotesMember" id="Fact000786" name="RENB:AgreementDescription">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company
entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange resulted
in a $591,198 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor
elected to convert the entire note balance for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_23A_zffeY4VvJkBh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_23D_zOxoRp2niu6b" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z2gK2nMOvbv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zzOG1EBn68p6" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-03-30_custom_PromissoryNoteMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Promissory
Note&#8221;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zV8p3Ne46pq5" title="Maturity date"><ix:nonNumeric contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact000791" name="us-gaap:DebtInstrumentMaturityDate">November 1, 2024</ix:nonNumeric></span> (the &#8220;Maturity
Date&#8221;). The Promissory Note, as amended, bears interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_ztolvObqDSl" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement
to exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20250706__20250707__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zWvXZwAg0X2i" title="Loss on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-07-062025-07-07_custom_PromissoryNoteMember" id="Fact000795" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">694,985</ix:nonFraction></span> loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The Promissory Note balance at September 30, 2025 was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#8217;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000797" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8XmZpDs95zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8212; <span id="xdx_82A_zUL94QJsaYf2">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>Purchase Agreement with Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC
(&#8220;Lincoln Park&#8221;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zTZPX7Wi74sj" title="Obligation to purchase"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2023-06-20" id="Fact000799" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span> of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration for entering into
the 2023 Purchase Agreement, the Company issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zAmPVcJqWM63" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">69,602</ix:nonFraction></span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the quarter ended September
30, 2025 and 2024, <span id="xdx_904_eus-gaap--SharesIssued_iI_do_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zDQlJGvWSAo2" title="Number of shares issued"><span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zoK3VoMnK95e" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_custom_PurchaseAgreementMember" id="Fact000803" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_custom_PurchaseAgreementMember" id="Fact000805" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_905_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zM33reuPpmw5" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ExchangeAgreementMember" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.7</ix:nonFraction></span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zhkkf4Hioj17" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember" id="Fact000809" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#8217;s
debt obligations and provide additional flexibility to support strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_90D_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zDoysBWxhjH" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_custom_ConvertibleNotesMember" id="Fact000811" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million principal amount into an aggregate of <span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zpKJK4rFX439" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07" id="Fact000813" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.36</ix:nonFraction></span> million shares
of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zHeasnzSz4Ra" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-07-07" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share conversion price. The $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteMember_zeYPJCOMEy7f" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-07-07_custom_ConvertibleNoteMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#8217;s common stock on July 7, 2025, the date
of execution and conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_23E_z8RDmQ3w0AZ2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zkkyQ3XYhy3i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zCLN2OePuSgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 25, 2025, the Company issued&#160;<span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20250725_zxGpBL8l2bA4" title="Shares Issued Common Stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-07-25" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,500</ix:nonFraction></span>
shares of Common Stock for settlement of accounts payable valued at $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_c20250725_zHAIFjsfV1Ak" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-07-25" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,050</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 5, 2025, the Company
issued&#160;<span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20250905_zG8YU4gXn7ml" title="Shares Issued Common Stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-05" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">79,647</ix:nonFraction></span> shares of Common Stock for settlement of accounts payable valued at $<span id="xdx_904_eus-gaap--AccountsPayableCurrent_iI_c20250905_z2Slmf6boFUg" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-09-05" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,259</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 18, 2025, the Company filed a Certificate of Amendment to the
Certificate of Incorporation of the Company (the &#8220;Certificate of Amendment&#8221;) with the Secretary of State of the State of Delaware
to effect a 1-for-10 reverse stock split of the shares of the Company&#8217;s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250918_zI1m7H15E856" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-18" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Common
Stock&#8221;), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September
29, 2025 (the &#8220;Reverse Stock Split&#8221;). All shares and the respective per-share amounts have been retroactively restated to
reflect the reverse split. The Common Stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on September
30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Stock-based Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model. During the three months ended September 30, 2025, the Company
granted no options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000830" name="RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_z3IIFIfLgHi" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BC_zhJPsOzgxV34" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 65%; text-align: left; text-indent: -10pt">Expected term (in years)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 25%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zMED0SY0N8A8"><ix:nonNumeric contextRef="From2025-07-012025-09-30_custom_RenovaroMember" format="ixt-sec:duryear" id="Fact000831" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zjkVOKNqE1Id" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">109.45</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zryWbYFyVhLd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">118.99</ix:nonFraction></span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zIp2xowPvwDa" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.86</ix:nonFraction></span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBIOoMMCbj73" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction></span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zbudH6P1eWui" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-07-012025-09-30_custom_RenovaroMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td>
<td style="text-align: left">%</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A7_zF6eimcGsW12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_c20250701__20250930_zMnSM7fQVBbj" title="Stock-based Compensation description"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" id="Fact000843" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;83,333&#160;shares of
Common Stock from the original&#160;100,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;97,826&#160;shares of Common
Stock of the Company with a per-share exercise price of $6.90. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $185,373&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div id="xdx_23E_zgUn85UXuFu5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zt04OZEcNS3g" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zS2liUfkupMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_234_zOGbmMK9mBsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #212529; background-color: white">In
total, the Company recognized stock-based compensation expense of $<span id="xdx_90D_ecustom--StockbasedCompensationExpense_c20250701__20250930_zRDNhYXk9YXc" title="Stock-based compensation expense"><ix:nonFraction name="RENB:StockbasedCompensationExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,312</ix:nonFraction></span> net a recapture of $127,032 related to options and $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250701__20250930_z353EWRLHNQi" title="restricted option stock awards"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-07-01to2025-09-30" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,973</ix:nonFraction></span>
related to restricted stock awards for the three months ended September 30, 2025. For the three months ended September 30, 2024, the Company
recognized stock-based compensation expense related to options of $</span><span id="xdx_904_ecustom--StockbasedCompensationExpenseRelatedToOptions_iI_c20250930_zDOMNDiwpbEg" title="Stock-based compensation expense related to options"><ix:nonFraction name="RENB:StockbasedCompensationExpenseRelatedToOptions" contextRef="AsOf2025-09-30" id="Fact000851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,648</ix:nonFraction></span>. <span style="background-color: white">At
September 30, 2025, the Company had approximately $<span id="xdx_906_ecustom--UnrecognizedCompensationCost_iI_c20250930_zOwfm5jPxmvk" title="Unrecognized compensation cost"><ix:nonFraction name="RENB:UnrecognizedCompensationCost" contextRef="AsOf2025-09-30" id="Fact000853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,608</ix:nonFraction></span>&#160;of unrecognized compensation cost related to non-vested options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="color: #212529; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000855" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjkhUIGXmatc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_82E_zvLu64xVDt4k">COMMITMENTS AND CONTINGENCIES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#8220;G Tech&#8221;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#8220;HBV License&#8221;) for a treatment under development
(the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV) infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $<span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHjXAZNuFNRf" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zfHKplGnMJZa" title="Royalty percentage"><ix:nonFraction name="RENB:RoyaltyPercentage" contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">2</ix:nonFraction></span>% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUnteZzD23Ib" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember" id="Fact000861" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement during the quarters ending September 30, 2025, and 2024.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G
Tech and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#8220;Development License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $<span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_z3JEQty9Hhwi" title="Up-front payment"><ix:nonFraction name="RENB:UpfrontPayment" contextRef="From2019-11-142019-11-15" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span> and a $<span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zAKQ39BPSdNj" title="Payment for expenditures"><ix:nonFraction name="RENB:PaymentForExpenditures" contextRef="From2019-11-142019-11-15" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,000</ix:nonFraction></span> payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div id="xdx_23B_zbg6Ihu4rUj5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zKXaXyo6jnN7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zej4eiSlED58" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_238_zMdtrwH4qDSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $600,000 and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zg4mD4k8vul7" title="Initial payment"><ix:nonFraction name="RENB:InitialPayment" contextRef="From2022-09-092022-09-10" id="Fact000869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">G Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation.</i>
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
&#8220;Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement that, subject to final approval by the United States District Court for the Central District of California,
provides for resolution of the Securities Class Action Litigation. The Court granted the lead plaintiff&#8217;s motion for preliminary
approval of the settlement on August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation.
</i>On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central
District of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. The parties in the Koenig Matter, the Solak Matter (defined
below), and the Midler Matter (defined below) have entered into a stipulation of settlement that, subject to final approval by the United
States District Court for the Central District of California, provides for resolution of the Koenig Matter, Solak Matter, and Midler Matter
(the &#8220;Koenig-Solak-Midler Settlement&#8221;). On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary
approval of the Koenig-Solak-Midler Settlement with the United States District Court for the Central District of California. The defendants
have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div id="xdx_230_zaDJe0vTSaAd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zyprjFdd7Zad" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zweizoCh4yUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_239_zosSOLB6o3c4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the
United States District Court for the Central District of California. The Solak Matter is stayed pending approval of the Koenig-Solak-Midler
Settlement. The defendants have not yet responded to the complaint. Management is unable to determine the likelihood of a loss, including
a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation.</i>
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. On November 3, 2025,
plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the United States District
Court for the Central District of California. The defendants have not yet responded to the complaint. Management is unable to determine
the likelihood of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div id="xdx_230_zLbK3yt5gNuk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zLbwnw75B91f" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zNZBgaVmJ1Dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative
action in the United States District Court for the Central District of California against certain officers, directors, and investors of
the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science and Wittekind&#8217;s demand for corrective
action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#8220;Derivative
Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange
Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion to dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. On
October 22, 2024, the plaintiffs filed a notice of certain subsequent events that they allege relate to their pending motion to dismiss.
On October 29, 2024, the court granted the director defendants&#8217; motion to dismiss and dismissed the Derivative Complaint without
prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div id="xdx_237_zMPnSWKv5h85" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zYAhI8iRDhB5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zowwHRsB0Qhf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_231_zJtvAO6UUyGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 21, 2024, the Company filed
suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint. A hearing took place on
June 25, 2025, and on November 7, 2025, the Court granted defendants&#8217; motion and dismissed the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai commenced an action against Predictive Oncology, Inc. (&#8220;POAI&#8221;)
in the Delaware Court of Chancery claiming that POAI breached a &#8220;definitive&#8221; January 2025 Letter Agreement pursuant to which
Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition impossible and dramatically devalued the share
price of stock Lunai had already acquired as well as the value of the company it was contractually entitled to acquire. Lunai sought specific
performance or, in the alternative, money damages. The parties have exchanged paper discovery and noticed depositions. The action has
been held in abeyance while the parties attempt to negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000876" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zCEcYsdNQn33" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8&#160;&#8212;&#160;<span id="xdx_827_zhkBkw65VVX7">RELATED PARTY TRANSACTIONS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of September 30, 2025, the Company
has accrued $<span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_z4dfIcMmNdx9" title="Accrued balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-07-012025-09-30_custom_MarkDybulMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,949</ix:nonFraction></span> of compensation related expenses for the Company&#8217;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_znR4ACdnwolj" title="Common stock forfeited shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-08-022024-08-23" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,333</ix:nonFraction></span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zBTPDhQU1z9j" title="Shares of common stock  granted"><ix:nonFraction name="RENB:SharesOfCommonStockGranted" contextRef="AsOf2024-08-23" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zbyDOG3NMfSi" title="Purchase shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-08-222025-08-23" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,826</ix:nonFraction></span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z2JjN2VsOA5k" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-16_custom_RSBioMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.90</ix:nonFraction></span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_90F_ecustom--UnrecognizedCompensationExpense_c20250701__20250930_zaYYR0Gl5ZOf" title="Unrecognized compensation expense"><ix:nonFraction name="RENB:UnrecognizedCompensationExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,373</ix:nonFraction></span>&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div id="xdx_232_zh1WINJyaRG7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zVEw0eGBqkQh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zx8OGPGpzbsg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000891" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zHyfyqBq4SLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 &#8212; <span id="xdx_82C_zRFdcpLCAao7">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the period ending September
30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately
because they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 17%"><span style="font-size: 10pt"><b>Reportable Segment</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; white-space: nowrap; width: 82%"><span style="font-size: 10pt"><b>Description </b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>RENB</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify; white-space: nowrap"><span style="font-size: 10pt">Developing new immunotherapies to combat cancer </span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>BioSymetrics</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>RENC</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the period ending September 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision
maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported
on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On September
2, 2025, the Court of Amsterdam (the &#8220;Court&#8221;) declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;), an indirect subsidiary
of Lunai Bioworks, Inc. (&#8220;Lunai&#8221;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary
petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company
deconsolidated Gedi Cube B.V. due to the loss of control of the subsidiary during the period ended September 30, 2025. As a result of
the deconsolidation, the Company recognized a gain on the bankruptcy of the subsidiary for $<span id="xdx_904_ecustom--GainOnBankruptcyOfSubsidiary_c20250701__20250930_z6Nro9z5IBA" title="Gain on the bankruptcy of the subsidiary"><ix:nonFraction name="RENB:GainOnBankruptcyOfSubsidiary" contextRef="From2025-07-01to2025-09-30" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,019,227</ix:nonFraction></span> during the period ended September
30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000895" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zl3UjjoJCAFg" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8BF_znSclxIs2OVa" style="display: none">Schedule of segment operating loss and
    asset information</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98D_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--US_zoXvK22NSIt5" title="Operating income loss" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_country_US" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,505</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--US_zLMNOtpYM9f" title="Assets" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-09-30_country_US" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,678</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zHxQYfENaOjf" title="Operating income loss" style="text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,951</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zU3bpurJp9vi" title="Assets" style="text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-09-30_custom_BioSymetricsMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,092,985</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--NL_zoh9hc52xkyb" title="Operating income loss" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_country_NL" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,904</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--NL_zELrnKOQL6L4" title="Assets" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98C_ecustom--SegmentOperatingLoss_c20250701__20250930_z3laU0XWcxy2" title="Operating income loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,308,360</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98E_ecustom--SegmentAsset_iI_c20250930_zhYv8k0cAFPj" title="Assets" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-09-30" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,960,663</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

</ix:nonNumeric><p id="xdx_8AA_zLe5xPcSKy9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 1 -->
    <div id="xdx_230_zkonlMqWbAIk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zsGVuo0GyW6i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zsF75FO9HRk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><p id="xdx_23F_ztKrVEWJiYg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Information
regarding each reportable segment for the three months ended September 30, 2025, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000915" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zyp3mTzmvGI9" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zM37Ncm1thJ7" style="display: none">Schedule of information regarding segment reporting</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zQJTAsNXGBv7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zS52jXRMbaIj" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zVDJG83iJ9C1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_492_20250701__20250930_zSJKwiFigb4b" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zFKV4qpZi2Z" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30_custom_RENBMember" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,822,729</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,883</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30_custom_RENCMember" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,904</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,410,516</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_d0_zUHo0UTEE4Rf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_RENBMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,419</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_RENCMember" id="Fact000924" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-01to2025-09-30" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,407</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--LonglivedAssetImpairment_d0_zeYAcMKqhg63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LonglivedAssetImpairment" contextRef="From2025-07-012025-09-30_custom_RENBMember" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,915</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LonglivedAssetImpairment" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203" id="Fact000928" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LonglivedAssetImpairment" contextRef="From2025-07-012025-09-30_custom_RENCMember" id="Fact000929" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:LonglivedAssetImpairment" contextRef="From2025-07-01to2025-09-30" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,915</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_d0_zwmbc9Xuru3a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-07-012025-09-30_custom_RENBMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,442</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,080</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-07-012025-09-30_custom_RENCMember" id="Fact000934" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-07-01to2025-09-30" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,522</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SegmentOperatingLoss_zBctX5wAQC47" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_custom_RENBMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,505</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,951</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-012025-09-30_custom_RENCMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,904</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2025-07-01to2025-09-30" id="Fact000940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,308,360</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zpAWyNEe8O1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><b><span style="text-decoration: underline">Geographic information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#8217;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000942" name="us-gaap:AssetAcquisitionTextBlock"><p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zXMAhFfllGQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8212; <span id="xdx_827_zHzhWO5CDFpl">ACQUISITIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><i><span style="text-decoration: underline">BioSymetrics Inc. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#8220;<span style="text-decoration: underline">Lunai</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#8220;<span style="text-decoration: underline">Merger Sub</span>&#8221;), and Biosymetrics,
Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Biosymetrics</span>&#8221;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#8220;<span style="text-decoration: underline">Transaction</span>&#8221;). On April 8, 2025, Lunai consummated the Transaction and issued <span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z1LDcOJVwUre" title="Transaction issued shares"><ix:nonFraction name="RENB:TransactionIssuedShares" contextRef="AsOf2025-04-08" id="Fact000944" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="Shares">1.5</ix:nonFraction></span> million shares of Lunai&#8217;s
common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_zpOhG5NxifQ5" title="Common stock per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-04-08" id="Fact000946" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The offer and sale of the Shares have not been registered
under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), in reliance on the exemption from registration
requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon representations contained in the Merger Agreement
that all those receiving Shares in connection with the Transaction are &#8220;accredited investors&#8221; as defined in Rule 501(a) under
the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with ASC 805-10 -&#160;<i>Business Combinations</i>. </span>The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zw5pBNuEud2a" title="Fair value of consideration transferred amount"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember" id="Fact000948" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6</ix:nonFraction></span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000950" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zU7KCdvHkyvj" summary="xdx: Disclosure - ACQUISITIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zi98MeJPpdq7" style="display: none">Schedule of acquisition
fair value of the consideration</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zcAs7fAkP0O6" title="Common stock" style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="RENB:BusinessCombinationContingentConsiderationCommonStock" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIBrP5JZi34" title="Total consideration transferred" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2025-02-122025-02-26_custom_GEDiCubeMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A0_zkFmAnTI7vC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 24; Value: 1 -->
    <div id="xdx_234_zm7A5W9gQ3d3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zcQB6R1xxrV9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_znl4AyTCsEHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000957" name="us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_zBQP4KQJ1yF9" summary="xdx: Disclosure - ACQUISITIONS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_ziFGFF2h85L3" style="display: none">Schedule of fair values of the assets acquired and liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zpH20Z6vHkM9" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Cash_iNI_di_zvVIVuF7ayNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,822</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zGMzIm9usq4a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,405</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--FixedAssets_iI_zTRAFjWfK49e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:FixedAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,365</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zz4YiPNvScnl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,948</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUc7o0VpXCe5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zA7iS78FDRMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,594</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_zXfb4WadhM59" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,879</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zQZU0nj1jVvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,448</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_z9RKZtW6plFi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000975" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,500</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr id="xdx_409_ecustom--Software_iI_zQfXg32ElGZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:Software" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--TradeName_iI_zaQaoGbFU818" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="RENB:TradeName" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z14YeUveV2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000981" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_z1Pgjx5WTLM5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact000983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AA_ztcmOgh91ur5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
three-month period ended September 30, 2024. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000985" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zoh8Mp8d3flb" summary="xdx: Disclosure - ACQUISITIONS (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zQwuKaPvkeU5" style="display: none">Schedule of statement of operations</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250225__20250226_zRDLIIuXY5uf" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--BusinessAcquisitionsRevenue_zezObfd0icki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Revenues</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="RENB:BusinessAcquisitionsRevenue" contextRef="From2025-02-252025-02-26" id="Fact000987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,918</ix:nonFraction></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--BusinessAcquisitionsNetIncomeLoss_zq3Loq7qiMTl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:BusinessAcquisitionsNetIncomeLoss" contextRef="From2025-02-252025-02-26" id="Fact000989" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,499,586</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

</ix:nonNumeric><p id="xdx_8A2_zfM9RCw63iG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 25; Value: 1 -->
    <div id="xdx_23F_z3q507OsR6Wb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_z90S9GnG8APe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zeo879kNQpi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zUtirRDeLeI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact000993" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z2o6wJjOvO0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 &#8212; <span id="xdx_824_zraXJ1wSCrv8">SUBSEQUENT EVENTS </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 4, 2025, the Company
issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUnlgD23PCRk" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-11-032025-11-04_us-gaap_SubsequentEventMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztf0pFwe4Ohh" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-11-032025-11-04_us-gaap_SubsequentEventMember" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,680</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 30, 2025, the Company
cancelled<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251030_zYjA3IOtShdj" title="Issuance of common stock shares">&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-10-282025-10-30" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Common Stock upon termination, previously issued to the former Chief Executive Officer of Renovaro Cube
valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251030_zWn2Jhb6rB6" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-10-282025-10-30" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,500</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 29, 2025, the Company
issued&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zByHRN2FL6M8" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-10-282025-10-29_custom_SettlementAgreementMember_us-gaap_SubsequentEventMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">237,500</ix:nonFraction></span>&#160;shares of Common Stock pursuant to a settlement agreement valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember_zqLmYbWR24O6" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-10-282025-10-29_custom_SettlementAgreementMember" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 17, 2025, the Company
issued&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zPkPZBh1ZFae" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-162024-10-17" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251016__20251017_zozyEjy2Lrcd" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-10-162025-10-17" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span>.</p>

</ix:nonNumeric><p id="xdx_813_zut6PbrxnuB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Forward-Looking Statement Notice </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Certain statements made in this
Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; (within the meaning of the Private Securities Litigation Reform
Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance, or achievements of Lunai Bioworks Inc. (&#8220;Lunai,&#8221;
and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included
herein are based on current expectations that involve numerous risks and uncertainties. Our actual future results and trends may differ
materially depending on a variety of factors, including, but not limited to, the risks and uncertainties discussed in Part I, Item 1A,
&#8220;Risk Factors&#8221; in our Annual Report on Form 10-K as filed with the SEC on September 29, 2025. The Company&#8217;s plans and
objectives are based, in part, on assumptions involving the continued expansion of the business. Assumptions relating to the foregoing
involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions,
all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company
believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and,
therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light
of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should
not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">As of
September 30, 2025, Lunai Bioworks Inc. operates through two subsidiaries, Renovaro Biosciences and BioSymetrics. BioSymetrics refers
to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. During the quarter ended
September 30, 2025, GediCube, B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. As a result, beginning
in the second quarter of 2026, the Company will no longer report on its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Biosciences Overview</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers,
and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Therapeutic Technologies</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences aims to train
the immune system to allow a person to better fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with
healthy longevity, and free from toxic chemotherapy, for those with cancer and other serious diseases. Renovaro Biosciences will seek
to leverage general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote
the recognition and elimination of disease cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="text-decoration: underline">Allogeneic Cell Therapy </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The strategic benefit of the allogeneic
cell therapy technologies is to potentially allow for the manufacture of large, &#8220;off-the-shelf&#8221; banks of therapeutic cells
that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="text-decoration: underline">Gene Therapy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Renovaro Biosciences may also seek
to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of the patient&#8217;s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no
risk of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the
host immune system. Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient&#8217;s immune
system therefore will have a very short survival time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Biosciences Focus Areas:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">Oncology:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-DC11: Genetically modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors; specifically Pancreatic tumors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Allogeneic Cell Therapy Platform
&#8211; Completed pre-IND, IND-enabling phase.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Based
on learnings from our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune
modulation, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission
from some of the deadliest solid tumors such as pancreatic, liver, triple negative breast and head &amp; neck cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The platform
may one day enable broad immune enhancements that are combined with cancer specific antigens that could be applicable to a wide range
of solid tumors. This approach allows us to quickly adapt our approach to any patient solid tumor using the same banked allogenic drug
substance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-DC20: Genetically modified Allogeneic Dendritic
Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of Triple Negative Breast Cancer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Triple Negative Breast Cancer (TNBC)
is a subtype of breast cancer that is negative for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human epidermal
growth factor receptor 2 (HER2). TNBC is characterized by its unique molecular profile, aggressive nature, and distinct metastatic patterns
that lack targeted therapies. TNBC is well known for its aggressive behavior and is characterized by onset at a younger age, high mean
tumor size, and higher-grade tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Based upon our internal research,
literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we believe we may have
the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some of the deadliest and
hard-to-treat solid tumors that include triple negative breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">Infectious Diseases:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span style="text-decoration: underline">RENB-HV12: Genetically Modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of HIV; A Chronic Infectious Disease</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The oncology therapeutic vaccine
technology could potentially be adapted to target infectious disease antigens and be a viable therapeutic approach in difficult to treat
chronic infectious diseases. As described above, the engineered allogenic dendritic cell drug substance is thought to be able to be loaded
with various cancer antigens for specific solid tumors but could or may be loaded with infectious disease antigens to elicit a more robust
immune response to viruses and other difficult to treat infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BioSymetrics Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">BioSymetrics is a biomedical artificial
intelligence company focused on integrating multimodal data sources, including genomics, imaging, electronic health records, and other
real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. BioSymetrics has developed proprietary
machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. These
insights are designed to support pharmaceutical research, early disease detection, and personalized treatment strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">BioSymetrics collaborates with
pharmaceutical companies, healthcare providers, and academic institutions to co-develop analytical tools and translational research programs.
Application areas of the BioSymetrics platform include: (i) multi-omics integration for target identification and validation; (ii) predictive
modeling of therapeutic efficacy and safety; (iii) clinical trial optimization, including patient stratification and response monitoring;
and (iv) experimental screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The key to the BioSymetrics approach
is Contingent AI. In Contingent AI, any &#8220;settable&#8221; parameter for data processing, data integration, or feature selection is
permuted and the corresponding effects on the downstream predictive model measured. This process is similar in nature to hyperparameter
tuning in machine learning, however instead of optimizing only the machine learning model, the entire data science pipeline (including
model selection) is subject to optimization. We have applied this method extensively in drug discovery, producing marked improvements
in experiment interpretation and lead generation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_001.jpg" alt="A diagram of a process&#10;&#10;Description automatically generated" style="height: 260px; width: 463px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="Shape&#10;&#10;Description automatically generated" style="height: 165px; width: 143px"/><br/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">Another
major component of BioSymetrics&#8217; platform is the Phenograph. The Phenograph<sup>TM</sup> is BioSymetrics&#8217; proprietary knowledge
graph. The purpose of the Phenograph<sup>TM</sup> is to map human genes and phenotypes to those of model systems, allowing <b>virtual
phenotypic screening</b>, target nomination, and active learning feedback. The Phenograph<sup>TM</sup> contains 5,856 diseases associated
with one or more phenotypes in humans, and 16,676 human genes with one or more orthologous zebrafish genes. Zebrafish genes are mapped
to phenotypic terms using over 300 individually-trained machine learning models, that fill in the gaps of known gene-phenotype associations.
Leveraging this platform, we can prioritize human genes on the basis of predicted experimental phenotype, reducing the number of required
experiments to produce human-informed <i>in vivo</i> disease models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Finally, one important component of the BioSymetrics platform is that it couples AI-based prediction
with experimental validation. BioSymetrics has designed deep learning-based computer vision software that automatically identifies and
characterizes organ systems relevant to neurological, cardiovascular, and muscle development (<b>Figure below</b>). Additionally, BioSymetrics
has developed a proprietary light stimulus battery and characterized a small number of known CNS therapeutics and unknown compounds, providing
an initial basis for evaluation of chemical effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_001.gif" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 18.85pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>A large-scale behavioral profiling
platform for identification of neurotherapeutics.</b> (A) 96-well plate containing 8 zebrafish larvae per well, as used for behavioral
profiling. (B-C) Line plots showing activity over time for 48 replicate wells focusing in on a small (5 min) part of the behavioral profile.
Unlike control wells (B), drug-treated wells (C) show much higher activity levels. (D-H) Example profiles for 5 different reference compounds
showing the average behavioral profiles for control and compound-treated wells (n= 4 wells; orange and blue lines, respectively). Note
that each of the 5 compounds causes a distinct behavioral profile. (I) Examples of morphological segmentation. Colored micrographs of
laterally oriented zebrafish larvae show computer-vision-based organ segmentation using trained ML classifiers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In prior work, we leveraged our
motion profiling capabilities to identify novel neuroactive compounds capable of resolving epilepsy-related phenotypes. Specifically,
we screened 1400 compounds from a proprietary small molecule library both with and without addition of a chemical convulsant. The experimental
component of this screen was completed by one technician in 10 days, giving us an approximate pace of 1,000 compounds screened per technician
per week. This study resulted in identification of a hit compound that later showed efficacy in a mouse seizure model, now being further
progressed as a potential therapeutic by BioSymetrics. Additionally, during the course of this study we screened approximately 100 known
neuroactives, including clinical anticonvulsants, antidepressants, antipsychotics, and dopaminergic signaling activators and inhibitors.
This study produced two key observations that are critical for this application. The result is both an experimental platform and coupled
computational model that can identify both neurotherapeutics and neurotoxins, the former through direct experimental screening, and the
latter through machine-learning based prediction based on chemical structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We next examined the ability of
one of these compounds (BioS_831) to resolve seizures in a murine model using a previously established electroshock seizure assay. Briefly,
after dosing each mouse with either BioS_831, negative control (vehicle), or positive control (Sodium Valproate), electroshock is delivered
transauricularly using stimulation at 50 Hz and 50 mA for 0.8 seconds with a pulse width of 10 milliseconds. The total number of hind
limb flexes, hind limb extensions, and mortality rate is monitored for 60 seconds following electroshock, as are other adverse events.
We screened BioS_831 at both a low and high dose and found that at 40 mg/kg of BioS_831 significantly increased latency time to tonic
seizure induction and significantly reduced the number of observed tonic extension seizures, as compared to vehicle control. Notably,
unlike the ASM Sodium Valproate, BioS_831 did not cause sedation or ataxia. Sodium Valproate (VPA) while effective in this model at this
concentration, results in high levels of neurotoxicity, and has been associated with multi-organ failure, underscoring the importance
of not observing negative neurological effects with our novel compound. Post-study PK analysis showed good distribution of BioS_831 into
the brains of the test animals (average brain to plasma ratio 0.68). Since the electroshock seizure model is not based on seizure induction
through hypofunction of KCC2, these findings suggest that our zebrafish epilepsy primary screening model is capable of identifying novel
compounds that show translation to mammalian generalized epilepsy models and suggest that BioS_831 could further be optimized as a potential
anti-epileptic therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Additionally, during the course
of this study we screened approximately 100 known neuroactives in our zebrafish model including clinical anticonvulsants, antidepressants,
antipsychotics, and dopaminergic signaling activators and inhibitors. The result is both an experimental platform and coupled computational
model that can identify both neurotherapeutics and neurotoxins, the former through direct experimental screening, and the latter through
machine-learning based prediction based on chemical structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">BioSymetrics intends to expand the use of its platform
across the biopharmaceutical and healthcare markets. The company is developing its technology in compliance with applicable healthcare
data privacy regulations, including HIPAA and GDPR, and is focused on building AI solutions that address the growing demand for robust,
transparent, and reliable applications of artificial intelligence in life sciences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions, and improvements to inventions that we consider
important for the development of our business. We rely on a combination of patent, copyright, trademark, and trade secret laws, as well
as continuing technological innovations, proprietary knowledge, and various third-party agreements, including, without limitation, confidentiality
agreements, materials transfer agreements, research agreements, and licensing agreements, to establish and protect our proprietary rights.
We aim to take advantage of all of the intellectual property rights that are available to us and seek the protection of those rights so
that we can fully exploit our innovations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We also protect our proprietary
information by requiring our employees, consultants, contractors, and other advisors to execute nondisclosure and assignment of invention
agreements upon commencement of their respective employment or engagement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We were incorporated under the
laws of the State of Delaware on January 18, 2011, under the name Putnam Hills Corp. and in 2014 we merged with and changed our name to
DanDrit Biotech USA, Inc. In 2018, we acquired Enochian Biopharma and changed our name to Enochian BioSciences Inc. In August 2023, the
Company changed its corporate name to Renovaro Biosciences Inc. On February 13, 2024, the Company changed its corporate name to Renovaro
Inc. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries, in which Renovaro Cube became a wholly-owned
subsidiary of Renovaro Inc. On April 8, 2025, the Company acquired BioSymetrics, Inc. and its subsidiary, as a wholly owned subsidiary.
On August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Going Concern and Management&#8217;s Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations. As of September 30, 2025, the Company had cash and cash equivalents of $624,808 and an accumulated deficit
of $507,643,549 and a working capital deficit of $18,922,114. These conditions raise substantial doubt about the Company&#8217;s ability
to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management has reduced overhead
and administrative costs by streamlining the organization to focus around the development and validation of its AI-driven cancer diagnostics
platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to secure additional required
funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding.
Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions,
could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our
cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material
adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least
until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy
protection or other alternatives that could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Results of Operations for the Three Months ended September 30, 2025
and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth
our revenues, expenses and net income, loss for the three months ended September 30, 2025 and 2024. The financial information below is
derived from our unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,410,516</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,301,251</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">(2,890,735</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 10%; text-align: right">(55</td>
<td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Research and development</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">24,407</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">390,189</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(365,782</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(94</td>
<td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Goodwill impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">47,614,729</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(47,614,729</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(100</td>
<td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">100</td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">41,522</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">32,385</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">9,137</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">28</td>
<td style="padding-bottom: 1pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">3,308.360</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">53,338,554</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(50,030,194</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(94</td>
<td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(3,308,360</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(53,338,554</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">50,030,194</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(94</td>
<td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expenses)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">370,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">9,250,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(8,880,000</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(96</td>
<td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of equity securities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">156,849</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">156,849</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">100</td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Gain on bankruptcy of subsidiary</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">12,019,227</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">12,019,227</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">100</td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(6,329,592</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(6,329,592</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(100</td>
<td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest expense</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(122,400</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(250,080</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">127,680</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(51</td>
<td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest income and other income (expense)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">33,297</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">126,598</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(93,301</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(74</td>
<td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">6,127,381</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">9,126,518</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(2,999,137</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(33</td>
<td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET INCOME (LOSS)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">2,819,021</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(44,212,036</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">47,031,057</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(106</td>
<td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Expenses </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our operating expenses for the
three months ended September 30, 2025 and 2024, were&#160;$3,308,360 and $53,338,554, respectively, representing a decrease of $50,030,194,
or approximately 94%. The decrease in operating expenses primarily relates to the decrease in goodwill impairment of $47,614,729 and by
the decrease in&#160;general and administrative expenses of $2,890,735, partially offset by the impairment of fixed assets and right of
use assets of $831,915 due to no longer using assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; color: #212529"><span style="background-color: white">General
and administrative expenses for the three months ended September 30, 2025, and 2024, were $2,410,516 and $5,301,251, respectively, representing
a decrease of $2,890,735 or approximately 55%. The variance is primarily related to a decrease in consulting fees of $1,576,761, legal
expenses of $899,802 and compensation and related expenses of $205,381. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Research and development expenses
for the three months ended September 30, 2025, and 2024, were $24,407 and $390,189, respectively, representing a decrease of $365,782
or approximately 94%. The variance is primarily driven by a decrease of $346,100 in consumables and reagents used in discontinued product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="color: #212529; background-color: white">The
Company recorded other income of $6,127,381 for the three months ended September 30, 2025, compared to other income of $9,126,518 for
the three months ended September 30, 2024, representing a decrease in other income (expense) of $2,999,137 or 33%. The variance is primarily
due to</span> the decrease in fair value of contingent consideration of $8,880,000 and loss on extinguishment of debt of $6,329,592, partially
offset by the gain on the bankruptcy of Gedi Cube B.V. of $12,019,227.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Income (Loss) </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net income (loss) for the three
months ended September 30, 2025, and 2024, was $2,819,021 and $(44,212,036), respectively, representing a decrease in net loss of $47,031,057
or approximately 106%. The decrease in net loss was primarily due to the decrease in goodwill impairment of $47,614,729 in the prior period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We have historically satisfied
our capital and liquidity requirements through funding from stockholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations, and we expect this to continue until our therapies or products are
approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be
profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As noted above under the heading
&#8220;Going Concern and Management&#8217;s Plans,&#8221; through September 30, 2025, we have incurred substantial losses. We will need
additional funds both in the next twelve months and beyond for (a) research and development, (b) increases in personnel, (c) the purchase
of equipment, and investment in the development and validation of our technology. The availability of any required additional funding
cannot be assured. In addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in the future
may be involved could adversely affect our liquidity and financial position. We may raise such funds from time to time through public
or private sales of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure
to raise capital when needed could materially adversely affect our growth plans and our financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of September 30, 2025, the Company
had $624,808 in cash and working capital deficit of $18,922,114 as compared to $92,700 in cash and working capital deficit of $28,109,502
as of June 30, 2025, an increase of 574% and decrease of 33%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total assets at September 30, 2025,
were $6,960,663 compared to $8,230,840 as of June 30, 2025. The decrease in assets is primarily due to the impairment of operating lease
right-of-use assets of $687,371, amortization of prepaid assets of $390,529, partially offset by the increase of cash of $532,108 in the
current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Liabilities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total liabilities at September
30, 2025, were $20,001,437 compared to $29,580,681 as of June 30, 2025. The decrease in total liabilities was primarily related to the
decrease of $7,285,741 in notes payable &#8211; related parties, $974,383 in accrued expenses, $461,411 in accounts payable, $370,000
in contingent consideration liability and $306,853 in other current liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following is a summary of the
Company&#8217;s cash flows (used in) or provided by operating, investing, and financing activities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months <br/> Ended <br/> September 30,<br/> 2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months<br/> Ended <br/> September 30,<br/> 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net Cash Used in Operating Activities</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(1,349,110</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(2,016,328</td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Provided by Investing Activities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">544,700</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Provided by Financing Activities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,343,357</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,029,183</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Effect of exchange rates on cash</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(6,839</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(12,751</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in Cash and Cash Equivalents</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">532,108</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">104</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The decrease in our cash used in
operating activities is primarily related to the changes in our operating assets and liabilities. The change is primarily driven by our
net income offset by significant non-cash charges such as stock-based compensation, impairments and change in fair value of contingent
consideration. Additionally, our operating cash flow was positively impacted by changes in our operating assets and liabilities, primarily
other receivables, prepaid expenses and accounts payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash used provided by investing
activities during the period related to proceeds from the sale of equity securities of $544,700.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash provided by financing activities
during the period primarily related to net proceeds of $1,343,357 from issuance of $1,615,000, net of $18,495 placement costs, in notes
payable that were partially offset by $271,643 in repayment of a finance agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Arrangements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on the Company&#8217;s financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Significant Accounting Policies and Critical Accounting
Estimates </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The methods, estimates, and judgments
that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some
of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding
matters that are inherently uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For a summary of our accounting
policies, see Note 1 to the unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span>Item 3. Quantitative and Qualitative Disclosures
About Market Risk. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As a &#8220;smaller reporting company&#8221;
as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this
Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_011"></span>Item 4. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Chief Executive Officer and
Chief Financial Officer (the &#8220;Certifying Officers&#8221;) are responsible for establishing and maintaining disclosure controls and
procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material information
is made known to them, particularly during the period in which this Report was prepared.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Certifying Officers are responsible
for establishing and maintaining adequate internal control over financial reporting for the Company and used the &#8220;Internal Control
over Financial Reporting Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations (&#8220;COSO&#8221;) to conduct
an extensive review of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in the Exchange Act, Rules 13a-15(e)
and 15-d-15(e)) as of the end of each of the periods covered by this Report (the &#8220;Evaluation Date&#8221;). Based upon that evaluation,
the Certifying Officers concluded that, as of September 30, 2025, our disclosure controls and procedures were not effective in ensuring
that the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as
amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. The deficiency is attributed
to the Company not having adequate resources to address complex accounting matters. This control deficiency will be monitored, and attention
will be given to this matter as we grow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Certifying Officers based their
conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed above. We expect
to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate internal accounting
staff.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Changes in Internal Controls </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There have been no changes in our
internal controls over financial reporting during the three months ended September 30, 2025, that have materially affected or are reasonably
likely to materially affect our internal controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_012"></span>PART II &#8212; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_013"></span>Item 1. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation.</i>
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
&#8220;Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement that, subject to final approval by the United States District Court for the Central District of California,
provides for resolution of the Securities Class Action Litigation. The Court granted the lead plaintiff&#8217;s motion for preliminary
approval of the settlement on August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation.
</i>On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central
District of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. The parties in the Koenig Matter, the Solak Matter (defined
below), and the Midler Matter (defined below) have entered into a stipulation of settlement that, subject to final approval by the United
States District Court for the Central District of California, provides for resolution of the Koenig Matter, Solak Matter, and Midler Matter
(the &#8220;Koenig-Solak-Midler Settlement&#8221;). On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary
approval of the Koenig-Solak-Midler Settlement with the United States District Court for the Central District of California. The defendants
have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the
United States District Court for the Central District of California. The Solak Matter is stayed pending approval of the Koenig-Solak-Midler
Settlement. The defendants have not yet responded to the complaint. Management is unable to determine the likelihood of a loss, including
a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation.</i>
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. On November 3, 2025,
plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the United States District
Court for the Central District of California. The defendants have not yet responded to the complaint. Management is unable to determine
the likelihood of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science
and Wittekind&#8217;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#8217;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 21, 2024, the Company filed
suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint. A hearing took place on
June 25, 2025, and on November 7, 2025, the Court granted defendants&#8217; motion and dismissed the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai commenced an action against Predictive Oncology, Inc. (&#8220;POAI&#8221;)
in the Delaware Court of Chancery claiming that POAI breached a &#8220;definitive&#8221; January 2025 Letter Agreement pursuant to which
Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition impossible and dramatically devalued the share
price of stock Lunai had already acquired as well as the value of the company it was contractually entitled to acquire. Lunai sought specific
performance or, in the alternative, money damages. The parties have exchanged paper discovery and noticed depositions. The action has
been held in abeyance while the parties attempt to negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_014"></span>Item 1A. Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As a &#8220;smaller reporting company&#8221;
as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this
Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">On July 7, 2025, the Company issued 5.36 million shares
of common stock, valued at $16.1 million upon the conversion of convertible notes (see Note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_016"></span>Item 3. Defaults Upon Senior Securities. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_017"></span>Item 4. Mine Safety Disclosures. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_018"></span>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Insider Trading Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_902_eecd--MtrlTermsOfTrdArrTextBlock_c20250701__20250930_zapmNprZyFh7"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" escape="true" id="Fact001010" name="ecd:MtrlTermsOfTrdArrTextBlock">During the quarter ended September
30, 2025, no director or Section 16 officer <span id="xdx_90B_eecd--Rule10b51ArrAdoptedFlag_dbT_c20250701__20250930_zP271nqHp1w2"><span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20250701__20250930_z1it0bUSHWma"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact001011" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact001012" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>, modified, or <span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zmMAfAgk6U0a"><span id="xdx_902_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zKqdvKEKxPtg"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact001013" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-07-01to2025-09-30" format="ixt:booleantrue" id="Fact001014" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule
10b5-1 trading arrangement&#8221; (in each case, as defined in Item 408(a) of Regulation S-K).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_019"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibits required by Item 601 of Regulation S-K:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 7%"><span style="font-size: 10pt">Exhibit&#160;No.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 92%; text-align: justify"><span style="font-size: 10pt">Description </span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;2.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_ex2-1.htm"><span style="font-size: 10pt">Agreement and Plan of Merger, dated February 26, 2025, by and among Renovaro, Inc, Renovaro Acquisition Sub and Biosymetrics, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed with the SEC on February 28, 2025)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">3.1 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000248/e5415_ex3-1.htm"><span style="font-size: 10pt">Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 10-Q filed with the SEC on February 14, 2024)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000883/e5703_ex3-1.htm"><span style="font-size: 10pt">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to Form 8-K filed with the SEC on May 24, 2024)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1&#8224;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000258/e6372_ex10-2.htm"><span style="font-size: 10pt">Employment Agreement by and between Nathen Fuentes and Renovaro Inc., dated as of January 6, 2025. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q filed with the SEC on February 19, 2025)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-1.htm"><span style="font-size: 10pt">Form
of Exchange Agreement (incorporated herein by reference to Exhibit 99.1 to Form 8-K filed with the SEC on July 9, 2025)</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">31.1**</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="e7036_ex31-1.htm"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934&#160;</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">31.2**&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="e7036_ex31-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934&#160;</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">32.1***</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="e7036_ex32-1.htm"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">32.2***</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="e7036_ex32-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.INS </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.SCH </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.CAL </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.DEF </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.LAB </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.PRE </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top; background-color: transparent">
    <td style="width: 29px"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: transparent">
    <td><span style="font-size: 10pt">***</span></td>
    <td><span style="font-size: 10pt">Furnished herewith. </span></td></tr>
  <tr style="vertical-align: top; background-color: transparent">
    <td><span style="font-size: 10pt">&#8224;</span></td>
    <td><span style="font-size: 10pt">Denotes a management contract or compensatory plan or arrangement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_020"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: November 14, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>LUNAI BIOWORKS INC. </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ David Weinstein</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">David Weinstein </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Nathen Fuentes</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Nathen Fuentes</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e7036_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>OFFICER&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, David Weinstein, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the period ended September 30, 2025, of Lunai Bioworks Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a)&nbsp;Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b)&nbsp;Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c)&nbsp;Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d)&nbsp;Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a)&nbsp;All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b)&nbsp;Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;Date: November 14, 2025</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt"><I>/s/ David Weinstein</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">David Weinstein</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer<BR>
(Principal Executive Officer) </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e7036_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OFFICER&rsquo;S CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Nathen Fuentes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the period ended September 30, 2025, of Lunai Bioworks Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a&nbsp;material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a)&nbsp;Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b)&nbsp;Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c)&nbsp;Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our&nbsp;conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d)&nbsp;Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a)&nbsp;All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b)&nbsp;Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: November 14, 2025</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt"><I>/s/ Nathen Fuentes</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Nathen Fuentes</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e7036_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of Lunai Bioworks
Inc. (the &ldquo;<U>Company</U>&rdquo;) on Form 10-Q for the period ended September 30, 2025 as filed with the U.S. Securities and Exchange
Commission on the date hereof (the &ldquo;<U>Report</U>&rdquo;), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: November 14, 2025</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt"><I>/s/ David Weinstein</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">David Weinstein</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer<BR>
(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the
Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>e7036_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of Lunai Bioworks
Inc. (the &ldquo;<U>Company</U>&rdquo;) on Form 10-Q for the period ended September 30, 2025, as filed with the U.S. Securities and Exchange
Commission on the date hereof (the &ldquo;<U>Report</U>&rdquo;), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: November 14, 2025</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt"><I>/s/ Nathen Fuentes</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Nathen Fuentes</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer <BR>
(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the
Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ <\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"*]R+^XY_Y
M:-_.H1GUJ>]_Y"%Q_P!=&_G40KZA;'YV]V*,^M.7/K2 4X"AAY"C/K3AGUH
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M*]C2_F_(W5N+=E=A<1%4.'(<87Z\\4?;;030Q?:8=\P)C <?.!UQZUBOI-W
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M H%. I#L&*<!0!3@*12$Q3@**<!0-"8IV!1BG8I,H0"E 'I2TN*0[#<"C%/
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M@_Y^9?KY8Q_.M-(?;K4OD<=*;Q%1A' 44M5<P9='EQFWE2;_ &<;6_(]:S)
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MX9OHC*^RRW7,%U%(JL0(#*VX;..0.AZ=2:EB\-WD=S&G^AF$7D5VUSD^<I1
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M_P"=+_9T'J_YT44^9C=./8&TZ$=W_.F-I\..K_G1134F9^SCV(CIT/\ >?\
M.HVTV#^\_P"8HHI\S'[./8:=-@_O/^8J>RTV$7:8:3OW'I]***ER=BHTXW6A
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "E (\# 2(  A$! Q$!_\0
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0];*Z<80DXKJ<F*DVU<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EAK ++ ?<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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M@ PBD>.&5.'_HT6 J!'-B 0;&9 =J1$?N4[GII!J=V] )&DN^7B947UM1XI
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M_EA^)/ 70 FA"SH5&;*9^LA3'21%MTEEDU=<V(8G'N=WIHF3'QIX(9HZY <
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M@J$" CS A4' BP' !KP"); 8U1O U&N]?DBZ@5*?VUNV^'D2WQN^2"L1 1
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MRCPEZM?1X:Q^ZMCQ)(#@'J[.!=>QU+$.K YW>H;1KN_Z/1E(YX@LKU/, @B
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M@8_W'*29L&=3023E>6TUDT##HYNMR8 \<S5J VBR ADA9Z L& MK3A-(%1B
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M*WAAO.1-I(YPNV7\D"4\%SE-6_H\'\OI@<TU462M2(+!LY 'J5O#LYY)4P+
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M7_.SWK'0"U98L>\MBQA@!5%D72X@&H88%XY802N (77L@JL;$5!4W_G=FT
MK!*.7Q3>N?I-8&=)8.Y,F .68;QY4BH4C L;X,*YL!F.WA>>N&+AWNQ5#[+X
M*EGHPU4@X@N& JM#&,/H8._!WO6P LOU09Y@7Q,F"S1-81)VBQ=V81\F6//4
M.!XNV/_]_5\'P0R*S>$,X1#".Y5# 6._PY+%V-[-Q3NR@)G&K6 E!@"-*@G
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MSQSX3U3@94X2B1T;FLY<J(XZ1A0^G*",:@44,\'$T*'LT,PB3N(P,P#(Q4=
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MK5R9,:,+H"M4I[)8\02*GI$ 2#PA>53&C!Q;W<I8T5!&CAQ<8CB<>J4+6+D
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M44(IFND>4\4D@(@MR1QP&+-\A050H(,.E=>61(\+*>]=B*-\K7#U)"]Y*C#
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M-MBF3_#L@Z#@79J.UJTN86%;1T,:'[# PD%A:6E(05YAL->AM)U+?!X*!/C
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ML=<%7" F#B<F5^ %W$)-OH,MR.9[8\5B ZAR>Y. /OB#Z8-?!F!S#3@0E45
M$CB!$-A I'% ;W*!GK59&_AY&T@G$J-;)>AYH2=Z:M-^L&<(AC!_7&!V#L(%
M9L@%8B &80AL7\)"Q,5"_J<MOA.'<2@(VE)R5T" 32$Y0-B'?O@I F0UY@8
M+% R'&,FPI(ER-0%(H<C%U@=54A':G-Q&%=KE%AV*@A_8S &9L<%:^AP-W(E
MGOC_B?$':';W!8/P!:B(@_V'+5^ ;/['2&BEATN19']XBPBX@&DC1$=1B*1#
M)4&V*\'288^X)@G&)CP#)SY2<#AB=H-V(X,&")]H"&=HAJ08;*2HAH<@!ES
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M!84(?2Z<S=J\S48YFWS1HOTYJQ7G(*^C%S(0,,3*@[F!. \<R!0KLD[KRTY
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M/ %^#7FWL9SQN#6][;B%9/A"2[:8M[+NA<E<V)-9^6JCL](U*&QW$PCKX :
MOFGP9><33)(H(A28I$8A\TK_X5Y (K^FV<^&I]*=QR)F,-@!CUO68(4UMG9
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MB$%I#=., KG]B+ATM5(].$T]4#2 #-?5TS.-G*46/"^(%$X.?;G!3"J^3-(
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MA1M>G#5%'4Z8F;;F5UDIE5MLH=$$'%\S[07JME -6)MTFJ$7V8#BVMK>;4X
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M*[PB+;XB*S1@E5A!+>XB*\I@TU@!(N#B"HB<2H342H1@ .(BT\A  /(@.ZW
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MS' $%,1,'43!@GXIF(+B_YGIF:(I"0$>?=*BG)J2A@XKL1I("<QHL2:K@LC
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M:+^/+!XD8>6&0<)'WYH0X#ZM8J66<BM72DXV%_G,8YMI!5"R&5_G[A*3(
M=#654TNW?,TW(DRV=M2"=9V'1_8"9ND'DVY.?N,W->TW=B6(2\$T1,L-EG;7
M;T$13GTV@ TW(<D"@RA(1*R "P*A:N^%$6 !%D2(Q2[# %0 !JRD>L-USW8%
MFD12<PD""SW7($ WX\[WA%$XL!AB7:EB==G_]X4+PGW/J4&.,A!3U6T#$7\S
M2;JJX F(#4P%$H!IU&C9%+8L-/R^ A"XH"J6>$28F+X<V)<^2'4PPX)1"*]\
MDC^[5;'$\!HB+T&,,3]-F 2>((7-^(33E877%X;9F$IH1%75Z7[G0I%*=6[=
ME@,_PS-F5"#CM"'+TH@!H12;%1"Z8(E3K N<&,:@N!;=+:,N P8L.&L#YG)I
MC;$.K@LC#VPOPB#NPTI4@'S/.)3)%O/4V(7;^)2%)X9YQ'TJ['[H-4%683.M
MX%H<] .U;0YE[3.BDV]+E&>!N.O8KNRNX)!3C"U 8S.:A%]"(RF&B\$H^7HI
M,VWO,V$.*VM9BEP#_\R:1+E)25F#&<R443F<2\8OU@(O7'5,)VA%3/5?U@).
M/_%G>9;K7@G[,(J8N\ *9 #(5.BN4*B?^WF83B:RGIF#L9G M!D -%4/"CJ&
M%IHA0/FEQG:;NY7FU!><Q?FB>><O=F0N_()U$8G8H"^(^3@4)X@L)FB!RT[%
M\!F5O;FAF:N#96=0#L*'R_B;#..3"V9\;<HP7%JBE4FYLBD<X[5MB;JHC?J-
MJZ*<Z<)&2$2"C&5O>9GKS.=5NR 0G+B97[BE)76#GZD!2^.AG8FF/]E*<B-T
M5> )]O*E".FA0[>EI 2L0[FG$T:H5170C/JNV=.)A_HN1&0/0N3U\-J&?_]X
M9Z%:6%\U$%+,B2]:J[>V0#F/#B-U=D!%4WOX"<BXIE6#C"O[H%F*!"K;LHL"
MM+E)4ZM"M'<LHI5)KHLB &MG+2P:HS%Z7&&[>9[ ,_24+8<W%#>-01!91&;@
M*C":L3%7M8<*"OJ2N)NB*::B,,[Z+]1BM6>*4\D81BL[K9U)BXKBDQ%IK,EX
MFE^(*M['KA ZP7#*8(":))";]6['OV9[M@MC!62[D#(:,-Z[-.I;E54YOJF$
MOJO@AX,WG=G";(1G=V!8N*_7NY])D ;B+R0[IP:%,"Z[OT&;X JBA^%;KU3
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M:-URWK8^-?T7M?G3H7YN=+*["]1?%WKQXG3T1UMW 3RN=VFE8 T+:#G_K+"
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MIQUO4;(4F'7!.1'.:,(DT-<0O=;"389P2!J]$;@S7&EQT=<F_&+W!H>IW&/
MS%F!VU<J0!IQN-"*F&,I^WLNRJ=ZV4>0G=)P,7;"#!K4B]G'+!$XEAFB_5HZ
MW=GC1M/_1[3%.06* =QU,S:E:;S:K4FZ6/F0[ S;#PRJE-.55P6P71D-7+F
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M5%()B3\X(WX3$)%R TN%=9';<V..M;II.I2P[;&@1*.CMJ ##ICU49*'!2
M1WMBD,&9>(1UA911HO7%M?XD:R$C!SI6Q4HK!%K2RJH[LD:OABU!P0 8BB[G
MDQ,T"N,G:"K!)3DIHHNM<R,$ZZ&!X$MV)_NJ<$NJ"&>$3Z#Y,/O/U:Y<[BD
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/9U_[V^=^][W_?<T&!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>renb-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaGHubPtxZ97WekhsmR/bYkKfyMvcXOfWy93eGlmwV0F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:RENB="http://renovarobio.com/20250930" elementFormDefault="qualified" targetNamespace="http://renovarobio.com/20250930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://renovarobio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" id="CondensedConsolidatedStatementsOfOperationsunaudited">
          <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" id="ConsolidatedStatementsOfComprehensiveLossunaudited">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" id="ConsolidatedStatementOfStockholdersEquityDeficit">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" id="CondensedConsolidatedStatementsOfCashFlowsunaudited">
          <link:definition>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999014 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999015 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
          <link:definition>999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Debt" id="Debt">
          <link:definition>999017 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999018 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999020 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999021 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Acquisitions" id="Acquisitions">
          <link:definition>999022 - Disclosure - ACQUISITIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
          <link:definition>999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999028 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsTables" id="AcquisitionsTables">
          <link:definition>999029 - Disclosure - ACQUISITIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999031 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
          <link:definition>999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
          <link:definition>999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
          <link:definition>999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" id="IntangibleAssetsAndGoodwillDetails">
          <link:definition>999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" id="IntangibleAssetsAndGoodwillDetails1">
          <link:definition>999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
          <link:definition>999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999038 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
          <link:definition>999039 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999040 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
          <link:definition>999043 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails1" id="SegmentReportingDetails1">
          <link:definition>999044 - Disclosure - SEGMENT REPORTING (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999045 - Disclosure - SEGMENT REPORTING (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsDetails" id="AcquisitionsDetails">
          <link:definition>999046 - Disclosure - ACQUISITIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsDetails1" id="AcquisitionsDetails1">
          <link:definition>999047 - Disclosure - ACQUISITIONS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsDetails2" id="AcquisitionsDetails2">
          <link:definition>999048 - Disclosure - ACQUISITIONS (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" id="AcquisitionsDetailsNarrative">
          <link:definition>999049 - Disclosure - ACQUISITIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="RENB_RenovaroCubeMember" name="RenovaroCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BlackScholesOptionPricingModelMember" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BioSymetricsMember" name="BioSymetricsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SoftwarePlatformMember" name="SoftwarePlatformMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TrademarkMember" name="TrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LessAccumulatedAmortizationMember" name="LessAccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_JanuaryNote2024Member" name="JanuaryNote2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DecemberNote2023Member" name="DecemberNote2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PasecoApSMember" name="PasecoApSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TheNotesMember" name="TheNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNotesMember" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RenovaroMember" name="RenovaroMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GTechMember" name="GTechMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MarkDybulMember" name="MarkDybulMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RSBioMember" name="RSBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENBMember" name="RENBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENCMember" name="RENCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GEDiCubeMember" name="GEDiCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DefiniteLifeIntangibleAssetsNet" name="DefiniteLifeIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationLiabilityCurrent" name="ContingentConsiderationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotesPayableRelatedPartiesNetCurrent" name="NotesPayableRelatedPartiesNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ChangeInFairValueOfContingentConsideration" name="ChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GainOnBankruptcyOfSubsidiary" name="GainOnBankruptcyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestIncomeAndOtherIncomeExpense" name="InterestIncomeAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" name="IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" name="IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRendered" name="RestrictedSharesIssuedForServicesRendered" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" name="RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" name="IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" name="IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" name="SharesAddedForFractionalSharesPursuantToReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" name="SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LossOnExtinguishmentOfDebt" name="LossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NoncashStockbasedCompensationExpense" name="NoncashStockbasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GainOnBankruptcysOfSubsidiary" name="GainOnBankruptcysOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GainOnSettlementOfAccountsPayable" name="GainOnSettlementOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AmortizationOfDiscountOnNotePayable" name="AmortizationOfDiscountOnNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RepaymentsOfFinanceAgreement" name="RepaymentsOfFinanceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CashPaidDuringYearForAbstract" name="CashPaidDuringYearForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" name="DebtDiscountRelatedToConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CancellationOfRestrictedStockAwards" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CancellationOfStockOptions" name="CancellationOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessPolicyTextBlock" name="BusinessPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BankruptcyPolicyTextBlock" name="BankruptcyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" name="InvestmentinEquitySecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" name="ScheduleOfContingentConsiderationLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BankruptcyResultedInGain" name="BankruptcyResultedInGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchasedEquitySecurities" name="PurchasedEquitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssets" name="NetDefinitelifeIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssetsAmortization" name="NetDefinitelifeIntangibleAssetsAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" name="IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" name="IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Software" name="Software" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Trademark" name="Trademark" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotesBalance" name="NotesBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SaleOfStockConsiderationReceivedCashTransaction" name="SaleOfStockConsiderationReceivedCashTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PlacementCosts" name="PlacementCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestRate" name="InterestRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AmortizationPlacementCost" name="AmortizationPlacementCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockbasedCompensationExpense" name="StockbasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockbasedCompensationExpenseRelatedToOptions" name="StockbasedCompensationExpenseRelatedToOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PaymentForExpenditures" name="PaymentForExpenditures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InitialPayment" name="InitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesOfCommonStockGranted" name="SharesOfCommonStockGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationExpense" name="UnrecognizedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentOperatingLoss" name="SegmentOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentAsset" name="SegmentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LonglivedAssetImpairment" name="LonglivedAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationContingentConsiderationCommonStock" name="BusinessCombinationContingentConsiderationCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_FixedAssets" name="FixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TradeName" name="TradeName" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsRevenue" name="BusinessAcquisitionsRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsNetIncomeLoss" name="BusinessAcquisitionsNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TransactionIssuedShares" name="TransactionIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>renb-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfOperationsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementsOfComprehensiveLossunaudited" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfCashFlowsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetailsNarrative" roleURI="http://renovarobio.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails" roleURI="http://renovarobio.com/role/AcquisitionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails1" roleURI="http://renovarobio.com/role/AcquisitionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails2" roleURI="http://renovarobio.com/role/AcquisitionsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="loc_RENBDefiniteLifeIntangibleAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_RENBDefiniteLifeIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="loc_us-gaapFiniteLivedTrademarksGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapFiniteLivedTrademarksGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:label="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcyOfSubsidiary" xlink:label="loc_RENBGainOnBankruptcyOfSubsidiary" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBGainOnBankruptcyOfSubsidiary" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:label="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcysOfSubsidiary" xlink:label="loc_RENBGainOnBankruptcysOfSubsidiary" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBGainOnBankruptcysOfSubsidiary" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaapImpairmentExcludingLessorAssetUnderOperatingLease" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentExcludingLessorAssetUnderOperatingLease" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnSettlementOfAccountsPayable" xlink:label="loc_RENBGainOnSettlementOfAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBGainOnSettlementOfAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999014 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999015 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999017 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999021 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999022 - Disclosure - ACQUISITIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999028 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999029 - Disclosure - ACQUISITIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999031 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999038 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999039 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999040 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999043 - Disclosure - SEGMENT REPORTING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999044 - Disclosure - SEGMENT REPORTING (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetailsNarrative" xlink:title="999045 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails" xlink:title="999046 - Disclosure - ACQUISITIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails1" xlink:title="999047 - Disclosure - ACQUISITIONS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails2" xlink:title="999048 - Disclosure - ACQUISITIONS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999049 - Disclosure - ACQUISITIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>renb-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfOperationsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementsOfComprehensiveLossunaudited" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfCashFlowsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetailsNarrative" roleURI="http://renovarobio.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails" roleURI="http://renovarobio.com/role/AcquisitionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails1" roleURI="http://renovarobio.com/role/AcquisitionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails2" roleURI="http://renovarobio.com/role/AcquisitionsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRendered_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRendered_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" xlink:label="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplit_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" xlink:label="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplitShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplitShares_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999014 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999015 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999017 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999021 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999022 - Disclosure - ACQUISITIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999028 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999029 - Disclosure - ACQUISITIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999031 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBConvertibleNotesMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_190" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Software" xlink:label="loc_RENBSoftware_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSoftware_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Trademark" xlink:label="loc_RENBTrademark_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBTrademark_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999038 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PasecoApSMember" xlink:label="loc_RENBPasecoApSMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBPasecoApSMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNotesMember" xlink:label="loc_RENBPromissoryNotesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNotesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesBalance" xlink:label="loc_RENBNotesBalance_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBNotesBalance_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PlacementCosts" xlink:label="loc_RENBPlacementCosts_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPlacementCosts_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestRate" xlink:label="loc_RENBInterestRate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBInterestRate_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationPlacementCost" xlink:label="loc_RENBAmortizationPlacementCost_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAmortizationPlacementCost_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaapMaturitiesOfTimeDepositsDescription_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMaturitiesOfTimeDepositsDescription_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AgreementDescription" xlink:label="loc_RENBAgreementDescription_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAgreementDescription_310" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_310" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999039 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999040 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNoteMember" xlink:label="loc_RENBConvertibleNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBConvertibleNoteMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpense" xlink:label="loc_RENBStockbasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpense_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpenseRelatedToOptions" xlink:label="loc_RENBStockbasedCompensationExpenseRelatedToOptions_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpenseRelatedToOptions_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationCost" xlink:label="loc_RENBUnrecognizedCompensationCost_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCost_150" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesOfCommonStockGranted" xlink:label="loc_RENBSharesOfCommonStockGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBSharesOfCommonStockGranted_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="loc_RENBUnrecognizedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBUnrecognizedCompensationExpense_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999043 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="loc_countryNL_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999044 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBBioSymetricsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LonglivedAssetImpairment" xlink:label="loc_RENBLonglivedAssetImpairment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBLonglivedAssetImpairment_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetailsNarrative" xlink:title="999045 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails" xlink:title="999046 - Disclosure - ACQUISITIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails1" xlink:title="999047 - Disclosure - ACQUISITIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCash_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_FixedAssets" xlink:label="loc_RENBFixedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBFixedAssets_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Software" xlink:label="loc_RENBSoftware_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBSoftware_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TradeName" xlink:label="loc_RENBTradeName_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTradeName_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails2" xlink:title="999048 - Disclosure - ACQUISITIONS (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999049 - Disclosure - ACQUISITIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TransactionIssuedShares" xlink:label="loc_RENBTransactionIssuedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTransactionIssuedShares_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SettlementAgreementMember" xlink:label="loc_RENBSettlementAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSettlementAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>renb-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroCubeMember" xlink:label="RENB_RenovaroCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroCubeMember" xlink:to="RENB_RenovaroCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroCubeMember_lbl" xml:lang="en-US">Renovaro Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="RENB_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertibleNotesMember" xlink:to="RENB_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="RENB_BlackScholesOptionPricingModelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BlackScholesOptionPricingModelMember" xlink:to="RENB_BlackScholesOptionPricingModelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BlackScholesOptionPricingModelMember_lbl" xml:lang="en-US">Black Scholes Option Pricing Model [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="RENB_BioSymetricsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BioSymetricsMember" xlink:to="RENB_BioSymetricsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BioSymetricsMember_lbl" xml:lang="en-US">Bio Symetrics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SoftwarePlatformMember" xlink:label="RENB_SoftwarePlatformMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SoftwarePlatformMember" xlink:to="RENB_SoftwarePlatformMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SoftwarePlatformMember_lbl" xml:lang="en-US">Software Platform [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TrademarkMember" xlink:label="RENB_TrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TrademarkMember" xlink:to="RENB_TrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TrademarkMember_lbl" xml:lang="en-US">Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="RENB_LessAccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LessAccumulatedAmortizationMember" xlink:to="RENB_LessAccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LessAccumulatedAmortizationMember_lbl" xml:lang="en-US">Less Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillMember" xlink:label="us-gaap_GoodwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_JanuaryNote2024Member" xlink:label="RENB_JanuaryNote2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_JanuaryNote2024Member" xlink:to="RENB_JanuaryNote2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_JanuaryNote2024Member_lbl" xml:lang="en-US">January Note 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DecemberNote2023Member" xlink:label="RENB_DecemberNote2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DecemberNote2023Member" xlink:to="RENB_DecemberNote2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DecemberNote2023Member_lbl" xml:lang="en-US">December Note 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="RENB_ExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExchangeAgreementMember" xlink:to="RENB_ExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="RENB_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertiblePromissoryNoteMember" xlink:to="RENB_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PasecoApSMember" xlink:label="RENB_PasecoApSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PasecoApSMember" xlink:to="RENB_PasecoApSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PasecoApSMember_lbl" xml:lang="en-US">Paseco Ap S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TheNotesMember" xlink:label="RENB_TheNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TheNotesMember" xlink:to="RENB_TheNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TheNotesMember_lbl" xml:lang="en-US">The Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNotesMember" xlink:label="RENB_PromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNotesMember" xlink:to="RENB_PromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNotesMember_lbl" xml:lang="en-US">Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNoteMember" xlink:label="RENB_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNoteMember" xlink:to="RENB_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PurchaseAgreementMember" xlink:label="RENB_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseAgreementMember" xlink:to="RENB_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNoteMember" xlink:label="RENB_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertibleNoteMember" xlink:to="RENB_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroMember" xlink:label="RENB_RenovaroMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroMember" xlink:to="RENB_RenovaroMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroMember_lbl" xml:lang="en-US">Renovaro [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GTechMember" xlink:label="RENB_GTechMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GTechMember" xlink:to="RENB_GTechMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GTechMember_lbl" xml:lang="en-US">G Tech [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LicenseAgreementMember" xlink:label="RENB_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LicenseAgreementMember" xlink:to="RENB_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_MarkDybulMember" xlink:label="RENB_MarkDybulMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MarkDybulMember" xlink:to="RENB_MarkDybulMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MarkDybulMember_lbl" xml:lang="en-US">Mark Dybul [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RSBioMember" xlink:label="RENB_RSBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RSBioMember" xlink:to="RENB_RSBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RSBioMember_lbl" xml:lang="en-US">RS Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENBMember" xlink:label="RENB_RENBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENBMember" xlink:to="RENB_RENBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENBMember_lbl" xml:lang="en-US">RENB [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENCMember" xlink:label="RENB_RENCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENCMember" xlink:to="RENB_RENCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENCMember_lbl" xml:lang="en-US">RENC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GEDiCubeMember" xlink:label="RENB_GEDiCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GEDiCubeMember" xlink:to="RENB_GEDiCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GEDiCubeMember_lbl" xml:lang="en-US">GEDi Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SettlementAgreementMember" xlink:label="RENB_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SettlementAgreementMember" xlink:to="RENB_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaids and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="RENB_DefiniteLifeIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DefiniteLifeIntangibleAssetsNet" xlink:to="RENB_DefiniteLifeIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DefiniteLifeIntangibleAssetsNet_lbl" xml:lang="en-US">Definite life intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Software platform, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="us-gaap_FiniteLivedTrademarksGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedTrademarksGross" xlink:to="us-gaap_FiniteLivedTrademarksGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedTrademarksGross_lbl" xml:lang="en-US">Trademarks, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="RENB_ContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationLiabilityCurrent" xlink:to="RENB_ContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotesPayableRelatedPartiesNetCurrent" xlink:to="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xml:lang="en-US">Notes payable &#8211; related parties, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 350,000,000 shares authorized, 23,180,277 shares issued and outstanding at September 30, 2025; 17,739,291 shares issued and outstanding at June 30, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Long-lived asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="RENB_ChangeInFairValueOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_lbl" xml:lang="en-US">Change in fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcyOfSubsidiary" xlink:label="RENB_GainOnBankruptcyOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnBankruptcyOfSubsidiary" xlink:to="RENB_GainOnBankruptcyOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GainOnBankruptcyOfSubsidiary_lbl" xml:lang="en-US">Gain on bankruptcy of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestIncomeAndOtherIncomeExpense" xlink:to="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xml:lang="en-US">Interest income and other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign Currency Translation, net of taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_lbl" xml:lang="en-US">Issuance of common stock under private placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_lbl" xml:lang="en-US">Issuance of common stock under private placement offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRendered" xlink:label="RENB_RestrictedSharesIssuedForServicesRendered" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRendered" xlink:to="RENB_RestrictedSharesIssuedForServicesRendered_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRendered_lbl" xml:lang="en-US">Restricted shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_lbl" xml:lang="en-US">Restricted shares issued for services rendered and executive compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeited shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeited shares of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xml:lang="en-US">Issuance of common stock pursuant to conversion of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Issuance of common stock pursuant to conversion of convertible notes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" xlink:label="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" xlink:to="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable_lbl" xml:lang="en-US">Issuance of common stock pursuant to settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" xlink:label="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" xlink:to="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to settlement of accounts payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" xlink:label="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" xlink:to="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit_lbl" xml:lang="en-US">Shares added for fractional shares pursuant to reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" xlink:label="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" xlink:to="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares_lbl" xml:lang="en-US">Shares added for fractional shares pursuant to reverse stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">ADJUSTMENTS TO RECONCILE NET INCOME (LOSS) TO NET CASH USED IN OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="RENB_LossOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_LossOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xml:lang="en-US">Change in value of contingent consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment_2_lbl" xml:lang="en-US">Change in value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="RENB_NoncashStockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NoncashStockbasedCompensationExpense" xlink:to="RENB_NoncashStockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NoncashStockbasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcysOfSubsidiary" xlink:label="RENB_GainOnBankruptcysOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnBankruptcysOfSubsidiary" xlink:to="RENB_GainOnBankruptcysOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_GainOnBankruptcysOfSubsidiary_lbl" xml:lang="en-US">Gain on bankruptcy of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" xlink:label="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" xlink:to="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease_lbl" xml:lang="en-US">Long-lived asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnSettlementOfAccountsPayable" xlink:label="RENB_GainOnSettlementOfAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnSettlementOfAccountsPayable" xlink:to="RENB_GainOnSettlementOfAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_GainOnSettlementOfAccountsPayable_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="RENB_AmortizationOfDiscountOnNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AmortizationOfDiscountOnNotePayable" xlink:to="RENB_AmortizationOfDiscountOnNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AmortizationOfDiscountOnNotePayable_lbl" xml:lang="en-US">Amortization of discount of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses/deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Sale of equitable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="RENB_RepaymentsOfFinanceAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_RepaymentsOfFinanceAgreement_lbl" xml:lang="en-US">Repayment of finance agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rates on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="RENB_CashPaidDuringYearForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CashPaidDuringYearForAbstract" xlink:to="RENB_CashPaidDuringYearForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:to="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xml:lang="en-US">Debt discount related to convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CancellationOfRestrictedStockAwards" xlink:label="RENB_CancellationOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CancellationOfRestrictedStockAwards" xlink:to="RENB_CancellationOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CancellationOfRestrictedStockAwards_lbl" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CancellationOfStockOptions" xlink:label="RENB_CancellationOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CancellationOfStockOptions" xlink:to="RENB_CancellationOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CancellationOfStockOptions_lbl" xml:lang="en-US">Cancellation of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">ACQUISITIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessPolicyTextBlock" xlink:label="RENB_BusinessPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessPolicyTextBlock" xlink:to="RENB_BusinessPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessPolicyTextBlock_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BankruptcyPolicyTextBlock" xlink:label="RENB_BankruptcyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BankruptcyPolicyTextBlock" xlink:to="RENB_BankruptcyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BankruptcyPolicyTextBlock_lbl" xml:lang="en-US">Bankruptcy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency &amp; Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:label="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:to="RENB_InvestmentinEquitySecuritiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InvestmentinEquitySecuritiesPolicyTextBlock_lbl" xml:lang="en-US">Investment in Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xml:lang="en-US">Schedule of key input to valuing the contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:label="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:to="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurement on recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of definite-life and indefinite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of future amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:label="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:to="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment operating loss and asset information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of information regarding segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of acquisition fair value of the consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:label="us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:to="us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_lbl" xml:lang="en-US">Schedule of fair values of the assets acquired and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US">Schedule of statement of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BankruptcyResultedInGain" xlink:label="RENB_BankruptcyResultedInGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BankruptcyResultedInGain" xlink:to="RENB_BankruptcyResultedInGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BankruptcyResultedInGain_lbl" xml:lang="en-US">Bankruptcy resulted in a gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PurchasedEquitySecurities" xlink:label="RENB_PurchasedEquitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchasedEquitySecurities" xlink:to="RENB_PurchasedEquitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchasedEquitySecurities_lbl" xml:lang="en-US">Purchased equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_WorkingCapitalDeficit" xlink:label="RENB_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WorkingCapitalDeficit" xlink:to="RENB_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Balance June 30, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Fair value adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Contingent Consideration Liability at September 30, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Contingent shares issuable in connection with the acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Contingent consideration liability was recorded at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="RENB_NetDefinitelifeIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_lbl" xml:lang="en-US">Net definite-life intangible assets at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net definite-life intangible assets, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:to="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xml:lang="en-US">Net definite-life intangible assets, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Net definite-life intangible assets, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Net definite-life intangible assets, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xml:lang="en-US">Net definite-life intangible assets at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Software" xlink:label="RENB_Software" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Software" xlink:to="RENB_Software_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Software_lbl" xml:lang="en-US">Software</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Trademark" xlink:label="RENB_Trademark" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Trademark" xlink:to="RENB_Trademark_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Trademark_lbl" xml:lang="en-US">Trademark</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bear interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesBalance" xlink:label="RENB_NotesBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotesBalance" xlink:to="RENB_NotesBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotesBalance_lbl" xml:lang="en-US">Notes balance</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="RENB_SaleOfStockConsiderationReceivedCashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:to="RENB_SaleOfStockConsiderationReceivedCashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SaleOfStockConsiderationReceivedCashTransaction_lbl" xml:lang="en-US">Sale of stock issued cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PlacementCosts" xlink:label="RENB_PlacementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PlacementCosts" xlink:to="RENB_PlacementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PlacementCosts_lbl" xml:lang="en-US">Placement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestRate" xlink:label="RENB_InterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestRate" xlink:to="RENB_InterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Notes balance</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationPlacementCost" xlink:label="RENB_AmortizationPlacementCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AmortizationPlacementCost" xlink:to="RENB_AmortizationPlacementCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AmortizationPlacementCost_lbl" xml:lang="en-US">Amortization placement cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Notes balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Note interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="us-gaap_MaturitiesOfTimeDepositsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfTimeDepositsDescription" xlink:to="us-gaap_MaturitiesOfTimeDepositsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturitiesOfTimeDepositsDescription_lbl" xml:lang="en-US">Maturity description</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AgreementDescription" xlink:label="RENB_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AgreementDescription" xlink:to="RENB_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Obligation to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares Issued Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_lbl" xml:lang="en-US">Stock-based Compensation description</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpense" xlink:label="RENB_StockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpense" xlink:to="RENB_StockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_StockbasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">restricted option stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpenseRelatedToOptions" xlink:label="RENB_StockbasedCompensationExpenseRelatedToOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpenseRelatedToOptions" xlink:to="RENB_StockbasedCompensationExpenseRelatedToOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockbasedCompensationExpenseRelatedToOptions_lbl" xml:lang="en-US">Stock-based compensation expense related to options</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationCost" xlink:label="RENB_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationCost" xlink:to="RENB_UnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationCost_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for license</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RoyaltyPercentage" xlink:label="RENB_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RoyaltyPercentage" xlink:to="RENB_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UpfrontPayment" xlink:label="RENB_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UpfrontPayment" xlink:to="RENB_UpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UpfrontPayment_lbl" xml:lang="en-US">Up-front payment</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PaymentForExpenditures" xlink:label="RENB_PaymentForExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PaymentForExpenditures" xlink:to="RENB_PaymentForExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PaymentForExpenditures_lbl" xml:lang="en-US">Payment for expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InitialPayment" xlink:label="RENB_InitialPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InitialPayment" xlink:to="RENB_InitialPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InitialPayment_lbl" xml:lang="en-US">Initial payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Accrued balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Common stock forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesOfCommonStockGranted" xlink:label="RENB_SharesOfCommonStockGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesOfCommonStockGranted" xlink:to="RENB_SharesOfCommonStockGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesOfCommonStockGranted_lbl" xml:lang="en-US">Shares of common stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="RENB_UnrecognizedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationExpense" xlink:to="RENB_UnrecognizedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentOperatingLoss" xlink:label="RENB_SegmentOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentOperatingLoss_lbl" xml:lang="en-US">Operating income loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentAsset" xlink:label="RENB_SegmentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentAsset" xlink:to="RENB_SegmentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentAsset_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LonglivedAssetImpairment" xlink:label="RENB_LonglivedAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LonglivedAssetImpairment" xlink:to="RENB_LonglivedAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_LonglivedAssetImpairment_lbl" xml:lang="en-US">Long-lived asset impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_SegmentOperatingLoss_2_lbl" xml:lang="en-US">Segment operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnBankruptcyOfSubsidiary" xlink:to="RENB_GainOnBankruptcyOfSubsidiary_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_GainOnBankruptcyOfSubsidiary_2_lbl" xml:lang="en-US">Gain on the bankruptcy of the subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:to="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xml:lang="en-US">Common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid &amp; Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_FixedAssets" xlink:label="RENB_FixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_FixedAssets" xlink:to="RENB_FixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_FixedAssets_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total Assets Acquired:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total Liabilities Assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net Assets Acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TradeName" xlink:label="RENB_TradeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TradeName" xlink:to="RENB_TradeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TradeName_lbl" xml:lang="en-US">Trade Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="RENB_BusinessAcquisitionsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsRevenue" xlink:to="RENB_BusinessAcquisitionsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsNetIncomeLoss" xlink:to="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TransactionIssuedShares" xlink:label="RENB_TransactionIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TransactionIssuedShares" xlink:to="RENB_TransactionIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TransactionIssuedShares_lbl" xml:lang="en-US">Transaction issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock per value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Fair value of consideration transferred amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock for consulting services value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LossOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">LossOnExtinguishmentOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnBankruptcysOfSubsidiary" xlink:to="RENB_GainOnBankruptcysOfSubsidiary_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GainOnBankruptcysOfSubsidiary_2_lbl" xml:lang="en-US">GainOnBankruptcysOfSubsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" xlink:to="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease_2_lbl" xml:lang="en-US">Impairment, Excluding Lessor Asset under Operating Lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GainOnSettlementOfAccountsPayable" xlink:to="RENB_GainOnSettlementOfAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GainOnSettlementOfAccountsPayable_2_lbl" xml:lang="en-US">GainOnSettlementOfAccountsPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RepaymentsOfFinanceAgreement_2_lbl" xml:lang="en-US">RepaymentsOfFinanceAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xml:lang="en-US">NetDefinitelifeIntangibleAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpense" xlink:to="RENB_StockbasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockbasedCompensationExpense_2_lbl" xml:lang="en-US">StockbasedCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LonglivedAssetImpairment" xlink:to="RENB_LonglivedAssetImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LonglivedAssetImpairment_2_lbl" xml:lang="en-US">LonglivedAssetImpairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>renb-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfOperationsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementsOfComprehensiveLossunaudited" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CondensedConsolidatedStatementsOfCashFlowsunaudited" roleURI="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SegmentReportingDetailsNarrative" roleURI="http://renovarobio.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails" roleURI="http://renovarobio.com/role/AcquisitionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails1" roleURI="http://renovarobio.com/role/AcquisitionsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetails2" roleURI="http://renovarobio.com/role/AcquisitionsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="loc_RENBDefiniteLifeIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_RENBDefiniteLifeIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="loc_us-gaapFiniteLivedTrademarksGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedTrademarksGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:label="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcyOfSubsidiary" xlink:label="loc_RENBGainOnBankruptcyOfSubsidiary" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBGainOnBankruptcyOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRendered" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRendered" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit" xlink:label="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares" xlink:label="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplitShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesAddedForFractionalSharesPursuantToReverseStockSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:label="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcysOfSubsidiary" xlink:label="loc_RENBGainOnBankruptcysOfSubsidiary" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBGainOnBankruptcysOfSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaapImpairmentExcludingLessorAssetUnderOperatingLease" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentExcludingLessorAssetUnderOperatingLease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnSettlementOfAccountsPayable" xlink:label="loc_RENBGainOnSettlementOfAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBGainOnSettlementOfAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="loc_RENBCashPaidDuringYearForAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_RENBCashPaidDuringYearForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBCashPaidDuringYearForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CancellationOfRestrictedStockAwards" xlink:label="loc_RENBCancellationOfRestrictedStockAwards" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCancellationOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_CancellationOfStockOptions" xlink:label="loc_RENBCancellationOfStockOptions" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCancellationOfStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999014 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999015 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999017 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999018 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999021 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999022 - Disclosure - ACQUISITIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessPolicyTextBlock" xlink:label="loc_RENBBusinessPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBBusinessPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BankruptcyPolicyTextBlock" xlink:label="loc_RENBBankruptcyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBBankruptcyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:label="loc_RENBInvestmentinEquitySecuritiesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBInvestmentinEquitySecuritiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaapFairValueConcentrationOfRiskTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueConcentrationOfRiskTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:label="loc_RENBScheduleOfContingentConsiderationLiabilityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_RENBScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:label="loc_RENBScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999028 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999029 - Disclosure - ACQUISITIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:label="loc_us-gaapScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaapScheduleOfComprehensiveIncomeLossTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BankruptcyResultedInGain" xlink:label="loc_RENBBankruptcyResultedInGain" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBBankruptcyResultedInGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PurchasedEquitySecurities" xlink:label="loc_RENBPurchasedEquitySecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBPurchasedEquitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999031 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_WorkingCapitalDeficit" xlink:label="loc_RENBWorkingCapitalDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_RENBWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Software" xlink:label="loc_RENBSoftware" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Trademark" xlink:label="loc_RENBTrademark" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBTrademark" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999038 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PasecoApSMember" xlink:label="loc_RENBPasecoApSMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBPasecoApSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNotesMember" xlink:label="loc_RENBPromissoryNotesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_NotesBalance" xlink:label="loc_RENBNotesBalance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBNotesBalance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PlacementCosts" xlink:label="loc_RENBPlacementCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBPlacementCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InterestRate" xlink:label="loc_RENBInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AmortizationPlacementCost" xlink:label="loc_RENBAmortizationPlacementCost" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAmortizationPlacementCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaapMaturitiesOfTimeDepositsDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMaturitiesOfTimeDepositsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_AgreementDescription" xlink:label="loc_RENBAgreementDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999039 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999040 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_ConvertibleNoteMember" xlink:label="loc_RENBConvertibleNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpense" xlink:label="loc_RENBStockbasedCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_StockbasedCompensationExpenseRelatedToOptions" xlink:label="loc_RENBStockbasedCompensationExpenseRelatedToOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpenseRelatedToOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationCost" xlink:label="loc_RENBUnrecognizedCompensationCost" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SharesOfCommonStockGranted" xlink:label="loc_RENBSharesOfCommonStockGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBSharesOfCommonStockGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="loc_RENBUnrecognizedCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBUnrecognizedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999043 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999044 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_LonglivedAssetImpairment" xlink:label="loc_RENBLonglivedAssetImpairment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBLonglivedAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetailsNarrative" xlink:title="999045 - Disclosure - SEGMENT REPORTING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GainOnBankruptcyOfSubsidiary" xlink:label="loc_RENBGainOnBankruptcyOfSubsidiary" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_RENBGainOnBankruptcyOfSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails" xlink:title="999046 - Disclosure - ACQUISITIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails1" xlink:title="999047 - Disclosure - ACQUISITIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_FixedAssets" xlink:label="loc_RENBFixedAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_Software" xlink:label="loc_RENBSoftware" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TradeName" xlink:label="loc_RENBTradeName" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTradeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetails2" xlink:title="999048 - Disclosure - ACQUISITIONS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_RENBBusinessAcquisitionsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999049 - Disclosure - ACQUISITIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_TransactionIssuedShares" xlink:label="loc_RENBTransactionIssuedShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTransactionIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250930.xsd#RENB_SettlementAgreementMember" xlink:label="loc_RENBSettlementAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lunai Bioworks Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2259340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3400 Cottage Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite G2 #32562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">&#160;Sacramento<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">95825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-9301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LNAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,432,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 624,808<span></span>
</td>
<td class="nump">$ 92,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">387,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaids and other assets</a></td>
<td class="nump">175,552<span></span>
</td>
<td class="nump">566,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">800,360<span></span>
</td>
<td class="nump">1,046,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,465<span></span>
</td>
<td class="nump">367,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DefiniteLifeIntangibleAssetsNet', window );">Definite life intangible assets, net</a></td>
<td class="nump">17,610<span></span>
</td>
<td class="nump">14,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software platform, net</a></td>
<td class="nump">129,288<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedTrademarksGross', window );">Trademarks, net</a></td>
<td class="nump">6,082<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">5,963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">31,858<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">687,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">6,147,838<span></span>
</td>
<td class="nump">6,816,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">6,960,663<span></span>
</td>
<td class="nump">8,230,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">12,094,428<span></span>
</td>
<td class="nump">12,555,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,868,686<span></span>
</td>
<td class="nump">5,843,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">71,429<span></span>
</td>
<td class="nump">378,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">277,775<span></span>
</td>
<td class="nump">313,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, net</a></td>
<td class="nump">1,038,495<span></span>
</td>
<td class="nump">3,580,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotesPayableRelatedPartiesNetCurrent', window );">Notes payable &#8211; related parties, net</a></td>
<td class="nump">866,661<span></span>
</td>
<td class="nump">5,610,372<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">19,722,474<span></span>
</td>
<td class="nump">29,156,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">278,963<span></span>
</td>
<td class="nump">424,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">278,963<span></span>
</td>
<td class="nump">424,547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">20,001,437<span></span>
</td>
<td class="nump">29,580,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 350,000,000 shares authorized, 23,180,277 shares issued and outstanding at September 30, 2025; 17,739,291 shares issued and outstanding at June 30, 2025</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">494,728,618<span></span>
</td>
<td class="nump">478,296,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(507,643,549)<span></span>
</td>
<td class="num">(510,462,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)</a></td>
<td class="num">(128,161)<span></span>
</td>
<td class="nump">10,814,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Deficit</a></td>
<td class="num">(13,040,774)<span></span>
</td>
<td class="num">(21,349,841)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="nump">$ 6,960,663<span></span>
</td>
<td class="nump">$ 8,230,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DefiniteLifeIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DefiniteLifeIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotesPayableRelatedPartiesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotesPayableRelatedPartiesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedTrademarksGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedTrademarksGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,180,277<span></span>
</td>
<td class="nump">17,739,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,180,277<span></span>
</td>
<td class="nump">17,739,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,410,516<span></span>
</td>
<td class="nump">$ 5,301,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,407<span></span>
</td>
<td class="nump">390,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,614,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived asset impairment</a></td>
<td class="nump">831,915<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41,522<span></span>
</td>
<td class="nump">32,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">3,308,360<span></span>
</td>
<td class="nump">53,338,554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(3,308,360)<span></span>
</td>
<td class="num">(53,338,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">9,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment', window );">Change in fair value of equity securities</a></td>
<td class="nump">156,849<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GainOnBankruptcyOfSubsidiary', window );">Gain on bankruptcy of subsidiary</a></td>
<td class="nump">12,019,227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(6,329,592)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(122,400)<span></span>
</td>
<td class="num">(250,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestIncomeAndOtherIncomeExpense', window );">Interest income and other income (expense)</a></td>
<td class="nump">33,297<span></span>
</td>
<td class="nump">126,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="nump">6,127,381<span></span>
</td>
<td class="nump">9,126,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,819,021<span></span>
</td>
<td class="num">$ (44,212,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET LOSS PER COMMON SHARE</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (2.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET LOSS PER COMMON SHARE</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (2.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</a></td>
<td class="nump">22,520,245<span></span>
</td>
<td class="nump">15,999,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</a></td>
<td class="nump">22,520,245<span></span>
</td>
<td class="nump">15,999,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GainOnBankruptcyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GainOnBankruptcyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestIncomeAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestIncomeAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in earnings from investment in debt and equity securities measured at fair value with change in fair value recognized in net income, and recognized from transfer of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity) to investment in debt security measured at fair value with change in fair value recognized in net income (trading). Excludes other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,819,021<span></span>
</td>
<td class="num">$ (44,212,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation, net of taxes</a></td>
<td class="num">(10,943,003)<span></span>
</td>
<td class="nump">6,468,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (8,123,982)<span></span>
</td>
<td class="num">$ (37,743,975)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 1,585<span></span>
</td>
<td class="nump">$ 464,601,486<span></span>
</td>
<td class="num">$ (332,455,081)<span></span>
</td>
<td class="num">$ (170,846)<span></span>
</td>
<td class="nump">$ 131,977,144<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2024</a></td>
<td class="nump">15,845,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue', window );">Issuance of common stock under private placement offering</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">2,096,166<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,096,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares', window );">Issuance of common stock under private placement offering, shares</a></td>
<td class="nump">142,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRendered', window );">Restricted shares issued for services rendered</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,399,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares', window );">Restricted shares issued for services rendered and executive compensation, shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited shares of common stock</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeited shares of common stock, shares</a></td>
<td class="num">(83,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">357,648<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">357,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,212,036)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44,212,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,468,061<span></span>
</td>
<td class="nump">6,468,061<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">468,455,289<span></span>
</td>
<td class="num">(376,667,117)<span></span>
</td>
<td class="nump">6,297,215<span></span>
</td>
<td class="nump">98,086,998<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">16,104,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2025</a></td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="nump">478,296,114<span></span>
</td>
<td class="num">(510,462,570)<span></span>
</td>
<td class="nump">10,814,842<span></span>
</td>
<td class="num">(21,349,841)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2025</a></td>
<td class="nump">17,739,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Issuance of common stock pursuant to conversion of convertible notes</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">16,066,892<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,067,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of common stock pursuant to conversion of convertible notes, shares</a></td>
<td class="nump">5,355,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable', window );">Issuance of common stock pursuant to settlement of accounts payable</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">184,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">184,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares', window );">Issuance of common stock pursuant to settlement of accounts payable, shares</a></td>
<td class="nump">85,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">181,312<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit', window );">Shares added for fractional shares pursuant to reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares', window );">Shares added for fractional shares pursuant to reverse stock split, shares</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,819,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,819,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,943,003)<span></span>
</td>
<td class="num">(10,943,003)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2025</a></td>
<td class="nump">$ 2,318<span></span>
</td>
<td class="nump">$ 494,728,618<span></span>
</td>
<td class="num">$ (507,643,549)<span></span>
</td>
<td class="num">$ (128,161)<span></span>
</td>
<td class="num">$ (13,040,774)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2025</a></td>
<td class="nump">23,180,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,819,021<span></span>
</td>
<td class="num">$ (44,212,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>ADJUSTMENTS TO RECONCILE NET INCOME (LOSS) TO NET CASH USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41,522<span></span>
</td>
<td class="nump">32,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">6,329,593<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in value of contingent consideration</a></td>
<td class="num">(370,000)<span></span>
</td>
<td class="num">(9,250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment', window );">Change in value of equity securities</a></td>
<td class="num">(156,849)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NoncashStockbasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">181,312<span></span>
</td>
<td class="nump">357,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GainOnBankruptcysOfSubsidiary', window );">Gain on bankruptcy of subsidiary</a></td>
<td class="num">(12,019,227)<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease', window );">Long-lived asset impairment</a></td>
<td class="nump">831,915<span></span>
</td>
<td class="nump">47,614,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GainOnSettlementOfAccountsPayable', window );">Gain on settlement of accounts payable</a></td>
<td class="num">(22,324)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">18,495<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AmortizationOfDiscountOnNotePayable', window );">Amortization of discount of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Other receivables</a></td>
<td class="num">(6,407)<span></span>
</td>
<td class="num">(195,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses/deposits</a></td>
<td class="nump">269,264<span></span>
</td>
<td class="nump">183,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">532,206<span></span>
</td>
<td class="nump">1,953,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">205,738<span></span>
</td>
<td class="nump">46,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases, net</a></td>
<td class="num">(3,369)<span></span>
</td>
<td class="num">(2,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(1,349,110)<span></span>
</td>
<td class="num">(2,016,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of equitable securities</a></td>
<td class="nump">544,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="nump">544,700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RepaymentsOfFinanceAgreement', window );">Repayment of finance agreement</a></td>
<td class="num">(271,643)<span></span>
</td>
<td class="num">(223,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,096,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">1,615,000<span></span>
</td>
<td class="nump">156,947<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">1,343,357<span></span>
</td>
<td class="nump">2,029,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="num">(6,839)<span></span>
</td>
<td class="num">(12,751)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH</a></td>
<td class="nump">532,108<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">92,700<span></span>
</td>
<td class="nump">220,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, END OF PERIOD</a></td>
<td class="nump">624,808<span></span>
</td>
<td class="nump">220,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CashPaidDuringYearForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">8,559<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes', window );">Debt discount related to convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CancellationOfRestrictedStockAwards', window );">Cancellation of restricted stock awards</a></td>
<td class="nump">36,973<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CancellationOfStockOptions', window );">Cancellation of stock options</a></td>
<td class="nump">$ 127,032<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AmortizationOfDiscountOnNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AmortizationOfDiscountOnNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CancellationOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CancellationOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtDiscountRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GainOnBankruptcysOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GainOnBankruptcysOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GainOnSettlementOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GainOnSettlementOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NoncashStockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NoncashStockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RepaymentsOfFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RepaymentsOfFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in earnings from investment in debt and equity securities measured at fair value with change in fair value recognized in net income, and recognized from transfer of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity) to investment in debt security measured at fair value with change in fair value recognized in net income (trading). Excludes other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of impairment for long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,819,021<span></span>
</td>
<td class="num">$ (44,212,036)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">During the quarter ended September
30, 2025, no director or Section 16 officer <span id="xdx_90B_eecd--Rule10b51ArrAdoptedFlag_dbT_c20250701__20250930_zP271nqHp1w2"><span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20250701__20250930_z1it0bUSHWma">adopted</span></span>, modified, or <span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zmMAfAgk6U0a"><span id="xdx_902_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zKqdvKEKxPtg">terminated</span></span> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule
10b5-1 trading arrangement&#8221; (in each case, as defined in Item 408(a) of Regulation S-K).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmM2k5cnxo5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8212; <span id="xdx_82E_zjmZBzzAvfB5">ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_ecustom--BusinessPolicyTextBlock_zM8bhbJd7Yuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zMJazVCBCdBc">Business</span> &#8211;</b>&#160;On
August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. (&#8220;Lunai&#8221;). On April 8, 2025,
Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics, Corp.&#8221;), as a wholly owned subsidiary pursuant
to a stock purchase agreement. On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro
Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) and
acquired GEDi Cube Intl Ltd and its subsidiaries GediCube B.V. and Grace Systems B.V. (&#8220;Renovaro Cube&#8221;), as a wholly owned
subsidiary pursuant to a stock purchase agreement. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform
for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights,
enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfhaeqhssCx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zRGXCqp0TaXi">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2025, and 2024
and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s June 30, 2025 audited financial
statements. The results of operations for the period ended September 30, 2025 are not necessarily indicative of the operating results
for the full year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zjYCGxlKlCRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zOQrRNCWX6Ne">Consolidation</span> &#8211;</b> For
the three months ended September 30, 2025, and 2024, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_848_ecustom--BankruptcyPolicyTextBlock_zxMyMLvyswRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86C_zayuz0B64oh5">Bankruptcy </span>-</b> The Company
accounts for bankruptcy under ASC 810, Consolidation. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;),
an indirect subsidiary of Lunai Bioworks, Inc. As of September 30, 2025 the Company deconsolidated Gedi Cube B.V., derecognizing its net
liabilities and releasing the cumulative translation adjustment balance to earnings. The bankruptcy resulted in a gain of $<span id="xdx_90B_ecustom--BankruptcyResultedInGain_c20250701__20250930_zYAcaX7EBWyj" title="Bankruptcy resulted in a gain">12,019,227</span>
during the three months ended September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_z472sHq2DJw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zIUBCJ90PhLh">Accounting Estimates</span> &#8211;</b>
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zrgDFSUyEJoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_z2kWuceihXFb">Loss Per Share</span>&#160;</b>&#8211;Basic earnings per common share (EPS) are based on the weighted average
number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed
as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings
per share calculation include in-the-money stock options that have been granted but have not been exercised and shares issuable upon conversion
of convertible common stock and convertible notes. The Company had <span id="xdx_904_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250930_zz8t1Bt16A38" title="Common stock outstanding">1,244,888</span> and <span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240930_z2JKPdRrqSs2" title="Common stock outstanding">1,729,342</span> potential shares of Common Stock excluded from
the Diluted EPS calculation as of September 30, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zbjCC4VyiJja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zn14GVueakDa">Functional Currency &amp; Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended September 30, 2025, and 2024. Translation gains and losses are deferred
and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement
of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_849_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zRyaUyKr69Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zjlPOJV9f471">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchasedEquitySecurities_iI_c20250228_zgRDsGVwMiib" title="Purchased equity securities">500,000</span> of equity securities. During the period ended September 30, 2025, the Company recorded a change in fair value of equity
securities for $<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_c20250701__20250930_zbnqDYItSFFb" title="Fair value of equity securities">156,849</span> and sold the securities for $<span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiGainLoss_c20250701__20250930_zckIHg6vJ15c" title="Investment in equity securities">544,700</span>. The investment in equity securities balance at September 30, 2025, was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0NQ2pJr1opd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z1i7QDoyRl8d">New Accounting Pronouncements
Not Yet Adopted</span></b>&#160;- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMijwZetCg3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_823_zYNOhBxI1J8c">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations. As of September 30, 2025, the Company had cash and cash equivalents of $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250930_z7WMSpJD6zjc" title="Cash and cash equivalents">624,808</span>, an accumulated deficit
of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250930_z2q6zHX4ktSi" title="Accumulated deficit">507,643,549</span> and a working capital deficit of $<span id="xdx_90F_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250930_zT7GrhiBR2X3" title="Working capital deficit">18,922,114</span>. These conditions raise substantial doubt about the Company&#8217;s ability
to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Management has reduced overhead
and administrative costs by streamlining the organization to focus around the development, validation, and commercialization of its AI-driven
neurology and oncology diagnostics and therapeutic development platform. The Company has tailored its workforce to focus on these activities.
In addition, the Company intends to secure additional required funding through equity or debt financing. However, there can be no assurance
that the Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on
reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders.
If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially
reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with
third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds
to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders
losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zo30AvUygzBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_827_znoD4YYDhpyg">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Level 3 liabilities held as of
September 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_906_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTPM5SKbod3" title="Contingent shares issuable in connection with the acquisition">7,083,418</span>
shares of Common Stock, and (ii) the right to receive up to <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zRgbLgqbUiml" title="Contingent shares issuable in connection with the acquisition">1,189,954</span> contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_90B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zNoAPtuTCE0k" title="Contingent consideration liability was recorded at fair value">20,557,500</span>
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of September 30, 2025,
there were <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250701__20250930__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zfc8vJkVAleh" title="Contingent shares issuable in connection with the acquisition">267,695</span> contingent shares issuable in connection with the Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#8217;s
underlying stock. The key inputs to valuing the contingent consideration liability as of September 30, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--FairValueConcentrationOfRiskTextBlock_zVIeTjspzAje" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details )">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zTbxwmiSnMid" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAiDKvghFQXf" title="Stock Price">1.42</span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ziE7IUTNWTpa" title="Exercise Price">5.30</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zsIQsBDmJDXh" title="Exercise Price">19.20</span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOcOIkbpe40g" title="Volatility">115.5</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z2MChPVYK1i6" title="Volatility">143.3</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zieq7CsH6482" title="Risk Free Rate">3.54</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAtgEuBTleve" title="Risk Free Rate">3.94</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20250701__20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zfDogYXT7rvf" title="Expected Dividends">0</span></td>
<td style="padding-bottom: 1pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zLpgHT05ft7b" title="Expected Term (years)">2.45</span> &#8211; <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdaNRZRjMswi" title="Expected Term (years)">8.13</span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AB_zBjVMOv9TQUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets forth the Level 3 liability
at September 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_zhEvZ0FZbhNf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B2_zjBOizIiVET3" style="display: none">Schedule of fair value measurement on recurring basis</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_491_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYZKbCbh3COk" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_490_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z99ZK5ouloBl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze9UsuxrdEY7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fair Value Measurements at</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">&#160;<br/> Reporting Date Using</p></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z4zHG0uKm5Xl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Balance June 30, 2025</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 11%; text-align: right">630,000</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zX4x6YbgKuha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(370,000</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zHn0Z3nefF8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at September 30, 2025</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">260,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p id="xdx_8AD_z0KVcI4xDDTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_802_eus-gaap--IntangibleAssetsDisclosureTextBlock_zzg7412r9SB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8212; <span id="xdx_82A_zFHAbe2E1Yea">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 8, 2025, the Company acquired
Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $<span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQqqsZfF9uRf" title="Goodwill">5,963,500</span>, software valued at $<span id="xdx_905_ecustom--Software_iI_c20250408_zkTjkjbtTqhd" title="Software">143,000</span> and Trademark valued at $<span id="xdx_90F_ecustom--Trademark_iI_c20250408_zqyg6ofM0flf" title="Trademark">8,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At September 30, 2025 and June
30, 2025, definite-life and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z3evUhPnV3mc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6TEfz3w8Q9f" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt">Software platform</td>
<td style="width: 2%">&#160;</td>
<td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zc0nO79haeUh" title="Useful life">5</span> Years</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z5Oj6hiCJaN" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning">143,000</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zqupOR3oik0d" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zr27SdhVsM0e" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization">(13,712</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zdDY9nqAbTog" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zZVvRURXm30g" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z0uGuh274ZNb" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">129,288</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z06kiu0KEXV8" title="Useful life">2</span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlxnjTe714qb" style="text-align: right" title="Net definite-life intangible assets at beginning">8,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXfn5AY8mBg8" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zSpbmCUBXS51" style="text-align: right" title="Net definite-life intangible assets, Amortization">(1,918</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zDZArRFfc3K1" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zWvG7PmMKi2" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zFt0ve4ldaif" style="text-align: right" title="Net definite-life intangible assets at ending">6,082</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdgXdGKDQs54" title="Useful life">20</span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zN2aI7lYTa7a" style="text-align: right" title="Net definite-life intangible assets at beginning">313,010</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXpbFKOw1iZ2" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGSu1yyOMQF8" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuYNstgZR2a7" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwBDWp3vi0f" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,093</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxYIHPHW9Jj" style="text-align: right" title="Net definite-life intangible assets at ending">311,917</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zIilEfxn708f" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(298,016</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zYQTgXXpVolc" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zbXb3sF8kPOd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(2,659</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z0SZ4FSwEwV4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zc8RdkimNFvb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">6,368</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zoSETgpApoH" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(294,307</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930_zgAPNZBLRsm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">165,994</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z0bhNBNcAsqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930_z8GcL5TFmKDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(18,289</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930_zw7dnYUvfrr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930_zlmMWp4mj791" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">5,275</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930_zUZ4Mkw61TUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">152,980</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIrKAOOAP0xb" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">5,963,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zAyDwYSbZJn9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_988_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIC6TfGmdYua" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zHFq70etLZc" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9IeGzNOei4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zXDGJ52QWeOj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930_zTZNX1tENBcl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">5,963,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z9kONEG67yGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930_zZn8LSkWOBSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930_zd0gEmogMmKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930_z9yYRn4vm0y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930_z5EIu2Mhz8Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A0_zr9O3zVLSYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zt8uoumTSSza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_z501rc3v58Rf" style="display: none">Schedule of future amortization expense</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years ended&#160;June 30,</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 57%; text-align: left; text-indent: -10pt">2026</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250930_zUVcNtu43dyb" style="width: 30%; text-align: right" title="2026">32,420</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250930_zaeQzlm9Q0Gb" style="text-align: right" title="2027">32,420</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2028</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250930_zV85U7gkWS02" style="text-align: right" title="2028">29,380</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2029</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250930_zu5NoeDnxCzc" style="text-align: right" title="2029">29,380</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250930_zhmQ7e0Oassl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">29,380</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250930_z8oeWpFbbx8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">152,980</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A0_zUCqy0lX6wGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zaOAFQIyG1Te" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_82B_zMhzSOo81tl1">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>The January 2024 Note &#8212;</i></b>
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zCHwHAoLb57i" title="Principal amount">125,000</span> (the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zPi57CkjqAL4" title="Gross proceeds">125,000</span> in gross proceeds.&#160;The
January 2024 Note bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zX3BgDUPOfb2" title="Bear interest percentage">12</span>% per annum and matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zhpM7Ldgj3Qa" title="Debt maturity period">December 29, 2024</span>. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#8217;s
Common Stock at the Note Conversion Price of $33.80.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note that matured on December 29, 2024, was amended extending
the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29, 2025. Accordingly, the Note unless otherwise
amended, replaced, or otherwise altered by this First Amendment, any and all terms contained in the Note continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>December 2023 Notes &#8212;
</i></b>On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH0hPbkQyxIc" title="Principal amount">120,000</span> (the &#8220;December 2023 Notes&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z27msV7Ftt1a" title="Gross proceeds">120,000</span> from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of <span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zj2egcfRJdNe" title="Bear interest percentage">12</span>% per annum and matured one year after
their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The January 2024 Note and December
2023 Notes balance at September 30, 2025, was $<span id="xdx_909_ecustom--NotesBalance_iI_c20250930_zhvEpYczffVd" title="Notes balance">245,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818_zveo9YHxfvU5" title="Sale of stock issued cash consideration">1,000,000</span> incurring $<span id="xdx_901_ecustom--PlacementCosts_iI_c20250818_zs08gZ5k0yT2" title="Placement costs">80,000</span> of placement costs. The Notes bear an interest
rate of&#160;<span id="xdx_906_ecustom--InterestRate_iI_dp_c20250818_zK6cVGTXSved" title="Interest rate">18</span>%&#160;per annum and mature on&#160;the 6-month anniversary of the Issue Date,&#160;(the &#8220;Maturity Date&#8221;).
The Company is required to pay principal and interest on the Maturity Date. These notes balance at September 30, 2025, was $<span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20250930_zoE4FRQKgMO7" title="Notes balance">938,495</span> net
amortization placement cost of $<span id="xdx_90F_ecustom--AmortizationPlacementCost_iI_c20250930_ziosMPfH3ja3" title="Amortization placement cost">18,495</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">From July 3, 2025, to August 19,
2025, the Company issued Promissory Notes in the aggregate principal amount of $<span id="xdx_902_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703_zykCEXEf9MXf" title="Sale of stock issued cash consideration">695,000</span>. The Notes bear an interest rate of&#160;<span id="xdx_906_ecustom--InterestRate_iI_dp_c20250819_zlnoec1u1Eng" title="Interest rate">10</span>%&#160;per
annum and mature on&#160;June 30, 2026,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal and interest
on the Maturity Date<b>. </b>These notes balance at September 30, 2025, was $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20250703_zxGYUoD05xSi" title="Notes balance">695,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zXt7wWrr0A7f" title="Sale of stock issued cash consideration">9.7</span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_90F_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_z7sKOxM4EG6b" title="Sale of stock issued cash consideration">16.1</span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange resulted in a $6,329,592 loss on extinguishment
of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_z9SDHgLpktnh" title="Sale of stock issued cash consideration">16.1</span> million principal amount into an aggregate
of <span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zAQhZ08Hn1qh" title="Sale of stock issued cash consideration">5.36</span> million shares of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zUNFAe8oGjNg" title="Conversion price">3.00</span> per share conversion price. The
$3.00 (on a post reverse split basis) per share conversion price of the Convertible Notes represented a premium to the closing price of
the Company&#8217;s common stock on July 7, 2025, the date of execution and conversion. As a result, the issuance of the <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707_zMCCXt3MOs2k" title="Issuance of common stock shares">5.36</span> million
shares of common stock upon conversion of the Convertible Notes did not constitute a &#8220;below market&#8221; issuance under applicable
Nasdaq listing rules and did not trigger stockholder approval requirements under Nasdaq Listing Rule 5635(d). The shares were issued without
any additional consideration from the Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Bridge Loans &#8212; </i></b>From June 4, 2025
to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;)
and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zGX7GCjzbG8c" title="Principal amount">1,725,000</span> to each note holder. The Company received $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zfBUrIuoyvqf" title="Gross proceeds">3,450,000</span>
in gross proceeds. The notes bear an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zUOaMX1twB9g" title="Note interest rate">10</span>% per annum and mature on December 31, 2025. On July 7, 2025, the Company entered
into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a
$<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250604__20250614_zTrkgFozO786" title="Loss on extinguishment of debt">2,262,774</span> loss on extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors
elected to convert the entire note balance for shares of common stock. The notes balance at September 30, 2025, was zero with Paseco ApS
and Laksya Ventures Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zbxqySSgYwve" title="Principal amount">2,650,000</span>. The Company received $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zEfbYnqY3vV" title="Gross proceeds">2,650,000</span> in gross proceeds. The notes bear an
interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zYJniwo5in62" title="Note interest rate">10</span>% per annum and mature from December 31, 2024 to December 31, 2025. <span id="xdx_90E_eus-gaap--MaturitiesOfTimeDepositsDescription_c20250701__20250930_zjDFf0d9V311" title="Maturity description">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange
Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a $1,821,843 loss on
extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors elected to convert
the entire note balance for shares of common stock. The note balance at September 30, 2025, was zero with Paseco ApS and Laksya Ventures
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_903_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zY8fWR4upXVj" title="Agreement description">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory
notes. The exchange resulted in a $364,303 loss on extinguishment of debt. Immediately following the issuance of the convertible notes
on July 7, 2025, the investors elected to convert the entire note balance for shares of common stock. The note balance at September 30,
2025 was approximately zero with Paseco ApS and Laksya Ventures Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zXApi2uHurpk" title="Agreement description">On November 1, 2024, Renovaro Cube
entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at September 30, 2025 was approximately
$270,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zS5FT7Prpbo3" title="Agreement description">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing
promissory note for a new convertible promissory note. The exchange resulted in a $71,112 loss on extinguishment of debt. Immediately
following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of
common stock. The note balance at September 30, 2025 was zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zdlFjVTqPdA2" title="Agreement description">On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025,
the Company entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange
resulted in a $41,319 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the
investor elected to convert the entire note balance for shares of common stock. The note balance at September 30, 2025 was zero with Paseco
ApS and Laksya Ventures Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zCZqGmge1wgh" title="Agreement description">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to
exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $80,343 loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zM95opSLRQa2" title="Agreement description">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory
note for a new convertible promissory note. The exchange resulted in a $401,715 loss on extinguishment of debt. Immediately following
the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of common stock.
The note balance, net of discount at September 30, 2025 was zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zsIr3326eOJe" title="Agreement description">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company
entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange resulted
in a $591,198 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor
elected to convert the entire note balance for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zzOG1EBn68p6" title="Principal amount">5,000,000</span> (the &#8220;Promissory
Note&#8221;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zV8p3Ne46pq5" title="Maturity date">November 1, 2024</span> (the &#8220;Maturity
Date&#8221;). The Promissory Note, as amended, bears interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_ztolvObqDSl" title="Interest rate">12</span>% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement
to exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20250706__20250707__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zWvXZwAg0X2i" title="Loss on extinguishment of debt">694,985</span> loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The Promissory Note balance at September 30, 2025 was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company&#8217;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#8217;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8XmZpDs95zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8212; <span id="xdx_82A_zUL94QJsaYf2">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>Purchase Agreement with Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC
(&#8220;Lincoln Park&#8221;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zTZPX7Wi74sj" title="Obligation to purchase">20,000,000</span> of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration for entering into
the 2023 Purchase Agreement, the Company issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zAmPVcJqWM63" title="Number of shares issued">69,602</span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the quarter ended September
30, 2025 and 2024, <span id="xdx_904_eus-gaap--SharesIssued_iI_do_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zDQlJGvWSAo2" title="Number of shares issued"><span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zoK3VoMnK95e" title="Number of shares issued">no</span></span> shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_905_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zM33reuPpmw5" title="Sale of stock issued cash consideration">9.7</span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zhkkf4Hioj17" title="Sale of stock issued cash consideration">16.1</span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#8217;s
debt obligations and provide additional flexibility to support strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_90D_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zDoysBWxhjH" title="Sale of stock issued cash consideration">16.1</span> million principal amount into an aggregate of <span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zpKJK4rFX439" title="Sale of stock issued cash consideration">5.36</span> million shares
of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zHeasnzSz4Ra" title="Conversion price">3.00</span> per share conversion price. The $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteMember_zeYPJCOMEy7f" title="Conversion price">3.00</span> per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#8217;s common stock on July 7, 2025, the date
of execution and conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 25, 2025, the Company issued&#160;<span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20250725_zxGpBL8l2bA4" title="Shares Issued Common Stock">5,500</span>
shares of Common Stock for settlement of accounts payable valued at $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_c20250725_zHAIFjsfV1Ak" title="Accounts payable">17,050</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 5, 2025, the Company
issued&#160;<span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20250905_zG8YU4gXn7ml" title="Shares Issued Common Stock">79,647</span> shares of Common Stock for settlement of accounts payable valued at $<span id="xdx_904_eus-gaap--AccountsPayableCurrent_iI_c20250905_z2Slmf6boFUg" title="Accounts payable">167,259</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 18, 2025, the Company filed a Certificate of Amendment to the
Certificate of Incorporation of the Company (the &#8220;Certificate of Amendment&#8221;) with the Secretary of State of the State of Delaware
to effect a 1-for-10 reverse stock split of the shares of the Company&#8217;s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250918_zI1m7H15E856" title="Common stock, par value">0.0001</span> per share (the &#8220;Common
Stock&#8221;), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September
29, 2025 (the &#8220;Reverse Stock Split&#8221;). All shares and the respective per-share amounts have been retroactively restated to
reflect the reverse split. The Common Stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on September
30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Stock-based Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model. During the three months ended September 30, 2025, the Company
granted no options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_z3IIFIfLgHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BC_zhJPsOzgxV34" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 65%; text-align: left; text-indent: -10pt">Expected term (in years)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 25%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zMED0SY0N8A8">5.5</span></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zjkVOKNqE1Id" title="Volatility">109.45</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zryWbYFyVhLd" title="Volatility">118.99</span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zIp2xowPvwDa" title="Risk free interest rate">3.86</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBIOoMMCbj73" title="Risk free interest rate">4.40</span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zbudH6P1eWui" title="Dividend yield">0</span></td>
<td style="text-align: left">%</td></tr>
</table>


<p id="xdx_8A7_zF6eimcGsW12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_c20250701__20250930_zMnSM7fQVBbj" title="Stock-based Compensation description">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;83,333&#160;shares of
Common Stock from the original&#160;100,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;97,826&#160;shares of Common
Stock of the Company with a per-share exercise price of $6.90. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $185,373&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="color: #212529; background-color: white">In
total, the Company recognized stock-based compensation expense of $<span id="xdx_90D_ecustom--StockbasedCompensationExpense_c20250701__20250930_zRDNhYXk9YXc" title="Stock-based compensation expense">181,312</span> net a recapture of $127,032 related to options and $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250701__20250930_z353EWRLHNQi" title="restricted option stock awards">36,973</span>
related to restricted stock awards for the three months ended September 30, 2025. For the three months ended September 30, 2024, the Company
recognized stock-based compensation expense related to options of $</span><span id="xdx_904_ecustom--StockbasedCompensationExpenseRelatedToOptions_iI_c20250930_zDOMNDiwpbEg" title="Stock-based compensation expense related to options">357,648</span>. <span style="background-color: white">At
September 30, 2025, the Company had approximately $<span id="xdx_906_ecustom--UnrecognizedCompensationCost_iI_c20250930_zOwfm5jPxmvk" title="Unrecognized compensation cost">192,608</span>&#160;of unrecognized compensation cost related to non-vested options.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="color: #212529; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjkhUIGXmatc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_82E_zvLu64xVDt4k">COMMITMENTS AND CONTINGENCIES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#8220;G Tech&#8221;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#8220;HBV License&#8221;) for a treatment under development
(the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV) infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $<span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHjXAZNuFNRf" title="Payment for license">1.2</span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zfHKplGnMJZa" title="Royalty percentage">2</span>% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUnteZzD23Ib" title="Payment for license">1.2</span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement during the quarters ending September 30, 2025, and 2024.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G
Tech and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#8220;Development License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $<span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_z3JEQty9Hhwi" title="Up-front payment">10,000,000</span> and a $<span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zAKQ39BPSdNj" title="Payment for expenditures">760,000</span> payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $600,000 and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zg4mD4k8vul7" title="Initial payment">600,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">G Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Securities Class Action Litigation.</i>
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
&#8220;Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement that, subject to final approval by the United States District Court for the Central District of California,
provides for resolution of the Securities Class Action Litigation. The Court granted the lead plaintiff&#8217;s motion for preliminary
approval of the settlement on August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>Federal Derivative Litigation.
</i>On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central
District of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. The parties in the Koenig Matter, the Solak Matter (defined
below), and the Midler Matter (defined below) have entered into a stipulation of settlement that, subject to final approval by the United
States District Court for the Central District of California, provides for resolution of the Koenig Matter, Solak Matter, and Midler Matter
(the &#8220;Koenig-Solak-Midler Settlement&#8221;). On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary
approval of the Koenig-Solak-Midler Settlement with the United States District Court for the Central District of California. The defendants
have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the
United States District Court for the Central District of California. The Solak Matter is stayed pending approval of the Koenig-Solak-Midler
Settlement. The defendants have not yet responded to the complaint. Management is unable to determine the likelihood of a loss, including
a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><i>State Derivative Litigation.</i>
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. On November 3, 2025,
plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the United States District
Court for the Central District of California. The defendants have not yet responded to the complaint. Management is unable to determine
the likelihood of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative
action in the United States District Court for the Central District of California against certain officers, directors, and investors of
the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science and Wittekind&#8217;s demand for corrective
action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#8220;Derivative
Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange
Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion to dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. On
October 22, 2024, the plaintiffs filed a notice of certain subsequent events that they allege relate to their pending motion to dismiss.
On October 29, 2024, the court granted the director defendants&#8217; motion to dismiss and dismissed the Derivative Complaint without
prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On June 21, 2024, the Company filed
suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint. A hearing took place on
June 25, 2025, and on November 7, 2025, the Court granted defendants&#8217; motion and dismissed the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai commenced an action against Predictive Oncology, Inc. (&#8220;POAI&#8221;)
in the Delaware Court of Chancery claiming that POAI breached a &#8220;definitive&#8221; January 2025 Letter Agreement pursuant to which
Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition impossible and dramatically devalued the share
price of stock Lunai had already acquired as well as the value of the company it was contractually entitled to acquire. Lunai sought specific
performance or, in the alternative, money damages. The parties have exchanged paper discovery and noticed depositions. The action has
been held in abeyance while the parties attempt to negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zCEcYsdNQn33" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8&#160;&#8212;&#160;<span id="xdx_827_zhkBkw65VVX7">RELATED PARTY TRANSACTIONS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of September 30, 2025, the Company
has accrued $<span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_z4dfIcMmNdx9" title="Accrued balance">384,949</span> of compensation related expenses for the Company&#8217;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_znR4ACdnwolj" title="Common stock forfeited shares">83,333</span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zBTPDhQU1z9j" title="Shares of common stock  granted">100,000</span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zbyDOG3NMfSi" title="Purchase shares">97,826</span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z2JjN2VsOA5k" title="Warrant exercise price per share">6.90</span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_90F_ecustom--UnrecognizedCompensationExpense_c20250701__20250930_zaYYR0Gl5ZOf" title="Unrecognized compensation expense">185,373</span>&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zHyfyqBq4SLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 &#8212; <span id="xdx_82C_zRFdcpLCAao7">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the period ending September
30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately
because they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 17%"><span style="font-size: 10pt"><b>Reportable Segment</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; white-space: nowrap; width: 82%"><span style="font-size: 10pt"><b>Description </b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>RENB</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify; white-space: nowrap"><span style="font-size: 10pt">Developing new immunotherapies to combat cancer </span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>BioSymetrics</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 10pt"><b>RENC</b></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the period ending September 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision
maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported
on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">On September
2, 2025, the Court of Amsterdam (the &#8220;Court&#8221;) declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;), an indirect subsidiary
of Lunai Bioworks, Inc. (&#8220;Lunai&#8221;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary
petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company
deconsolidated Gedi Cube B.V. due to the loss of control of the subsidiary during the period ended September 30, 2025. As a result of
the deconsolidation, the Company recognized a gain on the bankruptcy of the subsidiary for $<span id="xdx_904_ecustom--GainOnBankruptcyOfSubsidiary_c20250701__20250930_z6Nro9z5IBA" title="Gain on the bankruptcy of the subsidiary">12,019,227</span> during the period ended September
30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zl3UjjoJCAFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8BF_znSclxIs2OVa" style="display: none">Schedule of segment operating loss and
    asset information</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98D_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--US_zoXvK22NSIt5" style="width: 12%; text-align: right" title="Operating income loss">2,700,505</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--US_zLMNOtpYM9f" style="width: 12%; text-align: right" title="Assets">867,678</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zHxQYfENaOjf" style="text-align: right" title="Operating income loss">273,951</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zU3bpurJp9vi" style="text-align: right" title="Assets">6,092,985</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--NL_zoh9hc52xkyb" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">333,904</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--NL_zELrnKOQL6L4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0907">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98C_ecustom--SegmentOperatingLoss_c20250701__20250930_z3laU0XWcxy2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">3,308,360</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98E_ecustom--SegmentAsset_iI_c20250930_zhYv8k0cAFPj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">6,960,663</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p id="xdx_8AA_zLe5xPcSKy9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Information
regarding each reportable segment for the three months ended September 30, 2025, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zyp3mTzmvGI9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zM37Ncm1thJ7" style="display: none">Schedule of information regarding segment reporting</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zQJTAsNXGBv7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zS52jXRMbaIj" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zVDJG83iJ9C1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_492_20250701__20250930_zSJKwiFigb4b" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zFKV4qpZi2Z" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,822,729</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">253,883</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">333,904</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,410,516</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_d0_zUHo0UTEE4Rf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">20,419</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,988</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">24,407</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--LonglivedAssetImpairment_d0_zeYAcMKqhg63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_d0_zwmbc9Xuru3a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">25,442</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,080</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">41,522</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SegmentOperatingLoss_zBctX5wAQC47" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,700,505</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">273,951</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">333,904</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,308,360</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A1_zpAWyNEe8O1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"><b><span style="text-decoration: underline">Geographic information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#8217;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ACQUISITIONS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zXMAhFfllGQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8212; <span id="xdx_827_zHzhWO5CDFpl">ACQUISITIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><i><span style="text-decoration: underline">BioSymetrics Inc. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#8220;<span style="text-decoration: underline">Lunai</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#8220;<span style="text-decoration: underline">Merger Sub</span>&#8221;), and Biosymetrics,
Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Biosymetrics</span>&#8221;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#8220;<span style="text-decoration: underline">Transaction</span>&#8221;). On April 8, 2025, Lunai consummated the Transaction and issued <span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z1LDcOJVwUre" title="Transaction issued shares">1.5</span> million shares of Lunai&#8217;s
common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_zpOhG5NxifQ5" title="Common stock per value">0.0001</span> per share (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The offer and sale of the Shares have not been registered
under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), in reliance on the exemption from registration
requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon representations contained in the Merger Agreement
that all those receiving Shares in connection with the Transaction are &#8220;accredited investors&#8221; as defined in Rule 501(a) under
the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with ASC 805-10 -&#160;<i>Business Combinations</i>. </span>The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zw5pBNuEud2a" title="Fair value of consideration transferred amount">6</span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zU7KCdvHkyvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zi98MeJPpdq7" style="display: none">Schedule of acquisition
fair value of the consideration</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zcAs7fAkP0O6" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock">6,058,500</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIBrP5JZi34" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">6,058,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A0_zkFmAnTI7vC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_zBQP4KQJ1yF9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_ziFGFF2h85L3" style="display: none">Schedule of fair values of the assets acquired and liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zpH20Z6vHkM9" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Cash_iNI_di_zvVIVuF7ayNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 18%; text-align: right">(3,822</td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zGMzIm9usq4a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">17,405</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--FixedAssets_iI_zTRAFjWfK49e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">13,365</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zz4YiPNvScnl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">26,948</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUc7o0VpXCe5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">975</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zA7iS78FDRMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">7,594</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_zXfb4WadhM59" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">73,879</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zQZU0nj1jVvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">82,448</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_z9RKZtW6plFi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(55,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr id="xdx_409_ecustom--Software_iI_zQfXg32ElGZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">143,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--TradeName_iI_zaQaoGbFU818" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z14YeUveV2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">5,963,000</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_z1Pgjx5WTLM5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">6,058,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AA_ztcmOgh91ur5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
three-month period ended September 30, 2024. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zoh8Mp8d3flb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zQwuKaPvkeU5" style="display: none">Schedule of statement of operations</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250225__20250226_zRDLIIuXY5uf" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--BusinessAcquisitionsRevenue_zezObfd0icki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Revenues</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">318,918</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--BusinessAcquisitionsNetIncomeLoss_zq3Loq7qiMTl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(44,499,586</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<p id="xdx_8A2_zfM9RCw63iG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-50/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z2o6wJjOvO0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 &#8212; <span id="xdx_824_zraXJ1wSCrv8">SUBSEQUENT EVENTS </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On November 4, 2025, the Company
issued&#160;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUnlgD23PCRk" title="Issuance of common stock shares">20,000</span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztf0pFwe4Ohh" title="Common stock for consulting services value">16,680</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 30, 2025, the Company
cancelled<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251030_zYjA3IOtShdj" title="Issuance of common stock shares">&#160;25,000</span> shares of Common Stock upon termination, previously issued to the former Chief Executive Officer of Renovaro Cube
valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251030_zWn2Jhb6rB6" title="Issuance of common stock shares, value">177,500</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 29, 2025, the Company
issued&#160;<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zByHRN2FL6M8" title="Issuance of common stock shares">237,500</span>&#160;shares of Common Stock pursuant to a settlement agreement valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember_zqLmYbWR24O6" title="Issuance of common stock shares, value">228,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 17, 2025, the Company
issued&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zPkPZBh1ZFae" title="Issuance of common stock shares">20,000</span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251016__20251017_zozyEjy2Lrcd" title="Common stock for consulting services value">24,000</span>.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessPolicyTextBlock', window );">Business</a></td>
<td class="text"><p id="xdx_846_ecustom--BusinessPolicyTextBlock_zM8bhbJd7Yuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zMJazVCBCdBc">Business</span> &#8211;</b>&#160;On
August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. (&#8220;Lunai&#8221;). On April 8, 2025,
Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics, Corp.&#8221;), as a wholly owned subsidiary pursuant
to a stock purchase agreement. On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro
Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) and
acquired GEDi Cube Intl Ltd and its subsidiaries GediCube B.V. and Grace Systems B.V. (&#8220;Renovaro Cube&#8221;), as a wholly owned
subsidiary pursuant to a stock purchase agreement. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform
for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights,
enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfhaeqhssCx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zRGXCqp0TaXi">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).
The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2025, and 2024
and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s June 30, 2025 audited financial
statements. The results of operations for the period ended September 30, 2025 are not necessarily indicative of the operating results
for the full year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zjYCGxlKlCRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zOQrRNCWX6Ne">Consolidation</span> &#8211;</b> For
the three months ended September 30, 2025, and 2024, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BankruptcyPolicyTextBlock', window );">Bankruptcy</a></td>
<td class="text"><p id="xdx_848_ecustom--BankruptcyPolicyTextBlock_zxMyMLvyswRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86C_zayuz0B64oh5">Bankruptcy </span>-</b> The Company
accounts for bankruptcy under ASC 810, Consolidation. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;),
an indirect subsidiary of Lunai Bioworks, Inc. As of September 30, 2025 the Company deconsolidated Gedi Cube B.V., derecognizing its net
liabilities and releasing the cumulative translation adjustment balance to earnings. The bankruptcy resulted in a gain of $<span id="xdx_90B_ecustom--BankruptcyResultedInGain_c20250701__20250930_zYAcaX7EBWyj" title="Bankruptcy resulted in a gain">12,019,227</span>
during the three months ended September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_z472sHq2DJw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zIUBCJ90PhLh">Accounting Estimates</span> &#8211;</b>
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zrgDFSUyEJoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86A_z2kWuceihXFb">Loss Per Share</span>&#160;</b>&#8211;Basic earnings per common share (EPS) are based on the weighted average
number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed
as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings
per share calculation include in-the-money stock options that have been granted but have not been exercised and shares issuable upon conversion
of convertible common stock and convertible notes. The Company had <span id="xdx_904_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250930_zz8t1Bt16A38" title="Common stock outstanding">1,244,888</span> and <span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240930_z2JKPdRrqSs2" title="Common stock outstanding">1,729,342</span> potential shares of Common Stock excluded from
the Diluted EPS calculation as of September 30, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency &amp; Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zbjCC4VyiJja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zn14GVueakDa">Functional Currency &amp; Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended September 30, 2025, and 2024. Translation gains and losses are deferred
and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement
of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InvestmentinEquitySecuritiesPolicyTextBlock', window );">Investment in Equity Securities</a></td>
<td class="text"><p id="xdx_849_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zRyaUyKr69Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zjlPOJV9f471">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchasedEquitySecurities_iI_c20250228_zgRDsGVwMiib" title="Purchased equity securities">500,000</span> of equity securities. During the period ended September 30, 2025, the Company recorded a change in fair value of equity
securities for $<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_c20250701__20250930_zbnqDYItSFFb" title="Fair value of equity securities">156,849</span> and sold the securities for $<span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiGainLoss_c20250701__20250930_zckIHg6vJ15c" title="Investment in equity securities">544,700</span>. The investment in equity securities balance at September 30, 2025, was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0NQ2pJr1opd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_865_z1i7QDoyRl8d">New Accounting Pronouncements
Not Yet Adopted</span></b>&#160;- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BankruptcyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BankruptcyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InvestmentinEquitySecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InvestmentinEquitySecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of key input to valuing the contingent consideration liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--FairValueConcentrationOfRiskTextBlock_zVIeTjspzAje" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details )">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zTbxwmiSnMid" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAiDKvghFQXf" title="Stock Price">1.42</span></td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ziE7IUTNWTpa" title="Exercise Price">5.30</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zsIQsBDmJDXh" title="Exercise Price">19.20</span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOcOIkbpe40g" title="Volatility">115.5</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z2MChPVYK1i6" title="Volatility">143.3</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zieq7CsH6482" title="Risk Free Rate">3.54</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAtgEuBTleve" title="Risk Free Rate">3.94</span>%</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20250701__20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zfDogYXT7rvf" title="Expected Dividends">0</span></td>
<td style="padding-bottom: 1pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zLpgHT05ft7b" title="Expected Term (years)">2.45</span> &#8211; <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdaNRZRjMswi" title="Expected Term (years)">8.13</span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock', window );">Schedule of fair value measurement on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_zhEvZ0FZbhNf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B2_zjBOizIiVET3" style="display: none">Schedule of fair value measurement on recurring basis</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_491_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYZKbCbh3COk" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_490_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z99ZK5ouloBl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49A_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze9UsuxrdEY7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fair Value Measurements at</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">&#160;<br/> Reporting Date Using</p></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">The roll forward of the contingent consideration liability is as follows:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z4zHG0uKm5Xl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Balance June 30, 2025</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 11%; text-align: right">630,000</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zX4x6YbgKuha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Fair value adjustment</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(370,000</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zHn0Z3nefF8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent Consideration Liability at September 30, 2025</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">260,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of definite-life and indefinite-life intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z3evUhPnV3mc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6TEfz3w8Q9f" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt">Software platform</td>
<td style="width: 2%">&#160;</td>
<td style="width: 11%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zc0nO79haeUh" title="Useful life">5</span> Years</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z5Oj6hiCJaN" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning">143,000</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zqupOR3oik0d" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zr27SdhVsM0e" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization">(13,712</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zdDY9nqAbTog" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zZVvRURXm30g" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">&#8212;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 2%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z0uGuh274ZNb" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">129,288</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z06kiu0KEXV8" title="Useful life">2</span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlxnjTe714qb" style="text-align: right" title="Net definite-life intangible assets at beginning">8,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXfn5AY8mBg8" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zSpbmCUBXS51" style="text-align: right" title="Net definite-life intangible assets, Amortization">(1,918</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zDZArRFfc3K1" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zWvG7PmMKi2" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zFt0ve4ldaif" style="text-align: right" title="Net definite-life intangible assets at ending">6,082</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td>
<td>&#160;</td>
<td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdgXdGKDQs54" title="Useful life">20</span> Years</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zN2aI7lYTa7a" style="text-align: right" title="Net definite-life intangible assets at beginning">313,010</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXpbFKOw1iZ2" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGSu1yyOMQF8" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_982_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuYNstgZR2a7" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwBDWp3vi0f" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,093</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxYIHPHW9Jj" style="text-align: right" title="Net definite-life intangible assets at ending">311,917</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zIilEfxn708f" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(298,016</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zYQTgXXpVolc" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zbXb3sF8kPOd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(2,659</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z0SZ4FSwEwV4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zc8RdkimNFvb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">6,368</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zoSETgpApoH" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(294,307</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930_zgAPNZBLRsm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">165,994</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z0bhNBNcAsqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930_z8GcL5TFmKDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(18,289</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930_zw7dnYUvfrr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930_zlmMWp4mj791" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">5,275</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930_zUZ4Mkw61TUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">152,980</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td>&#160;</td>
<td style="text-align: left; padding-left: 5.4pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIrKAOOAP0xb" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">5,963,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zAyDwYSbZJn9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_988_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIC6TfGmdYua" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zHFq70etLZc" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9IeGzNOei4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zXDGJ52QWeOj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930_zTZNX1tENBcl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">5,963,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z9kONEG67yGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930_zZn8LSkWOBSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98B_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930_zd0gEmogMmKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930_z9yYRn4vm0y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930_z5EIu2Mhz8Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zt8uoumTSSza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_z501rc3v58Rf" style="display: none">Schedule of future amortization expense</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years ended&#160;June 30,</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 57%; text-align: left; text-indent: -10pt">2026</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250930_zUVcNtu43dyb" style="width: 30%; text-align: right" title="2026">32,420</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250930_zaeQzlm9Q0Gb" style="text-align: right" title="2027">32,420</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2028</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250930_zV85U7gkWS02" style="text-align: right" title="2028">29,380</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2029</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250930_zu5NoeDnxCzc" style="text-align: right" title="2029">29,380</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250930_zhmQ7e0Oassl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">29,380</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250930_z8oeWpFbbx8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">152,980</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_z3IIFIfLgHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BC_zhJPsOzgxV34" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 65%; text-align: left; text-indent: -10pt">Expected term (in years)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 25%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zMED0SY0N8A8">5.5</span></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zjkVOKNqE1Id" title="Volatility">109.45</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zryWbYFyVhLd" title="Volatility">118.99</span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zIp2xowPvwDa" title="Risk free interest rate">3.86</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBIOoMMCbj73" title="Risk free interest rate">4.40</span></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zbudH6P1eWui" title="Dividend yield">0</span></td>
<td style="text-align: left">%</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment operating loss and asset information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zl3UjjoJCAFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8BF_znSclxIs2OVa" style="display: none">Schedule of segment operating loss and
    asset information</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98D_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--US_zoXvK22NSIt5" style="width: 12%; text-align: right" title="Operating income loss">2,700,505</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_987_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--US_zLMNOtpYM9f" style="width: 12%; text-align: right" title="Assets">867,678</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zHxQYfENaOjf" style="text-align: right" title="Operating income loss">273,951</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98D_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zU3bpurJp9vi" style="text-align: right" title="Assets">6,092,985</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--NL_zoh9hc52xkyb" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">333,904</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--NL_zELrnKOQL6L4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0907">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98C_ecustom--SegmentOperatingLoss_c20250701__20250930_z3laU0XWcxy2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">3,308,360</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td id="xdx_98E_ecustom--SegmentAsset_iI_c20250930_zhYv8k0cAFPj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">6,960,663</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of information regarding segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zyp3mTzmvGI9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zM37Ncm1thJ7" style="display: none">Schedule of information regarding segment reporting</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zQJTAsNXGBv7" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zS52jXRMbaIj" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zVDJG83iJ9C1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_492_20250701__20250930_zSJKwiFigb4b" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zFKV4qpZi2Z" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">1,822,729</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">253,883</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">333,904</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">2,410,516</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_d0_zUHo0UTEE4Rf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">20,419</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,988</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">24,407</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--LonglivedAssetImpairment_d0_zeYAcMKqhg63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Long-lived asset impairment</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">831,915</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_d0_zwmbc9Xuru3a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">25,442</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">16,080</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">41,522</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SegmentOperatingLoss_zBctX5wAQC47" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,700,505</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">273,951</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">333,904</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,308,360</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of acquisition fair value of the consideration</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zU7KCdvHkyvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zi98MeJPpdq7" style="display: none">Schedule of acquisition
fair value of the consideration</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zcAs7fAkP0O6" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock">6,058,500</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIBrP5JZi34" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">6,058,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock', window );">Schedule of fair values of the assets acquired and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_zBQP4KQJ1yF9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_ziFGFF2h85L3" style="display: none">Schedule of fair values of the assets acquired and liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zpH20Z6vHkM9" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Cash_iNI_di_zvVIVuF7ayNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td>
<td style="width: 10%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 18%; text-align: right">(3,822</td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zGMzIm9usq4a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">17,405</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--FixedAssets_iI_zTRAFjWfK49e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">13,365</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zz4YiPNvScnl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">26,948</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUc7o0VpXCe5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">975</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zA7iS78FDRMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">7,594</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_zXfb4WadhM59" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">73,879</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zQZU0nj1jVvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">82,448</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_z9RKZtW6plFi" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(55,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr id="xdx_409_ecustom--Software_iI_zQfXg32ElGZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">143,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--TradeName_iI_zaQaoGbFU818" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">8,000</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z14YeUveV2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">5,963,000</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_z1Pgjx5WTLM5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">6,058,500</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Schedule of statement of operations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zoh8Mp8d3flb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zQwuKaPvkeU5" style="display: none">Schedule of statement of operations</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20250225__20250226_zRDLIIuXY5uf" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--BusinessAcquisitionsRevenue_zezObfd0icki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Revenues</td>
<td style="width: 10%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">318,918</td>
<td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--BusinessAcquisitionsNetIncomeLoss_zq3Loq7qiMTl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(44,499,586</td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BankruptcyResultedInGain', window );">Bankruptcy resulted in a gain</a></td>
<td class="nump">$ 12,019,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">1,244,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchasedEquitySecurities', window );">Purchased equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Fair value of equity securities</a></td>
<td class="nump">$ 156,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Investment in equity securities</a></td>
<td class="nump">$ 544,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BankruptcyResultedInGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BankruptcyResultedInGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PurchasedEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PurchasedEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 624,808<span></span>
</td>
<td class="nump">$ 92,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">507,643,549<span></span>
</td>
<td class="nump">$ 510,462,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="nump">$ 18,922,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details ) - Black Scholes Option Pricing Model [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 1.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">115.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">3.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 19.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">143.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">3.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at September 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at September 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2025</a></td>
<td class="nump">630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="num">(370,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at September 30, 2025</a></td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - Renovaro Cube [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability was recorded at fair value</a></td>
<td class="nump">$ 20,557,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="nump">7,083,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="nump">1,189,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 165,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(18,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">5,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">152,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">5,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">$ 5,963,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember', window );">Software Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(13,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">$ 129,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember', window );">Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(1,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">$ 6,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 313,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="num">(1,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">311,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember', window );">Less Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="num">(298,016)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(2,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">6,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="num">(294,307)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">5,963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">$ 5,963,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 32,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">32,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">29,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">29,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Thereafter</a></td>
<td class="nump">29,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 152,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,963,000<span></span>
</td>
<td class="nump">$ 5,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Trademark', window );">Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,963,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Software">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Software</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Trademark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Trademark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2025</div></th>
<th class="th"><div>Jun. 14, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Nov. 03, 2024</div></th>
<th class="th"><div>Sep. 16, 2024</div></th>
<th class="th"><div>Sep. 06, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 03, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 19, 2025</div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 04, 2025</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotesBalance', window );">Notes balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="nump">$ 5,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PlacementCosts', window );">Placement costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Notes balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AmortizationPlacementCost', window );">Amortization placement cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Notes balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Issuance of common stock shares</a></td>
<td class="nump">5,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,262,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,329,592)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfTimeDepositsDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange
Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a $1,821,843 loss on
extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors elected to convert
the entire note balance for shares of common stock. The note balance at September 30, 2025, was zero with Paseco ApS and Laksya Ventures
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember', window );">The Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AgreementDescription', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 1, 2024, Renovaro Cube
entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at September 30, 2025 was approximately
$270,000.<span></span>
</td>
<td class="text">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company
entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange resulted
in a $591,198 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor
elected to convert the entire note balance for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.<span></span>
</td>
<td class="text">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing
promissory note for a new convertible promissory note. The exchange resulted in a $71,112 loss on extinguishment of debt. Immediately
following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of
common stock. The note balance at September 30, 2025 was zero.<span></span>
</td>
<td class="text">On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025,
the Company entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange
resulted in a $41,319 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the
investor elected to convert the entire note balance for shares of common stock. The note balance at September 30, 2025 was zero with Paseco
ApS and Laksya Ventures Inc.<span></span>
</td>
<td class="text">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to
exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $80,343 loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory
note for a new convertible promissory note. The exchange resulted in a $401,715 loss on extinguishment of debt. Immediately following
the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of common stock.
The note balance, net of discount at September 30, 2025 was zero.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory
notes. The exchange resulted in a $364,303 loss on extinguishment of debt. Immediately following the issuance of the convertible notes
on July 7, 2025, the investors elected to convert the entire note balance for shares of common stock. The note balance at September 30,
2025 was approximately zero with Paseco ApS and Laksya Ventures Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 694,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember', window );">Paseco Ap S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember', window );">Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Paseco Ap S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AmortizationPlacementCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AmortizationPlacementCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PlacementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PlacementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SaleOfStockConsiderationReceivedCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SaleOfStockConsiderationReceivedCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfTimeDepositsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of time deposit maturities, including certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfTimeDepositsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_DecemberNote2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Renovaro [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=RENB_RenovaroMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">109.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=RENB_RenovaroMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">118.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=RENB_RenovaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=RENB_RenovaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 18, 2025</div></th>
<th class="th"><div>Sep. 05, 2025</div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
<th class="th"><div>Jul. 25, 2025</div></th>
<th class="th"><div>Jul. 07, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,360,000<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares Issued Common Stock</a></td>
<td class="nump">23,180,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,739,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise', window );">Stock-based Compensation description</a></td>
<td class="text">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;83,333&#160;shares of
Common Stock from the original&#160;100,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;97,826&#160;shares of Common
Stock of the Company with a per-share exercise price of $6.90. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $185,373&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockbasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 181,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">restricted option stock awards</a></td>
<td class="nump">36,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockbasedCompensationExpenseRelatedToOptions', window );">Stock-based compensation expense related to options</a></td>
<td class="nump">357,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 192,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNoteMember', window );">Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember', window );">Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SaleOfStockConsiderationReceivedCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SaleOfStockConsiderationReceivedCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockbasedCompensationExpenseRelatedToOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockbasedCompensationExpenseRelatedToOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The policy, if any, for issuing shares (or other type of equity) upon exercise or conversion of equity-based awards into shares of stock or units, including the source of those shares or units (that is, new share, new unit, treasury shares or treasury units).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 10, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Nov. 15, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UpfrontPayment', window );">Up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PaymentForExpenditures', window );">Payment for expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InitialPayment', window );">Initial payment</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember', window );">G Tech [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PaymentForExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PaymentForExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Aug. 23, 2025</div></th>
<th class="th"><div>Feb. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Common stock forfeited shares</a></td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesOfCommonStockGranted', window );">Shares of common stock granted</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember', window );">Mark Dybul [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Accrued balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesOfCommonStockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesOfCommonStockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">$ 3,308,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">6,960,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">2,700,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">867,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">273,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">6,092,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">333,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,410,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,407<span></span>
</td>
<td class="nump">$ 390,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LonglivedAssetImpairment', window );">Long-lived asset impairment</a></td>
<td class="nump">831,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41,522<span></span>
</td>
<td class="nump">$ 32,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">3,308,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember', window );">RENB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,822,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LonglivedAssetImpairment', window );">Long-lived asset impairment</a></td>
<td class="nump">831,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">25,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">2,700,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">253,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LonglivedAssetImpairment', window );">Long-lived asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">273,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember', window );">RENC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">333,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LonglivedAssetImpairment', window );">Long-lived asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">$ 333,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LonglivedAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LonglivedAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_GainOnBankruptcyOfSubsidiary', window );">Gain on the bankruptcy of the subsidiary</a></td>
<td class="nump">$ 12,019,227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_GainOnBankruptcyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_GainOnBankruptcyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Details) - GEDi Cube [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationContingentConsiderationCommonStock', window );">Common stock</a></td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationContingentConsiderationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationContingentConsiderationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember', window );">GEDi Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid &amp; Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_FixedAssets', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total Assets Acquired:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_TradeName', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_FixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_FixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Software">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Software</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_TradeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_TradeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS (Details 2)<br></strong></div></th>
<th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsRevenue', window );">Revenues</a></td>
<td class="nump">$ 318,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,499,586)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Details Narrative) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 18, 2025</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_TransactionIssuedShares', window );">Transaction issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of consideration transferred amount</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_TransactionIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_TransactionIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
<th class="th"><div>Oct. 30, 2025</div></th>
<th class="th"><div>Oct. 29, 2025</div></th>
<th class="th"><div>Oct. 17, 2025</div></th>
<th class="th"><div>Oct. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock for consulting services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_SettlementAgreementMember', window );">Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock for consulting services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock for consulting services value</a></td>
<td class="nump">$ 16,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>262</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Acquisitions</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReporting</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Acquisitions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/GoingConcern</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SEGMENT REPORTING (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails1</Role>
      <ShortName>SEGMENT REPORTING (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SEGMENT REPORTING (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>SEGMENT REPORTING (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - ACQUISITIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsDetails</Role>
      <ShortName>ACQUISITIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - ACQUISITIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsDetails1</Role>
      <ShortName>ACQUISITIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - ACQUISITIONS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsDetails2</Role>
      <ShortName>ACQUISITIONS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - ACQUISITIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsDetailsNarrative</Role>
      <ShortName>ACQUISITIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="e7036_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SubsequentEvents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="e7036_10q.htm">e7036_10q.htm</File>
    <File>renb-20250930.xsd</File>
    <File>renb-20250930_cal.xml</File>
    <File>renb-20250930_def.xml</File>
    <File>renb-20250930_lab.xml</File>
    <File>renb-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.gif</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="389">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e7036_10q.htm": {
   "nsprefix": "RENB",
   "nsuri": "http://renovarobio.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "e7036_10q.htm"
     ]
    },
    "schema": {
     "local": [
      "renb-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "renb-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "renb-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "renb-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "renb-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 201,
   "keyCustom": 61,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 26,
   "hidden": {
    "total": 54,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://renovarobio.com/20250930": 18,
    "http://fasb.org/us-gaap/2025": 31
   },
   "contextCount": 136,
   "entityCount": 1,
   "segmentCount": 45,
   "elementCount": 510,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 389,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://renovarobio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited",
     "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999013 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://renovarobio.com/role/GoingConcern",
     "longName": "999014 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://renovarobio.com/role/FairValueMeasurements",
     "longName": "999015 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwill",
     "longName": "999016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://renovarobio.com/role/Debt",
     "longName": "999017 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://renovarobio.com/role/StockholdersEquity",
     "longName": "999018 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingencies",
     "longName": "999019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactions",
     "longName": "999020 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://renovarobio.com/role/SegmentReporting",
     "longName": "999021 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://renovarobio.com/role/Acquisitions",
     "longName": "999022 - Disclosure - ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://renovarobio.com/role/SubsequentEvents",
     "longName": "999023 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsTables",
     "longName": "999025 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:FairValueConcentrationOfRiskTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:FairValueConcentrationOfRiskTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables",
     "longName": "999026 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://renovarobio.com/role/StockholdersEquityTables",
     "longName": "999027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://renovarobio.com/role/SegmentReportingTables",
     "longName": "999028 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://renovarobio.com/role/AcquisitionsTables",
     "longName": "999029 - Disclosure - ACQUISITIONS (Tables)",
     "shortName": "ACQUISITIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:BankruptcyResultedInGain",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "RENB:BankruptcyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:BankruptcyResultedInGain",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "RENB:BankruptcyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://renovarobio.com/role/GoingConcernDetailsNarrative",
     "longName": "999031 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "RENB:WorkingCapitalDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails",
     "longName": "999032 - Disclosure - FAIR VALUE MEASUREMENTS (Details )",
     "shortName": "FAIR VALUE MEASUREMENTS (Details )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails1",
     "longName": "999033 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "999034 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_RenovaroCubeMember",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_RenovaroCubeMember",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
     "longName": "999035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1",
     "longName": "999036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "longName": "999037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:Trademark",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://renovarobio.com/role/DebtDetailsNarrative",
     "longName": "999038 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "RENB:NotesBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "RENB:NotesBalance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails",
     "longName": "999039 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_RenovaroMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_RenovaroMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999040 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-20",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-20",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-08-022024-08-23",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-08-022024-08-23",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails",
     "longName": "999043 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:SegmentOperatingLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "RENB:SegmentAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails1",
     "longName": "999044 - Disclosure - SEGMENT REPORTING (Details 1)",
     "shortName": "SEGMENT REPORTING (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://renovarobio.com/role/SegmentReportingDetailsNarrative",
     "longName": "999045 - Disclosure - SEGMENT REPORTING (Details Narrative)",
     "shortName": "SEGMENT REPORTING (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-07-01to2025-09-30",
      "name": "RENB:GainOnBankruptcyOfSubsidiary",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://renovarobio.com/role/AcquisitionsDetails",
     "longName": "999046 - Disclosure - ACQUISITIONS (Details)",
     "shortName": "ACQUISITIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://renovarobio.com/role/AcquisitionsDetails1",
     "longName": "999047 - Disclosure - ACQUISITIONS (Details 1)",
     "shortName": "ACQUISITIONS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:Software",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://renovarobio.com/role/AcquisitionsDetails2",
     "longName": "999048 - Disclosure - ACQUISITIONS (Details 2)",
     "shortName": "ACQUISITIONS (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-02-252025-02-26",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-252025-02-26",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
     "longName": "999049 - Disclosure - ACQUISITIONS (Details Narrative)",
     "shortName": "ACQUISITIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:TransactionIssuedShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:TransactionIssuedShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999050 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-10-282025-10-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-282025-10-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e7036_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r832"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable \u2013 trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r46"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r63",
      "r111",
      "r583",
      "r613",
      "r614",
      "r1043"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11",
      "r16",
      "r466",
      "r469",
      "r514",
      "r609",
      "r610",
      "r954",
      "r955",
      "r956",
      "r970",
      "r971",
      "r972",
      "r973"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r832",
      "r1097"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r970",
      "r971",
      "r972",
      "r973",
      "r1044",
      "r1100"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADJUSTMENTS TO RECONCILE NET INCOME (LOSS) TO NET CASH USED IN OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r896",
      "r922"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r899",
      "r925"
     ]
    },
    "RENB_AgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "AgreementDescription",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r918",
      "r926",
      "r930",
      "r938"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r936"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AmortizationOfDiscountOnNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "AmortizationOfDiscountOnNotePayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of discount of notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance cost",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r770",
      "r771",
      "r960",
      "r1052"
     ]
    },
    "RENB_AmortizationPlacementCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "AmortizationPlacementCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization placement cost"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACQUISITIONS",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r1042"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r90",
      "r105",
      "r132",
      "r134",
      "r135",
      "r165",
      "r178",
      "r196",
      "r200",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r458",
      "r462",
      "r490",
      "r571",
      "r572",
      "r578",
      "r666",
      "r760",
      "r761",
      "r772",
      "r832",
      "r844",
      "r845",
      "r856",
      "r1003",
      "r1004",
      "r1055"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r112",
      "r132",
      "r134",
      "r135",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r458",
      "r462",
      "r490",
      "r832",
      "r1003",
      "r1004",
      "r1055"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "RENB_BankruptcyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BankruptcyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bankruptcy"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BankruptcyResultedInGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BankruptcyResultedInGain",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bankruptcy resulted in a gain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "RENB_BioSymetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BioSymetricsMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Symetrics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option Pricing Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails",
      "http://renovarobio.com/role/AcquisitionsDetails1",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r616",
      "r781",
      "r782",
      "r1034",
      "r1035",
      "r1037"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails",
      "http://renovarobio.com/role/AcquisitionsDetails1",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r616",
      "r781",
      "r782",
      "r1034",
      "r1035",
      "r1037"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent shares issuable in connection with the acquisition",
        "documentation": "Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r786",
      "r787",
      "r818",
      "r819"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails",
      "http://renovarobio.com/role/AcquisitionsDetails1",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r400",
      "r401",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r447",
      "r448",
      "r449",
      "r452",
      "r784",
      "r789",
      "r1034",
      "r1035",
      "r1037"
     ]
    },
    "RENB_BusinessAcquisitionsNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BusinessAcquisitionsNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessAcquisitionsRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BusinessAcquisitionsRevenue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r449",
      "r784",
      "r786"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of consideration transferred amount",
        "documentation": "Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r819"
     ]
    },
    "RENB_BusinessCombinationContingentConsiderationCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BusinessCombinationContingentConsiderationCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance June 30, 2025",
        "periodEndLabel": "Contingent Consideration Liability at September 30, 2025",
        "label": "Contingent consideration liability was recorded at fair value",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r449",
      "r481",
      "r482",
      "r483",
      "r784",
      "r788"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets Acquired:",
        "documentation": "Amount of asset acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r430"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable",
        "documentation": "Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date, classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived",
        "documentation": "Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities Assumed",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r430"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Assets Acquired",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r786",
      "r1036",
      "r1038"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Consideration",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1038"
     ]
    },
    "RENB_BusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "BusinessPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CancellationOfRestrictedStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "CancellationOfRestrictedStockAwards",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CancellationOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "CancellationOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software platform, net",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r738"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash",
        "label": "Cash [Default Label]",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r580",
      "r639",
      "r661",
      "r832",
      "r844",
      "r845",
      "r856",
      "r950"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r102",
      "r742"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH, END OF PERIOD",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r68",
      "r131"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CHANGE IN CASH",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r68"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CashPaidDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "CashPaidDuringYearForAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ChangeInFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ChangeInFairValueOfContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited",
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of contingent consideration",
        "negatedLabel": "Change in value of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r110",
      "r132",
      "r135",
      "r157",
      "r158",
      "r160",
      "r162",
      "r167",
      "r168",
      "r211",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r304",
      "r305",
      "r307",
      "r308",
      "r310",
      "r313",
      "r316",
      "r317",
      "r319",
      "r322",
      "r328",
      "r490",
      "r618",
      "r619",
      "r620",
      "r621",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r653",
      "r674",
      "r697",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r947",
      "r965",
      "r967",
      "r974"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r136",
      "r329"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r258",
      "r259",
      "r725",
      "r997",
      "r1002"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r847",
      "r848",
      "r850",
      "r851",
      "r852",
      "r853",
      "r970",
      "r971",
      "r973",
      "r1044",
      "r1096",
      "r1100"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock per value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r653"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Shares Issued Common Stock",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r56",
      "r653",
      "r672",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 350,000,000 shares authorized, 23,180,277 shares issued and outstanding at September 30, 2025; 17,739,291 shares issued and outstanding at June 30, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r305",
      "r312",
      "r582",
      "r832"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive Loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r114",
      "r116",
      "r120",
      "r569",
      "r591",
      "r592"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r750"
     ]
    },
    "RENB_ContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to conversion of convertible notes, shares",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes balance",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "RENB_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "verboseLabel": "Notes balance",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r1065"
     ]
    },
    "RENB_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited",
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of equity securities",
        "negatedLabel": "Change in value of equity securities",
        "documentation": "Amount of unrealized gain (loss) recognized in earnings from investment in debt and equity securities measured at fair value with change in fair value recognized in net income, and recognized from transfer of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity) to investment in debt security measured at fair value with change in fair value recognized in net income (trading). Excludes other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r132",
      "r133",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r264",
      "r265",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r291",
      "r298",
      "r299",
      "r301",
      "r464",
      "r506"
     ]
    },
    "RENB_DebtDiscountRelatedToConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "DebtDiscountRelatedToConvertiblePromissoryNotes",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount related to convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r278"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r506",
      "r507",
      "r768",
      "r769",
      "r831"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r277"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r464",
      "r575",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r831",
      "r963",
      "r964",
      "r966",
      "r969",
      "r1051",
      "r1053"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r767",
      "r1046",
      "r1047"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r44",
      "r78",
      "r79",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r464",
      "r575",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r831",
      "r963",
      "r964",
      "r966",
      "r969",
      "r1051",
      "r1053"
     ]
    },
    "RENB_DecemberNote2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "DecemberNote2023Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Note 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "RENB_DefiniteLifeIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "DefiniteLifeIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Definite life intangible assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits and other assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r124",
      "r165",
      "r183",
      "r200",
      "r744",
      "r760",
      "r761"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r870",
      "r882"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r121",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r155",
      "r157",
      "r160",
      "r161",
      "r162",
      "r164",
      "r303",
      "r390",
      "r398",
      "r455",
      "r477",
      "r478",
      "r570",
      "r593",
      "r751"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r121",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r157",
      "r160",
      "r161",
      "r162",
      "r164",
      "r303",
      "r390",
      "r398",
      "r455",
      "r477",
      "r478",
      "r570",
      "r593",
      "r751"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r163"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rates on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r95",
      "r96",
      "r97",
      "r117",
      "r118",
      "r119",
      "r139",
      "r140",
      "r141",
      "r143",
      "r150",
      "r152",
      "r154",
      "r166",
      "r212",
      "r213",
      "r243",
      "r302",
      "r330",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r454",
      "r455",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r508",
      "r509",
      "r514",
      "r590",
      "r609",
      "r610",
      "r611",
      "r627",
      "r697"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r487",
      "r743"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r980"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of equity securities",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r980"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r896",
      "r922"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r883",
      "r893",
      "r919"
     ]
    },
    "RENB_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r784",
      "r788",
      "r826"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r784",
      "r788",
      "r826"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r525",
      "r526",
      "r527",
      "r739",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r823",
      "r826",
      "r830"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of key input to valuing the contingent consideration liability",
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1049"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r332",
      "r337",
      "r343",
      "r480",
      "r485",
      "r488",
      "r525",
      "r739",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r823",
      "r830"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r332",
      "r337",
      "r343",
      "r345",
      "r480",
      "r481",
      "r485",
      "r488",
      "r526",
      "r739",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r823",
      "r830"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r527",
      "r739",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r823",
      "r826",
      "r830"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r525",
      "r526",
      "r527",
      "r739",
      "r768",
      "r769",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r823",
      "r826",
      "r830"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r577"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r738",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r738",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r738",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r738",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r738",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r238",
      "r239",
      "r532",
      "r533",
      "r616",
      "r738",
      "r741",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r236",
      "r238",
      "r239",
      "r241",
      "r532",
      "r738",
      "r741",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r238",
      "r239",
      "r616",
      "r738",
      "r741",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r991"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Additions",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Translation adjustment",
        "documentation": "Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedTrademarksGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedTrademarksGross",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks, net",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r991"
     ]
    },
    "RENB_FixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "FixedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r492",
      "r493",
      "r494",
      "r496",
      "r694"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional Currency &amp; Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r926"
     ]
    },
    "RENB_GEDiCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "GEDiCubeMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails",
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEDi Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "GTechMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G Tech [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GainOnBankruptcyOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "GainOnBankruptcyOfSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
      "http://renovarobio.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on bankruptcy of subsidiary",
        "verboseLabel": "Gain on the bankruptcy of the subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GainOnBankruptcysOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "GainOnBankruptcysOfSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on bankruptcy of subsidiary",
        "label": "GainOnBankruptcysOfSubsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GainOnSettlementOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "GainOnSettlementOfAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on settlement of accounts payable",
        "label": "GainOnSettlementOfAccountsPayable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35",
      "r36"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r676"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r214",
      "r568",
      "r761",
      "r766",
      "r784",
      "r785",
      "r786",
      "r820",
      "r825",
      "r832",
      "r983",
      "r984",
      "r1041"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r215",
      "r221",
      "r225",
      "r227",
      "r452",
      "r766",
      "r825"
     ]
    },
    "us-gaap_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "documentation": "Asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentExcludingLessorAssetUnderOperatingLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentExcludingLessorAssetUnderOperatingLease",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-lived asset impairment",
        "label": "Impairment, Excluding Lessor Asset under Operating Lease",
        "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of impairment for long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r513"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r960",
      "r996"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-lived asset impairment",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32",
      "r73",
      "r122",
      "r745",
      "r824"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, net",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r959"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses/deposits",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Additions",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Translation adjustment",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r918",
      "r926",
      "r930",
      "r938"
     ]
    },
    "RENB_InitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "InitialPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r942"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r942"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r942"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS AND GOODWILL",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r240",
      "r242",
      "r737",
      "r738"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r746",
      "r749",
      "r957"
     ]
    },
    "RENB_InterestIncomeAndOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "InterestIncomeAndOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income and other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r129",
      "r130"
     ]
    },
    "RENB_InterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "InterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InvestmentinEquitySecuritiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "InvestmentinEquitySecuritiesPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to settlement of accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to settlement of accounts payable, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOfferingShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement offering"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_JanuaryNote2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "JanuaryNote2024Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Note 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LessAccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "LessAccumulatedAmortizationMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Accumulated Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r47",
      "r48",
      "r49",
      "r51",
      "r52",
      "r53",
      "r54",
      "r132",
      "r134",
      "r135",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r459",
      "r462",
      "r463",
      "r490",
      "r652",
      "r754",
      "r772",
      "r856",
      "r1003",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r85",
      "r585",
      "r832",
      "r844",
      "r845",
      "r963",
      "r968",
      "r981",
      "r1050"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r101",
      "r132",
      "r134",
      "r135",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r459",
      "r462",
      "r463",
      "r490",
      "r832",
      "r1003",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r52",
      "r53",
      "r54",
      "r132",
      "r134",
      "r135",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r459",
      "r462",
      "r463",
      "r490",
      "r1003",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bear interest percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "RENB_LonglivedAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "LonglivedAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-lived asset impairment",
        "label": "LonglivedAssetImpairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "RENB_LossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "LossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt",
        "label": "LossOnExtinguishmentOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MarkDybulMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "MarkDybulMember",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark Dybul [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaturitiesOfTimeDepositsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MaturitiesOfTimeDepositsDescription",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity description",
        "documentation": "Description of time deposit maturities, including certificates of deposit."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r260",
      "r261",
      "r262",
      "r263",
      "r361",
      "r385",
      "r386",
      "r387",
      "r391",
      "r483",
      "r530",
      "r607",
      "r608",
      "r615",
      "r644",
      "r645",
      "r705",
      "r707",
      "r709",
      "r710",
      "r712",
      "r720",
      "r721",
      "r723",
      "r724",
      "r735",
      "r736",
      "r765",
      "r773",
      "r783",
      "r784",
      "r788",
      "r789",
      "r826",
      "r827",
      "r828",
      "r829",
      "r841",
      "r1005",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r481",
      "r482",
      "r483",
      "r784",
      "r788",
      "r789",
      "r826"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r784",
      "r788",
      "r789",
      "r826"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r260",
      "r261",
      "r262",
      "r263",
      "r361",
      "r385",
      "r386",
      "r387",
      "r391",
      "r483",
      "r530",
      "r607",
      "r608",
      "r615",
      "r644",
      "r645",
      "r705",
      "r707",
      "r709",
      "r710",
      "r712",
      "r720",
      "r721",
      "r723",
      "r724",
      "r735",
      "r736",
      "r765",
      "r773",
      "r783",
      "r784",
      "r788",
      "r789",
      "r826",
      "r827",
      "r828",
      "r841",
      "r1005",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "NL",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "NetDefinitelifeIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net definite-life intangible assets at beginning",
        "periodEndLabel": "Net definite-life intangible assets at ending",
        "label": "NetDefinitelifeIntangibleAssets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "NetDefinitelifeIntangibleAssetsAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited",
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS)",
        "label": "Net income",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r70",
      "r86",
      "r97",
      "r99",
      "r113",
      "r115",
      "r119",
      "r132",
      "r134",
      "r135",
      "r138",
      "r142",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r159",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r303",
      "r306",
      "r309",
      "r314",
      "r390",
      "r398",
      "r455",
      "r478",
      "r490",
      "r589",
      "r673",
      "r695",
      "r696",
      "r746",
      "r748",
      "r749",
      "r854",
      "r1003"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "RENB_NoncashStockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "NoncashStockbasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NotesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "NotesBalance",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable, net",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r1065",
      "r1066"
     ]
    },
    "RENB_NotesPayableRelatedPartiesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "NotesPayableRelatedPartiesNetCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable \u2013 related parties, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses [Default Label]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r746",
      "r749",
      "r755",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r82",
      "r961"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign Currency Translation, net of taxes",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r495",
      "r503"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1099"
     ]
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total indefinite life intangible assets and goodwill at beginning",
        "periodEndLabel": "Total indefinite life intangible assets and goodwill at ending",
        "label": "Other Indefinite-Lived Intangible Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r993"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r832"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r982"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r924"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r891",
      "r901",
      "r927"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r891",
      "r901",
      "r927"
     ]
    },
    "RENB_PasecoApSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PasecoApSMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paseco Ap S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r991",
      "r994",
      "r995"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r905"
     ]
    },
    "RENB_PaymentForExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PaymentForExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for license",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "RENB_PlacementCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PlacementCosts",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r316"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r653"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r316"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r653",
      "r672",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r305",
      "r311",
      "r581",
      "r832"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid &amp; Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of equitable securities",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r125",
      "r209",
      "r210"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r113",
      "r115",
      "r127",
      "r132",
      "r134",
      "r135",
      "r138",
      "r142",
      "r150",
      "r153",
      "r154",
      "r211",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r303",
      "r390",
      "r398",
      "r455",
      "r457",
      "r460",
      "r461",
      "r478",
      "r490",
      "r571",
      "r573",
      "r588",
      "r626",
      "r673",
      "r695",
      "r696",
      "r821",
      "r822",
      "r855",
      "r956",
      "r1003"
     ]
    },
    "RENB_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r512",
      "r576",
      "r587",
      "r832"
     ]
    },
    "RENB_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to purchase",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r969",
      "r1064"
     ]
    },
    "RENB_PurchasedEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "PurchasedEquitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "RENB_RENBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RENBMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RENCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RENCMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RSBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RSBioMember",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RS Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r260",
      "r261",
      "r262",
      "r263",
      "r331",
      "r361",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r483",
      "r528",
      "r529",
      "r530",
      "r607",
      "r608",
      "r615",
      "r644",
      "r645",
      "r705",
      "r707",
      "r709",
      "r710",
      "r712",
      "r720",
      "r721",
      "r723",
      "r724",
      "r735",
      "r736",
      "r765",
      "r773",
      "r783",
      "r784",
      "r788",
      "r789",
      "r826",
      "r827",
      "r828",
      "r829",
      "r841",
      "r848",
      "r1001",
      "r1005",
      "r1046",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "auth_ref": [
      "r173",
      "r260",
      "r261",
      "r262",
      "r263",
      "r331",
      "r361",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r483",
      "r528",
      "r529",
      "r530",
      "r607",
      "r608",
      "r615",
      "r644",
      "r645",
      "r705",
      "r707",
      "r709",
      "r710",
      "r712",
      "r720",
      "r721",
      "r723",
      "r724",
      "r735",
      "r736",
      "r765",
      "r773",
      "r783",
      "r784",
      "r788",
      "r789",
      "r826",
      "r827",
      "r828",
      "r829",
      "r841",
      "r848",
      "r1001",
      "r1005",
      "r1046",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information regarding segment reporting",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r872",
      "r883",
      "r893",
      "r919"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r208",
      "r338",
      "r357",
      "r518",
      "r519",
      "r579",
      "r586",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r671",
      "r704",
      "r1098"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued balance",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r518",
      "r519",
      "r1054"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r1054"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r208",
      "r518",
      "r519",
      "r520",
      "r677",
      "r678",
      "r681"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r208",
      "r338",
      "r357",
      "r518",
      "r519",
      "r579",
      "r586",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r671",
      "r704",
      "r1054",
      "r1098"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r519",
      "r521",
      "r623",
      "r624",
      "r625",
      "r679",
      "r680",
      "r681",
      "r701",
      "r703"
     ]
    },
    "RENB_RenovaroCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RenovaroCubeMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RenovaroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RenovaroMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RepaymentsOfFinanceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RepaymentsOfFinanceAgreement",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of finance agreement",
        "label": "RepaymentsOfFinanceAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r738",
      "r746",
      "r747",
      "r760",
      "r1063"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r884",
      "r894",
      "r920"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r885",
      "r895",
      "r921"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r928"
     ]
    },
    "RENB_RestrictedSharesIssuedForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RestrictedSharesIssuedForServicesRendered",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered and executive compensation, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r80",
      "r584",
      "r612",
      "r614",
      "r622",
      "r654",
      "r832"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r139",
      "r140",
      "r141",
      "r143",
      "r150",
      "r152",
      "r154",
      "r212",
      "r213",
      "r243",
      "r302",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r454",
      "r455",
      "r465",
      "r467",
      "r468",
      "r470",
      "r476",
      "r508",
      "r509",
      "r609",
      "r611",
      "r627",
      "r1100"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "RENB_SaleOfStockConsiderationReceivedCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SaleOfStockConsiderationReceivedCashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock issued cash consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of acquisition fair value of the consideration",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": [
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails",
      "http://renovarobio.com/role/AcquisitionsDetails1",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r400",
      "r401",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r447",
      "r448",
      "r449",
      "r452",
      "r784",
      "r789",
      "r1034",
      "r1035",
      "r1037"
     ]
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of statement of operations",
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ScheduleOfContingentConsiderationLiabilityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurement on recurring basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r40",
      "r41",
      "r42",
      "r339",
      "r340",
      "r341",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r577",
      "r1048"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r236",
      "r238",
      "r239",
      "r241",
      "r532",
      "r738",
      "r741",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of definite-life and indefinite-life intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r990"
     ]
    },
    "us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair values of the assets acquired and liabilities",
        "documentation": "Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137",
      "r138",
      "r518",
      "r519",
      "r520",
      "r677",
      "r678",
      "r681"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment operating loss and asset information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future amortization expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r992"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "RENB_SegmentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SegmentAsset",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r165",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r207",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r241",
      "r254",
      "r257",
      "r446",
      "r449",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r757",
      "r760",
      "r761",
      "r766",
      "r843",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "auth_ref": [
      "r170",
      "r205",
      "r206",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r571",
      "r572",
      "r573",
      "r574",
      "r641",
      "r642",
      "r643",
      "r706",
      "r708",
      "r711",
      "r713",
      "r720",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r740",
      "r752",
      "r774",
      "r775",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r848",
      "r1067",
      "r1068",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "RENB_SegmentOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SegmentOperatingLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income loss",
        "verboseLabel": "Segment operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r165",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r190",
      "r192",
      "r193",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r756",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Dividends",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Free Rate",
        "verboseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation description",
        "documentation": "The policy, if any, for issuing shares (or other type of equity) upon exercise or conversion of equity-based awards into shares of stock or units, including the source of those shares or units (that is, new share, new unit, treasury shares or treasury units)."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Term (years)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "restricted option stock awards",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SharesAddedForFractionalSharesPursuantToReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares added for fractional shares pursuant to reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesAddedForFractionalSharesPursuantToReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SharesAddedForFractionalSharesPursuantToReverseStockSplitShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares added for fractional shares pursuant to reverse stock split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "RENB_SharesOfCommonStockGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SharesOfCommonStockGranted",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Software": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "Software",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SoftwarePlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "SoftwarePlatformMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Platform [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r98",
      "r165",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r207",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r241",
      "r245",
      "r254",
      "r257",
      "r446",
      "r449",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r757",
      "r760",
      "r761",
      "r766",
      "r843",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r110",
      "r132",
      "r135",
      "r157",
      "r158",
      "r160",
      "r162",
      "r167",
      "r168",
      "r211",
      "r266",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r304",
      "r305",
      "r307",
      "r308",
      "r310",
      "r313",
      "r316",
      "r317",
      "r319",
      "r322",
      "r328",
      "r490",
      "r618",
      "r619",
      "r620",
      "r621",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r653",
      "r674",
      "r697",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r947",
      "r965",
      "r967",
      "r974"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r56",
      "r59",
      "r60",
      "r95",
      "r96",
      "r97",
      "r117",
      "r118",
      "r119",
      "r139",
      "r140",
      "r141",
      "r143",
      "r150",
      "r152",
      "r154",
      "r166",
      "r212",
      "r213",
      "r243",
      "r302",
      "r330",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r454",
      "r455",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r508",
      "r509",
      "r514",
      "r590",
      "r609",
      "r610",
      "r611",
      "r627",
      "r697"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r205",
      "r206",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r571",
      "r572",
      "r573",
      "r574",
      "r641",
      "r642",
      "r643",
      "r706",
      "r708",
      "r711",
      "r713",
      "r720",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r740",
      "r752",
      "r774",
      "r775",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r848",
      "r1067",
      "r1068",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r304",
      "r305",
      "r307",
      "r310",
      "r509",
      "r531",
      "r617",
      "r628",
      "r640",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r676",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r748",
      "r749",
      "r849",
      "r1098"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r208",
      "r304",
      "r305",
      "r307",
      "r310",
      "r509",
      "r531",
      "r617",
      "r628",
      "r640",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r676",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r748",
      "r749",
      "r849",
      "r1098"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r887",
      "r897",
      "r923"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock shares",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited shares of common stock, shares",
        "verboseLabel": "Common stock forfeited shares",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to conversion of convertible notes",
        "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock for consulting services value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited shares of common stock",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r55",
      "r56",
      "r80",
      "r621",
      "r697",
      "r717"
     ]
    },
    "RENB_StockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "StockbasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "StockbasedCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockbasedCompensationExpenseRelatedToOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "StockbasedCompensationExpenseRelatedToOptions",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense related to options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Deficit",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r72",
      "r655",
      "r672",
      "r698",
      "r699",
      "r832",
      "r856",
      "r963",
      "r967",
      "r968",
      "r981",
      "r1050",
      "r1100"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r464",
      "r475",
      "r700",
      "r702",
      "r719"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r523"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r524"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://renovarobio.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "RENB_TheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "TheNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "RENB_TradeName": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "TradeName",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Name"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Trademark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "Trademark",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademark"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_TrademarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "TrademarkMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_TransactionIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "TransactionIssuedShares",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction issued shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "RENB_UnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "UnrecognizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "UnrecognizedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up-front payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r169",
      "r171",
      "r172",
      "r173",
      "r571",
      "r573",
      "r753"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://renovarobio.com/role/CondensedConsolidatedStatementsOfOperationsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r162"
     ]
    },
    "RENB_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250930",
     "localname": "WorkingCapitalDeficit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-50/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001731122-25-001544-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-25-001544-xbrl.zip
M4$L#!!0    ( !.!;EM^E_WAF48! .13"@ -    93<P,S9?,3!Q+FAT;>Q]
MV7;:RK;HN[]"Q_NLNY-Q1:(><+)\!P9LD]C@ +:3O#"$5(!B(1$UMN'K;U5)
M @$")"'1V%KC[!,,:F;?U:Q97__?ZU EGH%A*KKV[W_I3]1_":!)NJQH_7__
M6VJ5:[7__K_SDZ\#"UX&+]7,?T\'EC4Z^_SYY>7ETPO[23?ZG^EBL?CY%5US
MZEQT]AIX'4-1].>?MS<M:0"&8D[13$O4)#"]256TI]7/1[].+^T:JC)W*?K&
M>PG[>>G1\%=Y=H/_8N&S\^/<I5;@I;QSJ>5=JI@ZQ]#Y=7 X5TQO>%UU+8U@
MAAB"GQ?-F]GE5O#ULTL_6X:HF3W=&(H69"%Z$I^CF!PC^!Z2,X$T]R#X]Z>^
M_KSQ.84<2WO/66+./*;HYZYH3BDN@P5R>^^$/\ [&-Z[T#9S?5$<32_NB687
M/];]8?%B0U>!&7@U_F7N<MDR<M9X!,Q@P.'/G]'/Z!XN1]$^;($D!X,/?YA[
MA:3;FF6,@R]V?YR[P32L9>CAEW,7-:OUB^E5!M#T9]'0NXK^2=*'^$*JR%*G
M2#&!*)^?$.B_KY9BJ>#\ZV?GWY.O0V")!'I&#ORUE>=_3\NZ9@'-RK4ASJ>$
MY/SU[ZD%7JW/6'L_P[L^.X_\^C^Y''&I %4^(UK ^D+4Q2$X(U[EUR]$K8(_
M="B&ZMRW_F$J5Z72'?P' 0;_^?"B6 /X;[5<^4CD<B&?Q7(=A'5G =N.AVWX
M)W$%YZ8\1<>XFR]V )11"#_\O](0:#+\GW6IBOU.3U1-$.%)%=^3*KIDXP<I
MIB2JOX!H7,)O3 2@$.&1E.^19=LPYIY8U>2*:(&.\_--BWJI*]3DMO3OOQ'>
M<+D2Z#M@*+KL@/V#CDG1J@;%<UR&#S5$M:;)X/4[&'<HZ!EX)I]G"N$?*UQ
MX:MTZ(YK9)WGPZ\B/(+IM :B 2 ;.MBE.,\P\7<1'E-!D-RYCV*7 -KJV7RG
MB4QRA_,_960;KB!V=7E,F-98!?^>]J!&GQ$T-;*(MC*$;ZF#%Z*I#T6-=+X@
MX7L,I8<,AZP\>[?)BCE2Q?$9H>D:0+\IKV?("  #6A;\AR++0$-F!OT%KZI#
MJ3 4R3$AKU83]/X]O33T(=*V')6'IM32G<_%'+13A *-Z:4H613ZCSTE-(@H
M?"]0SN84[/0<:]C7SW-O2>J]G/^]*]3Q]!SI8TH \'X 5BGOZ7DN1PGPYI2
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M\H%X^&AJ-4*;?0:_SR!V:T'C]QG$IB%'?+(U,J<  7TMKC]X5XBJ\_U,A9H
M&4J !:4U4I7@(N16<I9LC657B$4+4_ADS?JND RK;,G6.'?&POC*F&R5,Q6$
MEU?:? @(B1OWS6G:-D9"2#PFW@;>:+HO)!X!; 5[;*$7$D_MMTVUMI&H?.(:
MD!XVT>0M3Q\/9B$=3#ZQ: [;6P1Q0ZN^HC5N6S$'3H: %FOC5:K98K+NW5EB
MC9J]; 23HQ.S1!C,TE"'>?,$Q\&0?(J)86QH==T"(=*L=0Z*2V[1VF<TRZ(Y
MN#/T9P4ZVHOQ/0SE:UH-9O\F$H02O.D9)_\QJ<LG[J,@K!( LHE F*6ZBPN]
ML6DL))XCU2 <,&*QD)FJ+_:*A"9D,=F&!:37GG V ?9\;=U7]8%4'BJFJ1MC
M)+AK_>E:<B:WY(;!+B-NJZJK7=B5-4;HCYCRR2>WKN,$K:"/I&]C4U#'[77N
MU&\602K&6BWX[&\\1  :H >08P(F_ATUG)^9>"<!?"Z!MP><#0ST"GA5-^=U
M_GYZ->53]V?4[/WOJ:D,1]!F?9Z^9N[)SJM,W3;<-\&+<.?EF8N\T\ZV6F#<
M=FSO+H!;W+POIU]#XP1_Z"G (# 2(+!!OUS[/M\-MWCS]&6?@][FOFN$2Z)+
M()B6:%BHY_!\AHGWG-EOBW<!IT_Q?(;Q[-VR_P[O:__;O>]<4JXD[U2V:#I'
M'Q%)G7TGUOD,]NGSW5^2),Z1R=L<<>8D)Q7B"$=,'"$=XJQT(D=#ICF;Q<6P
M65S:-HMSN+<F1]T+L6<4=!SZ['OW%QE"\CI2%4FQ'#@)61FB>H&N^5?;(+'0
M[4ZO*ZHJZ!I:.2N]*N;IN7?9$LY?/P>^P@?<YT#HMM0D+C5-6L'L]2G\VV?\
M6OS?BQ"LJ':\?>X'(_Y>V!Z^Y/KV)2$T+=ZX<!Q/8+5+XO!9B'0P(5)ZR<8*
M9F<ATN&%2#L7@BQ$.H00:?>ZGX5(1Q,B[;X*E<4#^XH'#KBJMN5&@K<O. <3
M3QRS$&7QR-[BD6,6FRR>.?!XYO"%*TISX]L7HL.)@@ZK'V++WM&W+SB'&04=
MF1!E4=!A1$%')C99%'1,4=!A"==LN2R+?0YD18A+NS<OJ^ <:.RR3R'(8H]#
M6!':O>YGL<-AQPY[$(YC;9I)O:,]"Y$.)$3:Q?:%+$0Z\!!IYT*0A4B'$"+M
M7O>S$.EH0J1=" >38PI'&2*YL*= G-E"+9.CF>DGMB/9IJ4/H>5TSA0JVUU7
M/MYF&'5AF]!.FF9)@EID8H_IZ(\[EWR1"ANU))8*EU71--V][ <4ORVN!2-1
MB;H6C(0JU4:#T/+K_N(;<(#'&F0RG)8,.],: LF=2?%"%K]>=C/IW$6IQL_D
MY%WM\FI@QNYL56]%)N.*QH4J2D\M:8".Z71FW-P9D$9:_U:7P1NH9=P"T;0-
M[#YJVLBVT#&;/FD)@_X;3ENP))B&U;E5-&5H#^?CF+<J&Q#ALZ:H]5U!0'_.
MX9]H])()8#@!%%_?MP#Z\<\$,&4!7!DP9;8PLX7'$,RM%^#,EF8"?*P"_,;%
M-9.D]/+:N6WMEZ)BX .','G-&_ ,5/KXY6:*UL5X^O$:OD4TI,$8(SE?W5]#
MAOU%=;L=<!!$ B:3!!\9WK,DL)DD^,CPYB1AXT:9S$\<DI\XX#@CEB1E?F9?
M?N:M25+FI_;EIPY8DE9T)V8^[9!\VC[[5#.?=$@^Z= D(?,IAY'[I"X)7(XJ
M3"NKBMX:#X%E*-(1=R:B.O^T,? *Z'U#' T4253]1=0E3/?'8L2!U%E\K!WH
MJ1/'O[+0TGO6BVB@0]RLGFX,CU<'IC9-T10+W"C/Z% ]2+P^:H7%AX.9%^-;
M\8]NX,Y9GV8$T^ -&T A$X"#%H!=5_\R43@@43B>!-L5F[8ARF H&F]@=U)T
M>5E _ITXC8SEA\#R/;F)C/G[8?[Q. :ORG(''Z]91YQ7QY*3Z:'9?NS?NF/(
M6'Y +-]7]T#&_+TP_R@<@S]\O,'[%:=S,DI#W;"4"3Y@_IW)#HXI-I+C_5B2
M3$ .7D".PMIDPG0<PK3/4/5*U^4717T#VR=BA2OSZ+\?%Y.Q?\_L/QX'DHG*
M05F*U$?[TCF:\:*&;Z)FB\88S5!"/QX_ZTLOHH$5Q1<+!"*Y)P:[]$_/%> 7
M4,6,U?MA]>)8,,2+2&9_04"2-_LL?'J.F>8-%2!A:K@D>P/M@4%R$8SEGFR
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M%4)$N!R&IH:B=2S%9:(<NKYR(9RER2)]L,<5XG4.]W<T,2>GO.8&B@SY?D9
MN6:4UZZA0DHP/COD;I;<5F$*/H6I@)$!J8G/WH:?58 ^H.AZB$[SF.#OY\-*
MZ??-]P>^P1E<FF,BHZB''P<GF_0!?[0ME>N5+PS?8NI>_'UT-,DSJ71W9_P+
MZ:T9*G;&P3(D6PAA+I/OS5\J>.)F2]R3CRS.T"Q/KJ\4&#K7F5ZAHOQI=[E#
M;<A?4^U\6_*[Q+.8QB;VP?$LR5(%DA5B]+F]1WL3CE^;C$OLTR5YR"ZH=SR?
MW&:)9.:59\WW>UK4* 0Y@-G.M([B. !D^%'HR6F3SF3R4.;5A]&E?;FCXZFV
M7/NZ:;1:Q&6S<>OO3#I6^[)ABT\ #^.Y!'K[7:+)^X8WNS,K+-LV> 8Z2L(>
MS+047$2V->M8O8-_+'==U_1Y*75CF+F^B/KS3UNUQ$OILG<4O@%ORR8<?(@/
M+D;I3JYXBX(B=(!DFY"KN5QY(&I]4-,N1<7 G?Z-7AER!S(.TAU^,A492Y%;
MT)I;FKF2M,[DB9U0S<$-__.>/9#*EH,2H6A$#R+E3M%%1^Y.\<+[1::([:$:
MW*S6+\["DSYF3)# -CDVOVIFYR'H0WK$W>2Y$]AS5H0V,PGB;EIHK8"N5=)D
M9UM="RJ^@7?=W6L&@(^< /E*5#04PE1?)=5&JH>M;!L2L V&(]T0C?%LU6):
MUL;*WQKJ=W];C_)+]0 7@%;9 8 I09A34NQQ.2A9YL2T$Q'6*A>F.? "68@W
M;NJ 5HL8*OG5HNK,PR(.-K0+47LR[)$EC1N]EMV%YD>!K)O7)N[JX>=+OGVM
M_(G3>Y1*EP.$G8!"VYU"CQ3(G,*_+^N^CJ;QE(")W4E(,R1%0V/.'&SC45@]
M8)/7 W]*@IAF(EL&S(96?46^V%;,@;,6C@PAU@9_;/E3H^\?:_ISO[:C84+1
M^@M,$^D&F,,$Z8<,<4F5HQO*$QL)'5-%(JR2K2A7""2+#M MAECO7%=.VD-G
M4"R2;H@BF7!'T>SJ(!7_J8PUM $#F%X#HK^:@+2TWI$5O,2(U;3\(R^,S1_5
MQV]QAH:FX;<\\*%R8OCWJ8UK2!E3#V,O*-$,0W+Q$HZ]C@>-2L)->A<[X,49
M6R'AH:"^6-%#U*EPP<0 1_MS];OYD+'^<#F:Y&\J;5XY/ \YU4+%*=CAV?2X
M@N=^\0$L5O".;:%@38P:@I?Q]#_^X?4L2S+%$&'J>U[[WXIW&PP/NT62(<"P
M*<2D]60:C4*M)'BKS<@035>;N[>#H=YX4MN5."L*,9:.PO88K5\Y>!NRZ_G+
ME2R+:7!B-S<*),WD2;:0W.#(-VESXO%MD[&)W=18)+&Y"7.PPT[;CF*O-V9K
MS$DN'<X\ ["6>X^P%WCXSC>O:]8?H052]P*Q%Y/KU3:: ]6XK1(?4-/19F^P
M]4S&97+'&L 8W;#X.173"<1N.F7( ETD*2:&$W"'*\9V P?,L TI[V:.;3+_
MVQ^#P4%3BZK;;(A-\J$YMW5[4>8%]N4%]F3(%UAV46K5RGAV7Z5V<X\&N/F-
M.'%7;1*MZU*S>MSF?.$T1_]V3>^0'._HX O15"3W#,>%26MEH\Y4C1ONML5-
M3W-TZ(><WY1>D'RWC;I#-FAK5-$TG1>/!IK5N6>; _GJP?K]R%.U,M7_014;
MS>I#XYYZJ-:J];NV"O]75:L_'IJ7S?)%^Z%Z>=^\IR_;:K-=JQ:OX/]^-!^^
M73Q457CMK?YPSU\\W#>_/50?JM]_E#K+V#)KL*THJFT!.1A?G7UN//Y1;G]=
MSD[-]*3DL#!>:_P#.1S/;7/;GQ8=#5:7/S&AC7>*YOS9UH&GJJT]0_,]QR'K
MSHU=;6F61B-RM^7?SRJX*LO",5F:==CZ+<T2OH4G\='DVU?7)>&P+<V&.#.\
MJ=D0;W*1#@@/C#A3L#B;@(YT\/5ZH)E/^: X.27#DX7161B]51C]6*U=72-K
M57JH-DM75:)^?WL![57CTK%5>!BR9[S002=$X[[=:L.XNU:_(G 7 OV%P";^
MQ!>,[Z"3:6:]\S[K_8@Q!G()TA4-;K?1@-1&;^E([S71LOI<']U\5P:Z5)C:
M].W(E',(= B>KK*95JXA73XB/I!:G*7GQR^6^F/<38Q:KA =7D0>2;IBQKYA
M"S9Q#KF/R/%X&/#Q<HVI V5(GJ%(A@N:IQ#-C>ZQSW*F<<6MK--2Q'G?RE=O
M?M_W"F/Y[5DG:DOKM$0M^D'K7U9LY1LZ0#ZS3INLTX8XF8^7E^_.-FV"/U)R
ML@0_S9/%8I%DV:#>F00MT]<=' KEO>[8CCDYJD.AYHB\YG@E/CM>":+-OJOC
ME=[L,6+9N4UQ;,3BZ4U\M-.;8+ARUZQ>P^MJ#]435'4\3FI .ASAP5/C'[W7
MAY+PR\8;E-8=/!6*?[AJ_!:.G=JR,R>Q9&UVH%,Q\"2JFMG[9A:9'^"Z<*@G
M494"3Z+J@OJ?WV/YV^MW,6G 0Q8JLY.H]D^*["2J["2J["2J SB)JNHK7]T9
M>D]Q#C- NR(NVY/.Y/O33=.^[O^22CN=L^0_7BA^FRRPIOLF$%;+?56'==C-
MC/XQJ]BQ#\Z(T.AZ#&<*;>@<V$#G316Y*!-TMF]/74N9U5LS_0.7R_IP9( !
MT$SE&3@* 56CT6N+KW,SU<R'\B_EE=:%-#=#)S)';0ZC%3I^*,OGAP1+UG5Q
MA*Q:,407*4* 9B,E@,D!5"VM;!L&T*1QVQ U4\4CPTKR']NT4'(/E;^C3*<A
M8%__^_IJU'WHM]NM%/6?V4[_7=0(#S?"AQQ): "/,;'$UR.>Q+YIA.OVC(\7
M7@CQ]P!39)%C28H*ZF^-MR_OK6Z 38N[&X(:(<*AB"LGY'!"@:2$5';,9H[K
MJ!T7'RX:]79B8F\T,IL/Y>JU(OZ(,T)K1^'H?""*E/28.^HW>)XUG(OI4;:?
MRU4@:88EBX48YQ!MZ%#.>!C&;T29U!O,039/YF%P4,S'.(PH7)-YUI7R7KI2
MA*PK!:+-95TI65?*N^M*6>I'$:+UH^"^V>O&3:7:;.%-(ODO)]4?][7V+^)#
MI7I9*]?:*7=WO(4.E9UX@*@]+\4.37.=2:/Y-,I3#7KR)$3O>5D4D?\2B\)Q
MY#TO.VYP.:0$>)JH7E0ZTSQU*A+.B'L4..L:"G-*KXK9\:>S0UUK6;KT=(L;
M"CH3\_J^^5M_'GP'B;>X)(4G'QG/$A0<%)2+ZIVHR#6M+(X42U0]G%^^JTK^
MXKO5&PIIX!RAIR9<'\TF I4C$Z@)+%'1@.QM\O4H<U<N# L\,#7M3]@FG_7$
MBH79KNE7BBY@DF0/;15E%ZN*H!Y)@:K]X7]UK_E1?W\D34(-V<[DSV6^]N/:
MMGZ"X#Z.-]P/M_=6H?^@Q2+'@!/.CIDC 'H.7J(TA![?.@*P9_Z#0 XD5],(
MUX4< _ SVT140$^1E*,@N0_J\'T3AXL/GH>[:HV!O0C<3@E\;@B&: /X<&"8
MCB?J**W.Y ?_6C>%4OD^K^ZAP8VCUC2X+9C5;[8&4+<J,>UP#.@38H*>%Z;M
M:BM_7RSX!QHL;W2%A YB3M@886VT34W$!W,XNF!N!K/Y/0#FDB@*@RQ314T"
M)&$Z.R(7, _17QAJV7;#7L^2V>@Y)70A!_%V[^HL83-?7,]OO?>SP/$D(X0X
M875;0=BG$*;$T25SD01+A?@G8)!\(<0*2<;(A!BY-M]=8&KL4SDX@2,%BB:Y
M0K1.T'?#V@VKF3%Y&YRJ+QC?!,XE9QF2XWF2"C-%/BJ%5S:SOV?&AJXA+/!Z
M^^/,Z3P%O6T*6GSD?$Z2S0M,B]^.R-)D,9\G:2[=R"BH$^K"=V22:=HH-D7G
M^TZ#AGL8\QMWAO(,9?@.YDG .:BM!PQHJ/#:=F?RRBNEO[V'2>^ID'IG5+A5
M 0\5Y[!J7)\P$3:0\! =8N3@0XP\A.!U#D8)5M.*A?(VM'6BYO32E-Z?ZOA.
M^C/^5LQ/TY389%M*9T)KGG-(4$SJA.L0"AL+%[8;S4-S#,F&L;A[Z9Q,E/I8
M[Y,E?C[V7C$ZA-%\GR2/D#+DMSB3@BH*)"TD(?@[6A6*M$(3]LS?? &]:.V9
MOP>\4)8.28JID.0MZ>J"!XJ0XP5J89C$+G*(6)R%,4U@6H8B38?)(=H ^5(W
M6L!X5B1@-@$B#) [DV&%4HJUWY->G=]E'3M<?#C#PPU<" 5C@JA/F"XNA.$B
MDVA06(E!S9(F5U_A;1;,&E&,!_-'O,TF[1BQQG___GAUH73U62D[&NGP2:7
M@QT%E5/@MXP9$R)>LE%,<<NYK11%4O%.%=ZOC0S-C(0C]MC'*3(9E6/%B878
M1R'2)%LLDL5X1SZ_H:"H(&1QXB))\F\A3DQ8.Q?T;HMU.BX1KQ(4&7*+[0P.
MSA4;1<%W,!;691P+>^>A -GO@"%I>@#MZ>E,0+.7MW\6V#Y'[Z:"N+R+WP'%
MBVD6"F")1H AJ.9(T":RI1;W/35_-WLR!X6O/XW[-I$H3#@79I$E)C$2CN,B
MG2"PO 3C!70%EF39$$,&UBVSI&'&XC$BC"XGS(<(:RJK-N0>'O4/A?@1XKYB
MA'D,"=#_#04W12Z+]Q9)PF<D621)\EE!4,!66>R*7+(EG<DM:]AY]J?P\X4Y
MO,(=-HZYKNCL_YZ!?=!",&7L^Q9REJ*./,^;ZZY=4IW4O"]+1>@'6FCYXO.D
MP+US'\Q23.9P%DG"9KI(+6A9[&IR,EH6Y+#]$Q;KP)K-7NM,M!NJU+RY>N(L
M^4"ZKM!\8S5HY-0A*4CFC%T#D-6AETAR/'7H#06<.5,1,2X)T8S.4A'*T0G,
MG [3A7R4 G<\#3+)"]R\1-';;V](0J(V^>"@D:?..ZZ@TB#D+_#$*C0\<B)S
M=T9?*-Y<L8/#RZ2]P<62-[C8FHUO)<3I_-8P IGDI-MME'/+9V\($ *'Q"9L
M2]X6)<.:07IS>I81/S7B;TX$,^*G1OS-BP.)$_]MS"6/X(BCUN5B[=ECZ=B=
M4:D.*L\X'S40C;T194<#YV<31H08$T:JG<FS5+B]_R-=_2GG4R\<A1PE,G?Z
M7? \D4/T&:''C533Z]5I/K#5ATG=U"O\M%>GBE^[<M9(0CXNF0$D$=I!6&;+
M 20"2:.$*A]T^/Q[B'E"SG1/6A1";ZJ.(@OT%AV1 AVB&S*3@'U+0(054GJ+
MD2<%/!2#*10SF4A4)A(;J1&Y/,TD,"LE+Y""D"=I.E5GD=R8NV.0B'2L1+Q\
MC8G=4R&03#%/,G2,\T$R>[$CZ5C@=>S1+$68T!4$LE@,L;B?"+._9@>+[6-Y
M*X,E@R5M6()*."5<&."GA0$^W)!8OM"]O_LU;#X:RJ&4</S38/E=K\[/"C%,
MF+FOB_1.I!#SE[Z]?BU8OZ0+-L+<U]W56OA(DT%9=LMI2'DRSQ9AI!2B&OIF
M^HR2"& BLHF)/S>)S.=#C$XZ(.8L!YY[Y$N$X@03>[@2EX>A'!KL$F;(U0%Q
M:BLU2J9NL,BO4'6#[=O:>)HB.8$A^7R($F-2)8*W9O/BIO2QBX"0:06:(PM<
MB&-;,S4+8-U"[+!]_8VA298K0HXD%3^L[N\KAYQB4-8U&&.;$ 0T"DS#\797
M!2T@P2LM!9CXX-K9T>=F1[ECD]GI/RDID!=MODZ+<0+^E%L)5XX-'=D&^L5"
MI[A*4^HYETWIYQSTFD"V-C=CRQ>IS[B&>>"?SD&'85%,YJ>6:(B4_:0]L?6?
M K-Y<FL$%L0?R#4[S'D=K=>=R3T[D3MLX,MM-VJ+)UF>)PM4B$6?0]STE*2D
M)LL7-O8N*CY>X_:[9D:$+(2-/[I+("E!( O%$-'1489"8=LUV6S/U!))CF?/
MU(%HL:7/]'A!0^.WM" -S9,<$V*Q.FJ-&@8PZ\?8W[DA1EMO 0M&(\XH7)C#
MH9, S3MQC$Y'G@NT-L1D$_/W4YF^Y[[9+[T#V=H:*KXRI^BCRT27 ,3(H4#2
M$>[V/'''QT+.),#?U,+=VRKWV%-Y[5NW&RW<7<^.-(XLB$#UA(/A2//*EL>4
M\23-;6LZ=FNVMV1"PN2/WU^0$3V)V):+/9Z,+G DF\@PX&..XKC-^Y#>6V#+
MI3.D[$THZ^H0EHN_'(D5,8T9*FR(H6>V>BM?/C#*5:5X>/75;.C9 >(7UH[P
M[W#H62(^G8_=H$L7:)*EWWNQBL^&GBV1Y!T./=OHLOG8!?MD]"S(97.S\H:3
MHT*[@6?I>^\05>?[62C3!*BD!)QRTDA5K/FEO15^O_X K$F?&=[TXPP[3:/2
MY.!%B AA?*9.;XJR-WG=7^0P'+3=\H>)$$^TT'21 ">6ZTSQF9I:F4DH/>G?
M->%*:_6F9:;M>;%EE6E+DB=;Y1"VZPAEWWN2S6>K1TLD26?UZ*A)DITCN422
M=,;D'3-)A.2SRJ X;,WX6>&V^GPWTDO%YSA31%*NF*!)M H&]J"YG=5(7&G.
MRL]+)#GV\G/XR:"K ](P/?M"[(HS0Q;H(DDQVYZ9>_2B]E9:>$*+VNIBB!"[
M!2<I:=KDAB--H"W+RL7O9K[X;'0/I+R1C9W-QLZF3,FP=B^_.8;.B)\:\>F,
M^/LC_AX&+A_+\-$-V^*VG3ZZ9FDTWJ;'?(36IQ5[[6B*+'(L"1^6V.32Y4VK
M&?_#1:#Y",MQN^9G0&S*TC$FF%0[DZ'0,/Z\=J7NK_XNRT<AAYDLS:,-,='D
M )Q)Z#$HU?36T7YQKX7?O/WMM:$>WSS:B"MBA>U6Q!B6I M4-H\V^3@HH9WM
M460AOT4=BJ5W-5XNDX M)"!"\UH^_LB7(D?FF0(I9#*1L$PD-O B<HTZG\!<
M&0H=,<F2/)?JF.+W-8\V'8F(F\A%F%ZS*O"'=H..??Y$)B#I"LA"[+C]C!P:
MYG@<%6Z,V[8<=U._SQ;:&W)^<G+R=>07@#.<7Q%M90A,H@Y>B*8^%#72^8(D
M6L!0>E^(H6CT%?A@:OX]$LPLH#9,)61TGLKC4WMP"P"\O70X$K4Q2G3P.!74
M$0C5'_),M&4TQ0>)!LPRG5T<&I9#9"-.>HH&TR(%]11Z:9?Y*35@YXC\/[D<
M<:D 53XC[L0^^ *?\=<&,$<[(_)?"+SW';Z4R.7.3PCXWU=9>5ZK8,Q,P1PP
M<I8^.B,$)&SN%]X- K()<?!;1FK^953 RW!2[\?6P_,+T1Z/((XE0^PJTA>B
M#O7;H45=1VCS_IL^>W>A7Q %OWZ&! D@C0'$IUP7UX'.H#%$A(U(CBD3_99S
M_H5^P!# F$L'JC>+1:7$-7[5"](S)MWSF_MZJ49<U!J/C>;W%E&KES\1I7J%
M:-U?M&J56JE9J[:^?NZF"$.*R#E+"<AAB1T*'8SL+A24&_5*M=ZJ5@CXJ=6X
MJ55*;?A'JPW_N:W6VRVB<4F42ZUKXO*F\=CZVC4^GY]\@)2ZK]3@A1^/DR!S
M<HI=(/Q)55VGBGTT^AM22/+^]FIQ+"5T:)KI3!Y_7MG2[75;O1:A1[>'\)5C
M? FT1I[=)W)$1 +[2'L:'6W7B$NZJHHC$QHK[],7XD61K0%Z"O7/J5/S/8C^
M@<2:3*85["+;":B%3A1)YL1N:\1IQ77-^W'?GP3@E4[ H6*3QW&^^K<U? #&
M(&G OX8[G" 6RSU7'H+I$9JMH"0BL_7O:3[LQ&U/Y2]U X=O[8$!P[M;>-/
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MA*2&T<#HNMV;#/ZFN3\\X:3FLE8OU<M94K-U4N-M"&F"D3C&(T.]33"@U#<
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M( D20J0HV(I(J-%]@($%$JYG#RQCBJ("2<_2/4D8^,ST-QPIR_/5>_Z(:'-
M7X3\6(@Y5(;@V"81_B [0<Y8\"*3? *XJ5AB^H(\0(T$3O-7](:;V.=K%A?/
MV;N'U@&\=]O#4Q?KQ=+M+?FI62[>3F]:/?6ZOK?S8W+W0?8,#]%S)^OSF<'K
MM&\O%[HN+=V;HX2S_)H%14DJXR4(+PF5!;E8_'OF?[6X&G#IZJ?]/=@>RA,W
MQO?:@N"//G@[K=05]\LOI?WUL?F29N3AY<[NUV;Q;'@T_/ YM'WE8*<)$I^8
M2U0]#Y)!TLQ&@#DBIN%-J):<8" F6Y*.3CQLKF!4(?F/U'M=UOGFB*FBNJX_
MHHD?@*!@W*BTGQTQ&?6Q[9"/C"B/AJW"\SI3' 2^1'FO:*K HSTRQF. WTY^
M"VTI>$]"9L@UY50C(&%#-*OM0;=\QAGUIS&J0ZY8ST/?(? AJCQPZI[G$\.1
MZOT]8IQH!IS;D8AOS1O:;@@G>*,#^&'T0:>';P;@BVA4:%G*#QC4%X'$_9R$
MJW69 YW^FMN< I!0-!@:4\8*Y';(0#LT*%P@)X86<&$Z-3$'-AJ7\(.K.P\&
MV!_OF7G,^*SVF"P[TYW.$.1[MA:U+W:HS'[S=NH,VON=R\G>5]MX,?;2NITJ
M]S_\GFX,K_>['SX?H?,2=BR3+3/&PJ^@^YEQ&/1E]0(QCRB/'E>0.;*+K\D?
M]\XZGXC1VE6)M4]5<)K%CX3U /@WT"60@2B5,%%MJ#)ZWJ4+=6CFFN\!@5J8
M%,>I35=[PX#(VH;IXX+I6XEL@G]%6/4C6A6XAJ2Z3!WLDM/1(P!UC&T/8&@0
MAJCA]U )2M[OMGS&'TX[4=ROH,5.(.$)Z-9[JMEC+K2 "V <?ZAOP7KZ))K=
M1_EJ: $-0$W#A;L^^RWZ#ZAM]*0[/0-!0OS8=)](\&2FI3^V+9;;CLXXB;+8
M(-.= Y?F]EI:Y(_$A1)U_P]538[K=Y6(L8WKT<Q ]+T0O'-/PQNZ-0Z9LD=4
MO&G#*^UXI5JKW A4O%UQ3\+ESJVPG_?MW(T1JDK>Q@B')_N"?D>_B,VKE4JE
MT&@D]4>@LAU!'8>CL@P<*Q2.RM=O9]JY\ZOC*B\$QZ2\X*J2M^MF&ASK2K-0
MKB3E>5(XCN<1J/[$"!2%-'&:<"8#'"%"DVJ*+2;Z3^ +8YW$FLS)"\I-  8[
MU^>LE,%F6LH@QSFEO',['9X\_+AY.#';K;M ;OT>R83UA9()0Z"5;Z=7C5_?
M3J_O]4DES*EYN31#0AX<(V+X,18VWL:2DV[W_O&\>F;=KZ*ES$\@C.]I@]F$
MFU8CE6I<C=R'*X:=[/J. R@SN1!<F"U+NPA=*G/R>L06Z$NO>3OMWNWN5JXF
MQM<[]24M6ZM4.;CR@0C:ZH?/^RQ4 ZR9'TG^'W4T_E=F!Y6"7PMG$Q.\F'9*
M](]^N%J/OP;<.LA9:.L6'.,>TQ,(CU<MPQW*WQQ0K)S 5=?^]BT2Z?0B"TN)
M"Q-'&UMUSX=?\,7V+L\S%HOL4LP%HJE N.(N6-D:)F.T;=-4PUWNMMK1,&D\
M5A4:I\%'V 9)D(XM%\2B?&>,EBDUE=UD8SFBY 4?XCY =ZCK7NAT1666>PV)
MYNO9],L:^3*WT)E6OZ43&SO2Y9[X$$R3V^%1,WS>\A);GED=\;7'L*AJF(*)
M(095YP=)MD5T)%Y%YH( 4XKM#M-7 /":Q*(5U)F*"CBF"Z$% FA'/0TVR8O"
M7SGZ$,Y'LU3@W_@_5#4;VB;(6I=!G5GO;!=,/YO9!76Z.(9+$WND" SDONFC
MMX+%)(ES0HRQ "';0C1%%7"5[!86MU+1&<\?-WH"/))B07#B[L WM7?L9%#J
MD0@-K;I':!C6'KG+,$4B6Q@T0S_Y HO<3L\GZN7DFU-KWKQ<%$>YG=Z99Z=?
MKYI]G*WP.3P (@D]@I KPAW=<38?!!'% (\1K$7\F\R]Y8:))PGI"A@#*BLE
M#+,$+[/\Y)G-;$M[,TN213#Q $/SF@[:!E(,&L6ATXXR@Y&NHO-20ZX7_JU
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M<[&E;J?%D^_*^*M3LL?:BVEJU=MIR:A_;]N3<[.A??B,GQ.BT-%S2">V)]^
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M6MW:JA)F4I;3F0H/%LA@:'KH\$[+\E7FYU7'OYII/,8# &UQ0E:J^X&J@L@
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M2L%9FBS?:F1Y?[/NB6GS_O1D[Z!6GQRLJJ@\3T[BVET.Z7D/C3_9.GD'8&[
M83']:36..O<_3G<ZPTUX&-:>'[%V)T0&9CZ3N?=6,7-G@RZ,J58<[(WLP?'H
MVVJ._XVG-&["+Y&.D\T7JO9_*SC9>@&OQK0YN3FW*@^CXF35:,$+Y#P^CZ<B
M Z/_U"7D[JNXNI]C6MT[])7CX;1Q4UFW8^*U64,)N/;ZK2'FN_B/I\+Y/DN2
M--._>AP@1Z,%%^HT3\O3JZ/.C:\'-X%^B7^(CT*^,$:Z*Y_HC_*Y/5*M OU%
M0>[ 8OU_Y9'J@%'[CUR,^2G*-1&YQ[ 1^.Z:5U_#NA\^[SV-]1YV..O[GN\
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MPQV;ZN0?&= 3ML"O3K;[643'^NR_^QPR=B=P37C>__V@Y.XND,-[_.$S&5.
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M4V'7C7%2HS^!_70_GYQ>[,E5F04OY9@C5MFYG1X/IYU3NU'RS-*'S^V]G8N
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MKI:C)IRD0P3]R'&1';H&5QMXK/EA;WS3F_;[5T*S<?&;V?W A87SA[J4!>+
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M:7IWG4E$+RY7#T<C$&(@$P"&LS%+5(JD0!S%K\".R^2H$-)-VO$+KIXA%WD
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MPOP<SN4 =>[;#NU4R#/QTMC'\>[NM5<^/G65^] ])&PD<E*7W>L\S\&">UL
M)U<T+CABYF$?4@K[()4& K*EHIEF:$0S0YX+D/4QTX?SG:X.V@?J,/<Z-[G#
M^_<M+'%0QX#G/?2Y2">JJZF_9),9T(YOZK3S+?^$YQB# 5("[I"52,#[COT
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M#^"5^<Q,M$^XZ$G!GFWLS(R37N%GT)@(#A&T#**-J(BDO!S%9CB<'4=I1Q^
MD<>Z'S/;4TUG$4DH"&H(G6&$!B3V;#8T/8ICD5E,25]T:+\K[HMC\&,.VE!M
M2P/1ZV E+S$1Q(KWKT8C2<0.*0-NB>[PA$%]H8@G]T(B[AIW:E,2#\WNCM^%
M_1BJ,Q$F,,1L;[:3F5E2K='95>_KKQ_'M;"<#]0>M,1"JJ+[G,<HQ*UFL8C
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M >>5TSM)N:M(*TR5%#32SN84!IH.N[3'9,*8N,(%?RYX7P4DI3X__!-<P!C
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MQ*5MT*H]>,IWO$ AW@7(.2 *^9^E:*ZV:(2&-H.0 ILRFX=.B^)9<R/"B/O
MIIS8_ >JY0BP!)U#'X J1T.U5&U"1_' +02],4!D]G5+(^DL#X9-3=X.RXH&
MM/K8_<3B_Q_53Y%I\?0>]_A@=X U&3+3+%>(T@-2'^L/J59_[INZ5"IVMZJT
M'P?1=4DH&31.VNO"9-;AR'!-G0YR<7D0FQ[4AC^YO.B0)UG FST>_;)81D!@
M/\5!2>T&6&%HC"7!8)2S#$;#<X6(,&J^),%G%MRNKM^#TH%_-<!Z@)M11^H
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M$NL-47WI&YH/8@\,%,WW (S$9#2ZX?1Q1+V1%;0"@X4-C6= J5V@0_@'_=H
M!*>+XAVP7!VP8,!9P.8U6\=@@(<9B?B;"?'UT--KDF'=^0Y\'[Y,Y*P;"E=@
MN /;&3!7"(I9+'>C>T&M@:@]0O(*+>JG/A>>4(DL-Y1<65@LY6.-J+M,&"^+
MWB<3G G<,D0=AFTR J)GC(E.-B-A)$9S>9CL:4P8S3]G3A' 9*(TN_=DB9M7
M(O#L*';&&+&3E8 <[CE0/\+WT;TKT4A,(; -C@W-A+_''F,!&SJ',)8YN2;!
M*JTD6.4Y@C4&#Q$6].R1<TNS+'6+O++%'NL$APQYK*B8EGDF\(SR%L7MF+8U
M3TQG;R54X]> IQ2K0BR5R-4CNYGH'LG9MRTMC)(&"N$;R!=ISL\7*=Y.U?97
MO?APT5%;VN^6+U)?,E^D=CN=C)V[?4VK_U2U-Y0OLG\[?=2-J;T[K$PN7[K7
M6_-V:KN=TZ.=FEWN5?[DBRS;*Z'4Y"K*5WMH498OK5\Y%]DG'S8=4<E%61-(
M"V(D1Z70.A3R!=UCTF84\JBJD:F/4W5<RJ>$TUC,WB[QCL&;ZE83Y?[(-P<J
MLX,#3UD.=5V>4=>I/3-'8\^M@\M+Z^!2I@Y.4U5K>17P;$P5U.[(K3&M6UI9
MZY;7I'6OI!]R3]0:M6YI_?J>O*"^QTK@UZ;M11# <#EN< ,LQ^ZD<'=Q!5+.
MJT"B'Y>9N[@)WR*S:?&">*-JZO R[@%P0]LFU8RJ;(*Q+-3X2*H\AM\8^"XI
M&<:G\!GB7B:I$X5X>H>!M8.49P5A#4?'F <^A#EUOX,KC.!1BB.,!ZX"!W8Q
M<(/YKFIQ*VHA*=OQ2>F*PQ V9M<=V4!\<'V80+F+!:J3B'!E:)?D[XI8=,\F
M7J7\_JZ$;2XC;*,+<'$GS8@[V@?_>?U3TOIE8T[_5%$0CQ+%+$'416&V-@_3
M'%DG/:>'*57624MXF'BLFM51LXZ8O6RPXG9+"BVQ27:/2"\@+E- +*WB'%FC
M;)-RR#;YCVQ;IAUF:F_.4*!)2DF,*,>#HKM!V#-5=I'?$@D:)<H L:@,@S^*
MDHUG.LQ)QPZZYODCQ[_O^6$U^ ]LY:&.Y-F<M."EX#?A6T+W/KES(/^/.AK_
M*[=^R%] 9).L!];3;VX6>#O":T(9' *,6X%!&D7XBJQ; Y7*!( Q6Q'D$@I:
MS(?0@!:Z6-&A2RZ(L1$A&-6D4AT$)MQW@6="!+U(..WQ*Z3X[OHF[4("-J-G
MC$VT?X"D8%^N/^;$@/D+8@,\<GRL%M^UK[:4_P2EX-+8&,/6+! ]/,.F0U,9
M>K3X=@8X@+46=9;#:2U]0-4AOBU27=%' "-Y&^1O(,F!>Z!;&\GX 8C:]EV^
M:6HK8M(PP*'KH,0FR3GT1&CSPDD?0?\"%F2"V RVV7))%W7\;%@$&)<6+$<W
M2@E,JZ 5U!X_(:;02K&>R$HUZ"\#!Q-@0",-AJ-M\9@%7^W1]DV-L%$BXQ]Q
M @_AK+A^L/G  F:T6BZ(;FHA%Y-B=PIFRQ',Y@0.J@^J;\Y,9QH7+H$J*[@]
M%1.\T]PK!$(%2>AZ(F93H#BYUV/YRQ%;OB>F3I"V'X[']"T:[N>_(VD.3'6A
M'WC6KHP9#/65,7>>\B)%@I81E'0?=3YK*7ZA^X8#G+G%,E\$CD9:E49RA ,Y
M@9KQUFXH]@]9YD[T]P4I]CY)B-)T0"'@=CAGBRKD=[[58YS"-/2^6&C%C1$A
MA9;W3 C0__PP#.\%YDZ@3!0P6Y?D6TD 9A4MO *A!+H+@K:<9R>T:"@(-=E4
MLYCIS% (A6*DP0HERH3*Y?B*L]UO^7'R=FU!Z7L8M/# 9W:%SA^'0$,]WKPJ
M^+BD)A2&%RA#ZI*F%$1C(S<1 R\IJ+-L6C=#&#O^DI>ST,(_,O4LO#:0ER0[
M#_.<4,IIODEK*+KZ (U-GF;%)RU%].E21;0A* -Y4'O<*1I]%8M+\$ND@AXW
M[I*A&O27+C7PD/GW=5JRCK [5B=221@V11>=R*7HDK-OBSM"P4Q?I4]C50<_
M7&@:4,.MMHVJ-RDUG 0I=+8UP.Z]T:Y*A%&R[#34,9B+V;"21!JQ6)D,H[3E
MP2/DAAX,,#I!N&*J('E13#\=(3<!,1I47(*.P"UL,4LU_.1KY,0Y Z0@T/,$
M2(^ZW\H3KSHX\>]_MP!I8\D Z1Y"[=%ZK%=WFJ7^&PJ0MFZG)S]W!NK5Z&NI
M??<G)KDVU01=0%*=JR4_=%"+Y0YVV0-T @TU--[$OXAF7Z#M(OO)L )1;L+O
M+1][I5^ U/.27Y$BKY227FE/NK[)%P3[-?X,%X87$Y 17>*,BR^484J2OP=F
MI!1[D#?>XGZCL.R8ZUY7>$]&5%-+J"/@N=2!SWF( S&=B1@<"_0VOJ84JFZA
MH],-?)J!GL0_PARO%!Q!"]824?=+#5@=IYF >#VG>D)RWZM 98O@0('$*L\[
M\@%@UABTE$[$+YZZ=&B?MWH]4DPUX*;R+.3HQ:1OT]%IOSE)/#2LAC6I8"<1
MGR^80+QO/2T8X78< )K]X1RT +"+B"\L]$8&52L>)C?#]959MYZ@(Q!<.?6&
M.6P!XMX,BB"$#@U]8*T:5;G8+N@$633YL>J1[)IH=G 2 TZ:N"/>DI&88&0Q
M\<-A]87@!7>E7,A!!C )2S'%L3O!F:8FNR/><8RZ,EBG/P1S3T^JY^ALE5,
MXX8U/>*&;.;D+5%%D1;SAEB;V$)S!!J:%H^>)I"@F+4O!94'KX,-OWIK%2X7
M[#Z?] 88HVN(M3"<B3]$N-(,0TPS9+F,V6_MAMR!<3[X74$269WK@L4I)ZB^
M8H$6<=_0V%-8-"9&H3+92D'N.ZJ/(@T=<NCO(N8ILR@D-JV9!*[4'I,WKOY
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M:(FWG?A*2RKD!7#TU1*L4*A"VLQSU-!<B1I $3J1%-'<;,_O*Y;+!A6X.*J
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M4Q*//2$L+DH;ZH*9VZ-XOOFL>[[M!F?3L8-E&-%Z[?UMDS\ C6:(/DS,CT;
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M)P8I+@9&T<1CZ5L9,EWD;U$]5B1VS>D;@4QF]4D_$=#*&MRH&$=E+PE?,O=
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M2F1TGG:"SVW/I@FWJ3,)7<]L96\2]N/ <N18M'W7QN 5<[/W?(,-#5-5>^*
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MP/C]B(Z=-\C0M\R9P+=$[3 Q*H]PXBD#/A/-6&+Z\!/+["8Q)7YX[IB22>*
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M$I_3VSV['T]<:++/.?T6\6*$6 ICA/;)B-P%G@(9CZ:("94#=PY*C#$F#:+
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MVQ+=9=#OXTWBI(:0]2P!)HIZ&)<J6:Q<HJXAT^!#T#MILIIW@>186@-@9FH
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M=FZA)O=$?8R=S%!U]\S#N*]:K&4;N<'Q<!^U[%-=IX<3L45#MA(U9#.TAFQ
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M:L:1=,K9%+[C]#G&)!#'#/+XAZB2:W:B"%A@BA+_&JT-Q(<E*9[FA_1E8#P
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M[FKT^6^KJ;<M$KL/-PS\3[C.!X.X=/0RI1=5BAXO.*U"?;22ZJ-+GF:&0[V
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MC"7X ]>.1\E /BK=='@C5)4DNA[=D$T-*NB>P/QU0::9W" !!X,72XUSP9%
M\]Y)H[=YF?N SKFY,W@>U2<4E=Q=!^M<@UP(V\BK,O/I5]<MET2,2IWB>DTM
M"3(N5,XZRHW443[S>[H/,Y-=T^!X\V=P'(/C]5<5')]G\3]>5/SEA=W5P'G_
M3U7Y?TXZI^?FP8$I$M/-X_/W>Z?FP='^\>G'SOG!\=&CN$,>?$N7=7S5LHZO
MRJ9Y2! 0)RGHPXMV>16K@NX?FFFQX]F@0F%J/JAAA_#9D-.U,(//./;-#PE(
M@6J3A HCC/(G+?[$TO,H>C26S6.1.H_V>\0&'YH.3FCIMO?.*+@6KY:&*;X
M?^&1ADZ_EB K'\%V[KG9W[]E6VM BAV8F9,D%,:-CD.4,YN+,71V$6#6!5FW
M \(N1<C9@9U#%&'Y-8:Q=F"7X7O?M4T;(02C>,;-($)(\PQV&8.6-A4([D!Y
M1A#E /3%'@5R.>4OW4MTFP\="ZR^ *-XE->&9MPPLE+E&719T L05\F\<@/.
MUCAS>NQWJ)01T(5Q[!#X95F'.L;9I*F)3Z.+P*B4NZ4&P0@Y9+E:> ICFV ?
M!K87<=1C[$8>(^9HP2!&[X"O(IH6O$>I]F0*L%KO\[3)6"W<2LI&P1%&[L2@
M7\'5P(UX]W__K]JH_C8.^;^7/?XO8]+$9&_"OC/"2A@0B,3L=D>.<PEJ?FH2
M]^TQ2"Q*4>%F@Q:A]%H"?#>",?#:'($B1_H87A&^*#CY# V3(_ J\$#U%UF<
M;H3;(4QS# A-0N=;T@>Z$"[/],*8&["[ :Q^X(3"RV!'^N5*S].8<\?5'0H=
M=+1%)J4<^,--$Q9P#.2GS;\F RIX-\"("7#Y:([AN9J\6^Y@(*^6-E&>.?[,
M2'_&%Q91>)BBTBU':W#7Z?'F51K\<K%Z<;_$PZ !TX+8OX(;QQ96T8@?"=E(
M#%??-,[56H SNL(CF*>LV?$#G\OV!?>K;YH=<PQRPE;'.0*M!G^6*N25+0FV
M:@_0Z2#]P8ZLO3>$M]J&N^%.$D]%)R(GCCU.BV)_EHB"XXS01/ $/!C\(1R/
M*W$T,\/1+$-$QMCKCIX:+Y$SRO&)>;+#3+=W2/!C@J=G2"6_S0.J8G<\=PQ+
M"Z>&6IMXK[8;\.M.,@019U9: C_AI5K,=Q#:^TZ?\.QW'4)R0F>DMN<&"NQC
MG?!2SG-FCQ/',_<VS3\#(/>AND'1"&Q %I)P$=2P0H*O(":-8J+*N'S%'#Z2
MA$\=OD@SF:\L,4UL-^^,;&^0$Z:6Z=NXS8O9O;&:-%8"V&1/N1"GPKV(G)=?
MGI'[&-_V@S%=3?4,K<S(K$P(<2F<I?A+)70=Y?(*$EK.C:%I0'Z 1N:.^2:C
M:=<;&=2_H)^ V LQ8$4Y9VC/H_-6PF8AZ8TY_4? I;E]&9*QNW /%:#$,$38
M6>"-8X5WMXE =X+-JT2^?RD/8C"E9#Y>?=]P_6])".^'-Y.<C5+A"@QW&(0\
M(*7-Q6Z<2.@V":M-TI;^+3/L2')]L/T$%X<L-Y5<BZC86(XUHNXR%;PL>YY"
M<!9PRY1T!+5IC8+ZLQ+&$'=N&29[G!-&MZ]S21$@9*(Q._=BB;NL1!#R3O*5
MW&6GD> Z7,I-W1 !*J/K>,'U6TO9!A_=/J:.Y'YF\L_8XT4&)04PJ+W" PE6
MXUZ"U;Q%L.;V0]\+7GMFW<8L2RW1(R7QLS.UR)3'ZHII3?H)9Y2W+&WGM*W;
MQ/3BJ:1J_ /0J8I#"2HU&"L6V,W4B45PN:\56TF%\(=7%C0F6&E+)O@A&/E,
M5,;#BW_]@';!(+M&W[).H3HU*WHD-3Q+YP\A\N]H@!N/(_*SS&RAQ&>!;RPG
MYFDZ&)7EG+BZ76HC9QDGWM 6FK:RQ9=0",P9A8 UIEMT@J6EO+FRE#<62OG.
M!$QFL[FLB%],J9I@SYR:D.O&O>6Z^4!R_5X22-JZ#RC7C8>7*.8=)8K 3WPP
M>9(A #>2M"%5O"5F9Z2SRXLH<UD1I0%(XR027T:2^P["[(+"PR8UQNS<41#T
MN=H)P:'1-85I,-RM:@*?4!X>E<O@KQA VD)0<F*I=NA&"KX]EQXA%JF%(6%[
M?WCYB1YRI*,YIK9TC2L765D9VDED^U)/NY.4/4LH^R84!)O3' \#N'QP?)B&
MLX.I M.,<!5D5V119W3&)Q.OQO(6=<$T5Q&VV0&DN#-FQ!U7>SZM!6P\O&Q<
MT@(N:^+18,K21%UVSQ[,AKU%UAE/:</.E77&"C:LC(;5*CJ>=F_QMN)T*]4R
M'.PT*C; C&<0EW.VV+B/^?6 LLU80K:9/YIL6Y33LO4SIP5S6AJO*J?EQ\D\
M6=0-=&[&7JIA&=6*'D3-QP%W5*1OKC)%GY)*EY42:84 *57PI:YJR> ^ZT/&
M/'U()O*_2\9A<ME+I 9FF5]=SW/M,0S8IY8I\ %PGTO8 /60^B1]ZIUY[H!A
MONT&L*_OS/^SQY/?S,Y7\SWHD!3H-PX/=U@-.#L],#<0<3AM,Z?IA;L9X9<J
MA>F&2;>$RAQ('S$=?VBSDI*6[?6HQ4V,*0!]8,Y=ZL=D1*!7<>\1VV,U$S0X
M.&]+!O]5ZSLSEQS.#%@5Q8^Q[^W$0X,<>#SA$DTD=\:0_7L'= Z0R)&YS<OO
MG)Z5=H(OI>HOKC\ _NC?V,;$G<#4?-"%9%+)&4?O>XP\-+,Y0+4^^X=AM;XS
M9/U<U3E3D!TW6.$2R9XQ EP$&U\&220GS<X+K/^'?>AB=RW.1^$5H1,&5GH-
M!@'(1 _T.#7-SFPA\^Z,^B*J0[(W0:BY# D0RQ4BO)&1[1_XGVH#S@.(DC4V
M;0_8N>Z&_9)TT\O1KJDO"\IU4CJOL7\+B7H<7TU>N63$7:U9NF=64;FD[CF4
M;68H6UYPT,71G@C9>RP:?E#++S@$UIYQ>M1R9IZ_CW;(,BCEW_/8EDA55]1O
M+AW2S]( :L:YU-.S!; 'DAW&P@#@"+?\C"+[0I?F%SQIHNPZI4 O9NXRR\/(
MQ.DR)!E=4Q2GZ$#WW1 X<T<D>V@<#8Y$,- \&>V@J5;:2?70 Y&LDOW<,G+/
M4PY0WP$2"KDG%%N(WQ*_)SB%AR63&BR.M(X5Z$P$!G=\C4G@BOQ/#]*(EK*_
ME79KF?]S_Z 4(P.VV4:7@\5-0VD6KBR+PJ=5-9K9D>^SM(HE5G65V<%),!@7
M4$)1HN5\Q3'X4AZZ/;0GM1&-_(C2RA3F4#E=SNR@^,W,D"1]#R3?9@B/( Q\
M^\H-@9T>P!UB\SO2EB.Z!3&O$>D?,($TRYY-"-$F,+.]5$OB!PP@R:5'/N+#
M\+2X\(J!\-2Q@;SD6A/$Q@,IUT\\.F&CZPRY=3!G%M5D&P_=P*O4=:.6&<B5
MW9->^NRC\"-Z$QHA#'F!(#?BPX@]#LC\!PA3T>.RVH_VU*C(-W=B,>C4K&2'
MG'U:GQ$*9GZ4?TW5,&)QJ:W*GH3F)I5,8Y'"5&6-!?XPH&Z->HX6,4J1D(4Z
MAHAYN'Z12",7BI!A?+=B!]N:P52NW"&01!)A=AP]J&=<CI&;>-1\+DJ$CB!=
M/GIB9OK*GYRXB!.C"\;8DESXJP-:@'E&%78."N145]6_T;5<)=QQMQ<HO<@F
MX'.? -C.X9+'Q8\8F4<J18_L3KN))P<$=3W_&WGWSZ=P);KD#,L/M$!SIN^5
MUFSD?BA^I+Q\:?&[%#5?\)S<K& JR!26V9+*YSM"A"O&8I'!*26FY)A&*JE2
M1V.D?(HS%73"\<G;L>]T0PX,DW93:0D$?N FI\P64_8L159&0F5HP*)8X>F9
M^0XH:P),^2SCEYX[=&J.(%030?)(RV!VY_A@YD]3%MH:&<,B,#?<MZ@6DL\5
M-#XQI_><$B[55MAH\<4I,#U0 \D7E7H#55YZ3 W#8N"$Y,H3O;$I8<1C;U0H
M!B#WHDIS)D+<<&$N]@!XM@ E$+/ #-B +)S$1[*4(&4QEDB:Q3,2.@)KG#28
M_N(TOUKS0D?&4L01.=FAA)Q$B$";%YG#35$ESKC-/:<H8_NL5)NS,5&:M:]/
M*!!.U@K+Q3+M7TJUPA&030@>4XO<G$>WX KJ>;F&RBU>#S:\M"NP]=,5B*[
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M')[\Q3'!W0G/@1A.I@%T!3!-$1B*B.A/9KV*(A""=J<X@O1EE!(6I[EVL@Q
MF*1";+MA+GM(,W:S<VG/9A?H:!L%ARZX5X'3@S&'=,.T\-QF7$N<?$6W5G[G
M.13!"ICAK6D^=?MG$ 6#*%NO*HCR$R/PW@ID"FM5; _-T2!3MFA/)DY:JT)<
M2].I>BX! A,;D^&<^7RLB$&B..5W&'E4J]>@W^OJ9$&RO!$E;IJ)DG-4R?3U
MC,M*UUYB]D?-P66;S2P9.^$0:VC]J\"[DL<IG30DDJ\#T?:%T0.#"'.4[2@*
M>JXM$<K5O%3TK1=D,D.4>J3GLLN'],A(FK'.+A_-?0O:DPBTL"J3$/L'#E<B
MY&:1X*Y:26KY.R0HV.Q$!W VNSU@(!*&(2$E@[?$3H-Z# ?&6=^$B2-,4Y4%
MRTUK"3H/[3"A4&J]>;..8@Y%1GJA?W$TR>)&F!17$9'%6=69L0#@]83Z&TW<
MT.Y-3>78*S2?TF%E+%#+:I6YVEB^QFYX+&Z,DU#VU-"B 5.Y8MX"WITBTN-=
M96(5:G=&5<I<"&UK"_-&M#JU5.4D+9&Z5()Z:? U:\C !Y&8QANW9B,B4C&;
MR\-F%;#7 U=RF/BVRW",0)UL+/,)2TYU$CJ@;7*K&A\=F4.PM@[\WJ:R>D^.
M.P<J74_YAH5#>S:_CFX'LR1@%OAPF@FEBET(6(B,.9D%EA;65AOF(7OPTD0T
MW9E.U]K@E:%E0BFRI!7WN-4=OG,S7_*!GBR>A\63HI8SW*0.GXM<=KF,5>4C
MT4UH8^\)*F\!"J-6W$Q#='^,22B$+V&BFCPI,OT\>%=_*N?4U[TG^+AJZBWI
MD7@>QWIE7(V"&<CFW-@3<6(>;5.\**((N,H',+1\ &">EO0?4>603P:'A=CF
M8!ZIJXS\35:E,+R3\"J N6U/'(;JYZ1DW _6-O"R<<$.>MU9,6"J&MF10:GB
M9"YBFG[7F=)\.)TXUEZ'U:+C2<R];H<P,*5G:PA2+_1V%H AUW-@R)U-:D1G
M[ML]T5+TY7:7_=EZ[OGIJY&EK^JF^=GG$#P5^9S9'F=![7%_[ES[F\\1<2*!
MS+W&U%B@E .#S.D$DC:H:U1CL]9457FL\AB4N8">-V;:EBFX.DB"_U2:FQ7U
M>]$AB7J4  >,!&X#_RLF&4&=M,T-U<.S^?8!B>KIZ*<YTUUSUQG85*/Y>4*I
MO3ZF9*=T\V M-!^;2(Y W+W((]F::1SY$9&)SNP!.G:U_J8OZ"@(WMH#;0JN
MSHL\E%;V4+ HC<(\!ZFH64/N20LY\",7S>GSD,'B3SS;C]9OKG= DE(G\[W_
M_:)=KEXX3J]?*GV,0^_<"<?1\> \['?"\!R>W?: TU_T4$Z4M\J5BPOZJUTK
M7]S8D_'1)/QGNC_"*^=^_]4/_*,$[%ZW1YHX/'WJ#'Y_LQ\&8WRJ5-XJE2MQ
MP'^W2[7R&].)>J L__XF#O]_>]?:G"C6A+_OKTBE:JIVUTFXWV9WIHJ+(BB*
M(BI^V0(!01$4$)1?_P)J-#&)9G>23?;-ET0M+GVZG].GS^G;RKHN:2HL.Q"$
MBL;%I;OI^W5.W+>G:;O^P1VZ$"WSG5"Q_WG0@.B70P,B/S@<W@6'<!D(WSMV
MKQZRA]FQI["Y(-# H/SMM!GDCS9KGC[YRS1ZC_-'A@G(7]874 J?,IW:/357
MLR]^,.3&H*$J]<%<_]N,WTZ[[]?N.OYF!(%GY7O$4QE QS)X@LY7)@$^)N%I
M;EW_T+=?_@3N4?/C]'NIAG;_BFV=67I0OQ9P>"@EXA'9]\*Y'Y^1T%RB;7HR
MPU50?WJ^/1C,)<]M+,VD46VLY?BUV8X\)?D#F:], ?J,X(^)..16OTSTY6'>
M/L^NW$_E#[^!KN*=GM?#LH+346I@@9#=#?E3;_:]1L[<]&O1G;,(%!CKD?7U
MZGZ3TZV) I*[BNI=:[(O":W<- J3^(D1O$/_)0I^^B\+_R7YZ;]\75N2NF]+
MXK=7U;7C&F[\CC?@#_FSI_C>^<IV."!TJ@F^?=1F7W?>X*WS96QY7BZY<:XJ
MOU_G*T'Q?:&;YO[[B]^>NF;L%)>"7YX)+,[1_V<<[I]>GD&,=6]/ZG8^7>_F
M2&P^H:^,4E]!!WVU>S?Q9;_$'U%_$[F9M1W"G;"WG&X%MW=:/#9/7KH?T)>#
M9!ZYZD+2*/C+4U)YEF N-\M#=U&B[YC8_$_X0F8^-HKG1O8L1A\GX53LX<3X
M%0;1KS!"?H4Q[+=3V3XD.U>RYYBR)0*^A9X3WU/L>&;$C]_RE-ST*R<L["LG
MCA?? "!-T]O(&M].@@2@P['C)E8$6.9$#P%3CW4 PF""@$D S$TJ H$@&,Y-
M21!$(!BP<(0"_[+6\ UTZ\3S<\,_N)2*D\]B$URH*6GGY32W+>CO(JKO$K",
MK?MC&]K9M?P@T<.@])-]O?MZ11_YD9254=[!N$&TF5M%2&ZT]ZNY_EUD9:DP
MRT9CY>H:!_M%X"J7T .W[:$^4VYX7I$WC5T,R)VOMJA<?R\@?-?!Z;<[4>M/
M3H!3] WNE,YYR+T8%S\/2N]B4B&YL#[X?$+SSS!* A:&0E@^GY#+YM.V%WE9
MB*^82,(=M+?EE._Z&EZ(>N0,ZB'PIG,.]OO:4)^P?WW8P_\!U),DDJ.> )'+
M4;]/(2@#]JTROS57]1M/3Z,'0-\F/)W#^QF-7A0>@S]1_4:HAL!;J#SU0/_X
MX.@N;"08(PL;B8!S=.?:$[X$WM7YP@LVI95T5+)J:P+M*U>U]!R@N=8MPN]W
M?N0[0Z@P<_;&U/V"AOB^I-YERT$N"OB?KP?4IQGT9C/GHR\(Q92A"C,(QTDB
MGS(4==F*4*"QB"PX1*W<39P7+0@4==&*4 8^?.+ZK>P<Z!;Z_?=W@6PKMU/P
MPE"!7FJ?[Z)7Y#"'H[O0O1QRUGBU#?S<^0R/HRRWO@1$O]EV3"VJ)I6_8.;^
MEXLBMO8,^$3H:R,4_OWW!\Q^)SB]R.0XP2GK%(6?:ZZO^V4>^R=&/SQ&X4*+
MOC,U>N&QX4]1H\8)1(U+(;K-_B:OU%OEEKT]2B#'P$_<OCYNX7>(V[=1JY^8
M_9"8A4#H5F@I_^ZA]+,4#IEN\TKPBV($^0Z("\:K8K-TQDWW"8I_"@J%K;]W
M4/3T=> '\TVN5&+++Z/NE2))5/\$QRN#@Z6;'Q <K.Z-]T$F3=>?&7ID?4+E
ME:'"56L?$"K<+NWT$REOAY0FS7Q I#1UP_(^0?)6()&[U0\($GG;>?&"I0<H
M P=_O'[HXSL.4,RA\-B]<:C[.:U%3_-3..W>"U.+]3DA/;]#_QM2KY6>E\)?
M4WA?;D\/5R^((WS)F,^.[]$!GAO$*O3=R#D>R$MC(7_B&)YQJY^-Y=RFVNI7
MAV;PAP+D9:G(0^7 HIQ(43[F.(_AU:?EZ];Z>)#[=CZ- ?I,8RC2&*C_QS2&
M1\'R683MWH,?I&/ X%TZAB+P+;JG=JO*3\K#>&7>79X#)1\=\AXU&=NV9@CL
M7PY'M(7RA+"B.NU+"G/LNS[D;RCZ@9I%D,)87VW++KG1KBS(M@WF5923NVUE
M49;FV=;XWW8L^Z6L%+J]X.NV:/BJ*/-5/K H3QV$^=+PQ@4P_[ULM3>QZ;;+
M0=&,45]$N=;;?[K JKMX^>?T./_\L(DK]JC=EK^_^/7[-7S.3LNG<E-MT<(5
M([0'[6Y#N1):[+XJPDLMG2=-4 Q\/I=E?]E%5Z$/+GLI;8^FHSS/)6;S[=D=
MUO.Y.&=EX/X (N"*TQ/7+(H?^E&<_RF*UOT3$5R:=7,6=O>H^AOV[T\G:>N&
M.W4=OP/2?GW&M?W;VQ#X'YP9]\-EW\G$>$C4OT[04][I=T#:T;0XT%=XN(LV
MNZMM3=WG9\DKG ']7%MRM_\ZW7T]84*?\,O6YZZ7SZ8S;SOA+7H("'@M<_^5
M'WRTERMB)6[V^[GC7>4QDY%'=I#E;T=&V?6/1_;KY=TGF_5CCAZ;C\5F<_?W
M>+=YC\2/SF_%BO?[_K6Y_N-*X,H/?X$D\Y>U/ZJ-RI&6MUGBAAJTXPTZU50[
M:) 3U+;;Q$KK]<(>0+<ROA^P'&L8YC2D!*O#Z:S8#-V.'_& &E<V74.8BFN6
M[1G3]D@99"'2I#(53Z!E;Z!TR!'#& !26[0F[,#G7:TVH0=Q1V"G$W<P)7$$
MINVUE6IF$ C!FI 9AJ_.9[0^)'"$K:/( B)'SE*I;&@I015DF"V0CIVLY"3%
M< X'C56&*$( *2"M=7V'[C)-R1NG*@W*:K)B4Y&+%J/F IF%. /.TL9(MK#A
M,*N(%1=,033UQL"LJP=^74WGJI7,9\ *TS58S3B);)F34574-GR=$=11NEK6
M*,#O:2 $ZG,*@32)K$J]UD1?1T(G&E1#SH/CU)HL>"[5G'G5-YIFHD/SR5#3
M14X-62#KZDO!8<AN*V=IFD4HM7%4# JY8#BHPA[= WT+%?"FQ/&B..N-NHXV
M[(:I:XP"MA5D8G5-"=FF#AL+7B&M>(RA1F72=X(QI*FBQ_8WG2Q*^WV9AF!^
M&!AVRY581LI 1785:S *[&34CK#ADIZ%:%RI+ 5CT%9KZ<!+E+X0:HH<@HT6
MJZP&31EO1)A(=6MV<\37&^UUYG=LJ#L*_(&@(ETH84>+95>M;CPVX*EQ&N!T
M7VN/&'2EK]9^T.]LB"2V6A0UK/$2.*?K+<Z.^,%FI2V8<2)#M620\'+-AL.^
MW^"%S%ET^Z8R'[3=ON9"I"DZ7<(4ZW6=6P^<_C1A7<!*M) -- :DQ2QK2R)4
M:<@RD&9)17)'"H[YM!5HG<W(MVJK#(]D<9-ZG8:2] 8-0W,'HAM*#7=F#%VF
MEUG]@<!7VEE#S4(E&[FC*-2#*L T#"&) %<,:B.^E^C)(I('/999LH1JT5HE
M9NJX2&.:.@-BV$>8-5NKM-V54:],%Y.I"!&T"07C6>0*6!.#NAO5"#$+;:J:
M#X-CF2?;G!A%:"*:(\_)>0ITQH1&+D%O'B;MH&'K_6'+Y_ LXS!4-2IQ9B]:
M8X,0 M$,Q1D7KBQ%(A96*F5PN^&LG7H\)*C:<%D;=Z>4.(-;"29Q,M&.3(0?
MR*H:94C&^MH:41L*"2PJEI4M%309-9 Y48W9K-V;)6A[TU'1^<CHK]MU&G6M
M_K(:&3Z]'G"ZA3(@TPGMV$06QM1KP"K ^.2PGE!XDQU):WUN=$.-C%)'&A#I
M2L(G?1Y+.VVX@QN>LR(&#IKU-]F0\4%>GEM#U^VDHNX/46VF\BA*113C^;R&
M=KKP<H.K2HV4^;YA2)K:CPP9@3<C6,EF/@C:?$>'X,:D94O!N U+JRI"--?U
MZ:KE26, PZ>I3M7F:HC3<T0>95JS8C/]^8+E]'FM.\J6H-."O#X>"A5N3$_9
MNEH3[4K'(@5E.N][3<]>]-J^XG4Y!)OA;,;!4=V&[9@4&@MW#;1 *H6F\%+.
MK59PR36AB4UJ(@G@HTY0!Q>\NNDD4T 8KXV%OI*[&><3=*"D.-YH1J@/M:H(
MVI(F\HH@C3Z ]C:=<9K5!RVG@B\EKA>L07V=,#!%>#3:M,>TQYM*6Y'4-LHI
M?6\X&<YF#.FSPZR;10L27>I* VE6NX1GNY(C2K8#P@O(L#<>%;2Q2+'G4$<1
MM3&RK,XJS25:$?%Z5QZN!R#6=KT>2_5H:H(2HV6SU>:3GD!J2<1E$4S'T@BW
M-K()A%!']J-JB\\5:'_*AP._SQ%5FH*A&KBH-^QX"3-9.S;P"'.FCL>-,DO@
M9ZT(9BR_&W-8L/0<V!4WTS8A*8GH]WG(@<*>W9@G? XKI6<-]:;,Y[I7&TZK
M2]IRQHV.,>D1=A0J-8R=BB8;)SFGNDMXWB><2+"MZAP Q[6ZD([H5CV8RJ/*
MR(UK*KK!ACV;7+C^9ME&I].E+T;9#%,0!K,(@1"@)0W-Y('@$Q5H: 72N.^M
M-=];@U-K8XX1P<4T?[B"W)"W=7$E:1,.J#NK7F/#*8%$3*O!NCDGI,9BG-80
M)1G4-R@)SSLH#B#UODD3Q#*<(R0S[/EHE'[_OEU1 2,P-\5_)YY[/_X'4$L#
M!!0    ( !.!;EN!UB9V?0<  +X@   0    93<P,S9?97@S,2TQ+FAT;>5:
M;5/C.!+^3A7_09>JVX(JA_ RW ?(IBHA83=5'+"0O:O]J-CM1(=C>20[(?OK
M[VG)3@))!KB!F]H9/H18:G6WNI]^D97FKX-_7K5V=YJ_]MI=_!?\UQST!U>]
M5K/A_V.V44XW.S?=/\3]X(^KWL^U6*?YF3@ZS'(Q4!.RXIIFXDY/9!KX@4#<
MDU%Q#0NQ]+9:-Y%FI-(S<5B#B%L_^;=Z75PJ2J(S<5<D5+^5(Q+U>JO9[?_K
MZ;IZKC-(/<[R<U&.#'6>Z\F9..&QF8KR,:MU^/?:D^6L;MVJ/PF33#C4)B+C
MV742&3X(\!16)RI:3%:<_?Q1-5]K_90.;7;>;(!_J_Q<V4+CR1ZV[KYB<ON,
MY+6&K0P 9N<BI\>\+A,UPJ-1HW&.W7=:O<>Q&JI<G!P='#4;G=;'"7NOS7B'
M'*XY]YG4D-*<C-OCS>5E_Z)W]Y.QGPM]?B_P?=#'4'O0>Y\MOU6E;V"#V]_O
M[G]O7P_$X$;<]RX&_9MK<7)X_$$NKP2_(X!KK7X@NG*J(O%O4JG-\1% D,E5
M/!?Y6.9G[R3GPZ+N/X5E96NMHP/1%V,Y)6%HJFA&$3:@K/BMD 9V2^;BCC)M
M<J%3<:G-!$+KO^WNQ-J CD0&*3H2E$98>$]93I,A&;@S$,>'QZ>!T+&X*E*I
M1$?IF38/5O33\.!#M_3Q1CL^$!UIL6,893(7#ZF>)12-*/"V,]YBD8:,5.<B
MA&"ITMT=F<Y%D>:F(&%S"5L!FVPA"8DPMI*)B&6((2/T!)DPUYYNC2"ED*R5
M9LXD$_E SAD+GA9C$;11J4@XX[$,)@B5"8L)R%(LW]TIX#4C9F,5CH4M^&/)
M8$:&2BZ\A8FR"<E(I2,4K7R,+=J,0J?A"@Q"/<6R2 SGJX;XBSO[Y O.)A&K
M%-9DQRR-%["G08]YLT*@4D0-_*C 2*5A4G#,P$4KI@K@7L5!E\' # Y,RR19
M>K^TNWTF&PB+%#,.F*)(0 "7:[C%B;->H5#:L8@3/;,5( R-E,V-A"3)@X%@
M.J@9K+C55MJLJ?L7]^RG S%X8H2R+-O2=65&9]#K.%9X]';L"VG(N0*F5<.$
MV&*" (!AHNR8Z9EL@ICGN.?G2-DPT;; .LX&1B?6T61&AQ1AV(H]>" B^-2;
MN?<8CF6*KJR-,.,>S8JC$UD_.MVC?:_&T6GD'_<=*\5U+O5@8 &"@W$%(]YE
MK,RK)<6><RDHAJ J[R]MYG7A"O(^1>\;H:$<5$B)S/#D'QGZQ#VY[^5VR8(8
MYG)I<NG,W9TMW@PXAX>RL.MKM@( N71(<$PIRF=G71@P0"!.E77Q#2I*'1]N
M-!:987=G-;T82J1S=9F?E^X*RM3#DPII LJX8X+,G:9#JR(EC>(=*%]&7,9+
MF5-A.;.[V+"N#+ALH"U!HQSIASCS9>@;5%@DDM,8-N:T6)8(+/$%9[52XMN0
MF!")!NLI^G\[^MN@:[@1754<+["U-9#70/;Z%/!JK &?Z',!=$/2ZE1RMI,6
M^.,>@G$E352Y&*A3<J@2E<^YP&R2RY!W:'".]F!]0KK2@KBD^ECN*"M,!J19
MQKF088@SK]/ =2,C2E'I$@ .,]R$1HX$K98'%2"O,N2U'P-680FKWE0FA8MK
MMCC%,1H'-86I+*RXU@ L:M\K,I5_W-P3.!1A(9(,@PC$0UWDZRJ4+<CNSLOR
M M^<>![<6,4O-YUB6/5L+C+(VP(*G3/S'P('495>O('7/.7/(V7M=U,;\?"&
MI,(%28=A8=@?*[E_ ]>)MCG&^72.TR0T!*?/_LPI]K:LB0$M1/LSZE)S-+?D
MSE)(#VE:+!3;]VJ-I5W42LX3#HH4N13J+%)FM_GN3J(>*"E/5L\6!%]MI.\1
M?K76Z?_<2;M7#U&%T& 9MIQ&5D"R$L'LY5?;.UAO@1:Z2;1!N3;EZ8B)W AX
M3G#ZSHG6CTF+M4.-PL?SD8*"S$7L 4K(29:3'OYS-U8% 'TN%/3G?<1%&KHS
MV?YWW"^W<6;EUD+!UWRXY--&J B^H=+:BQ/MC.0#UP.R523[KL2]!*D.L&]R
M>=E@^C-:%=9B&=4RPD)+'.H^JK?BH^QEL 8^1L<1^*)D821;3& @]2>Y6E76
MG(UG_>\QXK_<S[915F*#6 K@"G()0"/@W7NDTNV!S\HJG>ID2IR:4SDJWX>9
M,FG0)$OTG# [&VN?*.035 $$;RY<7&S6$'/P([AG(6[0[ESUQ$7OZNK^MGW1
MO_[EY]IAS3W?MKO=ZOG-*JU<9BWNI$*=)#*S=":J;S5W<=<<W%4"IEP:4,^K
M+?C[@UIYO]<<="O"DO^INRN[O+D>;+HL.UR:MPNHG8EK.-V]DC[ZY%])-QN\
MEB\,N]MEO"BB,S_[(J-G=W+#IW=R"V-]>EE2L]]JV,;SZX9FH]]:50 ?=V^V
M[ *'JSMX09UK.:'-6W]AX=H&-BN_;LIMV]BD_+8UN<Y>LO- Y<F6G;VDR9<9
M7XP5Q:+W2&'!9Q]QXQN@9H?WNG?K#Z?(1FL4^V*SD1HN@%M??;GT,7=4;[T=
M/_G(R_&ON?S^*IOR[Q#X]P?^!PG\NX7_ E!+ P04    "  3@6Y;KYL /V$'
M  "A(   $    &4W,#,V7V5X,S$M,BYH=&WE6EM/Z\86?D?B/\R)U HDAW#9
M] '22 %"&XD#%-)*?9S8R\D4Q^,]8R<[_?7]UHR="TFX'$Y:[5T>0CR7=?W6
M93QI_MS[[TUK=Z?Y<Z=]A?^"_YJ];N^FTVHV_'_,-LKIYL7=U>_BL??[3>?'
M6JS3_$P<'6:YZ*D167%+$_&@1S(-_$ @'LFHN(:-V'I?[1M),U#IF3BL@<6]
MG_Q/O2ZN%271F7@H$JK?RP&)>KW5O.K^MKROGNL,7(^S_%R4(WV=YWIT)DYX
M;**B?,AB'7Y76]K.XM:M^I,PR0O[VD1D/+F+1(9/ C2%U8F*9I,593]_5,W7
M6M^G?9N=-QN@WRH_%U1H+.FP4?N*R/VS)6\U;&4 $#L7.7W)ZS)1 SP:-1CF
MT/ZBU?DR5'V5BY.C@^-FXZ*U/69;4R:D-"?CM+F[ONY>=AZ^-_9SH<\?!;[W
MNAAJ]SI;4F[&?*MZW?_Z\/AK^[8G>G?BL7/9Z][=BI/#;3FL8KPUC_U1V%S%
MTUJK&XA;F0\I%=<%,\7.D S/B7PH\[-M\MZ^=D<'HBN&<DS"T%C1A")HI:SX
MI9 &!DZFXH$R;7*AH;\V(S"M_[*[$VN#=20R<-&1H#3"QD?*<AKUR<#O@3@^
M/#X-A([%39%*)2Z4GFCS9$4W#0^VJM+VC79\("ZDA<8PRF@JGE(]22@:4.!M
M9[S%(@T>J<Y%",92I;L[,IV*(LU-0<+F$K8"GMA"$AQA;"43$<L00T;H$1)>
MKOTZ(;U.RZM2"LE::::\;B2?R'ED1MAB+()(*A4)9S=FQ M"9<)BA&4IMN_N
M%'"=$9.A"H?"%OPQ)S A0R45UF.D;$(R4ND !2H?0D^;4>C$7,!"J,?8%HG^
M=-$:7[G'3U[P.(E8I; F.V9NO(#=C?68-PL+5(K0@1\5"*DT3 H.'+AHP50!
MW*LX\C(8F!&":9DD<XR4=K?/> -FD6+" :\H$BR RS7<XMA9+U H[5#$B9[8
M"A"&!LKF1H*3Y,% \#J(&2RXU5;2K(C[E7OVTX'H+1FA+,RV=%V9ZQGT.HX5
M'KT=NT(:<JZ :54_(;:8( "@GR@[Y/6\;(3 Y^#GYTC9,-&VP#Y."48GUJW)
MC XIPK 5>_! 1/"I-W/G2SB4*3JP-L*,^S$KCDYD_>ATC_:]&$>GD7_<=Z04
M5\74@X$9" [&!8QXE[$P;^84>\HEHQB,JN0_MYF7A<O(5UT.RT&%E,@$3W[(
MT!/NR7W/]XHL%L-<+DW.G;F[L\&; 2?R4!9V=<]& ""7]@F.*5GY[*P+ P((
MQ+&R+KZQBE)'AUN066;8W5E,+X82Z5Q=YN>YNX(R]?"D0IJ ,.Y((',G:=^J
M2$FC6 /ERXC+>"E3*BQG=A<;UI4!EPVT)4B4(_T09[X,S8,*BT1R&H-B3HIY
MB< 67W 6RR6^]8D7(M%@/T5_MZ/_&73UUZ*KBN,9MC8&\@K(WIX"WHPUX'.L
M(@#=D+0ZE9SMI 7^N(=@7$D352X&ZI3LJT3E4RXPZ_@RY!T:G*,]6)>6+K0@
M+JE^*37*"I,!:99Q+F08XGSK)'#=R(!25+H$@,,,=Z*16X)^RX,*D%<9\MJ_
M U9A":O.6":%BVNV.,4Q&@<UAJDLK+C2 ,QJWQLRE7]<WQ,PBCQ_[$:F821A
M1U\7^0MRO,XT\!V*I\'=5?QZYRGZ5>/FPH.\02#0.1/_5X AJG*,-_"*N_S)
MI&P W-1:4+PCLW!5TF%8&/;'0@%80W6D;8YQ/M#C7 D)0>FS/WV*O0U[8N +
M(?]L=2DY.EQRIRKDB#0M9H+M>[&&TLX*)B<+!T6*7!YU%BE3W'1W)U%/E)3'
MJV<;@@\;Z5N$7ZUU^C^WT^XE1%0A-)B'+5>D!9 L1#![^<WV#E;[H)EL$KU0
MKDUY1.)%;@0T1SB'YT2K9Z79WKY&]>/Y2$% IB+V "7D),M)#_^Y):L"@#X7
M"O*S'G&1ANY@MO\--\UM'%RYOU#P-9\P^<@1*H)OJ+3V[%@[(?G$]8!L%<F^
M-7&O0ZI3[+M<7G:9_J!6A;681[6,L-$2A[J/ZHWX*!L:[(&/T78$OBA9&,D6
M(QA(_4FN5I4U9^V!_UN,^)>;VC;*2FP02P%<02X!: 2\>YE4NCWP65FE8YV,
MB5-S*@?EFS%3)@T:98F>$F8G0^T3A5Q"%4#P[L+%Q68%,0=_LZ7^633TVA<W
M'7'9N;EYO&]?=F]_^K%V6'//]^VKJ^KYW8(MW%[-+J%"G20RLW0FJF\U=U/7
M[#U4#,9<&E#/*T7\O56MO-!K]JZJA27]4W<Y=GUWVUMW.W;(^EX!9&?B%NYV
MKZ6//OG7TLT&[^*[P:O-U%\E?C$]>Y'0L^NW_O+UV\Q,GU[GU.RV&K;Q[!JB
MV>BV%OGCX^'=)ITA8E&!5Z2YE2-:K_FK&Y?E7R_[JB$W:;%.]DU[<IV]9N6>
MRI,-BKTFR<N$+X>*8G$]RS9WOO$1>_?^4(JAE<G]]>9IN)!M?3!A_%_+P@<N
MP$^V>?_]D?OM#YF!?VK /S'POSG@GR;\!5!+ P04    "  3@6Y;DG$%TP8%
M   S%   $    &4W,#,V7V5X,S(M,2YH=&WE6&UOXD80_H[$?Y@B]91(O).<
M>L1GR8#3(%'@P&F;CXN]AFW,KF]W'4)_?6=M3 AYH>F%5M5%$6#O[,PSS\[.
MS*YUY?TRL(L%Z\IU>O@-YL_R^M[ M:U:]HVCM<VPU1GU;F#JW0S<SZ50<-V&
M1CW6X+$E53"D*YB()>'E[$49IE2RL(03<>HXG[<D<LYX&^HE-#'.!G^H5."2
MT2AHPR2):&5,YA0J%=OJ]7]]/*^B18Q6F[&^@,V;F=!:+-O0,N]6+- + ZO^
M8^G1= .WHMB?% >-X$S(@,I,72<B_BV@3E B8L%V,-><C3?R\9+]@<]4?&'5
M4+^]^=QQH?;(AQ>]SY6,]T3^+K$Y :CL C2]UQ42L3D^2C9?Z*W^CNW>+]B,
M:6@UJPVKUK&/;O*;]6?+4G^RQ'M6?<HUE;C.';OK3KS^9;_K>/W1$,;7D^FU
M,_3 &[V/PV\%]!\PT/@)KJO3:K<*4[>;LM!HG=>_#_>WH>Y,P>F-QI[;^RYC
M(%_Y3_6/,+H$[\J%J3/I.$-W6AG]/G!OP.EZ9J19KS>/E KVUN3]#?R1*,W"
M=<GN<_ %Y]373'#,_'H!>D'A2T(D(HC6,*&QD!I$"(.$$P8=)E9"WJIBH<_]
M*IP8Z0]1\#41%]:UW17+F/"U5;NV/\CTY2F@WDLAEPBW\@5"(5,#,<(3 5 >
MT "QQIHN9U1"JUY&7IOG0!2$+,*Q+22S,5'23R33#%TF/ #WWE\0/J?% AI>
M,J6,$_AOY .B*2RHI A]#V7FTR[(<CHE0312(4%HU\R<K7$E)!)E[,6)5 GA
M&K2 G3RQ8<[DB7*Q@+!)(-";X)%\+F5B"N$86U,B9X1351G=1W0-CI]R;&+*
M8"'IM 53<,O%"GF8T_8QP^#X@=:H@H=N;\(I3"*,+1^C)3+<;A=9TJ\)DW2)
M\8\1AH0\\'M",)0D-,Y/@M,MB0_AD(="SF3C4^NL;,*(+-,@NS !\_^FL)E1
MR#ANHB5):<&]JPDS\<JRJ,_Y)0PW;[$02ZH,EV4S3J((;>"V9B1"IE6,W*HL
M\D/&"??->]08L%2WV6 HE41:&4(%;MG4J,K9WVSVZC%]_A=7S',Z Q>Z[F P
M'3O=_O#GSZ5Z*7T>.[U>_OQF%#O=]+8I]D44D5AA'YW_*J4G!\N;Y ;N3.+Q
M292CS@I7:7/ L+Q>+KC1?YXVZY<C+-;/=.N(LV3W<.W;,!1W6:YMG&6YUJJ9
M6>:LTGM9^T'EG77[545[QX'9X^/ EJ:SPY:LOEU3->B1.Q; ;Y1QI?'#JO7M
M70#X,7DSI]N0V/7@ )PA)ICG73^X''L./ _^*94ON?$<^)?F8%MTB&>/Z>@%
MSPXA>5UQ=\%HB D;D[=F=Q1&8<BPSEH=X^O)6#+,1#&FHB<2I\]S5$MWKOT^
M28)AL3!S6Q_C=SR,O:3_F.G-@4TK(_!DB?D]RO(V]A0KK)F:<E :,X*IM7G=
M#8H%['EVNI6R*;D"D[V$0/A)*DL2?.9FW=-J@$76SYL4QN</,U9,T:P;PM=I
MP3!XB$XDS3H<$L>42)66KG6,0$U=2WL!QHL%,X%&"$4*SGRX,YV9Z>X.^@#[
M+BRP"YA1E(VEP"V'$MA;[12PM-*M&%;'F>E -@45M:!,VEENA<)$<J86#QI>
M:TIAMR>5P+",(M@PA"3&-P8M5?JHQ?/X+<D_OGUJ'?/RZ5LNE]Z?&W/Y9R[]
MLEM <UGX%U!+ P04    "  3@6Y;PP%GN=L$  !D$P  $    &4W,#,V7V5X
M,S(M,BYH=&W=6&UOXC@0_H[$?YA#NJJ5"*_MZ99F(P5(MT@<L)">KA]-XH"O
MP<[:3BGWZV^<$ K==KE5Q8=>595BS^N3&<\3V[?^'T.G7+)O/;>/GV!^;'_@
M#SW'KN>?N%O?;MO=<?\>9O[]T/M<B037'6@V$@T^6U$%([J&J5@17LT7JC"C
MDD455$352:&W(G+!> <:%70QR3=_L2RX830..S!-8VI-R(*"93EV?_#GH9ZE
M18)>6XF^ANW*7&@M5AUHF[4U"_72A-7XM7*@;L*U%/N'XJ81G L94IF;Z\8D
M> "T"4K$+-QM%I;S_6:Q7W'.^%PEUW8=[3O;OWLIU ]R>#/[PLCDA<A_!;8
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M!H/!8?9PF! <!CRR>"C:P^#V]G![(;@]\$CJH5<(!A>RAPL)P86 !XX/HW
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MB)JK0VR\K#5-<.6LHO,^3>[&2NET 468*L0,@B,_H-K53YO @UV?]L(JY(I
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M+2GR2NASGL$,P?&<(ULW;;8SGQ_K<B7M%FV>#LJ*[EQC4XO'+,TK^@A]?,,
M*SF_N1Z,13CORA1K[$&.HEA S\]U"[(<^56]Y6A8"1EE)Z,?'EOU+6T+2@FJ
M,F8T,UYB48D51&,%)\@^<_EM9-A@"5\5MD4D'-ODY1.K(.*(S0\U  B,6;&:
MSRCPEQ+[ HF#7=L&/TT:6=+^'HX)%$G/KOMYP'W0=T KM$%0ET=+9^D<)Y?3
M:7BLN52&HCMM Z!)2P,6H+!!CVE]TKZ9E#T%(SI7:]'^2"PPT.&_GPL1,RU<
ML@*4#3(O,?-M-Y*V)P&I,%>86;WYMULML#,NT^FYYBO&C"GP$?[E'W\U=9TT
M![1E'#2C""-X262.%!">\L\%\.A"KGF>N;&>SN1D)0QGQ8AAB:+4BH&?T'$5
M"PK)I52<!/JI(4G$3(U;+ ET ERZ*2JK K@Z&-C94E.%/18IW;?1H;HF?[:?
M"E&(3L-LM&[R]="=_(G;P,BYZ0J2^!HX'4 YQTI=;;FK^X2W[")C9Y<H=( :
M( G=25AI<,_<!A^.D1P++FP<+16_!/OR DLJ"7?:"],8CJ!.(88%N@'0/I!L
MPXF.8<9#C;MJ&V6@DLH1Z3"FC0Q439>?D^N6_R2!B8I'2<7$^&-J/ZD",3OH
M#NIQ5[_@7M0,R#&D391VE6> [Q<Y][L$(:4CW%[Q!0D.*[,"R'36KF2:#RZC
M*7$$_#UM7M+*T>W"OVFNVJPG49+#C*+IN-0*.)4'953*=[@7-R4'&G[P@]U.
M7.X#5@W[ ,ILYM?P6&US$N0:' S8-<5$M_FOZ];JB76FND*+I<*QBZ-,V>YN
M,J=;(OF+8Q0$FOQV__+4,XI7? =XXU<%/DDX:*KG5QL;TPI00TI: +1C5%@:
M&PIH%ARXKD8FHKZG:"9#PX#PJ;LOH*Y9^7&Z*:WI?E2$]R@GX%U)W ]Z6@.;
MV.]2*R5@1&H39>Y2@I#C!&^M,G;W GS),D J(AQF=*F7A'4U/:$N1G2V2?>R
MGG_3&"AEID814 8\?ZGT8GOH !8;HU)-R/"I/*@9VY?"M\@$:F/(V?_%^4V0
M0XDBY"8!PSJP%C=[HJ]YBSH&_YVO.K [R9^X'.56%BS7<Y.K"^14-;-RQK$=
MUPI$8'4./TL&V5#N)60P<YN\=P]0 /J;L"3%9?PZ0! =N+5)_CP>K@QQ+;PY
MP-B3JC"+X+@UVU/MD>!OR'7P@5N 03\:<T.'^%--O#8UZUG6C YDCC.V\%"C
M%]&U_'X2@>(NCH#4@ JD_B/\Y\M=<FH;J[C2]^^OQM3$&9"B$D$AMLZES)3;
M\@;$U$AJ.-/!7-+3%A_@_&S?-MG1E_CC*">O:W2K.&DV)BD9K#$C0IP;SJ!D
M5JG):&BDQ]3W3U3IB]E/#Z7BU7B]7*7C*B))QNZTBK^&93@Q8/3+O['Q6LD@
MES^A.>+X,B]I'+%NQH>)B103"YUZ]",<$>M8P8@_*!^#BXP)52@![*T !L83
M'BB.VB\SX\"2A:>BO8ZH@4T?)/8?\&P"-X%M:1:V?OE#49P09YT%AB"%7%*Z
M#!7=LMML1[\_=G%Y(^H23!FG%%^':?VAK./D3L2-OB%(:GE!F,F_4Z1BT9BN
M#:&%OM5.C[3L7LP<?19FNJNA)XZR+IOJP?MRA,UM]>J%G.$_?V5./2)2%Z(J
MD&F#4@E8LO2IN(G_AOWU#Y&J9&4/ERP([QDG7)+2IP6T>O[X^\F]7#7[;/B,
MO()5@&@1<7'978'_[8JPA4"H"^0?IP>#M Q,L%\?6J%6'-8*B(BFP44P(_A@
M1Z,G$0:R:#NJ90V24_1DF!>&(96#^LSLP1J$2U[E(<Y'/X"$5^7*Q6C'A*E$
M=74$L*&[_3V; .BZ/H-$+'BMR?NU":+]F(:A^UCMV2WQGZ!.Z3DCA])2'1@>
M3I0Y;(MJHG(\?^L.-_B?O*@=A*/T;@=5U7?O!]L9.X2+=+*D2R,UE&CL_4,D
MC*&,D=J:23^[PU+ES[@/%?U9)P6NA//3*96$+$Z4.0T-VT<*>Y9&>R"EW;G]
MT@]7L'EE\JEJ[:@42DU)Y1@+8_S3V6.P$KPXP].F]5-#C8Q*C('<$5<%7-BK
M[;\J:,M ,3L,LS H!D7-./ K?PTHJP\U(<SZJN@7I"^BRGAV3E[X[((*LW9W
M-4Q+SE8Z S34(W%+:3FA4K2.BSRM8BJZ8&DT%HHT< '>E&%-F@L51 0U20PW
MC!Z>S78!G!9).?Q2I 4/)O@%&3OQ%="W;&H*P.Z!0>CQPW#9"'$_!\U7X_)\
M$?+(;[8IL64))2#D@7X]9; 55:5G4V.-&WUL"Z&)45I<"592RC1*%:RF:T11
MYBV50J0LF:N#0#_<,J\"UF$]N-\QD?5WQI1&@4.OX$:507C">M^S0-QI><Z/
M*&-*,TY3Y2]'=$.4"$=G)3,*E"  2V\3 +[.\DO)$:T#,QH2MB5L24TW(2C'
M;J]&!L4B1[)# OH(Y'CT+Z;OJ/M3H2Z'?3.F1TW26I__PRQ/D#7^!/O\XQ*3
MZHS]IFI7#WH.!Q]Y18L]%8C"&N,@8YJQ0!L00V_8!B<S,@"2* '=%(6G#4KS
MS^ (!V">B+V=10U)%-TL2+!>E: !&&>-CH3V).UJ)-ZKE"FT(C I:3DJ3(%?
ML8^( 7!)3%2B$RPJ@W,CK ;4BI^BG<U#S?.[L ,=N)BJXO/7Z^!I@/EEM_3F
MI61APSD280IYZO)'-HSS(*9O)9CV8?2.^S?H(9H\'/;!UL^;E6@GSN4WLWM/
MV-A(C '^)P@$(6OH#N4Z<:O,IH[\;%BPIFO4$[&D)S8^#6BT'!:UZ;XXL\N4
M/U!LX$#U]::;1XUU\XBVBR;)K@S?7JWX?S*<5GL\)W7O4(-45T>?7Z/[DQHS
M )GA5Y \R(G'<):Q?3[.Y>BL;(&O30J I8HE%X"OJ?:,+:-$>3UXHSKR@&9H
M4!"I*:8NQ(8<<YEV8.KM5-F[%$(KQ-6B0(F:1PE:, O0N(JLJ"[D8DD]V"_2
M.V'E*19&QQ*D*43,E8,Z438:4"->#X5B2V()46%!44 !L;B2B-S:7[GM@_/Z
M..&3)<F0PO]X(([]2(#G9$2_9N0NU;!J0Z16VK=.D.TU&@/"N,"( 9MN]_H.
MXS22 _N 0CX8'3I<G\0N\EY96]\.UV@8H&Q;HQB1%#,@9UK2H. &,W9(P72V
M F/ZF?I_;L)K=P.8E2W&#P3_"U=D84M[\-?2N/D!N)12&Q*[O->C1>7IMGI$
MU#P[LU>09@S2^%JE.=)\<R$"'8U8<@1&.CUW4-Z'7G6+A7,[L60=!*/A4E.;
MHD(@5F^DQ5Y<LLC_!5%)F-Y>*,4<[?$DE%,C[M%V@&97"FRRL.[&S%5MA^%P
MAX03&0H_G)[?OY\CFTV8&1OJ.7P;DI;Y6R*2F:27!\8LKR01CM;\ARJFA:*E
MR^"7= &_)<\F)X:*Q$4Q>'^+?ML(N@693<V)3 KQ\X(8ZZFJ+(QAZ,$R17M3
MN,!57"OA;2NDATH?TH(W'DLUBZ)P=*UW9NIT"VSAM.\9,U?(&(-BZ'D&A@5R
M5,TVF]QFT%L_PF@Q7 8"2Y!$*X+RLS$6\0*+&*\F B;CG:M6.J["(4<U(N11
MKMGX%W)7TY(>9JUUCI@!]6/#W/7Q@(JQ#3C28N=>)GA]B ZD<<$%#?]Z$@NM
M0')X\'_1P<=3]&=I LBP1B.R,?!L4T=+2$A#))55)/%EG1%02Q#7[,*(-5_6
M$[7TBIMR=O0O "S&"K_Z) @Y)>^OM*Z>DK^I*I,+3,OK+"LT\VG]P391Y6;4
MY#8GY?O@<5(:E)9H&QS49 $24<_-L3K *,/\2*/L'<9O5BHG"IP<E[Y3&MV!
M:+$YO+\SZZ#S 98%C5OTM?-F3/=%1@"MFA'[,==>P2W"VL/<<I1BST.'<-+6
M!H%&!CC6M0S<5O[(_ <_2E)LU$=Y2C7=6UO(A>_=!;YB@IGLV/>XE\X%,6?G
M!O#"'@:92T+1>J)[N5*^)V$K/U':+..YH":'UT53:2#QKLOA+Q9%ILT,/SQH
M%#]^1;_68MCS8+V$4S,]BK$LEBDW7J)Q12[#2ZI->\=W13M6W@Q9O4)0NZ.Q
MKPD#2'GNI>&[)P]\@S4_9C6XHV%K=3^11$J9F-=Z[ -='8@4DU@\@YR0D0LX
M0/5?.JKQL3 :8&[WFQ)+H9I,AU4CDCF_L]SP!?,3RY.8'9[YM*!R]F[6>IQ[
M-V6XOB8 @S^10T4<7]%DI!?V"@EQ^ZT..<WF.9EQN5^#>YO&X;F^@R<.W,H)
M.SZ(_-%T_(DXQ@#\)OT>)O,#/AG+JN$54G0#!O*!,A((T19P:(PUV*T%XB46
M-G-F#USG5(G'T1_2LMJ:RGV)DRE_G:J (*6\7;7OY\\%-SQ['O/QU#/?':UL
MJ71PE#73#DF)5O/\!V("363V.%XE[)64#*Q4#!$'AYY2?XE+D.O^M:QJ,U^?
M<"?AL-U2Z 2-:V%YC6\SEK)H9[\WT?7H4(L=2NV%@>/2B#MWOHR$:,!0M4!;
M+=:"^.J,LM1NQUY?>-^?6WP@'I0CILHY]]T5&.\LU3[1PV(V^]C%$O3AVK*Y
MB]^7@6%)O]5[HKA>V--TAG<0$5 E=9,^4X]C<T;<VT0H"\CCG_D7QI,9OF@^
MDD1ZWI'4WZ(K ^GQRWPX4=PSFBG93,_9$(ZM&K$)"L5G(5<.\WOK0:^DJ\42
MIJG)8"V/(I]G%<?_<!UP:M,F0_5$];(=))GO!CZ$6/P-E$:$("Q"=\C)HS9%
M]'/X!]'_8A&Y05";Q? 7K<\%+D'(ZVXZ HPF8;GA7+5E.G(>N+:H/&2U*LFX
M5NGIE0;NELTE^Y%]U-L<J0TKLWM\@@CA9H:PE/139HEL7,_,VZ@:]E+):T%I
M[206&2;AB<,LMM)*[%3:$]+XYIFLKH66LX-Y,S,."FTON-NTQ6-5Z*F5?QGQ
M*0FS[UV$86MY-"#W$>IF8$DBK!\1B0O_SZ9J35X0>E8(KTW7U?Y&.^ZW%G@W
M\GU%,XX;_:N2S%Z3,2>M2+.-;6&=N8]C5F@QU3ZCFX?-T-[7+VX0F3W!C=4&
M"@RVFE06)S21+8CP6_R$!U;:L4"C:"G\>7G39^"27)CHXHU[^$%Y9"'WUI?@
M@R"?6FF_@HMOR.S09DD"(C-/^H'6V((6!SG[ 200:_S7+;YX'MX(#H:J[G4F
MJ#XU7WRM,S%;K*P2[([0(>!+HM&#<E<GVQ6=4(]U@PT0%+NX46)1:L<]C"#4
M-9S93EZ!5LU7D8L_C<FQ9$%O[',8\WS:U Z1^TAM_)45WV';0S<^BA;>PTO&
M#^<?]!%R]+.(7M!N0CQ2= #[G]A%7OVM?M-[:4 [/6+_8$R@;5HT<+J3%M,*
M7Y@K&GHS,$W>1>/3TN$[(SG59P^=*2:?[=P<_O8NVNJ40!X^JFLA%[PYEDWJ
M\18>Z\*5[U"2Y!Y$/LC)6-LV5HC/>*^ ;B^44GX8VV9FQ=S94CHU@1,T@0V5
M9M)@8^-=49)G><IDSO.D7SWD\)42C6RXCMD;&';DN;,HVB;G=9S*6*;=AH%0
M5OP-\4E:9RN_H[GC1I@+,9]6G )>Y[;B>&R1<T\X2%TW2?)?X>"S@<GO3$7[
M+$62R!_1L]^?!3,G;ZA]K5*F-GDE6"@GEIR&M[@'..-(UV# %,MWSADG.'"V
M0GQA17C4RAM45X\^3XWL[/U]F_>?JX;/>!9Q.9G(#@7%G\^N?S!6<[1U=T0O
MIT)8(EE%#C9.MZ6WM_D_#M1%#N6-%*EM:#]:?FF]]7\I"/]@3Y$?F.TW''=C
M.(8YAO/H-UO?':F/-BO^3-+Z.(DW$LM,XG.+9.X]@YU\,C0SCZG8IYV(9%;>
M.^/=^%:VS:1B:]:S);,DZU(E=A3YD\][:P//;P-6O[I/P-'33 A_#YWK!J(O
M]FQ?N,9D8&Y>9FX+-YG]VSY3=> U- 6@?MO$*.0[LO*H[#'3SLGY=#9=>'[%
MU'O'"KN[[A'C_'4OT'L?KG8O+/H@_>OA\W\/DG\>YJ=$;*^;$WG7V%'/+_47
MDZO.WUJ+#0!R?=F?,A'/,P$']@U=IF\7)B(>JKP[ MN7GWO<+AJW1Q*8;W,\
M*XS\<GI_51^X%\ $:R>9TG[]S05<A^2\%KX=!/]Z'^]]GX:]U].*89'0-/\T
M!_"<=?\Y$O^X:;YZ$RTHSZ"^* 30J0WKS,%@L/\HX?ZO?U/8_^/@=#>B$!SQ
M_P].]81LD,J7B^!B,+LB>"JU",":9LVXA97:E1K_W^!4OP!<,5(GT<JV7 &H
M'*FN3*WXTZUUJ3?\UE*W.PC%^ZY402#F/QJ#E<)(=0-G%@IO4&,,G\:.U@FG
M@'A$1CQQ/*N]9Y3_ELZ+WQTLF0*L&^@3PZ630Q>JHV[<'TT->.,#DK3M[8\E
M@AWL,ENU2(K.:V)Z++&VSB!UWUL+CCL(&'<&,PE51830"'=F,T5F>[K?_E;7
M*AV#<WDCEQ_/]=-[_X/!?#\6=5-SO"ZKPXR\;Y+_KO]<0UJ0IGR1'J7T/78V
MI](>9++4%->A6B(6_V0:DA)&_C,M68S: VH:89E?MALIF:Z%;0\>PQZ+#J ,
MA%(&U.WMQXK(X&'P2&"23/-*-P PXD4R- S=[Z29#I,TC>:EB;0LF.A2]"!>
MQ<GZ1N'%:=\#UXI]?0QN#S+L6G0_Q01<X$"9W#(*:,$>@/$(RL:Z0)I8$1!U
M&:7O#8XYOGJ?YZY%/0&]2:%^ &,AE"ZC[:08[$&0"F$Q.MS3#7HLIHXJNC*C
MEA"F3J")#6Q: ,75;C/9QDLTX$97BR#?G=3@GOT]2>]#)C-)09^8(ZUUV-:!
M'3=,\6U<Y 4 UTOSH(@1QY2KF%QE>:$RX]L%N=',RV'@.I?I]I-7JQ#QU);(
M\LZ;$;3:LKL56ZJRIXE(QYZ<N_/K7KC?G>S:""A*-^*E#1N%.55MI.!!;YG]
MNNJ:HPFP(9=9E?,(,9'M\ BE9)CS&/DOI;M1>MNHNPGJR"ZNH+=N 4NFF14[
MU^QB7PENQCR6<Z=AD0\6-_ :[L1HBUSM2'K(;HMT3?N)S/1$!YU#,\>0SCD)
MM)@*8N^^8@QK<R_)Y?*@@H,$5S^MOGB;#Z_&>[O3]$<]NA>L?;\U]^@#)ZS4
M]F5M%WN6P!5^&M/Y9=]]6N(V7,S_V_(S?>%OT&,'K"YFXPKZD)/6V% 8Q)3(
M(CA*E_E>=L(45G-7JRL!M&S:V&;IG,Y=<GB[;+Y69_S/A_+R2].&3>?;]0;S
MM-9B:+(/FYU:(S4;5$V6]=_#XE?E^+LE2]'N>T+=_']_U?_;%MZ\>$V?,P)5
MW[S>[P^.?SPZ[@-/I1W1BMJ,9BJOVW:=G7_AO*%^_^V:YXJ$<LB@\T]]ZT2F
MM"-5W-*]JV(AUY@!NK8V'MCX%IS)MUJB>G,1E+=CF!&S4LUF8J(O*TGZ7UW?
M@+B)M;6<N)%)W>_\IFQ%7PH0XG/?<>^YM&/8TOFN5!>*U.5N'+4CPDXT\]^>
M^K':<,FN^8TC65%^]7KJ1P18W[^8A-[J9?9PZZ"]4&SZD6DA-3.(Q@Y -:4C
M4KI.L=9GZYI#3E8-/0)+:' ?9:.I4T*X/-;_HO#J 3B #<!%ZV,VN0:Z#XC7
MUX4(=01:F_Z0;C:>];;JW'U;TAZZ0%6G7CTO>A AP2&+T/"6C:*&FS[.5Q#$
MD35E*<9W)U"$#CE&-+O)$;;JU!0RSD3V31V^"&G*+%A?*&J 2 P''O+X!>_3
MG7"7<J''7S(Q*E0"]2!4XM O@M9QEJ0'04R([6%8"8NQG6@FLRET4"'"BL"2
M.=U+!?%9,<2$$'6;Q/\E.9V4*57(DM*BOX$ 6YF)AM?!UU6F4H:I.U9-&PQ6
M( [L/^]!YAJN9$J7XGVGM?CG_@2:&!]J68^75+;7!>=_D8R=4*9R9J<R<W*?
MN: ?0W1@0^N,FZKTG),?C5FFBYX!Z$57.0?]PNLU@J2;"%<N*#-8;+SE+><D
MP&RDF>*%Q!RWAF,JG/(2J_2"P+6N^+SWES%&=6X%]WRE.W10MRUMDJ1@T4F[
M9D?R?VQ)22U)MM*CGO/WI\Q^D");"2'!SW&X*7D-3=_D52M$/D*<.5D^R1E@
M@;Z2Z#!Y+&=]FG5 CEC7(L@ZY$%BS#G0Y*,C*">;*LS,\UXJ97[$*V%$TMBW
M7JY<3['0*?XZ8U6RX;5WU=)>O/C%4WM%8+=<1;%@,8="%P9YX? ,&7Q,-O8K
M*%!L>:RFC !+W[[&J8DD=78TG3-Q,BO2)7A2DC[JRRYWQL_P.!3M!6%\;P7*
M7 1R-3SI4T!GTNH!/Y,S?,L,LUMTEPM=G()*+XW5<R>,,8Y4+(K;<)QJ!3M1
M9?ECB# 1'?81E?G7GG0CR<$B_S9H!5F9K/;-V+1K\TP;0::"E>J5=+DEW_"'
M'[OTG?>'"0OW#94_.PJGS,4BM"73X[:/)2Z.]8N=,=&G7HY[#I*9C<O%C5OP
MN&G_SS/\*Y9F^)[+)QL,>=)Y5;-N^5HZFJMG:O2.>%1U!AUS%K,:0 R"MFV#
M/V9<L^M?M,S]"!0-MA HX>"/UV']UEA3V1J1AU_+F/ZE,2SS,FHU18YKZ+XN
MT,/G150)Q:W85?G_1JP ]E[LK!Q-M=KF-'ZN=#TRW_+(P7-PM4LN+M4R5M8U
MTJK)\9P^%R/?^]TG$ARCZ0[\[W(,;2PFD2*E>LG\2V:NYJNE:W8E_8N4N#)+
M'>U QE\:-RK"Q1U,3VD>PT/2+R4-;Z> 6&_+B*_OJ;J$):67+B-G/WI6*JJ7
M=1U=4<X9EAN#MH?4F?S=@-_(-F0;XH9KM=5OC(FRYKICGJ/)59S#:@=6<B8M
MF.3ZG;W.=_&\X_"0PEM-;4I/U\OE%>&643CU(MX..6:![4@2 +&T+W#OEX[P
MA4M34Q^_8:4D0HUCNJR[W+D9 SJ/%QJ9H!D@%KG<\IU!#.D31ZAA6V!(T2(*
M"KK*_)7X>;:A9;;OT$U$YC]LHEG^)AXA5=4NZ\G 5;R%IA!6@MRZ8*Y0!0,]
MIC^RH^_7>SE>/VM-A+,J541T7-:X2FD;^>_P+4T@-MD=J/KS Y ^S:VJT-1'
MFD.*5%V10.2< \,E"^%G^<\5OG;UZV=MB?\NZF"\P0<T3ANDVE>UN%+-1M*>
M=JB![8$1&MNY+F9]9+#GWX.UA(XYK@!ZHVC2R@5D_>C^.L>528JB2\>_U0^J
MT!OW^NSJ1"CF,0]6FT6K._>,U;]"XT;JI_XKB>'..B5WA"U\3)CBT!R4'LAN
M-HGV[,;SR.FK0B7P,\P7^.P2V.H;_!D[%(7K#9[*O5ZF.%$5Y4EOI@ ]]IBE
MBNCGC8Q)"X(CL9MISF</W4&G%N1?];^1#"CI,1GHM7>0-B64>X)8QXY\O@^;
M(I2Y^"3ZBSP'G09]0S9VQ>#'3I86P^4/P%X5*W(6<W0)R&G6)7OV(I-CP"W4
MISOQRF?PMEG\66<)#.7X96#L@3F 9#&&9$J); *T^S8@,30L\5'*VH,7YLP(
M7-=PT1;S5Z82$%L-^_G,!##C/4*&8U'C(O]./Y! -[:$1!U&0Z3S24M.UL;5
MF5C;-DG'@QGXZSL'LL4HDNV)TV<7NIQG6/@MBI7'7Z2@&Z0R:-"_,-9O_G8?
MHW)6Q6&*\6:_?D0"V_RM::1DU:%%DG3B+>#^!9/8-GK4$7HA! 81#2=^4X\@
M#YH@9&"N%=#2*K2(V*ZH+#2,$MF@+SQL)QK_,_(ZL9W_7*"V"] 8: ?%MOM\
MIS)5''&CP[.6P,I"*T0G&]D,C7P]"4*3(TA>B.3B0-"N$\.5"$!L_Z%Y1VNE
M$565S,(_$+C,&&U1%KVL$V\*9T<0'KHZ%FT !^Q#=K9D]#$U#26V#J5XL;4\
M"3QA]#EO2[BT\BR'1E3PQ_*@^L?0TCV7X0^WQ@IY6:/)*4'4H7<F<5*Z245X
MG_J(N>U<:%P"8=R*I[8!<?$: LD68^%?3YUP3FW_&T?2"Z?1% AE3$^X0['#
M^VL;"N<,+3&]X4^\/_G%_>*S24T'B4N4KG<1]DHMODLT<R/(6?&5>4F5$N"*
M"*-_P6< K6F9GSK9RD5_TXW&%DC.XD>F&@_4\P+2AR=KGMK&EB=8_F6X8@Q:
MPXWET?6,-F-\YTD5DN-C"$RM*B?W9A+S??ET#)]6)IDI$PY!+*(S6U!*3@^O
M3PVUUG'>&4LS?HFF)P$>/J<=$2>$.<7T6=A68J-%W]B*[7D')0##YR*<B1,?
MTB1^TOJ6K[%7"^2,YENK-0'4G AJXW.()*@X#B@X#R+1#\1:2+BLAF%@"T;Z
M[M/,]_ 8R[90\A?;0^*4(V@,T7@4FK8=$,4.^VMX-0?CV,JO2GY@K!1C6'I8
MN==G?[D<\E?"VI=8N?H<Y'VV:]U<Z73!2DDNON;,&?F4M[5<R[%P^(DT@$)"
M7TLH7JI'59Q30UVAL(+'%Q 8BSGH,]3NMHW5N> _-U2BV4(-VCRR3Z3%E,[^
MS@B9(!,X0NH"F@A\U1M$R'RQ$DWN!6=N)Y>@09T,M[]@+'6$I142/:KS&$ET
M4*A';TIH9EJ\27D:-8G=L@8K^JOWE)PXW D27H2=#G:D#AQ=0A&%I@*>!Q/3
MZ?=( !6AA@)ULJ 2EGBY>%OJ2T$Q!SZ'\2NL&(Q=(=N?8\*<.R&59&E3@*)+
M=';+R/!BFRF7]T,AIG>EP+P]QO!4Z0[>W^.XDJ:$1Y%&<DB6"#A(!8$K+C7]
MC'A;5/E"33=7ED=;K16!1UL'4!/$,QRDBNO /K*FHOY*:)!?;+!;K-]1G%M1
MP5_':0[B @C068,"2 9)./ I?$T*,5&RK'6B,0'QK>M(66.!G]TKD4:3:Q=5
M/3XC@#8 K',4W6.,BJ0T>Q( U9NB"3T"(STDYITJ51LD0[UZU3-$9LH&YAM$
MYKKZWQW5B"9D<$YP2=PXR/[%7"C4V.)LGQKJ$>.I+K5DULZP"P69K_>K6OOK
M,S*PC4#%PIT$:B 8H>$9(CT:' ,:G$1F$[)S-2$:H6I$-:%M?6%'<RM5\ZI>
M/=P-8C2@1.L&T4B]B2>LB1\MDPCP"5^B)K6 $=^%JN2U_ ]N[O4\FQ&HY(+D
MDQU^U'Q\*Q4SQ=H\I1O(9XPDWH3IZQ'CKS!"6<V!.HQ*1G$OBC\EB?!Y9,Q.
M+90;Q3GZ2-XW]<;J2"69*)9?&KQN$"W/$<ML6XQ S294S:K>33H;U=(IY5K^
M!+1S+5T;5;]ML)G5"#I,F(PWBAH5 12*G?G>U:IQGL;S54U@[/G79DW"+I3=
M+K+(QFY];&'%%EE%5]GX9EGGAL*.>A/Q>N/UKH;**I+S>@;;GE&?_P4A#'%R
MI*-0O\$O$Y\VKD/.N3IIO;?PK9Y"L7Y5L.(_<(>)<XLJ:6]59@=65+5Q0-]3
M9^=_F3TG/DW=D=59WD).F90-ISG40@.T2K4A.@.,%W4D> B<?16%K@.8G227
MXJ18"[D-@LB=+X%=3*)/G .NF>U*@CWXMD@YF2C><2@J.QU:<4-:QD-R+!VR
MOBU>',.5BL/><T/:F^VD^KT$5;V,YUVX6?V'^ITG/OBD2O6%/M6;ZO4[BO6,
M:#V4&WUF/L-V!O6F]4QF/GVX6<WH0EU:8O4E;_62Y*-&O@W_98[HYO?79S;L
MHXW2^XS\9A[.Z:RO>BL^LFD &W=85_7\A]9A: ,;RIT:F4$>MC;H;^ZT>P5W
MY&RT9K_WE6UTJ.X,*5^TNUW8!:*/33Y-R$YU&%:@^-=-T%5.2&VV%N@/5U;V
M#K[7J_BT5&Q.SK1T!&[V^YZFAEDAA0#]V+*FU[NF900R?><+_@E4$AQ3UA82
M<6%S#$T$M0?P8Y&/X8,;5,XG5<0 *IE#N4K#E>>(:N237[LFNX6&==X15<['
MTZ:F*GVKO<4(+'V&LPPF)CU:-CG[\FPGJZM0BN"FZ;[T 92(<M" N)^FW-[K
M*>P;L V0I'P;\K],/NF#?DT-NZ,3>N1W;8D/;>[6XV5/P@G/5G39X1@N'MET
M_+I [,P:?MTHICL?4OD"&Z;?:-<60GD"SZN<C_S<[*3Z-X9KOT0;AU)T,_>*
M/ERB.-3$,F=75?]H,$5JV^N,/F:8,76)/F>NU*$_.?EJ.T1Q:><.G^2868%H
M)KBI%+ Z-5TY41.X]CM =Y!O,_TP"O]A@%VL*TR^?Q*XV:GTUJ=_OM W-4S9
MW5%@NY@W.84EW"'F-URY.:':/:M@/Z22W5?X;ZEZZE.&T+H6'##O8KFH:LW-
M;@@W>J/YO#T=?:E">7(PJJ]@LL.8E1A)J();N44*??W=;HE/F0CQ7S%=YGQ9
MYWA\5_=;58_!QN2SS[ )6I\:F/#L2S\36E_W9#M*=%\Q&2&^;XO>1A_)^[!]
M)XRZX:U15'^<;*H?@D:MJMC?%=61&?C[LKTURI3E!I[K"H>+T8[E>#.UH''G
M?F*'JV^ 16B793/RAV(KTWLYP@<YQ'@U3-G9"0 T<R9"7EQ5BJ?NP.D:]NFK
ML^Y;["28MVF(RB+#$*IP,_G=?=&+>[&):-C?'#4&\=D&<W2\;O52D*T]DHVE
M3TT8BX^6*BT0^?; =S'-B%=01!(%[M=7^!*IBM5>2Y-EX50?3O8^L1*+9A(D
M11#285<89E1GBI/8='5)9'Y'R1K%$#_2SV^T@C_6BB>)B&X1T">)CZ#FV2,W
M7R1+IR('X,!UU9]02?1(/;&7.M=<WI4+VYU".(GV*F"G-*!/!B1[;&?)G9T
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MQS6^T6 7^TC<LW.'1S;6Q^Y13M;0+A<54\\Q,#)4V&;M3R04J?!Y87&L7[U
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M>8SU%:"_S'VM-'UJ%U+9.T,9F^/9=>-MY^,*=IVJ2;%^BZV,8L-?.;XTVK9
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MV#GF@* =1A9.2.'6J(%03.4$3WZ&110@1K596D]96>K53"J\IH)NNHVI5&?
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MQ*=79$#&3()1GP>(XCWUR8*3@F2)^ISH"I?XT3P>  '^F2( 6EA&,@;QH &
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MW'GOW?=_23:-Z-][#[YV5V\W/NODB6^^Y(J=CU[ZETVVG668DT=3^?^D004
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M[UBY#A1[53G#M#EA35W6)2S 8EF#I((.4EHMDCOA,@R0I!#"LY@61E(3(O\
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MS:?>_>0(''IN9UREO.9Y?N+HCDH\.S,?:^,1:<N[W.#-^RDDIC[ULMP)8J\
MP #V*E&R/&$0I@28_,Y5/<9Y0YM:?2#D#JTY%;Q9WCQ6[S3,FMX%J[O;\+(3
MG?/TO;P)"R)"]^_.?.-!^:Q'5=X-S(F[8.1R_PAKSAN1REPOZ;W@>GYZ<+[3
MU;>E$__Q>X?CA4R%/'O'TSJ&$88J1IZ:NX<J'KHG#(2(0B5A-H),6(!O[)P$
MI,2<,)9OB&),/%@ B>KS&M!,& (CH ;<(?T['-S(Q-SV:=Z:WES/27\AKKP-
MF]NY%1U\;ZJ95+_"]PJG8QA "_"X^QOUJ^2M)?[R4>+(0/**Y$@\FM_7$;HJ
MK-O9J1GR3^[&34,&JD*?U3_^><=)K>G#1=??"3_4'2:H8DJ(_FI U&2H "(
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M5FZ3AT2$%EOJ9TY5>(4_JIX99D/R:8SR.9^]J&[DU$[N=(@+:0K*\*2F<%P
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M(H9J67Y2!2KRIS>7HSN'8()&>>Y".NH&5:&S+[2#+EM@"&ST!W?Q![^3N7\
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MKW.=6'+9=]G-?G:TIUWM:V=[V]U^1AU-5NYRCSH5UNZ$HM![ZE_G>]_]_G?
M!Y[<RB9\X8U=+\0GWN)I1#SC]25/P4=>\I+?"U#P,GG,LSN'AN=\YSUOZ<R'
M7O19SRNW=M@IT%I]]*O?$TL__WK8QQZ)/F9][6W?1KVT7.NWY_WU9&_X"/\>
MPH.-?>^-?WSD)[_O>A-^\SVO<80NWB:*IW[U'U]EY6=?^]OG?O>]_WW-!@0
M.U!+ P04    "  3@6Y;Q/O(]EM/   +40  #0   &EM86=E7S P,2YJ<&><
MNG58'$W7/CB$($$# 8([P0DR^.#N[A""N[LG$&QP=Y<!@KL&"#) D&"#NP=W
MAR7/^S[?[_MC][IVM^>:F>JJ4Z?K2)USG^Y^GGU>!;R5E921!,#!P0$^OWP
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M9[MA)EQ.2K8-O.+)X\"/$)OOVNW!'3XQ+))2\\7DN;$ 56=^E/!V(3_<[^+
M>YM.]E$],ZE8.#AV#D0"$E8I14]<T%ECWSV#+VR;3W.*7+J".@[,//X*%*/!
M/ 8!3/25S([9D Q[-&X38& -?T$4S#&T_BZ8!:RQW&O G#.0[X[!Q\(5^J1@
MQ!WZ47>TF[1/=F%!H#Q6#&C31NU_@J?*"T^2ZJ2H&N^# =P;M#Y\Y*BPR?#<
M9.OH95C%UB@$?.&+9^ HF644)CQ;],M-^G8;A"&E3PA]ZFUM;)S^!$-6F#K$
M_GEFY\Y6QE"[&6D1LM_OQ8D>$NYC!^1FUY:@T+O.&/)Z6]L_'CPJC!HKZ8C
M8N6.((O7R?8CI7$$1_&,B=2* ML<I3<H&M&KU'_282=,<!PSTUNBW?ZA=8;!
MES^ I+ Z@\BFN+G>QG%"%FDNPR>KARHN!"G:F6'UY&!H4F9+= 9)+63-G&?9
M1#DW\Q(IJ(]XK'J)P>:0A)2NC^<RO[YEE/NE]#N5Y)#H,P:I8JD:QX)9\ C
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MF/#+7[3H:2#HR=_L[M:$;+1^@LR^X6,<5-8!2^6;(X[JM'YWBE0*05/2AV>
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MR3/;,,1=LH01VH[K]:$JD$Q5#8.1R5R(+7CW#7IKUMNK?M9 D0[)UJ6-HTS
M_"1A8<TH><8  !_*9=I 02Y!I;PBL3MO98#R"LD+CD&N./NZ-Z4E(LAJ@ZJ^
MHY:Q8"EDD-^4=TJLO?(51QAB!X%3?-6F1&=.CUSJ/M[XA7)!@2H] V>B'LY!
MUL-G=GQT=^H]^3T:;%&X#D] 9K#<CAK.@_S(V%9S\[63/N</*ECW,P"M%@!^
M'UOPHX^Y 5&GFN,+?_K9?56D;E3'=^O.DR!K>!$94&-[LD+4# G71E5GHPV,
MPJC?9LC7K'SI06$ZHUN0P.UI*$2"K[(X8+H2PYW^>.!!^F*P7+%GPK;RL,&
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MJ7G=<"$8F%6<.TZ^:"?UTN+>T?5?SD07R9&> 225-QP,B/BF B2*(@]6OL\
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MZ0VN/L;3^TH.$)/R'/?Q*G\4A]]M+N>W8=P]MM=8%B,2-8E6HZ!01,00>LF
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M$VY=8X/TY^QUKFCS9'HXA 3'[D^2R%!\X'RYK*=FTN2#@AQ_2%M=M#M6B--
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M:!2YI_;W>\PYTU#4 MHG"_=@%'<_5$H$!H+>7,0I;(S'24S>E)@>N@L<TI*
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MH?+''!DZ_(5PGX<22][OKB;^!U!+ P04    "  3@6Y;::A.S704   H%0
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M.\_"F.R- <@Z#"$KQ+ [C,D21BNX#[R8%M^5/W*QM"?5"_ 3HT*4#4U%7V&
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M%<>K Z@SMW7V4B9N/>JL0VEZIFD\1C*R8P 32P*Y^M)9V\IV'PXE#M$'JOX
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MJ]%_QJ1([4,13O^$@7RAN;<_0[.JX0,E-SOYF*EJ<>LZZS0&B)67T<1K,?N
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MC?VMF7(:T"D%CB&!% D[O]2#:QB$R0:@2I-5D*E.#K(&DY)>)W-M-O_:BR5
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M390FGEN5(U4^N7I4/*BCGO87 ,D!*X#DD"7 YJY".,X\4@K1*D)_Z^3;2#"
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MBS\SB($]:L[8M%##S)&+6(EVJC/FN2B%JU=ED/*1!U2NPCCE(HQ54:E=Z*+
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M+.HR8(4/OFW91!NF!KU**I,!"Z[2@!E6R+!&F:Y2%-(P_]%C=!)FF%2@HIE
MIJZB3%A"!'!N3O2;LJO%3N>)O7Q\-<VD-?;L)S(3C!W#C$0CO(_'+*_,BR(_
MK+ L&R!&:C<L,]*!Q$YQ5ZP!\QB3,8W"UX4/C_K0RZ,[SER+*)DK<YV_FMX4
M[EDSR.9\UO4(Z6HUBS9>BW2>J55I6JW[^-ZSN:"TMN<>XD_3M#A0^OZSHDFZ
MRG&.Y=B&@/I<LE<@E5]R3.1@^SZ.?12RF319M53=LJ\+.!GV(0 +7\2O- /J
M#X-7AFWX\$79\CG)'SXVO&"=VA_P%]/<2@U86DLPK=%M0H!:T5I'4$W-TE=&
M\E)8Z;NBK0(NG=>8)4-:Z])Q3&R]B=NK*7<F.RAU?Z[H:$)N*& !X> DI.Z,
M8H#=>8"\);7@8E<.NW0#IAT>FQI=0SXD4V2YH/)J9ABND/EXZ#NGE .)SK/(
MT;#5.F_,%A(;H/U"]^?OU<P: BW'?(+!V>)]R7O+_<TM7[+,LO<7BG:6\@+F
MT W;G$KEG$/,&VH_-4O*:;)!(7]2MO397SU<&R9J+^FM5]BV0S7NWREZ7.:8
MJ-1#\B&$%!X!8Q,AR[\F7$?OG;@F&CU2)GC'P%"=AF D8@"<%%2NCV:)<1B3
ME3OAT9BC*V30]TZN[>?HRGGT>,V$[*#XZR;Y=AJ"9A&F0$NIAYV\->A3-L&Z
MRT43KM,0Y$0,@,O=DA,1TL5*\G@]L%1(%]%=N&QZRW;[0I?6=D$Y>X\G39")
M:&J,CN$O4KX=0-PY6VD"(H58*MMW JV9-Y%0T3.KT&IYKU 31,ZB&)+HQ[)S
M+7&GXSC!4'-F6C:]D"R5Y:-+G4UN%@61(1P;:_ZU.$%%W>')PP4$6LD)Y-)9
MSO;&(3 :P/*ZRUZ">$CD1?.[E3E.<H^/9H\+^?&@+EW;/G,IXN./U!T]]FP3
MG<-X23?1$ 1S\@-BJFP#GWK7N6.L[,!PXL=DDT=*K6OL78=D^X,V[@C>6,S9
M5$,P+L@7B+4F6_GTLBG*^V#M?!2R YC71D/0S<L0"*NR^P W1";^ /L^\D=N
M[YGF;0QM?[&,<KCS':;"J@T!49(/^$Q-%7:):\DF=#_.["7JHA7V[<#O(M_T
M[!7@B4AJ2U1N"'[2G( (ENQXV$9K\X&(UMB,HKJ+G4\W*.2BOH@*9R[Y).[R
M;>B.7D&&0%A3;I&:,S5%BZH%=@@=?N_/D/K8X0?A+P_3-4UGH\X_?QT-NKW)
M]*\&L1@_MWJ_W?5G?ZA^"_XUE^UK+EL!0#XRW\SQTYF%[!@;\F$'"?GC?H#F
MAM-SR0A8 V&9I%2FD*89:UFD@E*O1[XQ*6! 'RFR7Z+FJ$J.Q#! (230<L(G
MRY:HED&1N:5>:_3C))E#N<%C^X7J3I4$*27F$5BI)9!-E#R);FF"6<)3/VMJ
M8_>)!(U![3(%M75#\*9 _9F^L_+";-*J-:U5B%-+\RHO\CH3TPBD?DM$M@R7
M/+GO%:E \L(LW2QEQ1SR:CJ($$G6>!9*-EVD]M1T8LEFR ,MA;I$=/2TXH%S
M 3NY?_UP>/_ZVK"]KX83TI=HPF7D(/)[SRMD!LBB9_B<<[[J^KQ7=)M#?G-9
M+>N0?NF;2 :ZWL_C]RNFKU(Y9!W)CQNNH?-F*%P-,JAGE:Y*\R:V_^W:0T@N
M7KWRKG\LK0,E4,\N1K6UZ]I/MH5<2X&M2W?]8^D<* %PUZ'?,0GO>8OW;[GG
M)7_Y?''^*7-@HOS1"V:*TXQ>2*9.'B@_4ME2-?)BX&Y1L*!/*#\1*X=0BE:B
MNIG"FV*B YE2>]'G.$=*%< DU.5)O-:#H1\XU7@EV!V=HUS=\O8U1[DD)S5Y
M9[7!3DO?;F7XUIN8:O,&ME1.4Z!T[1[@_&,%RS%1DY\XQ\AJ6-KQ&N8TR7SE
M^FZ9M<\T_9JO7(,9M?%:I/.L_9JO7#I?N2HGF>)\Y3S/6-DIR:K)5_[A90,G
MPSX$X <-\Y5__&'@.N0:0NGC:YY839?@^1+,*KLI^)I@5KME[6N"63GFZEHC
M'ICE/!.7VO=LY--TPF1#0B[\'LWQ62 3W]3HP;'G!O\Z;+;L_;FJ-5^1HRN(
M?@@5M5MQGV8[V!UB UOHI%2S@,A27O;9D%8YZIJ!36'.M/.'UII&IQG@%F-+
MN_5U*E.,G(T$*C0+-2X3H,M(V?F1:=*LUYM<6YW0\Q OZS>[?+,0XO$ NH0T
M&$1CPQMY<1J>*'IOC+Q(PZ0&%%2Y6=!),P0ZC;0]L('\:&/LV.;Z&GO4CMCN
M/#8J=ROL]IZ19]J\)!\5=MHLO:E<$)"^%<VQ"BV)*;.9VS0T=M=EZD&T3.35
M:0B,DGR ._;&738;Q5'97ZFOU>J[Q+C9>!>W7<55,T&/#5&46J0 J5G11+%%
M!GOR"-\,)Q07&?R';30$XX)\@5Z+DGVF=ZZ'3#QW[7_O$\?)JLRKTB!0Q&R
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ME&PQC_":MNT5 Z#E=KTLD&H-$XNBJ;CA3-L"BH+#V J,(0H;L"E7]<RC2)
MJ:!$RPZMZPT[(E7L*/)KY-#%3FU^C"+6=A0LD'>#7+(Q=<@.JVTMB<S\(+[
M I\A)]5E:BM[,*OX0E6:K;*W[R6<Q/J($+(@5'?)9MK!*RH#(8[<:@T$4,Q/
M3=,"]5@X6X]%?[DR;(]S'Q JWB0(A'R 1E#=2PHK#YEVQ!;Y[*!(IF3<+RG7
M_Q:\%R-3NTGXY64+7)GJY45N$ )<'D"OO6YN3.[%V@\YW)FI^[0[%LMGHVW^
M&=J^G;X;S*+\XR'E[<YO=_UI?_\2L"(/[&:+F>(EHV59"\:OI=KCRJ#.OUJG
M_I)VM\JVI(VO509.T,>:3V[:.U@9[/!=JV %#9RJ.;'!<HQIYTME44H_>DCX
M0*5$534^5Y'TQ5@Q):"3![9*V'3VU)8,;;V)2'M=NT/,$#\7Z5XA1?Y;^2&!
M>937Y==-J.W@Y8/M)EGYDU3WP=[K@:F;7)#KMTA;]RQ-40,3=\-2G#GMG&AL
M5G8,1#=3'I'G(8MS.RI/*TT N2A;$@.UY@TK8Z?'C+GY)+754Q9N\[K9>]WL
MO6[V7C=[KYN]U\V>GK"];O9>-WM:;O:.SZ1@^ MX8-!?586D%%A&;,G5;B<V
M]M#*L*WDX+[M6E%D1AS]#XN?5ZM!L C9J,D%<FT_;VY< *8F5:()\F61#$[,
MJN?EU#Y[LLUST;?(U&8_VG3A&#.16%6+WI(A7]L.$0'RR6_AD@,>O*<_LJ\F
MJ$&US(-K@9>@4)W0(\8B2/]@1I<+_;&QYN_0:R7C!U5#.;E &EHT0='Q#PN9
MIA>B/7Z222_U%:Q94M4;I!'R_$!(?GB9MB:2@2H+$W7>("VJ2QJ0#GY\"3HH
M97\JZO 'U359&_?I)>C7D'DMOP*IDHY^4'W:< [IT>>2PY7Q8_#=\*#\BYN?
MFP!&AEY(A)?EBG#F&18:&DM(AMO?FR+$?8)Y1W'-MVA]-P$ 10D[^FY@N'-[
M6[<>:R<@H@EZHT@JH'(J/U[,*8$;C*WOMN/4-NV*.GSY2B<E 5#!4@Y7]6%!
M%ZRPH,]R84$7M5]7X=ZXN92C6O7C=:]!3:]!3:]!3:]!39J<\[\&-;T&-;T&
M-3'1+3NHJ8$9= I%-RG.JI-Z5B-^'0I\O2=Q6;!*-^&^@HA\2.#*C%;J7LS8
M\$9>E#C,^FHX(1HC+Z*<$W(FKMP$T')RH^UZ0>)V3'1T5L[]H;BI!N%;C#=P
MG:$N]47XX*,_0YI;Z(FF])/8B']XFTE]<7<U[?UV1[-?]+Z2?S7:C1_P)[$3
MAVLHVH7OTR/::3-+:[.;%L%QN)/F\*[];OF0>-*5()4N5$'=;IDG?SY4!]QJ
M-,,Q*!6F:H6K*,J;*Y"V$!M]=[YEPJ/S3K<D"&MX"J<$%,'M,)L]M>EYA:.%
M"XW&=WZVB9R3-T&C[8ED>O=LE4;,2B*.-;HOD2919/%8915G< <ES'R.EL&E
M3I/0<5AH/>T<C5>M/M4I"H*8M?;<0]$'KFL5+*\J:H&C[UB6;'!\*)Q)"#NQ
M0S+[='C\_37VILA[LDWAP^K2[:AZU#GOKC4_4]JY<@$>(@?F\?BRFVDVO!R>
M)!:"U;G]]AX(1*85^_W&3ZO>,S)#ZIKKD!EACCUZ&<)UUF7%_(#]MJU_A7X0
M/2!2?7]]U[*?;"LTG&H[:W\W/(MN%:)>U Q9:E^N#'__$?FVYQGN/)I1_*OU
MKLS86$?3#:5[2WS;M<:.X=((7^&>NY+>REPZ])[-!25&;N$ EE9AD"I$,KWJ
M$$BHO.D(0*B#W2?D!31R=TQD8/L^]M9#'/#3@@AKO6#$)"568DR^&#K:/3_>
M 2K\8P#%D ]_JUOW6H#>ZB#+F+00=G-E0@S]YX&(A'SS_U!+ P04    "  3
M@6Y;'S'5-L-;   \%04 %0   ')E;F(M,C R-3 Y,S!?;&%B+GAM;.6]:W/C
M.)8F_/V-V/^ K7ECHCK"KLK+S/14U?1NR+:<I1ZGI+&4V=O;L5%!BY#-3HI4
M@932[E^_ '@GKM0%.,[MB*[,%,\!'Q /#@Z @X/_^)_/FQCM,<FB-/G3=V]_
M>/,=PLDJ#:/D\4_??5I<CA;7D\EW*,N#) SB-,%_^BY)O_N?_^.__7^(_N\_
M_OOE);J-<!S^C&[2U>4D6:>_H&FPP3^C#SC!),A3\@OZ',0[]DMZ&\68H.MT
MLXUQCNF#XL4_HW_[X5V +B\MBOV,DS EG^XG=;%/>;[-?O[QQZ]?O_Z0I/O@
M:TJ^9#^LTHU=@8L\R'=97=J;YS?E_PKU_XBCY,O/[#\/0881_5Q)]O-S%OWI
M._;>\K5?W_^0DL<?W[UY\_;'__7Q;K%ZPIO@,DK89UOA[RHM5HI,[^U//_WT
M(W]:B0J2SP\DKM[Q_L<*3ETR?1IIY%M(LNCGC,.[2U=!SEO=^!JDE&#_NJS$
M+ME/EV_?7;Y_^\-S%GY7?7S^!4D:XWN\1KR:/^<O6\JD+&)$^*[\[8G@M1Q,
M3,B/3/_'!#\&.0[9BWYB+WK[;^Q%_U3^?!<\X/@[Q"0I/Y3U^JE35JGTHVNP
M<TRB-!PGAZ'N:WN"3_L.R8^H0%O?>166:1[$!X%O:SJ'/<6'??%&S_V7IF8>
M'_:E6YIG@9V+D =_7OEWC=F/=_1O'8CX.:<#& XKD*P(C07F;^ #0UEV77JZ
MZI0;,VN>$K'N;&3D9:Z#[($7O,LN'X-@2U_P[E]_Q'&>5;]<LE_X1RA_^(V-
MC7B#DWS\^R[*7]C 35V ),]&SU%6O8M7]$_?6>K\V*\(TQZ1JC8!61D^22GQ
MXRJE ]HVOXR+CU^HKTFZL892?K_44N&W^*%^3_'1*11%A3IB!&?ICJSPH#9O
MUVK(%RY1;F*JQ7PXG%Q^6GSW/PI1U,BBOS'I__,?/S9O\$(QBFB3)HL\77WY
MB#</F"@J+9%S224ES#9]!"$PE%$AZ].DD$-<$/VM$/7/D5$81LQ5#>)Y$(63
MY#K81G0$UO+%H..2.U;PVSS2*H#AE W*/K\:'<24Z!0)E6IPV':/\R!*<#@.
M2$*GP9F69BIAE_S2 VX32RX)AE%:>'TJ5<*HDH;#H-%JM=OL8N; SO(G3-BH
M2_ 33K)HCR?)*MU@O>VRUW=JQX96JV/3;)7!L'$H8L'6S:XG:)3G)'K8Y<%#
MC%&>4JM'J/<%AZI7NXQVHBP;K:B#F'';K/'ME=(N:6B W":=0A0,Q?3X^H2J
MI)D7_Q E?/7N1&X\)>4#)\>;G]Z_X02Y'T^OJ$%F"ZHDO=X]R"V64LH%(0P0
M&1$4(MX)H,<E#G6%(&*2<&Q'/0^]CH,LFZWYK,%F94"4][(JH((M71'H"WNG
MD"U"88K'Q%"ZKB9YY[0?UVFRQR2/Z. W37,L=Z6UDL[LB!YJ;4OD8M[)8,8F
MSO1K8<2EX=B5CSC(=H1S>I)L=_F2ODMC5M3B+JV*"73;J*ADO=/($F"?2RUQ
MQ.414SBO:;F*@]67Q>J)5B6;;9DK-"?1BLX#/Z8AEB\-#=!S9G:&5*,V0C9*
MWKDT%*G@[3)55.JB0AF5VHBKG]EB921O62OZK\92T7_\=D_!RLQ2[YD+)DGA
M,+9T'GAGA Q-O]69-Q-E>;0*8M0V*^?<K3 T],<HB3:[C=2D2)Z[:G IK*K1
M.P]!-+P,D3".%#)^^_7'X%G?W-WGSII;!JMN[O9#&,TM020T=R$#Q_&\#2+"
MP\"N7NJ__AIA0K_?T\L=WM.&5;NAMLHNG=)A%6J[J'::WJEV$-P^#YE&$?Z'
M:AT4)"&:CCY#V2:O:\7]ZXQ7Z:UV$T&KX86$:NA2YHGB\.BFQ*CFV$4Q1<HN
M$%=#;P':OU:UW@TFV3LH)'LWC&3O7@')WAU(LG>P2?9^,,G>0R'9^V$D>_\*
M2/;^0)*]]^NXUPOA'W#Z2(+M$YM$*B;H&EE7#KT1;N7<*P6]D\@&79\^;;$S
MKQ!&Z>)E@W,2K30;#S(I=ZM_2HC-6I\@XKW9];B$=;PH1;4DH&$H2J(<WT5[
M'$Z2G )F.R&C+,-Y=O7R,?A[2OA&F6["-Z0$I\/4\*IUABU[=>]4/!RS,*SQ
M$BYY$:@I Q6%H(<7Q(M!Q?;I60W7(EWG7P."YW&0KU,B7XK22CHS8'JHM1&3
MBWEGCQF;L#Q="J-*^F0&3<&%)0E"O F(/#A>+N*L]17@ZF;O/8?1WG)0_8:N
MI>",6'/J:"6Y/ARY)^-RU)'":X\K'0'O7-"AZI.AE#EW7[_CD8!UT.EHDY(\
M^@</\U/W?@LE9_; N@*UA3!J>.?)()A]XC ]U%)$;4TXEN5#FH9?HUA_H*8O
MY-*VR &VC4M7PCMKM+"$*7$I!(<0(^KCA#>4L9KI3T_&Z4$$&;S.88.V !@R
MR% )AP:8#&)"YYUC_#E(=@%Y89%_].&_J,<7A:"S,44+M!Y'I%+>&]X(K=_Z
MI2P/R$1,^MPNQPU>\?)+=/)U>*VD,R+HH=9,D(O!H((66Y\+E7!-AG,OKP^)
M_-\]9%$84:HN@AA;1/ZKY9U&_IM@=R+_5<+>N62+4%B\H%*G#OP_?E9+HCT=
M[>9QL.+;"/KIK4+8Z3Q7"[@SX95*@J&/%IXP!2Z$42T-QQAQE\EP1J GX]Q9
MU9T&Z B 88<,E=Q9/7^L__AY]<3CAA\)5AL)O:@S/\4 MG94%'+>"6 !3D@N
M4TJC6OS<?FOK]-*<?OHHR]+"Q;8Z8297\7'43 =>=N9,)@^#,78@=:?0&K7"
MY04SP-QCOG@W#TC^LB1!D@4KPSEYK8;;U"!&Z-W\($IQ[RRSQR@>GRX67[D*
M:NF<=]2:!QE>I:/M0FV3!!%G-D@!KK8YO>?>6U\#2MRM85)HM$4+.#;D+DT>
M<TPV-_C!=)Y5+NK2:NC MLV%3,X[4RS "=LT5/1R2641$[YPX-$NGTP'XOL2
M[C;UI=":/?TG> ??I9B$'?VG4Q]T5]G]CONC:6*%H+LQ0 >T&0ED4C#:70=-
M7,#H>)>.66!+ L\<L*( 7 8,(<#9VY_6\8EZ(A9K%DI1=RS0@VV(()<#P@4M
M.($.I;27-0OKE0K?ZQ-VJQ+0K((.FBD/SGFF#'1&\L-CNO\QQ%$Q6Z!_:28)
M]!^_W>''(!XG>92_2.8&4@D7A-! 8TR0//9. 34F,3R+2J%"S$TB/76G[TLX
M3Z"GZ.;=Q]X;5XU)F30/S!J 8N4JNWII/QF^K"@M , JHZ9B%HN.$FWO[#L8
MLFI)DF<92!/26J&,\)F/EWQ8XM63VA!U'CNS0A)0M0EJ/?/.  4@(:03,1$X
MIH>M:,W6(T+8-AUS=C561B'KTJ!HX;9MAU30.TELT(E^:$RU4Q+DT9Y.2AH=
M;B/:_^;)J%'^%"2HJW16JW$7K7!B-9U52;H[AJ"%VIP]D(IY)X\9F^#&%L+N
M9K(? _+EYN5AITFS*(@X:WT%N+K9>\]AM+<<E)@PBWQ!7.S<+7R_N(ITDY7V
M8W<S%1%4,TUIGL%H41&0X ,N$#L;?];UAE6Z2W+R4K@(Y3\:[Z#\X3>*IEN#
M]@,7S2L"80W;_.J]204H_<;\-)TLQS=HL1PMQPN/33F]4R!G#UPV90.DW933
M.S!-64/I-^5TO/QU?'\WFMZ<MB&/2K%?W?VPP(\;VPOXY#I>4NWKX$O3[<L4
MO%-G"$HA^+X4.?,Z(_V/9MAN/74W:@N0FD&[?N2]:>5XA"&;"IS=]1I/K[5-
M>.VC":_537@-K FO34UX?>XF_#"^B?17YO0EW*VS2:$U2VV=QS":5(I)6'"C
M0M"NQ]D]9/CW';NG=4__8XCZ4TJ[/B"G@=P_'B<1]4X9.WS"Z%Q+(RY^RA#
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MK%19J&L3051IH[]5^OYY.<HRG&<&!O:%7')-#K#-JJX$&/Y(80G19HO%>+D
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MF:V2OZ5PG0VSTP##,"N8 M'*$9$?%J?F*EVCM+= ?L+!\FCV61@N?];*9*)
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MEF0M=;U[?P<"%I9.6^K54@//M,!CZE>TE#-9OB[N"N8LF:8YUM@^*S5GUF]
M)6K[9Z'CG5P#@1I)5>JRO_.3=F#LWR19$>80W.#BS];NPW6PC?(@-FQV#2G
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M>NM7)0B"0R9TPC9P(X]@#G.M:DS3_*^X]MBPUF[9J7GPBXR5D'A+2AT0G!L
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MT?EU&\%=!8!?5JKU"PXORYF3<&QU:X_AT(*\4_H4Z'447[,T+WN>YF73)-Q
ME,J$.1>$,?Z!K69[-\7-1[B-DBC'=]$>"PD7M*P_JB2GN[B'5[6SOSN\&.]\
M/QZ[CNTA7O/2+N-HC7EL5)1T?XN:W!L!?P<8WJ>Z+W&[8[%=HPV+E2PRW(V?
MMSC)\* .<9I7^.@II_PXLBYTBO+!]:T35DH[Q/"24- J"N&BK+-[27R-\BK(
MV F)%S:RC;X&).3G?&<\+RMS$XNPS2S;;?A/^D'D'"_PX$^=\,-(G*P3E.Z]
MMYRM2KJ^\A5'CT]TXGL9[*EK]\@'H:HPM*,O9S,17.[O\*E(X\#Q@ /V4\9
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M9;&2PXG<E/'*:"P /PV) :TL&$:GXU<73OD"0-[+D:L,IRO=>X\Z6Y5.T]=
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M:SEGCY,=YE<QC9]S3)(@OMY1'V*#239*0I8PFM\66]P1:[N:=TBAOI;U#O\
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M) UW*U.(^!F:K;P6(,MFR?B9#>&[*'OBV>G7-_A!=LV!2A1 <]DB%.\Y4*E
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M];(B..3P4>L^!RL,J 7B C4PRH,AU;NIO]G")<P%+X3IHL^$/RYSI<)AU8'
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M /SR2BV\\.+AQL*ZK2Y#ALN-VV+/1@Q$AE@2MGLHGA;*J^_"NF*G'+9EPW2
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MND9AG)&F")IJ= >*K 5;=Y[,)-BT;@(9V^&30\,'+_S6#=>I!1S3E1-X?Z3
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M]NMMS%%8\X2*]+!H\,R?Q"2ZFM',5[ M?Y,ZTR3N=JP0Y=1O\<)0NI$COH>
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M0*J9,JKYMTGLX5"=.O]:N'0N /J!C9&ET@"R:<F$V3LMJAE3; >5T@^62DG
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MP8D(^\W_!U!+ 0(4 Q0    ( !.!;EM^E_WAF48! .13"@ -
M  "  0    !E-S S-E\Q,'$N:'1M4$L! A0#%     @ $X%N6X'6)G9]!P
MOB   !               ( !Q$8! &4W,#,V7V5X,S$M,2YH=&U02P$"% ,4
M    "  3@6Y;KYL /V$'  "A(   $               @ %O3@$ 93<P,S9?
M97@S,2TR+FAT;5!+ 0(4 Q0    ( !.!;EN2<073!@4  #,4   0
M      "  ?Y5 0!E-S S-E]E>#,R+3$N:'1M4$L! A0#%     @ $X%N6\,!
M9[G;!   9!,  !               ( !,EL! &4W,#,V7V5X,S(M,BYH=&U0
M2P$"% ,4    "  3@6Y;7U)+/07*   6RP  #0              @ $[8 $
M:6UA9V5?,# Q+F=I9E!+ 0(4 Q0    ( !.!;EO$^\CV6T\   M1   -
M          "  6LJ @!I;6%G95\P,#$N:G!G4$L! A0#%     @ $X%N6VFH
M3LUT%   *!4   T              ( !\7D" &EM86=E7S P,BYJ<&=02P$"
M% ,4    "  3@6Y;?S3QKP4/  !!HP  $0              @ &0C@( <F5N
M8BTR,#(U,#DS,"YX<V102P$"% ,4    "  3@6Y;KS#94CT0   LQ   %0
M            @ '$G0( <F5N8BTR,#(U,#DS,%]C86PN>&UL4$L! A0#%
M  @ $X%N6]T7[UY>)   L3D" !4              ( !-*X" ')E;F(M,C R
M-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( !.!;EL?,=4VPUL  #P5!0 5
M          "  <72 @!R96YB+3(P,C4P.3,P7VQA8BYX;6Q02P$"% ,4
M"  3@6Y;KRKR4X5#  "_0 0 %0              @ &[+@, <F5N8BTR,#(U
B,#DS,%]P<F4N>&UL4$L%!@     -  T +P,  '-R P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>e7036_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RENB="http://renovarobio.com/20250930"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="renb-20250930.xsd" xlink:type="simple"/>
    <context id="From2025-07-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-11-10</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-08_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-08</instant>
        </period>
    </context>
    <context id="AsOf2025-04-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-04-08</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-20_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-19</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-08-18</instant>
        </period>
    </context>
    <context id="AsOf2025-07-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="AsOf2025-08-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-08-19</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-06-04_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-04_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="From2025-06-042025-06-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2025-06-04</startDate>
            <endDate>2025-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-21_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="From2024-11-122024-12-03_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="From2025-02-232025-02-24_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-23</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="From2024-09-152024-09-16_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-15</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-06_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-06</endDate>
        </period>
    </context>
    <context id="From2024-02-042024-02-05_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-04</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-02_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="From2024-11-022024-11-03_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-02</startDate>
            <endDate>2024-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="From2025-07-062025-07-07_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-06</startDate>
            <endDate>2025-07-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-07-25</instant>
        </period>
    </context>
    <context id="AsOf2025-09-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-09-05</instant>
        </period>
    </context>
    <context id="AsOf2025-09-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-09-18</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-30</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="From2019-11-142019-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2019-11-14</startDate>
            <endDate>2019-11-15</endDate>
        </period>
    </context>
    <context id="From2022-09-092022-09-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-10</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_MarkDybulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-08-022024-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-08-222025-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-08-22</startDate>
            <endDate>2025-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-16_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-16</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RENBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BioSymetricsMember412313203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RENCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-26_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-02-252025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2025-11-032025-11-04_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-03</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <context id="From2025-10-282025-10-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-30</endDate>
        </period>
    </context>
    <context id="From2025-10-282025-10-29_custom_SettlementAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-29</endDate>
        </period>
    </context>
    <context id="From2025-10-282025-10-29_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-29</endDate>
        </period>
    </context>
    <context id="From2024-10-162024-10-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="From2025-10-162025-10-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-07-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-07-01to2025-09-30" id="Fact000004">2026</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-07-01to2025-09-30" id="Fact000005">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-07-01to2025-09-30" id="Fact000006">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-07-01to2025-09-30" id="Fact000007">0001527728</dei:EntityCentralIndexKey>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0049"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:GainOnBankruptcyOfSubsidiary
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplit
      contextRef="From2025-07-01to2025-09-30"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:LossOnExtinguishmentOfDebt
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:GainOnSettlementOfAccountsPayable
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2025-07-01to2025-09-30"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-07-01to2025-09-30"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2025-07-01to2025-09-30"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:CancellationOfStockOptions
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SegmentAsset
      contextRef="AsOf2025-09-30_country_NL"
      id="xdx2ixbrl0907"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-07-01to2025-09-30" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-07-01to2025-09-30" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-07-01to2025-09-30" id="Fact000015">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-07-01to2025-09-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-07-01to2025-09-30" id="Fact000017">001-38758</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-07-01to2025-09-30" id="Fact000018">Lunai Bioworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-07-01to2025-09-30" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-07-01to2025-09-30" id="Fact000020">45-2259340</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-07-01to2025-09-30" id="Fact000021">3400 Cottage Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-07-01to2025-09-30" id="Fact000022">Suite G2 #32562</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-07-01to2025-09-30" id="Fact000023">&#160;Sacramento</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-07-01to2025-09-30" id="Fact000024">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-07-01to2025-09-30" id="Fact000025">95825</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-07-01to2025-09-30" id="Fact000026">(424)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-07-01to2025-09-30" id="Fact000027">222-9301</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-07-01to2025-09-30" id="Fact000028">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-07-01to2025-09-30" id="Fact000029">LNAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-07-01to2025-09-30" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-07-01to2025-09-30" id="Fact000031">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-07-01to2025-09-30" id="Fact000032">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-07-01to2025-09-30" id="Fact000033">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-07-01to2025-09-30" id="Fact000034">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-07-01to2025-09-30" id="Fact000035">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-07-01to2025-09-30" id="Fact000036">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-11-10"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">23432391</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000046"
      unitRef="USD">624808</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">92700</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000050"
      unitRef="USD">387851</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">175552</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">566081</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">800360</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">1046632</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">12465</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">367843</us-gaap:PropertyPlantAndEquipmentNet>
    <RENB:DefiniteLifeIntangibleAssetsNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">17610</RENB:DefiniteLifeIntangibleAssetsNet>
    <RENB:DefiniteLifeIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">14994</RENB:DefiniteLifeIntangibleAssetsNet>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000067"
      unitRef="USD">129288</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">143000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:FiniteLivedTrademarksGross
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">6082</us-gaap:FiniteLivedTrademarksGross>
    <us-gaap:FiniteLivedTrademarksGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">8000</us-gaap:FiniteLivedTrademarksGross>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">5963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">5963000</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">31858</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">687371</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">6147838</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000083"
      unitRef="USD">6816365</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">6960663</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">8230840</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">12094428</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">12555839</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">4868686</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">5843069</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">71429</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000101"
      unitRef="USD">378282</us-gaap:OtherLiabilitiesCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">260000</RENB:ContingentConsiderationLiabilityCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000104"
      unitRef="USD">630000</RENB:ContingentConsiderationLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000107"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">277775</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000110"
      unitRef="USD">313047</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">1038495</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000113"
      unitRef="USD">3580525</us-gaap:NotesPayable>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">866661</RENB:NotesPayableRelatedPartiesNetCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">5610372</RENB:NotesPayableRelatedPartiesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">19722474</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000119"
      unitRef="USD">29156134</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">278963</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000125"
      unitRef="USD">424547</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000127"
      unitRef="USD">278963</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000128"
      unitRef="USD">424547</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000130"
      unitRef="USD">20001437</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000131"
      unitRef="USD">29580681</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000136"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000137"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">23180277</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">23180277</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">17739291</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">17739291</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">2318</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">1774</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">494728618</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">478296113</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">-507643549</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">-510462570</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-128161</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">10814842</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">-13040774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">-21349841</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">6960663</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">8230840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">2410516</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">5301251</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">24407</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">390189</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">47614729</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">831915</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000204"
      unitRef="USD">41522</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">32385</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">3308360</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">53338554</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-3308360</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-53338554</us-gaap:OperatingIncomeLoss>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">370000</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">9250000</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">156849</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment>
    <RENB:GainOnBankruptcyOfSubsidiary
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">12019227</RENB:GainOnBankruptcyOfSubsidiary>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-6329592</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">122400</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">250080</us-gaap:InterestExpenseNonoperating>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">33297</RENB:InterestIncomeAndOtherIncomeExpense>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">126598</RENB:InterestIncomeAndOtherIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000234"
      unitRef="USD">6127381</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">9126518</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000237"
      unitRef="USD">2819021</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-01to2025-09-30"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-01to2025-09-30"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">-2.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000246"
      unitRef="USDPShares">-2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-01to2025-09-30"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">22520245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-01to2025-09-30"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">22520245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">15999337</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">15999337</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000256"
      unitRef="USD">2819021</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000257"
      unitRef="USD">-44212036</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000262"
      unitRef="USD">10943003</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-6468061</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-8123982</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-37743975</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">15845264</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">1585</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">464601486</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-332455081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-170846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000272"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">142346</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">14</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">2096166</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000280"
      unitRef="USD">2096181</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">200000</RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares>
    <RENB:RestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">200</RENB:RestrictedSharesIssuedForServicesRendered>
    <RENB:RestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">1399980</RENB:RestrictedSharesIssuedForServicesRendered>
    <RENB:RestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000288"
      unitRef="USD">1400000</RENB:RestrictedSharesIssuedForServicesRendered>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000298"
      unitRef="Shares">-83333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">-8</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">8</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000304"
      unitRef="USD">357648</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">6468061</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000316"
      unitRef="USD">6468061</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">16104277</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">1610</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">468455289</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-376667117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">6297215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000322"
      unitRef="USD">98086998</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">17739291</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">1774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">478296114</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-510462570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">10814842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-21349841</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">5355809</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">536</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">16066892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000338"
      unitRef="USD">16067427</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">85147</RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayableShares>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">9</RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">184300</RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable>
    <RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000346"
      unitRef="USD">184308</RENB:IssuanceOfCommonStockPursuantToSettlementOfAccountsPayable>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">181312</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000354"
      unitRef="USD">181312</us-gaap:ShareBasedCompensation>
    <RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplitShares
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">30</RENB:SharesAddedForFractionalSharesPursuantToReverseStockSplitShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">2819021</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000368"
      unitRef="USD">2819021</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-10943003</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-10943003</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000382"
      unitRef="Shares">23180277</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">2318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">494728618</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">-507643549</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">-128161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-13040774</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000387"
      unitRef="USD">2819021</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">-44212036</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000393"
      unitRef="USD">41522</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000394"
      unitRef="USD">32385</us-gaap:DepreciationAndAmortization>
    <RENB:LossOnExtinguishmentOfDebt
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-6329593</RENB:LossOnExtinguishmentOfDebt>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000399"
      unitRef="USD">370000</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">9250000</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000402"
      unitRef="USD">156849</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairment>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000405"
      unitRef="USD">181312</RENB:NoncashStockbasedCompensationExpense>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000406"
      unitRef="USD">357648</RENB:NoncashStockbasedCompensationExpense>
    <RENB:GainOnBankruptcysOfSubsidiary
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000408"
      unitRef="USD">12019227</RENB:GainOnBankruptcysOfSubsidiary>
    <RENB:GainOnBankruptcysOfSubsidiary
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-1400000</RENB:GainOnBankruptcysOfSubsidiary>
    <us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000411"
      unitRef="USD">831915</us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease>
    <us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000412"
      unitRef="USD">47614729</us-gaap:ImpairmentExcludingLessorAssetUnderOperatingLease>
    <RENB:GainOnSettlementOfAccountsPayable
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">22324</RENB:GainOnSettlementOfAccountsPayable>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000417"
      unitRef="USD">18495</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000418"
      unitRef="USD">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000421"
      unitRef="USD">23718</RENB:AmortizationOfDiscountOnNotePayable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">6407</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000427"
      unitRef="USD">195961</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-269264</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000430"
      unitRef="USD">-183701</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000432"
      unitRef="USD">532206</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000433"
      unitRef="USD">1953539</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000435"
      unitRef="USD">205738</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">46891</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000438"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000439"
      unitRef="USD">31325</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-3369</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000442"
      unitRef="USD">-2269</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-1349110</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000445"
      unitRef="USD">-2016328</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000450"
      unitRef="USD">544700</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000451"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000453"
      unitRef="USD">544700</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000459"
      unitRef="USD">271643</RENB:RepaymentsOfFinanceAgreement>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000460"
      unitRef="USD">223945</RENB:RepaymentsOfFinanceAgreement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000463"
      unitRef="USD">2096181</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000465"
      unitRef="USD">1615000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">156947</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">1343357</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">2029183</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-6839</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-12751</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000474"
      unitRef="USD">532108</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000475"
      unitRef="USD">104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000477"
      unitRef="USD">92700</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">220467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000480"
      unitRef="USD">624808</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000481"
      unitRef="USD">220571</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000489"
      unitRef="USD">8559</us-gaap:InterestPaidNet>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000496"
      unitRef="USD">24954</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000498"
      unitRef="USD">36973</RENB:CancellationOfRestrictedStockAwards>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000499"
      unitRef="USD">83</RENB:CancellationOfRestrictedStockAwards>
    <RENB:CancellationOfStockOptions
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000501"
      unitRef="USD">127032</RENB:CancellationOfStockOptions>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000504">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmM2k5cnxo5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_82E_zjmZBzzAvfB5"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--BusinessPolicyTextBlock_zM8bhbJd7Yuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMJazVCBCdBc"&gt;Business&lt;/span&gt; &#x2013;&lt;/b&gt;&#160;On
August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;). On April 8, 2025,
Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#x201c;BioSymetrics, Corp.&#x201d;), as a wholly owned subsidiary pursuant
to a stock purchase agreement. On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro
Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;) and
acquired GEDi Cube Intl Ltd and its subsidiaries GediCube B.V. and Grace Systems B.V. (&#x201c;Renovaro Cube&#x201d;), as a wholly owned
subsidiary pursuant to a stock purchase agreement. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform
for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights,
enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfhaeqhssCx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zRGXCqp0TaXi"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).
The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2025, and 2024
and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s June 30, 2025 audited financial
statements. The results of operations for the period ended September 30, 2025 are not necessarily indicative of the operating results
for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zjYCGxlKlCRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOQrRNCWX6Ne"&gt;Consolidation&lt;/span&gt; &#x2013;&lt;/b&gt; For
the three months ended September 30, 2025, and 2024, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--BankruptcyPolicyTextBlock_zxMyMLvyswRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zayuz0B64oh5"&gt;Bankruptcy &lt;/span&gt;-&lt;/b&gt; The Company
accounts for bankruptcy under ASC 810, Consolidation. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. (&#x201c;Gedi&#x201d;),
an indirect subsidiary of Lunai Bioworks, Inc. As of September 30, 2025 the Company deconsolidated Gedi Cube B.V., derecognizing its net
liabilities and releasing the cumulative translation adjustment balance to earnings. The bankruptcy resulted in a gain of $&lt;span id="xdx_90B_ecustom--BankruptcyResultedInGain_c20250701__20250930_zYAcaX7EBWyj" title="Bankruptcy resulted in a gain"&gt;12,019,227&lt;/span&gt;
during the three months ended September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z472sHq2DJw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zIUBCJ90PhLh"&gt;Accounting Estimates&lt;/span&gt; &#x2013;&lt;/b&gt;
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zrgDFSUyEJoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z2kWuceihXFb"&gt;Loss Per Share&lt;/span&gt;&#160;&lt;/b&gt;&#x2013;Basic earnings per common share (EPS) are based on the weighted average
number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed
as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings
per share calculation include in-the-money stock options that have been granted but have not been exercised and shares issuable upon conversion
of convertible common stock and convertible notes. The Company had &lt;span id="xdx_904_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250930_zz8t1Bt16A38" title="Common stock outstanding"&gt;1,244,888&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240930_z2JKPdRrqSs2" title="Common stock outstanding"&gt;1,729,342&lt;/span&gt; potential shares of Common Stock excluded from
the Diluted EPS calculation as of September 30, 2025, and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zbjCC4VyiJja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zn14GVueakDa"&gt;Functional Currency &amp;amp; Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#x201c;CAD&#x201d;).
The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#x2019;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended September 30, 2025, and 2024. Translation gains and losses are deferred
and accumulated as a component of other comprehensive income in stockholders&#x2019; equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement
of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zRyaUyKr69Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zjlPOJV9f471"&gt;Investment in Equity Securities&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#x2014;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $&lt;span id="xdx_90D_ecustom--PurchasedEquitySecurities_iI_c20250228_zgRDsGVwMiib" title="Purchased equity securities"&gt;500,000&lt;/span&gt; of equity securities. During the period ended September 30, 2025, the Company recorded a change in fair value of equity
securities for $&lt;span id="xdx_908_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_c20250701__20250930_zbnqDYItSFFb" title="Fair value of equity securities"&gt;156,849&lt;/span&gt; and sold the securities for $&lt;span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiGainLoss_c20250701__20250930_zckIHg6vJ15c" title="Investment in equity securities"&gt;544,700&lt;/span&gt;. The investment in equity securities balance at September 30, 2025, was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0NQ2pJr1opd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z1i7QDoyRl8d"&gt;New Accounting Pronouncements
Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&#160;- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <RENB:BusinessPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000506">&lt;p id="xdx_846_ecustom--BusinessPolicyTextBlock_zM8bhbJd7Yuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zMJazVCBCdBc"&gt;Business&lt;/span&gt; &#x2013;&lt;/b&gt;&#160;On
August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;). On April 8, 2025,
Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#x201c;BioSymetrics, Corp.&#x201d;), as a wholly owned subsidiary pursuant
to a stock purchase agreement. On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro
Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;) and
acquired GEDi Cube Intl Ltd and its subsidiaries GediCube B.V. and Grace Systems B.V. (&#x201c;Renovaro Cube&#x201d;), as a wholly owned
subsidiary pursuant to a stock purchase agreement. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. In August
2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform
for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights,
enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:BusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000508">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfhaeqhssCx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zRGXCqp0TaXi"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).
The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2025, and 2024
and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements
should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s June 30, 2025 audited financial
statements. The results of operations for the period ended September 30, 2025 are not necessarily indicative of the operating results
for the full year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000510">&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zjYCGxlKlCRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOQrRNCWX6Ne"&gt;Consolidation&lt;/span&gt; &#x2013;&lt;/b&gt; For
the three months ended September 30, 2025, and 2024, the condensed consolidated financial statements include the accounts and operations
of the Company and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <RENB:BankruptcyPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000512">&lt;p id="xdx_848_ecustom--BankruptcyPolicyTextBlock_zxMyMLvyswRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zayuz0B64oh5"&gt;Bankruptcy &lt;/span&gt;-&lt;/b&gt; The Company
accounts for bankruptcy under ASC 810, Consolidation. On September 2, 2025, the Court of Amsterdam declared bankrupt Gedi Cube B.V. (&#x201c;Gedi&#x201d;),
an indirect subsidiary of Lunai Bioworks, Inc. As of September 30, 2025 the Company deconsolidated Gedi Cube B.V., derecognizing its net
liabilities and releasing the cumulative translation adjustment balance to earnings. The bankruptcy resulted in a gain of $&lt;span id="xdx_90B_ecustom--BankruptcyResultedInGain_c20250701__20250930_zYAcaX7EBWyj" title="Bankruptcy resulted in a gain"&gt;12,019,227&lt;/span&gt;
during the three months ended September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:BankruptcyPolicyTextBlock>
    <RENB:BankruptcyResultedInGain
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000514"
      unitRef="USD">12019227</RENB:BankruptcyResultedInGain>
    <us-gaap:UseOfEstimates contextRef="From2025-07-01to2025-09-30" id="Fact000516">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z472sHq2DJw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zIUBCJ90PhLh"&gt;Accounting Estimates&lt;/span&gt; &#x2013;&lt;/b&gt;
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ
from those estimated. Significant estimates include the fair value of assets acquired in a business acquisition, contingent consideration,
and equity instruments issued for goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000518">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zrgDFSUyEJoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z2kWuceihXFb"&gt;Loss Per Share&lt;/span&gt;&#160;&lt;/b&gt;&#x2013;Basic earnings per common share (EPS) are based on the weighted average
number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed
as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings
per share calculation include in-the-money stock options that have been granted but have not been exercised and shares issuable upon conversion
of convertible common stock and convertible notes. The Company had &lt;span id="xdx_904_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250930_zz8t1Bt16A38" title="Common stock outstanding"&gt;1,244,888&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240930_z2JKPdRrqSs2" title="Common stock outstanding"&gt;1,729,342&lt;/span&gt; potential shares of Common Stock excluded from
the Diluted EPS calculation as of September 30, 2025, and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000520"
      unitRef="Shares">1244888</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">1729342</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000525">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zbjCC4VyiJja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zn14GVueakDa"&gt;Functional Currency &amp;amp; Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#x201c;CAD&#x201d;).
The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#x2019;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended September 30, 2025, and 2024. Translation gains and losses are deferred
and accumulated as a component of other comprehensive income in stockholders&#x2019; equity. Transaction gains and losses that arise from
exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement
of operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <RENB:InvestmentinEquitySecuritiesPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000527">&lt;p id="xdx_849_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zRyaUyKr69Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zjlPOJV9f471"&gt;Investment in Equity Securities&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#x2014;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $&lt;span id="xdx_90D_ecustom--PurchasedEquitySecurities_iI_c20250228_zgRDsGVwMiib" title="Purchased equity securities"&gt;500,000&lt;/span&gt; of equity securities. During the period ended September 30, 2025, the Company recorded a change in fair value of equity
securities for $&lt;span id="xdx_908_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_c20250701__20250930_zbnqDYItSFFb" title="Fair value of equity securities"&gt;156,849&lt;/span&gt; and sold the securities for $&lt;span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiGainLoss_c20250701__20250930_zckIHg6vJ15c" title="Investment in equity securities"&gt;544,700&lt;/span&gt;. The investment in equity securities balance at September 30, 2025, was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:InvestmentinEquitySecuritiesPolicyTextBlock>
    <RENB:PurchasedEquitySecurities
      contextRef="AsOf2025-02-28"
      decimals="0"
      id="Fact000529"
      unitRef="USD">500000</RENB:PurchasedEquitySecurities>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000531"
      unitRef="USD">156849</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000533"
      unitRef="USD">544700</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000535">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0NQ2pJr1opd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z1i7QDoyRl8d"&gt;New Accounting Pronouncements
Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&#160;- Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000537">&lt;p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMijwZetCg3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_823_zYNOhBxI1J8c"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#x2019;s continuing operations, and is dependent on additional
financing to fund operations. As of September 30, 2025, the Company had cash and cash equivalents of $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250930_z7WMSpJD6zjc" title="Cash and cash equivalents"&gt;624,808&lt;/span&gt;, an accumulated deficit
of $&lt;span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250930_z2q6zHX4ktSi" title="Accumulated deficit"&gt;507,643,549&lt;/span&gt; and a working capital deficit of $&lt;span id="xdx_90F_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250930_zT7GrhiBR2X3" title="Working capital deficit"&gt;18,922,114&lt;/span&gt;. These conditions raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities
that might be necessary should the Company be unable to continue in existence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Management has reduced overhead
and administrative costs by streamlining the organization to focus around the development, validation, and commercialization of its AI-driven
neurology and oncology diagnostics and therapeutic development platform. The Company has tailored its workforce to focus on these activities.
In addition, the Company intends to secure additional required funding through equity or debt financing. However, there can be no assurance
that the Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on
reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders.
If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially
reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with
third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds
to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders
losing some or all of their investment in us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000539"
      unitRef="USD">624808</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000541"
      unitRef="USD">-507643549</us-gaap:RetainedEarningsAccumulatedDeficit>
    <RENB:WorkingCapitalDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000543"
      unitRef="USD">18922114</RENB:WorkingCapitalDeficit>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000547">&lt;p id="xdx_80E_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zo30AvUygzBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_827_znoD4YYDhpyg"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company accounts for fair value
measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#x201c;Fair Value Measurements&#x201d;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;There were no Level 1, 2 or 3 assets,
nor any Level 1 or 2 liabilities as of September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Unless otherwise disclosed, the
fair value of the Company&#x2019;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Level 3 liabilities held as of
September 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of &lt;span style="background-color: white"&gt;Renovaro
Cube, (the &#x201c;Acquisition&#x201d;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) &lt;span id="xdx_906_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTPM5SKbod3" title="Contingent shares issuable in connection with the acquisition"&gt;7,083,418&lt;/span&gt;
shares of Common Stock, and (ii) the right to receive up to &lt;span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240212__20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zRgbLgqbUiml" title="Contingent shares issuable in connection with the acquisition"&gt;1,189,954&lt;/span&gt; contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zNoAPtuTCE0k" title="Contingent consideration liability was recorded at fair value"&gt;20,557,500&lt;/span&gt;
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of September 30, 2025,
there were &lt;span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250701__20250930__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zfc8vJkVAleh" title="Contingent shares issuable in connection with the acquisition"&gt;267,695&lt;/span&gt; contingent shares issuable in connection with the Acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#x2019;s
underlying stock. The key inputs to valuing the contingent consideration liability as of September 30, 2025, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--FairValueConcentrationOfRiskTextBlock_zVIeTjspzAje" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details )"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zTbxwmiSnMid" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAiDKvghFQXf" title="Stock Price"&gt;1.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ziE7IUTNWTpa" title="Exercise Price"&gt;5.30&lt;/span&gt; - $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zsIQsBDmJDXh" title="Exercise Price"&gt;19.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOcOIkbpe40g" title="Volatility"&gt;115.5&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z2MChPVYK1i6" title="Volatility"&gt;143.3&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zieq7CsH6482" title="Risk Free Rate"&gt;3.54&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAtgEuBTleve" title="Risk Free Rate"&gt;3.94&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20250701__20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zfDogYXT7rvf" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zLpgHT05ft7b" title="Expected Term (years)"&gt;2.45&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdaNRZRjMswi" title="Expected Term (years)"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_zBjVMOv9TQUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following table sets forth the Level 3 liability
at September 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_zhEvZ0FZbhNf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zjBOizIiVET3" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYZKbCbh3COk" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z99ZK5ouloBl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze9UsuxrdEY7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Fair Value Measurements at&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;br/&gt; Reporting Date Using&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z4zHG0uKm5Xl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Balance June 30, 2025&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;630,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zX4x6YbgKuha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(370,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zHn0Z3nefF8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at September 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;260,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8AD_z0KVcI4xDDTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">7083418</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2024-02-122024-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember"
      decimals="INF"
      id="Fact000551"
      unitRef="Shares">1189954</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember"
      decimals="0"
      id="Fact000553"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2025-07-012025-09-30_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact000555"
      unitRef="Shares">267695</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000558">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--FairValueConcentrationOfRiskTextBlock_zVIeTjspzAje" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details )"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zTbxwmiSnMid" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAiDKvghFQXf" title="Stock Price"&gt;1.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ziE7IUTNWTpa" title="Exercise Price"&gt;5.30&lt;/span&gt; - $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zsIQsBDmJDXh" title="Exercise Price"&gt;19.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zOcOIkbpe40g" title="Volatility"&gt;115.5&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z2MChPVYK1i6" title="Volatility"&gt;143.3&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zieq7CsH6482" title="Risk Free Rate"&gt;3.54&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zAtgEuBTleve" title="Risk Free Rate"&gt;3.94&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20250701__20250930__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zfDogYXT7rvf" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zLpgHT05ft7b" title="Expected Term (years)"&gt;2.45&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdaNRZRjMswi" title="Expected Term (years)"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2025-09-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000560"
      unitRef="USDPShares">1.42</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000562"
      unitRef="USDPShares">5.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000564"
      unitRef="USDPShares">19.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000566"
      unitRef="Ratio">1.155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000568"
      unitRef="Ratio">1.433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Ratio">0.0354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Ratio">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-07-012025-09-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000574"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000576">P2Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000578">P8Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000580">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_zhEvZ0FZbhNf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zjBOizIiVET3" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYZKbCbh3COk" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z99ZK5ouloBl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20250701__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze9UsuxrdEY7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Fair Value Measurements at&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;br/&gt; Reporting Date Using&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_z4zHG0uKm5Xl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Balance June 30, 2025&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;630,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zX4x6YbgKuha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Fair value adjustment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(370,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_zHn0Z3nefF8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent Consideration Liability at September 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;260,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000582"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000583"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000584"
      unitRef="USD">630000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000586"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000587"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2025-07-012025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000588"
      unitRef="USD">-370000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000590"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000591"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000592"
      unitRef="USD">260000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000594">&lt;p id="xdx_802_eus-gaap--IntangibleAssetsDisclosureTextBlock_zzg7412r9SB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_82A_zFHAbe2E1Yea"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 8, 2025, the Company acquired
Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $&lt;span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQqqsZfF9uRf" title="Goodwill"&gt;5,963,500&lt;/span&gt;, software valued at $&lt;span id="xdx_905_ecustom--Software_iI_c20250408_zkTjkjbtTqhd" title="Software"&gt;143,000&lt;/span&gt; and Trademark valued at $&lt;span id="xdx_90F_ecustom--Trademark_iI_c20250408_zqyg6ofM0flf" title="Trademark"&gt;8,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;At September 30, 2025 and June
30, 2025, definite-life and indefinite-life intangible assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z3evUhPnV3mc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6TEfz3w8Q9f" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"&gt;Software platform&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zc0nO79haeUh" title="Useful life"&gt;5&lt;/span&gt; Years&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z5Oj6hiCJaN" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;143,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zqupOR3oik0d" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zr27SdhVsM0e" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(13,712&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zdDY9nqAbTog" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zZVvRURXm30g" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z0uGuh274ZNb" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;129,288&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Trademark&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z06kiu0KEXV8" title="Useful life"&gt;2&lt;/span&gt; Years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlxnjTe714qb" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;8,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXfn5AY8mBg8" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zSpbmCUBXS51" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(1,918&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zDZArRFfc3K1" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zWvG7PmMKi2" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zFt0ve4ldaif" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;6,082&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Patents&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdgXdGKDQs54" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zN2aI7lYTa7a" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;313,010&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXpbFKOw1iZ2" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGSu1yyOMQF8" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuYNstgZR2a7" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwBDWp3vi0f" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,093&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxYIHPHW9Jj" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;311,917&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zIilEfxn708f" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(298,016&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zYQTgXXpVolc" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zbXb3sF8kPOd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,659&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z0SZ4FSwEwV4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zc8RdkimNFvb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;6,368&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zoSETgpApoH" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(294,307&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930_zgAPNZBLRsm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;165,994&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z0bhNBNcAsqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930_z8GcL5TFmKDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(18,289&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930_zw7dnYUvfrr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930_zlmMWp4mj791" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;5,275&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930_zUZ4Mkw61TUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;152,980&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIrKAOOAP0xb" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;5,963,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zAyDwYSbZJn9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIC6TfGmdYua" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zHFq70etLZc" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9IeGzNOei4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zXDGJ52QWeOj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930_zTZNX1tENBcl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z9kONEG67yGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930_zZn8LSkWOBSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930_zd0gEmogMmKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930_z9yYRn4vm0y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930_z5EIu2Mhz8Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zr9O3zVLSYue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Expected future amortization expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zt8uoumTSSza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_z501rc3v58Rf" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Years ended&#160;June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 57%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250930_zUVcNtu43dyb" style="width: 30%; text-align: right" title="2026"&gt;32,420&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250930_zaeQzlm9Q0Gb" style="text-align: right" title="2027"&gt;32,420&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250930_zV85U7gkWS02" style="text-align: right" title="2028"&gt;29,380&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250930_zu5NoeDnxCzc" style="text-align: right" title="2029"&gt;29,380&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250930_zhmQ7e0Oassl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;29,380&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250930_z8oeWpFbbx8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;152,980&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zUCqy0lX6wGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="AsOf2025-04-08_custom_BioSymetricsMember"
      decimals="0"
      id="Fact000596"
      unitRef="USD">5963500</us-gaap:Goodwill>
    <RENB:Software
      contextRef="AsOf2025-04-08"
      decimals="0"
      id="Fact000598"
      unitRef="USD">143000</RENB:Software>
    <RENB:Trademark
      contextRef="AsOf2025-04-08"
      decimals="0"
      id="Fact000600"
      unitRef="USD">8000</RENB:Trademark>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000604">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z3evUhPnV3mc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6TEfz3w8Q9f" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"&gt;Software platform&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zc0nO79haeUh" title="Useful life"&gt;5&lt;/span&gt; Years&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z5Oj6hiCJaN" style="width: 9%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;143,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zqupOR3oik0d" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zr27SdhVsM0e" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(13,712&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zdDY9nqAbTog" style="width: 9%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zZVvRURXm30g" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_z0uGuh274ZNb" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;129,288&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Trademark&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z06kiu0KEXV8" title="Useful life"&gt;2&lt;/span&gt; Years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlxnjTe714qb" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;8,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXfn5AY8mBg8" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zSpbmCUBXS51" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(1,918&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zDZArRFfc3K1" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zWvG7PmMKi2" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zFt0ve4ldaif" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;6,082&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Patents&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdgXdGKDQs54" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zN2aI7lYTa7a" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;313,010&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXpbFKOw1iZ2" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGSu1yyOMQF8" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuYNstgZR2a7" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGwBDWp3vi0f" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,093&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxYIHPHW9Jj" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;311,917&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zIilEfxn708f" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(298,016&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zYQTgXXpVolc" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zbXb3sF8kPOd" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(2,659&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z0SZ4FSwEwV4" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zc8RdkimNFvb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;6,368&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zoSETgpApoH" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(294,307&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20250701__20250930_zgAPNZBLRsm8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;165,994&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z0bhNBNcAsqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20250701__20250930_z8GcL5TFmKDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(18,289&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20250701__20250930_zw7dnYUvfrr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20250701__20250930_zlmMWp4mj791" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;5,275&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20250701__20250930_zUZ4Mkw61TUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;152,980&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIrKAOOAP0xb" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;5,963,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zAyDwYSbZJn9" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zIC6TfGmdYua" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zHFq70etLZc" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9IeGzNOei4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zXDGJ52QWeOj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20250701__20250930_zTZNX1tENBcl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20250701__20250930_z9kONEG67yGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20250701__20250930_zZn8LSkWOBSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_d0_c20250701__20250930_zd0gEmogMmKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20250701__20250930_z9yYRn4vm0y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20250701__20250930_z5EIu2Mhz8Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_custom_SoftwarePlatformMember"
      id="Fact000606">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">143000</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">-13712</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000614"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-012025-09-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-09-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000618"
      unitRef="USD">129288</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_custom_TrademarkMember"
      id="Fact000620">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000622"
      unitRef="USD">8000</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-012025-09-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000624"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2025-07-012025-09-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000626"
      unitRef="USD">-1918</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-012025-09-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-012025-09-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000630"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-09-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000632"
      unitRef="USD">6082</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_PatentsMember"
      id="Fact000634">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">313010</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-1093</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-09-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">311917</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">-298016</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000650"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">-2659</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-012025-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000656"
      unitRef="USD">6368</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-09-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">-294307</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000660"
      unitRef="USD">165994</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000662"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">-18289</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000668"
      unitRef="USD">5275</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">152980</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000676"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000678"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-012025-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-09-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000682"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000696">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zt8uoumTSSza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_z501rc3v58Rf" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Years ended&#160;June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 57%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250930_zUVcNtu43dyb" style="width: 30%; text-align: right" title="2026"&gt;32,420&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250930_zaeQzlm9Q0Gb" style="text-align: right" title="2027"&gt;32,420&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250930_zV85U7gkWS02" style="text-align: right" title="2028"&gt;29,380&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250930_zu5NoeDnxCzc" style="text-align: right" title="2029"&gt;29,380&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250930_zhmQ7e0Oassl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;29,380&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250930_z8oeWpFbbx8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;152,980&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000698"
      unitRef="USD">32420</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000700"
      unitRef="USD">32420</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">29380</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000704"
      unitRef="USD">29380</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000706"
      unitRef="USD">29380</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000708"
      unitRef="USD">152980</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000710">&lt;p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zaOAFQIyG1Te" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82B_zMhzSOo81tl1"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Convertible Notes Payable &#x2014;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;The January 2024 Note &#x2014;&lt;/i&gt;&lt;/b&gt;
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zCHwHAoLb57i" title="Principal amount"&gt;125,000&lt;/span&gt; (the &#x201c;January 2024 Note&#x201d;). The Company received a total of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zPi57CkjqAL4" title="Gross proceeds"&gt;125,000&lt;/span&gt; in gross proceeds.&#160;The
January 2024 Note bears an interest rate of &lt;span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zX3BgDUPOfb2" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and matured on &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zhpM7Ldgj3Qa" title="Debt maturity period"&gt;December 29, 2024&lt;/span&gt;. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#x2019;s
Common Stock at the Note Conversion Price of $33.80.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note that matured on December 29, 2024, was amended extending
the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29, 2025. Accordingly, the Note unless otherwise
amended, replaced, or otherwise altered by this First Amendment, any and all terms contained in the Note continue in full force and effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;December 2023 Notes &#x2014;
&lt;/i&gt;&lt;/b&gt;On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zH0hPbkQyxIc" title="Principal amount"&gt;120,000&lt;/span&gt; (the &#x201c;December 2023 Notes&#x201d;). The Company received a total of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z27msV7Ftt1a" title="Gross proceeds"&gt;120,000&lt;/span&gt; from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of &lt;span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zj2egcfRJdNe" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and matured one year after
their respective dates of issuance (the &#x201c;Maturity Date&#x201d;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The January 2024 Note and December
2023 Notes balance at September 30, 2025, was $&lt;span id="xdx_909_ecustom--NotesBalance_iI_c20250930_zhvEpYczffVd" title="Notes balance"&gt;245,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Notes Payable &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $&lt;span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818_zveo9YHxfvU5" title="Sale of stock issued cash consideration"&gt;1,000,000&lt;/span&gt; incurring $&lt;span id="xdx_901_ecustom--PlacementCosts_iI_c20250818_zs08gZ5k0yT2" title="Placement costs"&gt;80,000&lt;/span&gt; of placement costs. The Notes bear an interest
rate of&#160;&lt;span id="xdx_906_ecustom--InterestRate_iI_dp_c20250818_zK6cVGTXSved" title="Interest rate"&gt;18&lt;/span&gt;%&#160;per annum and mature on&#160;the 6-month anniversary of the Issue Date,&#160;(the &#x201c;Maturity Date&#x201d;).
The Company is required to pay principal and interest on the Maturity Date. These notes balance at September 30, 2025, was $&lt;span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20250930_zoE4FRQKgMO7" title="Notes balance"&gt;938,495&lt;/span&gt; net
amortization placement cost of $&lt;span id="xdx_90F_ecustom--AmortizationPlacementCost_iI_c20250930_ziosMPfH3ja3" title="Amortization placement cost"&gt;18,495&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;From July 3, 2025, to August 19,
2025, the Company issued Promissory Notes in the aggregate principal amount of $&lt;span id="xdx_902_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703_zykCEXEf9MXf" title="Sale of stock issued cash consideration"&gt;695,000&lt;/span&gt;. The Notes bear an interest rate of&#160;&lt;span id="xdx_906_ecustom--InterestRate_iI_dp_c20250819_zlnoec1u1Eng" title="Interest rate"&gt;10&lt;/span&gt;%&#160;per
annum and mature on&#160;June 30, 2026,&#160;(the &#x201c;Maturity Date&#x201d;). The Company is required to pay principal and interest
on the Maturity Date&lt;b&gt;. &lt;/b&gt;These notes balance at September 30, 2025, was $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_c20250703_zxGYUoD05xSi" title="Notes balance"&gt;695,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On July 7, 2025, Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;)
entered into an Exchange Agreement (the &#x201c;Exchange Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $&lt;span id="xdx_901_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zXt7wWrr0A7f" title="Sale of stock issued cash consideration"&gt;9.7&lt;/span&gt; million in outstanding secured promissory notes (the &#x201c;Secured Notes&#x201d;) for $&lt;span id="xdx_90F_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_z7sKOxM4EG6b" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million in new convertible promissory
notes (the &#x201c;Convertible Notes&#x201d;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange resulted in a $6,329,592 loss on extinguishment
of debt.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $&lt;span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_z9SDHgLpktnh" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million principal amount into an aggregate
of &lt;span id="xdx_909_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zAQhZ08Hn1qh" title="Sale of stock issued cash consideration"&gt;5.36&lt;/span&gt; million shares of common stock (the &#x201c;Conversion Shares&#x201d;), based on the stated $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zUNFAe8oGjNg" title="Conversion price"&gt;3.00&lt;/span&gt; per share conversion price. The
$3.00 (on a post reverse split basis) per share conversion price of the Convertible Notes represented a premium to the closing price of
the Company&#x2019;s common stock on July 7, 2025, the date of execution and conversion. As a result, the issuance of the &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707_zMCCXt3MOs2k" title="Issuance of common stock shares"&gt;5.36&lt;/span&gt; million
shares of common stock upon conversion of the Convertible Notes did not constitute a &#x201c;below market&#x201d; issuance under applicable
Nasdaq listing rules and did not trigger stockholder approval requirements under Nasdaq Listing Rule 5635(d). The shares were issued without
any additional consideration from the Investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Bridge Loans &#x2014; &lt;/i&gt;&lt;/b&gt;From June 4, 2025
to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;)
and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zGX7GCjzbG8c" title="Principal amount"&gt;1,725,000&lt;/span&gt; to each note holder. The Company received $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zfBUrIuoyvqf" title="Gross proceeds"&gt;3,450,000&lt;/span&gt;
in gross proceeds. The notes bear an interest rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zUOaMX1twB9g" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and mature on December 31, 2025. On July 7, 2025, the Company entered
into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a
$&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250604__20250614_zTrkgFozO786" title="Loss on extinguishment of debt"&gt;2,262,774&lt;/span&gt; loss on extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors
elected to convert the entire note balance for shares of common stock. The notes balance at September 30, 2025, was zero with Paseco ApS
and Laksya Ventures Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zbxqySSgYwve" title="Principal amount"&gt;2,650,000&lt;/span&gt;. The Company received $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zEfbYnqY3vV" title="Gross proceeds"&gt;2,650,000&lt;/span&gt; in gross proceeds. The notes bear an
interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zYJniwo5in62" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and mature from December 31, 2024 to December 31, 2025. &lt;span id="xdx_90E_eus-gaap--MaturitiesOfTimeDepositsDescription_c20250701__20250930_zjDFf0d9V311" title="Maturity description"&gt;Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange
Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a $1,821,843 loss on
extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors elected to convert
the entire note balance for shares of common stock. The note balance at September 30, 2025, was zero with Paseco ApS and Laksya Ventures
Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_903_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zY8fWR4upXVj" title="Agreement description"&gt;From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of &#x20ac;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory
notes. The exchange resulted in a $364,303 loss on extinguishment of debt. Immediately following the issuance of the convertible notes
on July 7, 2025, the investors elected to convert the entire note balance for shares of common stock. The note balance at September 30,
2025 was approximately zero with Paseco ApS and Laksya Ventures Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zXApi2uHurpk" title="Agreement description"&gt;On November 1, 2024, Renovaro Cube
entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#x20ac;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at September 30, 2025 was approximately
$270,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zS5FT7Prpbo3" title="Agreement description"&gt;On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#x201c;RS Bio&#x201d;), to issue a Promissory Note
for the principal amount of $100,000 (the &#x201c;September 2024 Note&#x201d;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing
promissory note for a new convertible promissory note. The exchange resulted in a $71,112 loss on extinguishment of debt. Immediately
following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of
common stock. The note balance at September 30, 2025 was zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zdlFjVTqPdA2" title="Agreement description"&gt;On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;), to issue a Promissory
Note for the principal amount of &#x20ac;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025,
the Company entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange
resulted in a $41,319 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the
investor elected to convert the entire note balance for shares of common stock. The note balance at September 30, 2025 was zero with Paseco
ApS and Laksya Ventures Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zCZqGmge1wgh" title="Agreement description"&gt;On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#x201c;February 2024 Note&#x201d;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to
exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $80,343 loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zM95opSLRQa2" title="Agreement description"&gt;On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory
note for a new convertible promissory note. The exchange resulted in a $401,715 loss on extinguishment of debt. Immediately following
the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of common stock.
The note balance, net of discount at September 30, 2025 was zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zsIr3326eOJe" title="Agreement description"&gt;On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company
entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange resulted
in a $591,198 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor
elected to convert the entire note balance for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Promissory Note &#x2014; &lt;/b&gt;On
March 30, 2020 (the &#x201c;Issuance Date&#x201d;), the Company issued a Promissory Note in the principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zzOG1EBn68p6" title="Principal amount"&gt;5,000,000&lt;/span&gt; (the &#x201c;Promissory
Note&#x201d;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zV8p3Ne46pq5" title="Maturity date"&gt;November 1, 2024&lt;/span&gt; (the &#x201c;Maturity
Date&#x201d;). The Promissory Note, as amended, bears interest at a fixed rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_ztolvObqDSl" title="Interest rate"&gt;12&lt;/span&gt;% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement
to exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20250706__20250707__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zWvXZwAg0X2i" title="Loss on extinguishment of debt"&gt;694,985&lt;/span&gt; loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The Promissory Note balance at September 30, 2025 was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#x2019;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#x201c;Collateral&#x201d;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact000712"
      unitRef="USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact000714"
      unitRef="USD">125000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact000716"
      unitRef="Ratio">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      id="Fact000718">2024-12-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-20_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact000720"
      unitRef="USD">120000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact000722"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2023-12-20_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact000724"
      unitRef="Ratio">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <RENB:NotesBalance
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000726"
      unitRef="USD">245000</RENB:NotesBalance>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-08-18"
      decimals="0"
      id="Fact000729"
      unitRef="USD">1000000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:PlacementCosts
      contextRef="AsOf2025-08-18"
      decimals="0"
      id="Fact000731"
      unitRef="USD">80000</RENB:PlacementCosts>
    <RENB:InterestRate
      contextRef="AsOf2025-08-18"
      decimals="INF"
      id="Fact000733"
      unitRef="Ratio">0.18</RENB:InterestRate>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000735"
      unitRef="USD">938495</us-gaap:ConvertibleLongTermNotesPayable>
    <RENB:AmortizationPlacementCost
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000737"
      unitRef="USD">18495</RENB:AmortizationPlacementCost>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-03"
      decimals="0"
      id="Fact000739"
      unitRef="USD">695000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:InterestRate
      contextRef="AsOf2025-08-19"
      decimals="INF"
      id="Fact000741"
      unitRef="Ratio">0.10</RENB:InterestRate>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-07-03"
      decimals="0"
      id="Fact000743"
      unitRef="USD">695000</us-gaap:ConvertibleNotesPayable>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ExchangeAgreementMember"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">9700000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ConvertibleNotesMember"
      decimals="-3"
      id="Fact000749"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">5360000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-07-07"
      decimals="INF"
      id="Fact000753"
      unitRef="USDPShares">3.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-07-07"
      decimals="-3"
      id="Fact000755"
      unitRef="Shares">5360000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-04_custom_PasecoApSMember"
      decimals="0"
      id="Fact000757"
      unitRef="USD">1725000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-07-012025-09-30_custom_PasecoApSMember"
      decimals="0"
      id="Fact000759"
      unitRef="USD">3450000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-06-04_custom_TheNotesMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Ratio">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-06-042025-06-14"
      decimals="0"
      id="Fact000763"
      unitRef="USD">2262774</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember"
      decimals="0"
      id="Fact000765"
      unitRef="USD">2650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">2650000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-10-21_custom_TheNotesMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Ratio">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MaturitiesOfTimeDepositsDescription contextRef="From2025-07-01to2025-09-30" id="Fact000771">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange
Agreement to exchange the existing promissory notes for new convertible promissory notes. The exchange resulted in a $1,821,843 loss on
extinguishment of debt. Immediately following the issuance of the convertible notes on July 7, 2025, the investors elected to convert
the entire note balance for shares of common stock. The note balance at September 30, 2025, was zero with Paseco ApS and Laksya Ventures
Inc.</us-gaap:MaturitiesOfTimeDepositsDescription>
    <RENB:AgreementDescription
      contextRef="From2024-11-122024-12-03_custom_PromissoryNotesMember"
      id="Fact000773">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of &#x20ac;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory notes for new convertible promissory
notes. The exchange resulted in a $364,303 loss on extinguishment of debt. Immediately following the issuance of the convertible notes
on July 7, 2025, the investors elected to convert the entire note balance for shares of common stock. The note balance at September 30,
2025 was approximately zero with Paseco ApS and Laksya Ventures Inc.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2025-02-232025-02-24_custom_PromissoryNotesMember"
      id="Fact000776">On November 1, 2024, Renovaro Cube
entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#x20ac;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at September 30, 2025 was approximately
$270,000.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-09-152024-09-16_custom_PromissoryNotesMember"
      id="Fact000778">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#x201c;RS Bio&#x201d;), to issue a Promissory Note
for the principal amount of $100,000 (the &#x201c;September 2024 Note&#x201d;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing
promissory note for a new convertible promissory note. The exchange resulted in a $71,112 loss on extinguishment of debt. Immediately
following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of
common stock. The note balance at September 30, 2025 was zero.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-09-052024-09-06_custom_PromissoryNotesMember"
      id="Fact000780">On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;), to issue a Promissory
Note for the principal amount of &#x20ac;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. On July 7, 2025,
the Company entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange
resulted in a $41,319 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the
investor elected to convert the entire note balance for shares of common stock. The note balance at September 30, 2025 was zero with Paseco
ApS and Laksya Ventures Inc.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-02-042024-02-05_custom_PromissoryNotesMember"
      id="Fact000782">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#x201c;February 2024 Note&#x201d;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to
exchange the existing promissory note for a new convertible promissory note. The exchange resulted in a $80,343 loss on extinguishment
of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance
for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-01-012024-01-02_custom_PromissoryNotesMember"
      id="Fact000784">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. On July 7, 2025, the Company entered into an Exchange Agreement to exchange the existing promissory
note for a new convertible promissory note. The exchange resulted in a $401,715 loss on extinguishment of debt. Immediately following
the issuance of the convertible note on July 7, 2025, the investor elected to convert the entire note balance for shares of common stock.
The note balance, net of discount at September 30, 2025 was zero.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-11-022024-11-03_custom_PromissoryNotesMember"
      id="Fact000786">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. On July 7, 2025, the Company
entered into an Exchange Agreement to exchange the existing promissory note for a new convertible promissory note. The exchange resulted
in a $591,198 loss on extinguishment of debt. Immediately following the issuance of the convertible note on July 7, 2025, the investor
elected to convert the entire note balance for shares of common stock. The note balance, net of discount at September 30, 2025 was zero.</RENB:AgreementDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      id="Fact000791">2024-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Ratio">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-062025-07-07_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact000795"
      unitRef="USD">694985</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000797">&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8XmZpDs95zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_82A_zUL94QJsaYf2"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement with Lincoln Park Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On June
20, 2023, the Company entered into a purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC
(&#x201c;Lincoln Park&#x201d;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $&lt;span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zTZPX7Wi74sj" title="Obligation to purchase"&gt;20,000,000&lt;/span&gt; of shares of Common Stock over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the
2023 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed
to provide Lincoln Park with certain registration rights related to the shares issued under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;In consideration for entering into
the 2023 Purchase Agreement, the Company issued &lt;span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zAmPVcJqWM63" title="Number of shares issued"&gt;69,602&lt;/span&gt; shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;During the quarter ended September
30, 2025 and 2024, &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_do_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zDQlJGvWSAo2" title="Number of shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zoK3VoMnK95e" title="Number of shares issued"&gt;no&lt;/span&gt;&lt;/span&gt; shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Common Stock Issuances &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On July 7, 2025, Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;)
entered into an Exchange Agreement (the &#x201c;Exchange Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $&lt;span id="xdx_905_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zM33reuPpmw5" title="Sale of stock issued cash consideration"&gt;9.7&lt;/span&gt; million in outstanding secured promissory notes (the &#x201c;Secured Notes&#x201d;) for $&lt;span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zhkkf4Hioj17" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million in new convertible promissory
notes (the &#x201c;Convertible Notes&#x201d;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#x2019;s
debt obligations and provide additional flexibility to support strategic initiatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $&lt;span id="xdx_90D_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zDoysBWxhjH" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million principal amount into an aggregate of &lt;span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707_zpKJK4rFX439" title="Sale of stock issued cash consideration"&gt;5.36&lt;/span&gt; million shares
of common stock (the &#x201c;Conversion Shares&#x201d;), based on the stated $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707_zHeasnzSz4Ra" title="Conversion price"&gt;3.00&lt;/span&gt; per share conversion price. The $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteMember_zeYPJCOMEy7f" title="Conversion price"&gt;3.00&lt;/span&gt; per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#x2019;s common stock on July 7, 2025, the date
of execution and conversion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On July 25, 2025, the Company issued&#160;&lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20250725_zxGpBL8l2bA4" title="Shares Issued Common Stock"&gt;5,500&lt;/span&gt;
shares of Common Stock for settlement of accounts payable valued at $&lt;span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_c20250725_zHAIFjsfV1Ak" title="Accounts payable"&gt;17,050&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On September 5, 2025, the Company
issued&#160;&lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20250905_zG8YU4gXn7ml" title="Shares Issued Common Stock"&gt;79,647&lt;/span&gt; shares of Common Stock for settlement of accounts payable valued at $&lt;span id="xdx_904_eus-gaap--AccountsPayableCurrent_iI_c20250905_z2Slmf6boFUg" title="Accounts payable"&gt;167,259&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On September 18, 2025, the Company filed a Certificate of Amendment to the
Certificate of Incorporation of the Company (the &#x201c;Certificate of Amendment&#x201d;) with the Secretary of State of the State of Delaware
to effect a 1-for-10 reverse stock split of the shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250918_zI1m7H15E856" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Common
Stock&#x201d;), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September
29, 2025 (the &#x201c;Reverse Stock Split&#x201d;). All shares and the respective per-share amounts have been retroactively restated to
reflect the reverse split. The Common Stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on September
30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;b&gt;Stock-based Compensation &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated
on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of
the stock options granted using the Black-Scholes option-pricing model. During the three months ended September 30, 2025, the Company
granted no options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_z3IIFIfLgHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zhJPsOzgxV34" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lunai Bioworks Inc.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 65%; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 25%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zMED0SY0N8A8"&gt;5.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zjkVOKNqE1Id" title="Volatility"&gt;109.45&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zryWbYFyVhLd" title="Volatility"&gt;118.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zIp2xowPvwDa" title="Risk free interest rate"&gt;3.86&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBIOoMMCbj73" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zbudH6P1eWui" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A7_zF6eimcGsW12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise_c20250701__20250930_zMnSM7fQVBbj" title="Stock-based Compensation description"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;83,333&#160;shares of
Common Stock from the original&#160;100,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;97,826&#160;shares of Common
Stock of the Company with a per-share exercise price of $6.90. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $185,373&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="color: #212529; background-color: white"&gt;In
total, the Company recognized stock-based compensation expense of $&lt;span id="xdx_90D_ecustom--StockbasedCompensationExpense_c20250701__20250930_zRDNhYXk9YXc" title="Stock-based compensation expense"&gt;181,312&lt;/span&gt; net a recapture of $127,032 related to options and $&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250701__20250930_z353EWRLHNQi" title="restricted option stock awards"&gt;36,973&lt;/span&gt;
related to restricted stock awards for the three months ended September 30, 2025. For the three months ended September 30, 2024, the Company
recognized stock-based compensation expense related to options of $&lt;/span&gt;&lt;span id="xdx_904_ecustom--StockbasedCompensationExpenseRelatedToOptions_iI_c20250930_zDOMNDiwpbEg" title="Stock-based compensation expense related to options"&gt;357,648&lt;/span&gt;. &lt;span style="background-color: white"&gt;At
September 30, 2025, the Company had approximately $&lt;span id="xdx_906_ecustom--UnrecognizedCompensationCost_iI_c20250930_zOwfm5jPxmvk" title="Unrecognized compensation cost"&gt;192,608&lt;/span&gt;&#160;of unrecognized compensation cost related to non-vested options.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2023-06-20"
      decimals="0"
      id="Fact000799"
      unitRef="USD">20000000</us-gaap:PurchaseObligation>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">69602</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ExchangeAgreementMember"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">9700000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ConvertiblePromissoryNoteMember"
      decimals="-3"
      id="Fact000809"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_custom_ConvertibleNotesMember"
      decimals="-3"
      id="Fact000811"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07"
      decimals="-3"
      id="Fact000813"
      unitRef="USD">5360000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-07-07"
      decimals="INF"
      id="Fact000815"
      unitRef="USDPShares">3.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-07-07_custom_ConvertibleNoteMember"
      decimals="INF"
      id="Fact000817"
      unitRef="USDPShares">3.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-07-25"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">5500</us-gaap:CommonStockSharesIssued>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-07-25"
      decimals="0"
      id="Fact000822"
      unitRef="USD">17050</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-05"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">79647</us-gaap:CommonStockSharesIssued>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-05"
      decimals="0"
      id="Fact000826"
      unitRef="USD">167259</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-18"
      decimals="INF"
      id="Fact000828"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000830">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_z3IIFIfLgHi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zhJPsOzgxV34" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lunai Bioworks Inc.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 65%; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 25%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zMED0SY0N8A8"&gt;5.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zjkVOKNqE1Id" title="Volatility"&gt;109.45&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zryWbYFyVhLd" title="Volatility"&gt;118.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zIp2xowPvwDa" title="Risk free interest rate"&gt;3.86&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20250930__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zBIOoMMCbj73" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20250930__dei--LegalEntityAxis__custom--RenovaroMember_zbudH6P1eWui" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-07-012025-09-30_custom_RenovaroMember"
      id="Fact000831">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact000833"
      unitRef="Ratio">1.0945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Ratio">1.1899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-012025-09-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact000837"
      unitRef="Ratio">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-07-012025-09-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-07-012025-09-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise contextRef="From2025-07-01to2025-09-30" id="Fact000843">On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;83,333&#160;shares of
Common Stock from the original&#160;100,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;97,826&#160;shares of Common
Stock of the Company with a per-share exercise price of $6.90. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $185,373&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPolicyForIssuingSharesUponExercise>
    <RENB:StockbasedCompensationExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000847"
      unitRef="USD">181312</RENB:StockbasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000849"
      unitRef="USD">36973</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <RENB:StockbasedCompensationExpenseRelatedToOptions
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000851"
      unitRef="USD">357648</RENB:StockbasedCompensationExpenseRelatedToOptions>
    <RENB:UnrecognizedCompensationCost
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000853"
      unitRef="USD">192608</RENB:UnrecognizedCompensationCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000855">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjkhUIGXmatc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_82E_zvLu64xVDt4k"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#x201c;HBV License Agreement&#x201d;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#x201c;G Tech&#x201d;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#x201c;SRI&#x201d;) (collectively the &#x201c;Licensors&#x201d;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#x201c;HBV License&#x201d;) for a treatment under development
(the &#x201c;Treatment&#x201d;) aimed to treat Hepatitis B Virus (HBV) infections.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $&lt;span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zHjXAZNuFNRf" title="Payment for license"&gt;1.2&lt;/span&gt; million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a &lt;span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zfHKplGnMJZa" title="Royalty percentage"&gt;2&lt;/span&gt;% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $&lt;span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zUnteZzD23Ib" title="Payment for license"&gt;1.2&lt;/span&gt; million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The cash funding for research costs
pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to
complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made
after January 31, 2022. The Company paid zero under the HBV License Agreement during the quarters ending September 30, 2025, and 2024.
The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies
sub-section below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#x201c;License Development Agreement&#x201d;), by and among the Company, G
Tech and SRI (collectively, the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#x201c;Development License&#x201d;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#x201c;Prevention and Treatment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $&lt;span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_z3JEQty9Hhwi" title="Up-front payment"&gt;10,000,000&lt;/span&gt; and a $&lt;span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zAKQ39BPSdNj" title="Payment for expenditures"&gt;760,000&lt;/span&gt; payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#x201c;ALC License Agreement&#x201d;) with Serhat
G&#xfc;mr&#xfc;kc&#xfc; and SRI (collectively, the &#x201c;Licensors&#x201d;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $600,000 and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $&lt;span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zg4mD4k8vul7" title="Initial payment"&gt;600,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;G Tech and SRI are controlled by
Anderson Wittekind, a stockholder of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;Service Agreements&lt;/b&gt; &lt;i&gt;&#x2013;&lt;/i&gt;The
Company maintains employment agreements with certain senior staff in the ordinary course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Securities Class Action Litigation.&lt;/i&gt;
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#x201c;Chow Action&#x201d; and the latter, the
&#x201c;Manici Action&#x201d;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#x2019;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#x2019;s relationship
with Serhat G&#xfc;mr&#xfc;kc&#xfc; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#x201c;Securities
Class Action Litigation&#x201d;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#x2019;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement that, subject to final approval by the United States District Court for the Central District of California,
provides for resolution of the Securities Class Action Litigation. The Court granted the lead plaintiff&#x2019;s motion for preliminary
approval of the settlement on August 18, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;Federal Derivative Litigation.
&lt;/i&gt;On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central
District of California (the &#x201c;Koenig Matter&#x201d;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc;
and certain of the Company&#x2019;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#x2019; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#x2019; motion to dismiss the Securities Class Action Litigation. The parties in the Koenig Matter, the Solak Matter (defined
below), and the Midler Matter (defined below) have entered into a stipulation of settlement that, subject to final approval by the United
States District Court for the Central District of California, provides for resolution of the Koenig Matter, Solak Matter, and Midler Matter
(the &#x201c;Koenig-Solak-Midler Settlement&#x201d;). On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary
approval of the Koenig-Solak-Midler Settlement with the United States District Court for the Central District of California. The defendants
have not yet responded to the complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#x201c;Solak Matter&#x201d;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#x2019; motion to dismiss the Securities Class Action Litigation.
On November 3, 2025, plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the
United States District Court for the Central District of California. The Solak Matter is stayed pending approval of the Koenig-Solak-Midler
Settlement. The defendants have not yet responded to the complaint. Management is unable to determine the likelihood of a loss, including
a possible range of losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;i&gt;State Derivative Litigation.&lt;/i&gt;
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#x201c;Midler
Matter&#x201d;). The Midler Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#x2019; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. On November 3, 2025,
plaintiff in the Koenig Matter filed a motion for preliminary approval of the Koenig-Solak-Midler Settlement in the United States District
Court for the Central District of California. The defendants have not yet responded to the complaint. Management is unable to determine
the likelihood of a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#xfc;mr&#xfc;kc&#xfc; (&#x201c;Gumrukcu&#x201d;), William Anderson Wittekind (&#x201c;Wittekind&#x201d;), G Tech Bio, SG &amp;amp; AW Holdings,
LLC, and SRI (collectively, the &#x201c;Defendants&#x201d;). The Complaint alleges that the Defendants engaged in a &#x201c;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#x201d; Specifically, &#x201c;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#x201d; As a result of the Defendants&#x2019; conduct, the Company claims that it &#x201c;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#x201d; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp;amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#x2019;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On December
4, 2023, the Defendants answered the Company&#x2019;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, &lt;i&gt;inter
alia&lt;/i&gt;, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp;amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#x2019; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On June
7, 2023, Weird Science LLC (&#x201c;Weird Science&#x201d;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#x201c;Trusts&#x201d;)
(collectively, &#x201c;Plaintiffs&#x201d;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#x201c;Investor Rights Agreement&#x201d;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#x201c;Holders&#x201d; of &#x201c;Registrable Securities&#x201d; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#x201c;FAC&#x201d;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#x2019; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#x2019;s
motion to dismiss under advisement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#x2019;s motion to dismiss Weird
Science&#x2019;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#x2019; allegations and remaining
claims and intends to vigorously defend against these claims.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#x2019;s books and records (the &#x201c;Demand&#x201d;) pursuant to Delaware General Corporation Law, &#xa7; 220 (&#x201c;Section
220&#x201d;). The Demand seeks the Company&#x2019;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#x201c;Special
Committee&#x201d;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp;amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative
action in the United States District Court for the Central District of California against certain officers, directors, and investors of
the Company, as well as other defendants, in connection with, &lt;i&gt;inter alia&lt;/i&gt;, Weird Science and Wittekind&#x2019;s demand for corrective
action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified Stockholder Derivative Complaint (&#x201c;Derivative
Complaint&#x201d;) alleges, among other claims, violations of Section 13(d) and 14(a) and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange
Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary duty, corporate waste, unjust enrichment, and contribution/indemnification.
Weird Science and Wittekind seek unspecified compensatory, exemplary, and punitive damages and certain injunctive relief. The Derivative
Complaint names the Company as a nominal defendant. On July 19, 2024, certain of the director defendants, who had agreed to waive service
of the summons and Derivative Complaint, filed a motion to dismiss the Derivative Complaint on a variety of procedural and substantive
grounds. A hearing on the motion to dismiss was held on October 3, 2024 and the court subsequently took the motion under submission. On
October 22, 2024, the plaintiffs filed a notice of certain subsequent events that they allege relate to their pending motion to dismiss.
On October 29, 2024, the court granted the director defendants&#x2019; motion to dismiss and dismissed the Derivative Complaint without
prejudice, but also without leave to amend.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#x2019;s decision granting the director defendants&#x2019; motion to dismiss. The appeal
remains pending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On June 21, 2024, the Company filed
suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company
and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently
concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted
in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment,
and civil conspiracy and seeks, &lt;i&gt;inter alia&lt;/i&gt;, equitable relief, including, but not limited to, return to the Company any shares received
in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss the complaint. A hearing took place on
June 25, 2025, and on November 7, 2025, the Court granted defendants&#x2019; motion and dismissed the complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Lunai commenced an action against Predictive Oncology, Inc. (&#x201c;POAI&#x201d;)
in the Delaware Court of Chancery claiming that POAI breached a &#x201c;definitive&#x201d; January 2025 Letter Agreement pursuant to which
Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition impossible and dramatically devalued the share
price of stock Lunai had already acquired as well as the value of the company it was contractually entitled to acquire. Lunai sought specific
performance or, in the alternative, money damages. The parties have exchanged paper discovery and noticed depositions. The action has
been held in abeyance while the parties attempt to negotiate a settlement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:RoyaltyPercentage
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact000859"
      unitRef="Ratio">0.02</RENB:RoyaltyPercentage>
    <us-gaap:PaymentsForFees
      contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact000861"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:UpfrontPayment
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact000863"
      unitRef="USD">10000000</RENB:UpfrontPayment>
    <RENB:PaymentForExpenditures
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact000865"
      unitRef="USD">760000</RENB:PaymentForExpenditures>
    <RENB:InitialPayment
      contextRef="From2022-09-092022-09-10"
      decimals="0"
      id="Fact000869"
      unitRef="USD">600000</RENB:InitialPayment>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000876">&lt;p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zCEcYsdNQn33" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8&#160;&#x2014;&#160;&lt;span id="xdx_827_zhkBkw65VVX7"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;As of September 30, 2025, the Company
has accrued $&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250701__20250930__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_z4dfIcMmNdx9" title="Accrued balance"&gt;384,949&lt;/span&gt; of compensation related expenses for the Company&#x2019;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_znR4ACdnwolj" title="Common stock forfeited shares"&gt;83,333&lt;/span&gt;&#160;shares of
Common Stock from the original&#160;&lt;span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zBTPDhQU1z9j" title="Shares of common stock  granted"&gt;100,000&lt;/span&gt;&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;&lt;span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zbyDOG3NMfSi" title="Purchase shares"&gt;97,826&lt;/span&gt;&#160;shares of Common
Stock of the Company with a per-share exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_z2JjN2VsOA5k" title="Warrant exercise price per share"&gt;6.90&lt;/span&gt;. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $&lt;span id="xdx_90F_ecustom--UnrecognizedCompensationExpense_c20250701__20250930_zaYYR0Gl5ZOf" title="Unrecognized compensation expense"&gt;185,373&lt;/span&gt;&#160;related to the vesting of the stocks options
during the quarter ended September 30, 2025. At September 30, 2025, the Company had zero unrecognized compensation cost related to the
options which fully vested on August 23, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;





</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-07-012025-09-30_custom_MarkDybulMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">384949</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-08-022024-08-23"
      decimals="INF"
      id="Fact000880"
      unitRef="Shares">83333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <RENB:SharesOfCommonStockGranted
      contextRef="AsOf2024-08-23"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">100000</RENB:SharesOfCommonStockGranted>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-08-222025-08-23"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">97826</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-16_custom_RSBioMember"
      decimals="INF"
      id="Fact000886"
      unitRef="USDPShares">6.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <RENB:UnrecognizedCompensationExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000888"
      unitRef="USD">185373</RENB:UnrecognizedCompensationExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000891">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zHyfyqBq4SLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_82C_zRFdcpLCAao7"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;For the period ending September
30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately
because they require different technology and marketing strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Reportable Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: justify; white-space: nowrap; width: 82%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Description &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;RENB&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;Developing new immunotherapies to combat cancer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;BioSymetrics&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;RENC&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The Company&#x2019;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the period ending September 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision
maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported
on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On September
2, 2025, the Court of Amsterdam (the &#x201c;Court&#x201d;) declared bankrupt Gedi Cube B.V. (&#x201c;Gedi&#x201d;), an indirect subsidiary
of Lunai Bioworks, Inc. (&#x201c;Lunai&#x201d;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary
petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company
deconsolidated Gedi Cube B.V. due to the loss of control of the subsidiary during the period ended September 30, 2025. As a result of
the deconsolidation, the Company recognized a gain on the bankruptcy of the subsidiary for $&lt;span id="xdx_904_ecustom--GainOnBankruptcyOfSubsidiary_c20250701__20250930_z6Nro9z5IBA" title="Gain on the bankruptcy of the subsidiary"&gt;12,019,227&lt;/span&gt; during the period ended September
30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zl3UjjoJCAFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_znSclxIs2OVa" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (RENB)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--US_zoXvK22NSIt5" style="width: 12%; text-align: right" title="Operating income loss"&gt;2,700,505&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--US_zLMNOtpYM9f" style="width: 12%; text-align: right" title="Assets"&gt;867,678&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (BioSymetrics)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zHxQYfENaOjf" style="text-align: right" title="Operating income loss"&gt;273,951&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zU3bpurJp9vi" style="text-align: right" title="Assets"&gt;6,092,985&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Netherlands (RENC)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--NL_zoh9hc52xkyb" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;333,904&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--NL_zELrnKOQL6L4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--SegmentOperatingLoss_c20250701__20250930_z3laU0XWcxy2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;3,308,360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--SegmentAsset_iI_c20250930_zhYv8k0cAFPj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;6,960,663&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p id="xdx_8AA_zLe5xPcSKy9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#x2019;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#x2019;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Information
regarding each reportable segment for the three months ended September 30, 2025, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zyp3mTzmvGI9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zM37Ncm1thJ7" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zQJTAsNXGBv7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zS52jXRMbaIj" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zVDJG83iJ9C1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_492_20250701__20250930_zSJKwiFigb4b" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioSymetrics&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zFKV4qpZi2Z" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;1,822,729&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;253,883&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;333,904&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;2,410,516&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_d0_zUHo0UTEE4Rf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;20,419&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,407&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--LonglivedAssetImpairment_d0_zeYAcMKqhg63" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Long-lived asset impairment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831,915&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831,915&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_d0_zwmbc9Xuru3a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;25,442&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,080&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;41,522&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zBctX5wAQC47" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;2,700,505&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;273,951&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;333,904&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,308,360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zpAWyNEe8O1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Geographic information:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#x2019;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <RENB:GainOnBankruptcyOfSubsidiary
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000893"
      unitRef="USD">12019227</RENB:GainOnBankruptcyOfSubsidiary>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000895">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zl3UjjoJCAFg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_znSclxIs2OVa" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (RENB)&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--US_zoXvK22NSIt5" style="width: 12%; text-align: right" title="Operating income loss"&gt;2,700,505&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--US_zLMNOtpYM9f" style="width: 12%; text-align: right" title="Assets"&gt;867,678&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (BioSymetrics)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zHxQYfENaOjf" style="text-align: right" title="Operating income loss"&gt;273,951&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zU3bpurJp9vi" style="text-align: right" title="Assets"&gt;6,092,985&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Netherlands (RENC)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--SegmentOperatingLoss_c20250701__20250930__srt--StatementGeographicalAxis__country--NL_zoh9hc52xkyb" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;333,904&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--SegmentAsset_iI_c20250930__srt--StatementGeographicalAxis__country--NL_zELrnKOQL6L4" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--SegmentOperatingLoss_c20250701__20250930_z3laU0XWcxy2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;3,308,360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--SegmentAsset_iI_c20250930_zhYv8k0cAFPj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;6,960,663&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_country_US"
      decimals="0"
      id="Fact000897"
      unitRef="USD">2700505</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-09-30_country_US"
      decimals="0"
      id="Fact000899"
      unitRef="USD">867678</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">273951</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-09-30_custom_BioSymetricsMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">6092985</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_country_NL"
      decimals="0"
      id="Fact000905"
      unitRef="USD">333904</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000909"
      unitRef="USD">3308360</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000911"
      unitRef="USD">6960663</RENB:SegmentAsset>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000915">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zyp3mTzmvGI9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zM37Ncm1thJ7" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zQJTAsNXGBv7" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zS52jXRMbaIj" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zVDJG83iJ9C1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_492_20250701__20250930_zSJKwiFigb4b" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioSymetrics&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zFKV4qpZi2Z" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;1,822,729&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;253,883&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;333,904&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;2,410,516&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_d0_zUHo0UTEE4Rf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;20,419&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,988&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,407&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--LonglivedAssetImpairment_d0_zeYAcMKqhg63" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Long-lived asset impairment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831,915&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;831,915&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_d0_zwmbc9Xuru3a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;25,442&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;16,080&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;41,522&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zBctX5wAQC47" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;2,700,505&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;273,951&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;333,904&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,308,360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">1822729</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203"
      decimals="0"
      id="Fact000918"
      unitRef="USD">253883</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">333904</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000920"
      unitRef="USD">2410516</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">20419</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203"
      decimals="0"
      id="Fact000923"
      unitRef="USD">3988</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000925"
      unitRef="USD">24407</us-gaap:ResearchAndDevelopmentExpense>
    <RENB:LonglivedAssetImpairment
      contextRef="From2025-07-012025-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">831915</RENB:LonglivedAssetImpairment>
    <RENB:LonglivedAssetImpairment
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203"
      decimals="0"
      id="Fact000928"
      unitRef="USD">0</RENB:LonglivedAssetImpairment>
    <RENB:LonglivedAssetImpairment
      contextRef="From2025-07-012025-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">0</RENB:LonglivedAssetImpairment>
    <RENB:LonglivedAssetImpairment
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000930"
      unitRef="USD">831915</RENB:LonglivedAssetImpairment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012025-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">25442</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203"
      decimals="0"
      id="Fact000933"
      unitRef="USD">16080</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012025-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000935"
      unitRef="USD">41522</us-gaap:DepreciationDepletionAndAmortization>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_custom_RENBMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">2700505</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_custom_BioSymetricsMember412313203"
      decimals="0"
      id="Fact000938"
      unitRef="USD">273951</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-012025-09-30_custom_RENCMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">333904</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2025-07-01to2025-09-30"
      decimals="0"
      id="Fact000940"
      unitRef="USD">3308360</RENB:SegmentOperatingLoss>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000942">&lt;p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zXMAhFfllGQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_827_zHzhWO5CDFpl"&gt;ACQUISITIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;BioSymetrics Inc. Acquisition:&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#x201c;&lt;span style="text-decoration: underline"&gt;Lunai&lt;/span&gt;&#x201d;), entered into an Agreement and Plan of Merger (the &#x201c;&lt;span style="text-decoration: underline"&gt;Merger Agreement&lt;/span&gt;&#x201d;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#x201c;&lt;span style="text-decoration: underline"&gt;Merger Sub&lt;/span&gt;&#x201d;), and Biosymetrics,
Inc., a Delaware corporation (&#x201c;&lt;span style="text-decoration: underline"&gt;Biosymetrics&lt;/span&gt;&#x201d;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#x201c;&lt;span style="text-decoration: underline"&gt;Transaction&lt;/span&gt;&#x201d;). On April 8, 2025, Lunai consummated the Transaction and issued &lt;span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z1LDcOJVwUre" title="Transaction issued shares"&gt;1.5&lt;/span&gt; million shares of Lunai&#x2019;s
common stock, par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_zpOhG5NxifQ5" title="Common stock per value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;&lt;span style="text-decoration: underline"&gt;Shares&lt;/span&gt;&#x201d;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The offer and sale of the Shares have not been registered
under the Securities Act of 1933, as amended (the &#x201c;&lt;span style="text-decoration: underline"&gt;Securities Act&lt;/span&gt;&#x201d;), in reliance on the exemption from registration
requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon representations contained in the Merger Agreement
that all those receiving Shares in connection with the Transaction are &#x201c;accredited investors&#x201d; as defined in Rule 501(a) under
the Securities Act.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
transaction was accounted for in accordance with ASC 805-10 -&#160;&lt;i&gt;Business Combinations&lt;/i&gt;. &lt;/span&gt;The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The acquisition-date
fair value of the consideration transferred totaled approximately $&lt;span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zw5pBNuEud2a" title="Fair value of consideration transferred amount"&gt;6&lt;/span&gt; million, which consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zU7KCdvHkyvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zi98MeJPpdq7" style="display: none"&gt;Schedule of acquisition
fair value of the consideration&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zcAs7fAkP0O6" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock"&gt;6,058,500&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIBrP5JZi34" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;6,058,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zkFmAnTI7vC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
fair value of the Company&#x2019;s common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock
as of the Acquisition Date. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;span style="background-color: white"&gt;The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_zBQP4KQJ1yF9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_ziFGFF2h85L3" style="display: none"&gt;Schedule of fair values of the assets acquired and liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zpH20Z6vHkM9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Cash_iNI_di_zvVIVuF7ayNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;(3,822&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zGMzIm9usq4a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,405&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--FixedAssets_iI_zTRAFjWfK49e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,365&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zz4YiPNvScnl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,948&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUc7o0VpXCe5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;975&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zA7iS78FDRMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,594&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_zXfb4WadhM59" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Current Liabilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;73,879&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zQZU0nj1jVvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;82,448&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_z9RKZtW6plFi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(55,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--Software_iI_zQfXg32ElGZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Software&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;143,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TradeName_iI_zaQaoGbFU818" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Trade Name&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z14YeUveV2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_z1Pgjx5WTLM5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,058,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AA_ztcmOgh91ur5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the goodwill is expected
to be deductible for income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
three-month period ended September 30, 2024. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zoh8Mp8d3flb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zQwuKaPvkeU5" style="display: none"&gt;Schedule of statement of operations&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250225__20250226_zRDLIIuXY5uf" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--BusinessAcquisitionsRevenue_zezObfd0icki" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Revenues&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;318,918&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessAcquisitionsNetIncomeLoss_zq3Loq7qiMTl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(44,499,586&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zfM9RCw63iG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;







</us-gaap:AssetAcquisitionTextBlock>
    <RENB:TransactionIssuedShares
      contextRef="AsOf2025-04-08"
      decimals="-3"
      id="Fact000944"
      unitRef="Shares">1500000</RENB:TransactionIssuedShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-04-08"
      decimals="INF"
      id="Fact000946"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember"
      decimals="-5"
      id="Fact000948"
      unitRef="USD">6000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000950">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zU7KCdvHkyvj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zi98MeJPpdq7" style="display: none"&gt;Schedule of acquisition
fair value of the consideration&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zcAs7fAkP0O6" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock"&gt;6,058,500&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zIBrP5JZi34" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;6,058,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <RENB:BusinessCombinationContingentConsiderationCommonStock
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">6058500</RENB:BusinessCombinationContingentConsiderationCommonStock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-02-122025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">6058500</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000957">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_zBQP4KQJ1yF9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_ziFGFF2h85L3" style="display: none"&gt;Schedule of fair values of the assets acquired and liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zpH20Z6vHkM9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Cash_iNI_di_zvVIVuF7ayNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;
&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 18%; text-align: right"&gt;(3,822&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssets_iI_zGMzIm9usq4a" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,405&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--FixedAssets_iI_zTRAFjWfK49e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,365&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zz4YiPNvScnl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,948&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUc7o0VpXCe5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;975&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zA7iS78FDRMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,594&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_zXfb4WadhM59" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Current Liabilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;73,879&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zQZU0nj1jVvb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;82,448&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_z9RKZtW6plFi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(55,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--Software_iI_zQfXg32ElGZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Software&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;143,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TradeName_iI_zaQaoGbFU818" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Trade Name&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z14YeUveV2Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,963,000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_z1Pgjx5WTLM5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,058,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">3822</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">17405</us-gaap:PrepaidExpenseAndOtherAssets>
    <RENB:FixedAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">13365</RENB:FixedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000965"
      unitRef="USD">26948</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">975</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000969"
      unitRef="USD">7594</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000971"
      unitRef="USD">73879</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000973"
      unitRef="USD">82448</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000975"
      unitRef="USD">-55500</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <RENB:Software
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000977"
      unitRef="USD">143000</RENB:Software>
    <RENB:TradeName
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">8000</RENB:TradeName>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">5963000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">6058500</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000985">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zoh8Mp8d3flb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITIONS (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zQwuKaPvkeU5" style="display: none"&gt;Schedule of statement of operations&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250225__20250226_zRDLIIuXY5uf" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--BusinessAcquisitionsRevenue_zezObfd0icki" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Revenues&lt;/td&gt;
&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;318,918&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--BusinessAcquisitionsNetIncomeLoss_zq3Loq7qiMTl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(44,499,586&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <RENB:BusinessAcquisitionsRevenue
      contextRef="From2025-02-252025-02-26"
      decimals="0"
      id="Fact000987"
      unitRef="USD">318918</RENB:BusinessAcquisitionsRevenue>
    <RENB:BusinessAcquisitionsNetIncomeLoss
      contextRef="From2025-02-252025-02-26"
      decimals="0"
      id="Fact000989"
      unitRef="USD">-44499586</RENB:BusinessAcquisitionsNetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact000993">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z2o6wJjOvO0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_824_zraXJ1wSCrv8"&gt;SUBSEQUENT EVENTS &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On November 4, 2025, the Company
issued&#160;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUnlgD23PCRk" title="Issuance of common stock shares"&gt;20,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251103__20251104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztf0pFwe4Ohh" title="Common stock for consulting services value"&gt;16,680&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On October 30, 2025, the Company
cancelled&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251030_zYjA3IOtShdj" title="Issuance of common stock shares"&gt;&#160;25,000&lt;/span&gt; shares of Common Stock upon termination, previously issued to the former Chief Executive Officer of Renovaro Cube
valued at $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251030_zWn2Jhb6rB6" title="Issuance of common stock shares, value"&gt;177,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On October 29, 2025, the Company
issued&#160;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zByHRN2FL6M8" title="Issuance of common stock shares"&gt;237,500&lt;/span&gt;&#160;shares of Common Stock pursuant to a settlement agreement valued at $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251028__20251029__us-gaap--StatementClassOfStockAxis__custom--SettlementAgreementMember_zqLmYbWR24O6" title="Issuance of common stock shares, value"&gt;228,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On October 17, 2025, the Company
issued&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zPkPZBh1ZFae" title="Issuance of common stock shares"&gt;20,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20251016__20251017_zozyEjy2Lrcd" title="Common stock for consulting services value"&gt;24,000&lt;/span&gt;.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-11-032025-11-04_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-11-032025-11-04_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000997"
      unitRef="USD">16680</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-10-282025-10-30"
      decimals="INF"
      id="Fact000999"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-10-282025-10-30"
      decimals="0"
      id="Fact001001"
      unitRef="USD">177500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-10-282025-10-29_custom_SettlementAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001003"
      unitRef="Shares">237500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-10-282025-10-29_custom_SettlementAgreementMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">228000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-162024-10-17"
      decimals="INF"
      id="Fact001007"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-10-162025-10-17"
      decimals="0"
      id="Fact001009"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="From2025-07-01to2025-09-30" id="Fact001010">During the quarter ended September
30, 2025, no director or Section 16 officer &lt;span id="xdx_90B_eecd--Rule10b51ArrAdoptedFlag_dbT_c20250701__20250930_zP271nqHp1w2"&gt;&lt;span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20250701__20250930_z1it0bUSHWma"&gt;adopted&lt;/span&gt;&lt;/span&gt;, modified, or &lt;span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zmMAfAgk6U0a"&gt;&lt;span id="xdx_902_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20250701__20250930_zKqdvKEKxPtg"&gt;terminated&lt;/span&gt;&lt;/span&gt; any &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule
10b5-1 trading arrangement&#x201d; (in each case, as defined in Item 408(a) of Regulation S-K).</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-07-01to2025-09-30" id="Fact001011">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-07-01to2025-09-30" id="Fact001012">true</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-07-01to2025-09-30" id="Fact001013">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-07-01to2025-09-30" id="Fact001014">true</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
